id,PMID,title,journal,abstract,abstract_type,plain_language_summary,benefit_raw_answer,benefit_answer,benefit_log_probabilities,rigor_raw_answer,rigor_answer,rigor_log_probabilities,importance_raw_answer,importance_answer,importance_log_probabilities,full_text_raw_answer,full_text_answer,full_text_log_probabilities,another_trial_raw_answer,another_trial_answer,another_trial_log_probabilities
58,10547391,"
Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer",J Natl Cancer Inst,"Background:
Treatment A has been shown to inhibit breast carcinogenesis in preclinical studies. We determined the efficacy of treatment A in preventing a second breast malignancy in women with breast cancer.
Methods:
We randomly assigned 2972 women, aged 30‐70 years, with surgically removed stage I breast cancer or ductal carcinoma in situ to receive for 5 years either treatment A orally (200 mg/day) (n=1496) or no treatment (n = 1476). Random assignment of patients was centrally managed by the coordinating center in Milan. All women were followed by use of the same procedures throughout the study period, and the radiologists who examined the mammograms were blinded to the allocated treatment arm. The primary end point was the incidence of contralateral breast cancer or ipsilateral breast cancer 7 years after randomization. The hazards of breast cancer occurrence were determined by Cox proportional hazards regression analysis. Statistical tests were two‐sided.
Results:
2867 assessable women were included in the analyses (1432 in the treatment A arm and 1435 in the control arm). At a median observation time of 97 months, there were no statistically significant differences in the occurrence of contralateral breast cancer (65 events in the treatment A arm versus 71 in the control arm; hazard ratio [HR] = 0.92; 95% confidence interval [CI] = 0.66‐1.29; P = .642) or ipsilateral breast cancer (treatment A group = 100 events; control group = 121 events; HR = 0.83; 95% CI = 0.64‐1.09; P = .177) between the two arms. There were no statistically significant differences between the two arms in tumors in other organs (38 in the treatment A arm versus 40 in the control arm), incidence of distant metastasis (HR = 0.98; 95% CI = 0.79‐1.22; P = .858), and all‐cause mortality (HR = 1.16; 95% CI = 0.92‐1.48; P = .215).
Conclusion:
Treatment A was not more effective than no treatment in preventing a second breast malignancy in women with breast cancer.",no_spin,"This study looked at whether a medicine called Treatment A could help prevent a second breast cancer from happening in women who already had breast cancer. The study randomly assigned 2972 women to either take Treatment A for 5 years or not take any treatment at all. The researchers followed the women for 7 years and looked at whether they got a second breast cancer during that time. They found that there was no difference between the two groups in the number of women who got a second breast cancer. So, the study concluded that Treatment A was not better than not taking any treatment at all in preventing a second breast cancer.",0,0,"[{'token': '0', 'bytes': [48], 'logprob': -0.02079458}, {'token': '1', 'bytes': [49], 'logprob': -4.2707944}, {'token': '2', 'bytes': [50], 'logprob': -5.0207944}, {'token': '3', 'bytes': [51], 'logprob': -11.520795}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.020794}, {'token': '4', 'bytes': [52], 'logprob': -17.520794}, {'token': ' ', 'bytes': [32], 'logprob': -20.270794}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -20.395794}, {'token': '02', 'bytes': [48, 50], 'logprob': -20.770794}, {'token': '5', 'bytes': [53], 'logprob': -21.145794}, {'token': '01', 'bytes': [48, 49], 'logprob': -21.270794}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.520794}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.895794}, {'token': ' Score', 'bytes': [32, 83, 99, 111, 114, 101], 'logprob': -22.395794}, {'token': '-', 'bytes': [45], 'logprob': -22.708294}, {'token': '00', 'bytes': [48, 48], 'logprob': -22.958294}, {'token': '０', 'bytes': [239, 188, 144], 'logprob': -23.270794}, {'token': '۰', 'bytes': [219, 176], 'logprob': -23.708294}, {'token': '_score', 'bytes': [95, 115, 99, 111, 114, 101], 'logprob': -23.708294}, {'token': 'Scores', 'bytes': [83, 99, 111, 114, 101, 115], 'logprob': -23.895794}]",5,5,"[{'token': '5', 'bytes': [53], 'logprob': -1.2380317}, {'token': '6', 'bytes': [54], 'logprob': -1.2380317}, {'token': '4', 'bytes': [52], 'logprob': -1.7380317}, {'token': '7', 'bytes': [55], 'logprob': -1.9880317}, {'token': '3', 'bytes': [51], 'logprob': -2.4880319}, {'token': '8', 'bytes': [56], 'logprob': -4.113032}, {'token': '2', 'bytes': [50], 'logprob': -4.863032}, {'token': '9', 'bytes': [57], 'logprob': -9.363031}, {'token': '1', 'bytes': [49], 'logprob': -11.113031}, {'token': '0', 'bytes': [48], 'logprob': -14.113031}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -15.613031}, {'token': '10', 'bytes': [49, 48], 'logprob': -15.738031}, {'token': ' ', 'bytes': [32], 'logprob': -17.425531}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.988031}, {'token': 'C', 'bytes': [67], 'logprob': -19.988031}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -20.425531}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -20.425531}, {'token': 'I', 'bytes': [73], 'logprob': -20.550531}, {'token': '-', 'bytes': [45], 'logprob': -20.613031}, {'token': 'D', 'bytes': [68], 'logprob': -20.613031}]",2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.2737152}, {'token': '3', 'bytes': [51], 'logprob': -1.5237153}, {'token': '1', 'bytes': [49], 'logprob': -4.273715}, {'token': '4', 'bytes': [52], 'logprob': -5.148715}, {'token': '0', 'bytes': [48], 'logprob': -6.523715}, {'token': '5', 'bytes': [53], 'logprob': -8.023715}, {'token': '6', 'bytes': [54], 'logprob': -11.023715}, {'token': '7', 'bytes': [55], 'logprob': -13.523715}, {'token': '8', 'bytes': [56], 'logprob': -16.273716}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.648716}, {'token': '9', 'bytes': [57], 'logprob': -18.148716}, {'token': ' ', 'bytes': [32], 'logprob': -18.398716}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.773716}, {'token': '02', 'bytes': [48, 50], 'logprob': -20.523716}, {'token': '10', 'bytes': [49, 48], 'logprob': -20.773716}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.523716}, {'token': 'I', 'bytes': [73], 'logprob': -21.586216}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.773716}, {'token': '-', 'bytes': [45], 'logprob': -21.836216}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.961216}]",0,0,"[{'token': '0', 'bytes': [48], 'logprob': -0.27967006}, {'token': '2', 'bytes': [50], 'logprob': -1.52967}, {'token': '1', 'bytes': [49], 'logprob': -3.77967}, {'token': '3', 'bytes': [51], 'logprob': -5.4046702}, {'token': '4', 'bytes': [52], 'logprob': -10.40467}, {'token': '5', 'bytes': [53], 'logprob': -12.52967}, {'token': '6', 'bytes': [54], 'logprob': -17.15467}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.15467}, {'token': ' ', 'bytes': [32], 'logprob': -19.27967}, {'token': '02', 'bytes': [48, 50], 'logprob': -19.27967}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -19.52967}, {'token': '7', 'bytes': [55], 'logprob': -20.02967}, {'token': '8', 'bytes': [56], 'logprob': -20.96717}, {'token': '9', 'bytes': [57], 'logprob': -21.09217}, {'token': '01', 'bytes': [48, 49], 'logprob': -21.21717}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.65467}, {'token': '-', 'bytes': [45], 'logprob': -21.96717}, {'token': 'I', 'bytes': [73], 'logprob': -22.65467}, {'token': '00', 'bytes': [48, 48], 'logprob': -22.84217}, {'token': '30', 'bytes': [51, 48], 'logprob': -22.90467}]",2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.57458454}, {'token': '0', 'bytes': [48], 'logprob': -1.0745845}, {'token': '1', 'bytes': [49], 'logprob': -2.5745845}, {'token': '3', 'bytes': [51], 'logprob': -3.9495845}, {'token': '4', 'bytes': [52], 'logprob': -8.699585}, {'token': '5', 'bytes': [53], 'logprob': -11.949585}, {'token': '6', 'bytes': [54], 'logprob': -15.324585}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.324585}, {'token': '7', 'bytes': [55], 'logprob': -17.699585}, {'token': ' ', 'bytes': [32], 'logprob': -18.074585}, {'token': '8', 'bytes': [56], 'logprob': -18.949585}, {'token': '9', 'bytes': [57], 'logprob': -19.199585}, {'token': '02', 'bytes': [48, 50], 'logprob': -19.199585}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.324585}, {'token': '01', 'bytes': [48, 49], 'logprob': -20.824585}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.012085}, {'token': '-', 'bytes': [45], 'logprob': -21.199585}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.574585}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.574585}, {'token': 'I', 'bytes': [73], 'logprob': -21.762085}]"
57,10547391,"
Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer",J Natl Cancer Inst,"Background:
Treatment A has been shown to inhibit breast carcinogenesis in preclinical studies. We determined the efficacy of treatment A in preventing a second breast malignancy in women with breast cancer.
Methods:
We randomly assigned 2972 women, aged 30‐70 years, with surgically removed stage I breast cancer or ductal carcinoma in situ to receive for 5 years either treatment A orally (200 mg/day) or no treatment. The primary end point was the incidence of contralateral breast cancer or ipsilateral breast cancer 7 years after randomization. Other end points considered post hoc were the same outcomes stratified by menopausal status, incidence of distant metastases, overall mortality, and tumors in other organs. The hazards of breast cancer occurrence were determined by Cox proportional hazards regression analysis. Statistical tests were two‐sided.
Results:
At a median observation time of 97 months, there were no statistically significant differences in the occurrence of contralateral breast cancer (P =.642) or ipsilateral breast cancer (P =.177) between the two arms. However, an interaction was detected between treatment A and menopausal status in both outcomes (P for interaction in both outcomes =.045), with a possible beneficial effect in premenopausal women (contralateral breast cancer: adjusted hazard ratio [HR] = 0.66, and 95% confidence interval [CI] = 0.41‐1.07; ipsilateral breast cancer: adjusted HR = 0.65, and 95% CI = 0.46‐0. 92) and an opposite effect in postmenopausal women (contralateral breast cancer: adjusted HR = 1.32, and 95% CI = 0.82‐2.15; ipsilateral breast cancer: adjusted HR = 1.19, and 95% CI = 0.75‐1. 89). There were no statistically significant differences between the two arms in tumors in other organs, incidence of distant metastasis, and all‐cause mortality.
Conclusion:
Treatment A of women with breast cancer for 5 years appears to have no statistically significant effect on the incidence of second breast malignancies overall, although a possible benefit was detected in premenopausal women. These studies, particularly the post hoc analyses, are considered exploratory and need to be confirmed.",spin,"The study looked at whether a medicine called treatment A could help prevent a second breast cancer from happening in women who already had breast cancer. They randomly gave the medicine to 2972 women for 5 years and then checked if they got a second breast cancer. They also looked at how the medicine affected women who were menopausal or not. The study found that the medicine did not have a big effect on preventing a second breast cancer overall, but it might have helped premenopausal women. However, the study was just an exploratory one and needs to be confirmed by more research.",4,4,"[{'token': '4', 'bytes': [52], 'logprob': -0.19454785}, {'token': '5', 'bytes': [53], 'logprob': -1.9445479}, {'token': '3', 'bytes': [51], 'logprob': -3.569548}, {'token': '6', 'bytes': [54], 'logprob': -5.1945477}, {'token': '2', 'bytes': [50], 'logprob': -10.944548}, {'token': '7', 'bytes': [55], 'logprob': -11.694548}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.569548}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.632048}, {'token': '1', 'bytes': [49], 'logprob': -17.819548}, {'token': ' ', 'bytes': [32], 'logprob': -18.819548}, {'token': 'C', 'bytes': [67], 'logprob': -19.819548}, {'token': '8', 'bytes': [56], 'logprob': -20.194548}, {'token': '0', 'bytes': [48], 'logprob': -20.944548}, {'token': '-', 'bytes': [45], 'logprob': -21.319548}, {'token': 'D', 'bytes': [68], 'logprob': -21.632048}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -21.757048}, {'token': 'Overall', 'bytes': [79, 118, 101, 114, 97, 108, 108], 'logprob': -21.819548}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.944548}, {'token': '４', 'bytes': [239, 188, 148], 'logprob': -21.944548}, {'token': 'I', 'bytes': [73], 'logprob': -22.069548}]",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.32692614}, {'token': '7', 'bytes': [55], 'logprob': -1.3269261}, {'token': '5', 'bytes': [53], 'logprob': -4.326926}, {'token': '8', 'bytes': [56], 'logprob': -8.201926}, {'token': '4', 'bytes': [52], 'logprob': -9.326926}, {'token': '3', 'bytes': [51], 'logprob': -15.826926}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.701925}, {'token': '9', 'bytes': [57], 'logprob': -17.201925}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.764425}, {'token': ' ', 'bytes': [32], 'logprob': -19.764425}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -19.889425}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -21.014425}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -21.014425}, {'token': 'C', 'bytes': [67], 'logprob': -21.389425}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.576925}, {'token': '2', 'bytes': [50], 'logprob': -21.639425}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -21.889425}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -22.014425}, {'token': '-', 'bytes': [45], 'logprob': -22.264425}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.264425}]",5,5,"[{'token': '5', 'bytes': [53], 'logprob': -0.5318023}, {'token': '6', 'bytes': [54], 'logprob': -1.2818023}, {'token': '4', 'bytes': [52], 'logprob': -2.0318022}, {'token': '7', 'bytes': [55], 'logprob': -5.656802}, {'token': '3', 'bytes': [51], 'logprob': -8.031802}, {'token': '8', 'bytes': [56], 'logprob': -14.781802}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -15.906802}, {'token': '2', 'bytes': [50], 'logprob': -16.156803}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.906803}, {'token': ' ', 'bytes': [32], 'logprob': -19.406803}, {'token': '9', 'bytes': [57], 'logprob': -20.656803}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.344303}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.469303}, {'token': 'C', 'bytes': [67], 'logprob': -21.844303}, {'token': '1', 'bytes': [49], 'logprob': -21.906803}, {'token': 'Rating', 'bytes': [82, 97, 116, 105, 110, 103], 'logprob': -22.156803}, {'token': ' Score', 'bytes': [32, 83, 99, 111, 114, 101], 'logprob': -22.281803}, {'token': '**', 'bytes': [42, 42], 'logprob': -22.406803}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -22.469303}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -22.594303}]",5,5,"[{'token': '5', 'bytes': [53], 'logprob': -0.6825481}, {'token': '6', 'bytes': [54], 'logprob': -0.9325481}, {'token': '4', 'bytes': [52], 'logprob': -2.432548}, {'token': '7', 'bytes': [55], 'logprob': -4.432548}, {'token': '3', 'bytes': [51], 'logprob': -6.557548}, {'token': '8', 'bytes': [56], 'logprob': -12.3075485}, {'token': '2', 'bytes': [50], 'logprob': -13.1825485}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -19.182549}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.432549}, {'token': '1', 'bytes': [49], 'logprob': -21.432549}, {'token': '9', 'bytes': [57], 'logprob': -21.932549}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -22.370049}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -22.682549}, {'token': '５', 'bytes': [239, 188, 149], 'logprob': -22.870049}, {'token': ' five', 'bytes': [32, 102, 105, 118, 101], 'logprob': -23.182549}, {'token': ' ', 'bytes': [32], 'logprob': -23.370049}, {'token': '六', 'bytes': [229, 133, 173], 'logprob': -23.682549}, {'token': ' seis', 'bytes': [32, 115, 101, 105, 115], 'logprob': -23.995049}, {'token': 'Five', 'bytes': [70, 105, 118, 101], 'logprob': -24.057549}, {'token': '４', 'bytes': [239, 188, 148], 'logprob': -24.245049}]",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.6018837}, {'token': '7', 'bytes': [55], 'logprob': -0.8518837}, {'token': '5', 'bytes': [53], 'logprob': -3.7268836}, {'token': '8', 'bytes': [56], 'logprob': -6.726884}, {'token': '4', 'bytes': [52], 'logprob': -7.976884}, {'token': '3', 'bytes': [51], 'logprob': -13.726884}, {'token': '9', 'bytes': [57], 'logprob': -15.101884}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.601883}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.164383}, {'token': '2', 'bytes': [50], 'logprob': -19.601883}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -19.976883}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -20.539383}, {'token': ' ', 'bytes': [32], 'logprob': -20.664383}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -21.164383}, {'token': 'I', 'bytes': [73], 'logprob': -21.414383}, {'token': '70', 'bytes': [55, 48], 'logprob': -21.539383}, {'token': '10', 'bytes': [49, 48], 'logprob': -22.039383}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -22.101883}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -22.414383}, {'token': 'C', 'bytes': [67], 'logprob': -22.476883}]"
45,10637238,"Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study",J Clin Oncol,"Purpose:
It is uncertain whether treatment A provides additional benefit compared with chemotherapy alone. This trial was initiated to explore this question.
Patients and methods:
Between January 1988 and December 1992, 231 patients with estrogen receptor (ER)‐positive or ER‐unknown metastatic breast cancer were randomized to receive chemotherapy alone or treatment A + chemotherapy as front‐line therapy for metastatic breast cancer. Patients who experienced a complete response to induction therapy either received or did not receive maintenance treatment as a secondary randomization.
Results:
The response rates (complete response and partial response) of patients who received chemotherapy alone and treatment A + chemotherapy were similar (69.2% v 68.9%, respectively; P =.99). Time to treatment failure (TTF) was slightly longer for patients who received treatment A + chemotherapy compared with chemotherapy alone patients (13.4 months v 10.3 months, respectively; P =.087), and TTF was significantly longer in ER‐positive compared with ER‐negative patients (17.4 months v 10.3 months, respectively; P =.048). However, ER status had no effect on overall survival (30.0 months for chemotherapy alone v 29.3 months for treatment A + chemotherapy).
Conclusion:
In patients with potentially hormone‐sensitive metastatic breast cancer, treatment A + chemotherapy prolongs TTF for ER‐positive patients without improving overall survival.",spin,"This passage is about a study that was done to see if a certain treatment (treatment A) helps people with a type of cancer called breast cancer. The study involved 231 people who had a type of breast cancer that could be treated with a hormone called estrogen. The people were randomly divided into two groups: one group got chemotherapy alone, and the other group got chemotherapy plus treatment A. The study found that the number of people who had a complete or partial response to the treatment was similar in both groups. However, the study also found that people who got treatment A plus chemotherapy had a slightly longer time before their cancer returned than people who got chemotherapy alone. However, this did not mean that they lived longer. The study also found that the hormone status of the people did not affect how long they lived. In summary, the study found that treatment A plus chemotherapy helped people with potentially hormone‐sensitive breast cancer live a little longer before their cancer returned, but it did not improve their overall survival.",5,5,"[{'token': '5', 'bytes': [53], 'logprob': -0.24082582}, {'token': '4', 'bytes': [52], 'logprob': -2.240826}, {'token': '6', 'bytes': [54], 'logprob': -2.240826}, {'token': '3', 'bytes': [51], 'logprob': -6.7408257}, {'token': '7', 'bytes': [55], 'logprob': -9.240826}, {'token': '2', 'bytes': [50], 'logprob': -13.365826}, {'token': '8', 'bytes': [56], 'logprob': -19.615826}, {'token': '1', 'bytes': [49], 'logprob': -20.490826}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.615826}, {'token': ' ', 'bytes': [32], 'logprob': -22.053326}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -22.115826}, {'token': ' five', 'bytes': [32, 102, 105, 118, 101], 'logprob': -23.053326}, {'token': 'C', 'bytes': [67], 'logprob': -23.615826}, {'token': '５', 'bytes': [239, 188, 149], 'logprob': -24.053326}, {'token': 'Five', 'bytes': [70, 105, 118, 101], 'logprob': -24.115826}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -24.178326}, {'token': 'five', 'bytes': [102, 105, 118, 101], 'logprob': -24.365826}, {'token': '-', 'bytes': [45], 'logprob': -24.678326}, {'token': ' Five', 'bytes': [32, 70, 105, 118, 101], 'logprob': -24.865826}, {'token': '\n\n', 'bytes': [10, 10], 'logprob': -25.053326}]",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.16508152}, {'token': '7', 'bytes': [55], 'logprob': -2.1650815}, {'token': '5', 'bytes': [53], 'logprob': -3.2900815}, {'token': '4', 'bytes': [52], 'logprob': -8.915082}, {'token': '8', 'bytes': [56], 'logprob': -9.915082}, {'token': '3', 'bytes': [51], 'logprob': -15.415082}, {'token': '9', 'bytes': [57], 'logprob': -18.665081}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.665081}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.852581}, {'token': ' ', 'bytes': [32], 'logprob': -19.415081}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -19.477581}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -20.790081}, {'token': 'C', 'bytes': [67], 'logprob': -21.352581}, {'token': '2', 'bytes': [50], 'logprob': -21.415081}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -21.665081}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -21.727581}, {'token': '六', 'bytes': [229, 133, 173], 'logprob': -22.040081}, {'token': '-', 'bytes': [45], 'logprob': -22.165081}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -22.540081}, {'token': ' seis', 'bytes': [32, 115, 101, 105, 115], 'logprob': -22.602581}]",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.26754594}, {'token': '5', 'bytes': [53], 'logprob': -1.5175459}, {'token': '7', 'bytes': [55], 'logprob': -4.2675457}, {'token': '4', 'bytes': [52], 'logprob': -6.5175457}, {'token': '3', 'bytes': [51], 'logprob': -13.517546}, {'token': '8', 'bytes': [56], 'logprob': -14.142546}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -19.267546}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.267546}, {'token': '2', 'bytes': [50], 'logprob': -20.767546}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.767546}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -20.830046}, {'token': ' seis', 'bytes': [32, 115, 101, 105, 115], 'logprob': -21.392546}, {'token': ' five', 'bytes': [32, 102, 105, 118, 101], 'logprob': -21.642546}, {'token': '六', 'bytes': [229, 133, 173], 'logprob': -22.517546}, {'token': ' ', 'bytes': [32], 'logprob': -22.642546}, {'token': '５', 'bytes': [239, 188, 149], 'logprob': -22.767546}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -23.205046}, {'token': ' cinco', 'bytes': [32, 99, 105, 110, 99, 111], 'logprob': -23.705046}, {'token': ' sei', 'bytes': [32, 115, 101, 105], 'logprob': -23.705046}, {'token': 'six', 'bytes': [115, 105, 120], 'logprob': -23.767546}]",5,5,"[{'token': '5', 'bytes': [53], 'logprob': -0.5467437}, {'token': '6', 'bytes': [54], 'logprob': -1.0467436}, {'token': '4', 'bytes': [52], 'logprob': -3.2967436}, {'token': '7', 'bytes': [55], 'logprob': -3.4217436}, {'token': '3', 'bytes': [51], 'logprob': -7.796744}, {'token': '8', 'bytes': [56], 'logprob': -10.921743}, {'token': '2', 'bytes': [50], 'logprob': -13.671743}, {'token': '9', 'bytes': [57], 'logprob': -17.796743}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.046743}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.109243}, {'token': '1', 'bytes': [49], 'logprob': -19.234243}, {'token': ' ', 'bytes': [32], 'logprob': -20.609243}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -21.234243}, {'token': '0', 'bytes': [48], 'logprob': -21.296743}, {'token': '５', 'bytes': [239, 188, 149], 'logprob': -21.796743}, {'token': 'I', 'bytes': [73], 'logprob': -21.984243}, {'token': 'C', 'bytes': [67], 'logprob': -22.234243}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -22.296743}, {'token': ' five', 'bytes': [32, 102, 105, 118, 101], 'logprob': -22.421743}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -22.671743}]",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.6105206}, {'token': '5', 'bytes': [53], 'logprob': -0.8605206}, {'token': '7', 'bytes': [55], 'logprob': -3.8605206}, {'token': '4', 'bytes': [52], 'logprob': -4.3605204}, {'token': '3', 'bytes': [51], 'logprob': -8.86052}, {'token': '8', 'bytes': [56], 'logprob': -10.86052}, {'token': '2', 'bytes': [50], 'logprob': -15.23552}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.235521}, {'token': '9', 'bytes': [57], 'logprob': -20.360521}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.548021}, {'token': ' ', 'bytes': [32], 'logprob': -21.673021}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -22.235521}, {'token': '1', 'bytes': [49], 'logprob': -22.485521}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -22.923021}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -23.548021}, {'token': ' five', 'bytes': [32, 102, 105, 118, 101], 'logprob': -23.798021}, {'token': 'Five', 'bytes': [70, 105, 118, 101], 'logprob': -23.798021}, {'token': 'C', 'bytes': [67], 'logprob': -23.923021}, {'token': '５', 'bytes': [239, 188, 149], 'logprob': -24.110521}, {'token': 'six', 'bytes': [115, 105, 120], 'logprob': -24.235521}]"
46,10637238,"Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study",J Clin Oncol,"Purpose:
It is uncertain whether treatment A provides additional benefit compared with chemotherapy alone. This trial was initiated to explore this question.
Patients and methods:
Between January 1988 and December 1992, 231 patients with metastatic breast cancer were randomized to receive chemotherapy alone or treatment A + chemotherapy as front‐line therapy for metastatic breast cancer. Patients who experienced a complete response to induction therapy either received or did not receive maintenance treatment as a secondary randomization. The two end points of interest for this study were time to treatment failure (TTF) and survival time.
Results:
Median survival was 30.0 months for chemotherapy alone and 29.3 months treatment A and chemotherapy, p=0.834. Time to treatment failure (TTF) was 13.4 months for patients who received treatment A + chemotherapy compared with 10.3 month for chemotherapy alone patients (P = .087). The response rates (complete response and partial response) was 69.2% of for patients who received chemotherapy alone and 68.9% for patients who received treatment A + chemotherapy, P =.99. There was no significant difference in toxicities seen between the two arms of the study. There were four lethal toxicities. Three infectious deaths occurred in patients receiving treatment A with chemotherapy.
Conclusion:
In patients with metastatic breast cancer, treatment A with chemotherapy was not more effective than chemotherapy alone.",no_spin,"This passage is about a study that was done to see if a certain treatment (treatment A) helps people with breast cancer that has spread to other parts of the body. The study involved 231 people who were randomly assigned to either receive chemotherapy alone or treatment A + chemotherapy. The researchers looked at how long it took for the cancer to come back (time to treatment failure) and how long people lived (survival time). They found that there was no significant difference between the two groups, meaning that treatment A did not help people live longer or have their cancer come back less often than chemotherapy alone.",2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.13867924}, {'token': '1', 'bytes': [49], 'logprob': -2.6386793}, {'token': '3', 'bytes': [51], 'logprob': -2.8886793}, {'token': '0', 'bytes': [48], 'logprob': -6.263679}, {'token': '4', 'bytes': [52], 'logprob': -7.638679}, {'token': '5', 'bytes': [53], 'logprob': -13.2636795}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.63868}, {'token': '6', 'bytes': [54], 'logprob': -17.63868}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.26368}, {'token': ' ', 'bytes': [32], 'logprob': -18.88868}, {'token': '02', 'bytes': [48, 50], 'logprob': -19.95118}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -20.63868}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -20.76368}, {'token': 'I', 'bytes': [73], 'logprob': -21.20118}, {'token': '-', 'bytes': [45], 'logprob': -21.26368}, {'token': '7', 'bytes': [55], 'logprob': -21.26368}, {'token': '01', 'bytes': [48, 49], 'logprob': -21.45118}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.51368}, {'token': '30', 'bytes': [51, 48], 'logprob': -21.70118}, {'token': ' Score', 'bytes': [32, 83, 99, 111, 114, 101], 'logprob': -22.38868}]",5,5,"[{'token': '5', 'bytes': [53], 'logprob': -0.74589694}, {'token': '6', 'bytes': [54], 'logprob': -0.74589694}, {'token': '4', 'bytes': [52], 'logprob': -3.4958968}, {'token': '7', 'bytes': [55], 'logprob': -3.8708968}, {'token': '3', 'bytes': [51], 'logprob': -8.495897}, {'token': '8', 'bytes': [56], 'logprob': -10.995897}, {'token': '2', 'bytes': [50], 'logprob': -14.995897}, {'token': '9', 'bytes': [57], 'logprob': -17.620897}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.620897}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.995897}, {'token': ' ', 'bytes': [32], 'logprob': -18.558397}, {'token': 'C', 'bytes': [67], 'logprob': -20.558397}, {'token': '1', 'bytes': [49], 'logprob': -20.683397}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -21.245897}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -21.433397}, {'token': '0', 'bytes': [48], 'logprob': -21.558397}, {'token': '-', 'bytes': [45], 'logprob': -21.620897}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.058397}, {'token': 'I', 'bytes': [73], 'logprob': -22.120897}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.183397}]",4,4,"[{'token': '4', 'bytes': [52], 'logprob': -0.6213534}, {'token': '5', 'bytes': [53], 'logprob': -1.3713534}, {'token': '3', 'bytes': [51], 'logprob': -1.6213534}, {'token': '6', 'bytes': [54], 'logprob': -4.621353}, {'token': '2', 'bytes': [50], 'logprob': -6.496353}, {'token': '7', 'bytes': [55], 'logprob': -10.121353}, {'token': '1', 'bytes': [49], 'logprob': -15.621353}, {'token': '8', 'bytes': [56], 'logprob': -17.621353}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -19.496353}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.496353}, {'token': ' ', 'bytes': [32], 'logprob': -20.871353}, {'token': '0', 'bytes': [48], 'logprob': -21.183853}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -23.871353}, {'token': '-', 'bytes': [45], 'logprob': -24.058853}, {'token': '9', 'bytes': [57], 'logprob': -24.058853}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -24.183853}, {'token': 'C', 'bytes': [67], 'logprob': -24.308853}, {'token': '**', 'bytes': [42, 42], 'logprob': -24.371353}, {'token': '\n\n', 'bytes': [10, 10], 'logprob': -24.433853}, {'token': '.', 'bytes': [46], 'logprob': -24.496353}]",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.3953455}, {'token': '4', 'bytes': [52], 'logprob': -1.3953454}, {'token': '2', 'bytes': [50], 'logprob': -2.7703454}, {'token': '5', 'bytes': [53], 'logprob': -4.1453457}, {'token': '6', 'bytes': [54], 'logprob': -8.270346}, {'token': '1', 'bytes': [49], 'logprob': -9.645346}, {'token': '7', 'bytes': [55], 'logprob': -12.270346}, {'token': '0', 'bytes': [48], 'logprob': -13.395346}, {'token': '8', 'bytes': [56], 'logprob': -17.520346}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.895346}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.395346}, {'token': ' ', 'bytes': [32], 'logprob': -19.207846}, {'token': '9', 'bytes': [57], 'logprob': -19.957846}, {'token': '-', 'bytes': [45], 'logprob': -21.707846}, {'token': 'I', 'bytes': [73], 'logprob': -21.832846}, {'token': '.', 'bytes': [46], 'logprob': -22.520346}, {'token': '30', 'bytes': [51, 48], 'logprob': -22.645346}, {'token': '03', 'bytes': [48, 51], 'logprob': -22.645346}, {'token': '04', 'bytes': [48, 52], 'logprob': -22.770346}, {'token': 'C', 'bytes': [67], 'logprob': -22.895346}]",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.4864311}, {'token': '4', 'bytes': [52], 'logprob': -1.4864311}, {'token': '2', 'bytes': [50], 'logprob': -1.9864311}, {'token': '5', 'bytes': [53], 'logprob': -3.8614311}, {'token': '6', 'bytes': [54], 'logprob': -7.736431}, {'token': '1', 'bytes': [49], 'logprob': -8.111431}, {'token': '0', 'bytes': [48], 'logprob': -10.111431}, {'token': '7', 'bytes': [55], 'logprob': -12.111431}, {'token': '8', 'bytes': [56], 'logprob': -16.361431}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.236431}, {'token': ' ', 'bytes': [32], 'logprob': -18.111431}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.236431}, {'token': '9', 'bytes': [57], 'logprob': -18.361431}, {'token': 'I', 'bytes': [73], 'logprob': -20.673931}, {'token': '-', 'bytes': [45], 'logprob': -20.923931}, {'token': '10', 'bytes': [49, 48], 'logprob': -21.548931}, {'token': 'D', 'bytes': [68], 'logprob': -21.736431}, {'token': '04', 'bytes': [48, 52], 'logprob': -21.736431}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.798931}, {'token': 'C', 'bytes': [67], 'logprob': -21.861431}]"
27,11261827,Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer,Breast Cancer Res Treat,"Purpose:
Efficacy and safety of treatment A was compared with comparator B in a group of postmenopausal women with advanced breast cancer, without previous systemic therapy for advanced breast cancer.
Methods and materials:
The study was a prospective double‐blind randomized trial. All treated patients presented with positive estrogen receptors. Main end points were response rates, toxicity profile analysis, time to progression and survival. WHO and ECOG criteria were employed for response evaluation while toxicity was assessed according to WHO guidelines. Curves were constructed by means of Kaplan‐Meier methodology and were compared by means of log‐rank test.
Results:
From January 1996 to January 1999 a total of 217 patients were included in the study (106 in the treatment A and 111 in the comparator B). Both groups of patients were homogeneous regarding the main prognostic factors. A response rate of 64% (68/106) was observed in the treatment A group as compared with a 52% (58/111) in the comparator B group. Median times to progression and overall survival were not significantly different. A lower incidence of undesirable effects was appreciated in the treatment A arm.
Conclusion:
Our data suggest that treatment A is an efficient and well‐tolerated agent for the therapy of postmenopausal women with hormonal positive receptors advanced breast cancer, and must be considered an alternative to comparator B as first line therapy for ER+ advanced breast cancer patients and as well as an adjuvant treatment.",spin,"The passage is about a study that compared two different treatments for women with advanced breast cancer who had not been treated before. The study was done in a group of women who had a hormone called estrogen receptor in their cancer cells. The two treatments were compared to see which one worked better and was safer. The study found that the first treatment was more effective in stopping the cancer from growing, but it had fewer side effects. So, the first treatment is a good option for women with advanced breast cancer who have hormone receptors in their cancer cells.",8,8,"[{'token': '8', 'bytes': [56], 'logprob': -0.16023053}, {'token': '7', 'bytes': [55], 'logprob': -1.9102305}, {'token': '9', 'bytes': [57], 'logprob': -12.035231}, {'token': '6', 'bytes': [54], 'logprob': -14.410231}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -17.28523}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -17.66023}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -17.78523}, {'token': 'Eight', 'bytes': [69, 105, 103, 104, 116], 'logprob': -18.66023}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -19.28523}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -19.41023}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -19.59773}, {'token': ' Eight', 'bytes': [32, 69, 105, 103, 104, 116], 'logprob': -19.84773}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -20.16023}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.22273}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -20.22273}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.47273}, {'token': ' ocho', 'bytes': [32, 111, 99, 104, 111], 'logprob': -21.03523}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -21.34773}, {'token': '-eight', 'bytes': [45, 101, 105, 103, 104, 116], 'logprob': -21.34773}, {'token': ' вось', 'bytes': [32, 208, 178, 208, 190, 209, 129, 209, 140], 'logprob': -21.59773}]",8,8,"[{'token': '8', 'bytes': [56], 'logprob': -0.16042092}, {'token': '7', 'bytes': [55], 'logprob': -1.9104209}, {'token': '9', 'bytes': [57], 'logprob': -8.660421}, {'token': '6', 'bytes': [54], 'logprob': -10.660421}, {'token': '5', 'bytes': [53], 'logprob': -17.535421}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.910421}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.910421}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -18.972921}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -19.347921}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -19.410421}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -19.597921}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -20.285421}, {'token': 'Eight', 'bytes': [69, 105, 103, 104, 116], 'logprob': -20.847921}, {'token': ' ', 'bytes': [32], 'logprob': -20.910421}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -21.410421}, {'token': '85', 'bytes': [56, 53], 'logprob': -21.785421}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -21.972921}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.097921}, {'token': '82', 'bytes': [56, 50], 'logprob': -22.097921}, {'token': '820', 'bytes': [56, 50, 48], 'logprob': -22.160421}]",8,8,"[{'token': '8', 'bytes': [56], 'logprob': -0.22578393}, {'token': '7', 'bytes': [55], 'logprob': -1.600784}, {'token': '9', 'bytes': [57], 'logprob': -8.100784}, {'token': '6', 'bytes': [54], 'logprob': -9.600784}, {'token': '5', 'bytes': [53], 'logprob': -15.600784}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -15.975784}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.288284}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -18.725784}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -18.788284}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -19.038284}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -19.163284}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -19.600784}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -20.350784}, {'token': 'I', 'bytes': [73], 'logprob': -20.725784}, {'token': 'Eight', 'bytes': [69, 105, 103, 104, 116], 'logprob': -20.850784}, {'token': '10', 'bytes': [49, 48], 'logprob': -20.913284}, {'token': '4', 'bytes': [52], 'logprob': -20.975784}, {'token': 'Rating', 'bytes': [82, 97, 116, 105, 110, 103], 'logprob': -21.038284}, {'token': ' Score', 'bytes': [32, 83, 99, 111, 114, 101], 'logprob': -21.163284}, {'token': ' ', 'bytes': [32], 'logprob': -21.350784}]",8,8,"[{'token': '8', 'bytes': [56], 'logprob': -0.06237891}, {'token': '7', 'bytes': [55], 'logprob': -2.812379}, {'token': '9', 'bytes': [57], 'logprob': -7.812379}, {'token': '6', 'bytes': [54], 'logprob': -11.937379}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -17.43738}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -18.68738}, {'token': '5', 'bytes': [53], 'logprob': -18.81238}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -18.81238}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -19.31238}, {'token': 'Eight', 'bytes': [69, 105, 103, 104, 116], 'logprob': -20.31238}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -20.49988}, {'token': ' вось', 'bytes': [32, 208, 178, 208, 190, 209, 129, 209, 140], 'logprob': -20.49988}, {'token': '10', 'bytes': [49, 48], 'logprob': -20.62488}, {'token': ' ocho', 'bytes': [32, 111, 99, 104, 111], 'logprob': -20.68738}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.18738}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -21.24988}, {'token': ' acht', 'bytes': [32, 97, 99, 104, 116], 'logprob': -21.37488}, {'token': ' Eight', 'bytes': [32, 69, 105, 103, 104, 116], 'logprob': -21.37488}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -21.68738}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -21.87488}]",8,8,"[{'token': '8', 'bytes': [56], 'logprob': -0.048876774}, {'token': '7', 'bytes': [55], 'logprob': -3.0488768}, {'token': '9', 'bytes': [57], 'logprob': -8.173877}, {'token': '6', 'bytes': [54], 'logprob': -11.798877}, {'token': '5', 'bytes': [53], 'logprob': -19.048878}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -20.298878}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -20.298878}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.673878}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -20.923878}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.236378}, {'token': '10', 'bytes': [49, 48], 'logprob': -21.673878}, {'token': 'Eight', 'bytes': [69, 105, 103, 104, 116], 'logprob': -21.861378}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -22.173878}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -22.173878}, {'token': ' вось', 'bytes': [32, 208, 178, 208, 190, 209, 129, 209, 140], 'logprob': -22.611378}, {'token': ' ocho', 'bytes': [32, 111, 99, 104, 111], 'logprob': -22.861378}, {'token': 'I', 'bytes': [73], 'logprob': -23.236378}, {'token': ' Eight', 'bytes': [32, 69, 105, 103, 104, 116], 'logprob': -23.236378}, {'token': '4', 'bytes': [52], 'logprob': -23.486378}, {'token': '۸', 'bytes': [219, 184], 'logprob': -23.611378}]"
28,11261827,Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer,Breast Cancer Res Treat,"Purpose:
Efficacy and safety of treatment A was compared with comparator B in a group of postmenopausal women with advanced breast cancer, without previous systemic therapy for advanced breast cancer.
Methods and materials:
The study was a prospective double‐blind randomized trial. All treated patients presented with positive estrogen receptors. Main end points were response rates, toxicity profile analysis, time to progression and survival. WHO and ECOG criteria were employed for response evaluation while toxicity was assessed according to WHO guidelines. Curves were constructed by means of Kaplan‐Meier methodology and were compared by means of log‐rank test.
Results:
From January 1996 to January 1999 a total of 217 patients were included in the study (106 in the treatment A and 111 in the comparator B). Both groups of patients were homogeneous regarding the main prognostic factors. Response rates were not statistically different between the two therapeutic arms. A response rate of 64% (68/106) was observed in the treatment A group as compared with a 52% (58/111) in the comparator B group. Median times to progression (hazard ratios (HR) = 1.016; 95% CI 0.80‐1.32; p=0.823) and overall survival (HR = 0.97 (95% CI 0.74‐1.29; p=0.532) were not statistically significantly different. A lower incidence of undesirable effects was appreciated in the treatment A arm.
Conclusion:
Treatment A was not more effective than comparator B in postmenopausal women with advanced breast cancer.",no_spin,"The passage is about a study that compared two different treatments for women with advanced breast cancer who had not received any treatment before. The study was done by randomly assigning the women to either treatment A or treatment B, and then comparing the results. The main goal of the study was to see if treatment A was better than treatment B in terms of how well it worked and how safe it was. The study found that the two treatments were not very different in terms of how well they worked, but that treatment A had fewer bad side effects. So, the conclusion is that treatment A was not better than treatment B for women with advanced breast cancer.",4,4,"[{'token': '4', 'bytes': [52], 'logprob': -0.40414178}, {'token': '3', 'bytes': [51], 'logprob': -1.1541418}, {'token': '5', 'bytes': [53], 'logprob': -4.279142}, {'token': '2', 'bytes': [50], 'logprob': -5.779142}, {'token': '6', 'bytes': [54], 'logprob': -8.654141}, {'token': '1', 'bytes': [49], 'logprob': -13.279141}, {'token': '7', 'bytes': [55], 'logprob': -14.654141}, {'token': '0', 'bytes': [48], 'logprob': -17.279142}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.279142}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.904142}, {'token': ' ', 'bytes': [32], 'logprob': -19.091642}, {'token': '8', 'bytes': [56], 'logprob': -21.154142}, {'token': '-', 'bytes': [45], 'logprob': -21.404142}, {'token': 'C', 'bytes': [67], 'logprob': -21.529142}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.904142}, {'token': 'I', 'bytes': [73], 'logprob': -22.029142}, {'token': '30', 'bytes': [51, 48], 'logprob': -22.279142}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.279142}, {'token': 'Three', 'bytes': [84, 104, 114, 101, 101], 'logprob': -22.279142}, {'token': '04', 'bytes': [48, 52], 'logprob': -22.341642}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.11687382}, {'token': '6', 'bytes': [54], 'logprob': -2.3668737}, {'token': '8', 'bytes': [56], 'logprob': -4.1168737}, {'token': '5', 'bytes': [53], 'logprob': -8.366874}, {'token': '9', 'bytes': [57], 'logprob': -13.866874}, {'token': '4', 'bytes': [52], 'logprob': -14.991874}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.116875}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -19.116875}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -19.241875}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.366875}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -20.304375}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -20.554375}, {'token': '3', 'bytes': [51], 'logprob': -20.616875}, {'token': ' ', 'bytes': [32], 'logprob': -20.741875}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -20.866875}, {'token': 'C', 'bytes': [67], 'logprob': -21.804375}, {'token': '70', 'bytes': [55, 48], 'logprob': -21.929375}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -22.054375}, {'token': '七', 'bytes': [228, 184, 131], 'logprob': -22.304375}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -22.429375}]",5,5,"[{'token': '5', 'bytes': [53], 'logprob': -0.50423115}, {'token': '4', 'bytes': [52], 'logprob': -1.2542312}, {'token': '6', 'bytes': [54], 'logprob': -2.2542312}, {'token': '3', 'bytes': [51], 'logprob': -5.379231}, {'token': '7', 'bytes': [55], 'logprob': -6.754231}, {'token': '2', 'bytes': [50], 'logprob': -12.629231}, {'token': '8', 'bytes': [56], 'logprob': -15.004231}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.25423}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.87923}, {'token': ' ', 'bytes': [32], 'logprob': -19.06673}, {'token': '1', 'bytes': [49], 'logprob': -19.19173}, {'token': '9', 'bytes': [57], 'logprob': -20.25423}, {'token': '0', 'bytes': [48], 'logprob': -21.62923}, {'token': 'C', 'bytes': [67], 'logprob': -21.94173}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.44173}, {'token': '-', 'bytes': [45], 'logprob': -22.50423}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.62923}, {'token': '**', 'bytes': [42, 42], 'logprob': -22.69173}, {'token': 'I', 'bytes': [73], 'logprob': -22.69173}, {'token': 'Rating', 'bytes': [82, 97, 116, 105, 110, 103], 'logprob': -22.75423}]",4,4,"[{'token': '4', 'bytes': [52], 'logprob': -0.31859186}, {'token': '3', 'bytes': [51], 'logprob': -1.5685918}, {'token': '5', 'bytes': [53], 'logprob': -2.8185918}, {'token': '2', 'bytes': [50], 'logprob': -5.568592}, {'token': '6', 'bytes': [54], 'logprob': -6.943592}, {'token': '7', 'bytes': [55], 'logprob': -10.943592}, {'token': '1', 'bytes': [49], 'logprob': -13.818592}, {'token': '0', 'bytes': [48], 'logprob': -16.318592}, {'token': '8', 'bytes': [56], 'logprob': -17.193592}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.318592}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.318592}, {'token': ' ', 'bytes': [32], 'logprob': -20.006092}, {'token': '9', 'bytes': [57], 'logprob': -20.631092}, {'token': '４', 'bytes': [239, 188, 148], 'logprob': -21.943592}, {'token': 'I', 'bytes': [73], 'logprob': -22.068592}, {'token': '-', 'bytes': [45], 'logprob': -22.131092}, {'token': '04', 'bytes': [48, 52], 'logprob': -22.318592}, {'token': 'C', 'bytes': [67], 'logprob': -22.443592}, {'token': '.', 'bytes': [46], 'logprob': -22.443592}, {'token': 'D', 'bytes': [68], 'logprob': -22.756092}]",4,4,"[{'token': '4', 'bytes': [52], 'logprob': -0.48292816}, {'token': '5', 'bytes': [53], 'logprob': -1.2329282}, {'token': '3', 'bytes': [51], 'logprob': -2.6079283}, {'token': '6', 'bytes': [54], 'logprob': -4.1079283}, {'token': '2', 'bytes': [50], 'logprob': -6.7329283}, {'token': '7', 'bytes': [55], 'logprob': -8.232928}, {'token': '1', 'bytes': [49], 'logprob': -13.482928}, {'token': '8', 'bytes': [56], 'logprob': -14.482928}, {'token': '0', 'bytes': [48], 'logprob': -15.482928}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.982927}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.107927}, {'token': '9', 'bytes': [57], 'logprob': -18.545427}, {'token': ' ', 'bytes': [32], 'logprob': -19.045427}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.920427}, {'token': 'I', 'bytes': [73], 'logprob': -21.982927}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.982927}, {'token': '-', 'bytes': [45], 'logprob': -22.170427}, {'token': 'C', 'bytes': [67], 'logprob': -22.170427}, {'token': '04', 'bytes': [48, 52], 'logprob': -22.545427}, {'token': '.', 'bytes': [46], 'logprob': -22.670427}]"
34,12177098,"Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial",J Clin Oncol,"Purpose:
To compare the efficacy and tolerability of treatment A with comparator B in the treatment of advanced breast cancer in patients whose disease progresses on prior endocrine treatment.
Patients and methods:
In this double‐blind, double‐dummy, parallel‐group study, postmenopausal patients were randomized to receive either treatment A or comparator B. The primary end point was time to progression (TTP). Secondary end points included time to treatment failure (TTF), objective response (OR) rate, duration of response (DOR), and tolerability.
Results:
Patients (n = 400) were followed for a median period of 16.8 months. Treatment A was not more effective than comparator B in terms of TTP (hazard ratio, 0.92; 95% confidence interval [CI], 0.74 to 1.14; P =.43); median TTP was 5.4 months with treatment A and 3.4 months with comparator B. There was no statistically significant difference between the 2 groups for TTF. Median TTF was 4.6 months for treatment A and 3.3 months for comparator B (HR, 0.96; 95% CI, 0.77 to 1.19; P = .69). At the time of this data analysis, the rate of deaths was respectively for treatment A and comparator B, 35.4% (n=73) vs. 33.5% (n=65). OR rates were 17.5% with both treatments. DOR was statistically significantly greater for treatment A compared with comparator B; the ratio of average response durations was 1.35 (95% CI, 1.10 to 1.67; P < 0.01). Both treatments were well tolerated.
Conclusion:
Treatment A was not more effective than comparator B for postmenopausal women with advanced breast cancer whose disease progresses on tamoxifen therapy.",no_spin,"This passage is about a study that compared two different treatments for breast cancer in women who had already tried one treatment and their cancer came back. The study looked at how well each treatment worked and how well it was tolerated. The study found that the second treatment was not better than the first treatment in terms of how long the cancer did not grow back. However, the second treatment did work better in terms of how long the women's cancer responded to the treatment. Both treatments were also found to be well tolerated.",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.34976864}, {'token': '4', 'bytes': [52], 'logprob': -1.3497686}, {'token': '2', 'bytes': [50], 'logprob': -3.3497686}, {'token': '5', 'bytes': [53], 'logprob': -7.2247686}, {'token': '1', 'bytes': [49], 'logprob': -10.724769}, {'token': '6', 'bytes': [54], 'logprob': -12.099769}, {'token': '0', 'bytes': [48], 'logprob': -15.099769}, {'token': '7', 'bytes': [55], 'logprob': -17.47477}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.22477}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.34977}, {'token': ' ', 'bytes': [32], 'logprob': -18.34977}, {'token': '-', 'bytes': [45], 'logprob': -21.53727}, {'token': '30', 'bytes': [51, 48], 'logprob': -21.97477}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.16227}, {'token': 'C', 'bytes': [67], 'logprob': -22.34977}, {'token': 'I', 'bytes': [73], 'logprob': -22.41227}, {'token': 'Three', 'bytes': [84, 104, 114, 101, 101], 'logprob': -22.53727}, {'token': '  ', 'bytes': [32, 32], 'logprob': -22.59977}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.66227}, {'token': '.', 'bytes': [46], 'logprob': -22.72477}]",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.32724288}, {'token': '7', 'bytes': [55], 'logprob': -1.3272429}, {'token': '5', 'bytes': [53], 'logprob': -4.327243}, {'token': '8', 'bytes': [56], 'logprob': -7.327243}, {'token': '4', 'bytes': [52], 'logprob': -10.702243}, {'token': '3', 'bytes': [51], 'logprob': -16.952244}, {'token': '9', 'bytes': [57], 'logprob': -19.327244}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -20.452244}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -21.077244}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.077244}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -21.702244}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -21.889744}, {'token': ' ', 'bytes': [32], 'logprob': -22.014744}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -22.389744}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -23.077244}, {'token': '2', 'bytes': [50], 'logprob': -23.139744}, {'token': ' seis', 'bytes': [32, 115, 101, 105, 115], 'logprob': -23.139744}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -23.327244}, {'token': 'C', 'bytes': [67], 'logprob': -23.764744}, {'token': '六', 'bytes': [229, 133, 173], 'logprob': -23.764744}]",4,4,"[{'token': '4', 'bytes': [52], 'logprob': -0.22810018}, {'token': '5', 'bytes': [53], 'logprob': -1.9781002}, {'token': '3', 'bytes': [51], 'logprob': -2.8531003}, {'token': '6', 'bytes': [54], 'logprob': -4.8531003}, {'token': '2', 'bytes': [50], 'logprob': -9.3531}, {'token': '7', 'bytes': [55], 'logprob': -9.6031}, {'token': '8', 'bytes': [56], 'logprob': -16.9781}, {'token': '1', 'bytes': [49], 'logprob': -17.1031}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.2281}, {'token': ' ', 'bytes': [32], 'logprob': -18.3531}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.3531}, {'token': '0', 'bytes': [48], 'logprob': -20.0406}, {'token': '9', 'bytes': [57], 'logprob': -20.8531}, {'token': 'C', 'bytes': [67], 'logprob': -21.9156}, {'token': '-', 'bytes': [45], 'logprob': -21.9781}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.2906}, {'token': '**', 'bytes': [42, 42], 'logprob': -22.4156}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.4781}, {'token': 'I', 'bytes': [73], 'logprob': -22.6031}, {'token': '.', 'bytes': [46], 'logprob': -22.7281}]",4,4,"[{'token': '4', 'bytes': [52], 'logprob': -0.43718234}, {'token': '3', 'bytes': [51], 'logprob': -1.1871823}, {'token': '5', 'bytes': [53], 'logprob': -3.1871824}, {'token': '2', 'bytes': [50], 'logprob': -4.9371824}, {'token': '6', 'bytes': [54], 'logprob': -7.4371824}, {'token': '7', 'bytes': [55], 'logprob': -11.312182}, {'token': '1', 'bytes': [49], 'logprob': -12.937182}, {'token': '0', 'bytes': [48], 'logprob': -15.312182}, {'token': '8', 'bytes': [56], 'logprob': -17.437181}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.812181}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.312181}, {'token': ' ', 'bytes': [32], 'logprob': -19.624681}, {'token': '9', 'bytes': [57], 'logprob': -20.499681}, {'token': '-', 'bytes': [45], 'logprob': -21.874681}, {'token': 'I', 'bytes': [73], 'logprob': -22.374681}, {'token': '４', 'bytes': [239, 188, 148], 'logprob': -22.437181}, {'token': '.', 'bytes': [46], 'logprob': -22.499681}, {'token': '04', 'bytes': [48, 52], 'logprob': -22.562181}, {'token': '30', 'bytes': [51, 48], 'logprob': -22.687181}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.812181}]",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.7434414}, {'token': '4', 'bytes': [52], 'logprob': -0.7434414}, {'token': '2', 'bytes': [50], 'logprob': -3.2434413}, {'token': '5', 'bytes': [53], 'logprob': -4.6184416}, {'token': '6', 'bytes': [54], 'logprob': -8.993442}, {'token': '1', 'bytes': [49], 'logprob': -10.618442}, {'token': '0', 'bytes': [48], 'logprob': -12.868442}, {'token': '7', 'bytes': [55], 'logprob': -13.368442}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.49344}, {'token': '8', 'bytes': [56], 'logprob': -18.61844}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.61844}, {'token': ' ', 'bytes': [32], 'logprob': -18.74344}, {'token': '9', 'bytes': [57], 'logprob': -20.43094}, {'token': '-', 'bytes': [45], 'logprob': -21.43094}, {'token': '04', 'bytes': [48, 52], 'logprob': -21.74344}, {'token': '03', 'bytes': [48, 51], 'logprob': -22.05594}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.05594}, {'token': 'I', 'bytes': [73], 'logprob': -22.11844}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.11844}, {'token': '30', 'bytes': [51, 48], 'logprob': -22.30594}]"
33,12177098,"Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial",J Clin Oncol,"Purpose:
To compare the efficacy and tolerability of treatment A with comparator B in the treatment of advanced breast cancer in patients whose disease progresses on prior endocrine treatment.
Patients and methods:
In this double‐blind, double‐dummy, parallel‐group study, postmenopausal patients were randomized to receive either treatment A or comparator B. The primary end point was time to progression (TTP). Secondary end points included objective response (OR) rate, duration of response (DOR), and tolerability.
Results:
Patients (n = 400) were followed for a median period of 16.8 months. Treatment A was as effective as comparator B in terms of TTP (hazard ratio, 0.92; 95% confidence interval [CI], 0.74 to 1.14; P =.43); median TTP was 5.4 months with treatment A and 3.4 months with comparator B. OR rates were 17.5% with both treatments. Clinical benefit rates (complete response + partial response + stable disease > or = 24 weeks) were 42.2% for treatment A and 36.1% for comparator B (95% CI, ‐4.00% to 16.41%; P =.26). In responding patients, median DOR (from randomization to progression) was 19.0 months for treatment A and 10.8 months for comparator B. Using all patients, DOR was significantly greater for treatment A compared with comparator B; the ratio of average response durations was 1.35 (95% CI, 1.10 to 1.67; P < 0.01). Both treatments were well tolerated.
Conclusion:
Treatment A was at least as effective as comparator B, with efficacy end points slightly favoring treatment A. Treatment A represents an additional treatment option for postmenopausal women with advanced breast cancer whose disease progresses on tamoxifen therapy.",spin,"This passage is about a study that compared two different treatments for advanced breast cancer in women who had already tried one treatment and their cancer came back. The study found that both treatments were effective, but one treatment was slightly better. This means that the women who got the better treatment lived longer without their cancer coming back. The study also found that both treatments were safe and well tolerated.",8,8,"[{'token': '8', 'bytes': [56], 'logprob': -0.47410285}, {'token': '7', 'bytes': [55], 'logprob': -0.97410285}, {'token': '6', 'bytes': [54], 'logprob': -10.849103}, {'token': '9', 'bytes': [57], 'logprob': -11.974103}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -17.099102}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -18.099102}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -18.724102}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -19.036602}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -19.286602}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -19.474102}, {'token': 'Eight', 'bytes': [69, 105, 103, 104, 116], 'logprob': -19.661602}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -19.724102}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -20.099102}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -20.536602}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.786602}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.849102}, {'token': ' Eight', 'bytes': [32, 69, 105, 103, 104, 116], 'logprob': -20.974102}, {'token': ' seventh', 'bytes': [32, 115, 101, 118, 101, 110, 116, 104], 'logprob': -21.286602}, {'token': ' ocho', 'bytes': [32, 111, 99, 104, 111], 'logprob': -21.536602}, {'token': '七', 'bytes': [228, 184, 131], 'logprob': -22.224102}]",8,8,"[{'token': '8', 'bytes': [56], 'logprob': -0.021437362}, {'token': '7', 'bytes': [55], 'logprob': -3.8964374}, {'token': '9', 'bytes': [57], 'logprob': -7.021437}, {'token': '6', 'bytes': [54], 'logprob': -12.896438}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.271437}, {'token': '5', 'bytes': [53], 'logprob': -19.208937}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -19.333937}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.521437}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -19.708937}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -19.771437}, {'token': '10', 'bytes': [49, 48], 'logprob': -20.333937}, {'token': 'Eight', 'bytes': [69, 105, 103, 104, 116], 'logprob': -21.146437}, {'token': ' ', 'bytes': [32], 'logprob': -21.333937}, {'token': '85', 'bytes': [56, 53], 'logprob': -21.771437}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -22.208937}, {'token': '820', 'bytes': [56, 50, 48], 'logprob': -22.333937}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -22.458937}, {'token': 'I', 'bytes': [73], 'logprob': -22.583937}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.583937}, {'token': '82', 'bytes': [56, 50], 'logprob': -22.583937}]",8,8,"[{'token': '8', 'bytes': [56], 'logprob': -0.10023795}, {'token': '7', 'bytes': [55], 'logprob': -2.3502378}, {'token': '9', 'bytes': [57], 'logprob': -10.475238}, {'token': '6', 'bytes': [54], 'logprob': -12.725238}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -19.600239}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -19.600239}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -19.975239}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -20.350239}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -21.162739}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -21.162739}, {'token': '5', 'bytes': [53], 'logprob': -21.787739}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.975239}, {'token': ' вось', 'bytes': [32, 208, 178, 208, 190, 209, 129, 209, 140], 'logprob': -22.037739}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -22.162739}, {'token': 'Eight', 'bytes': [69, 105, 103, 104, 116], 'logprob': -22.225239}, {'token': ' ocho', 'bytes': [32, 111, 99, 104, 111], 'logprob': -22.412739}, {'token': ' acht', 'bytes': [32, 97, 99, 104, 116], 'logprob': -22.600239}, {'token': ' Eight', 'bytes': [32, 69, 105, 103, 104, 116], 'logprob': -22.975239}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -23.037739}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -23.225239}]",8,8,"[{'token': '8', 'bytes': [56], 'logprob': -0.1603734}, {'token': '7', 'bytes': [55], 'logprob': -1.9103734}, {'token': '9', 'bytes': [57], 'logprob': -9.035374}, {'token': '6', 'bytes': [54], 'logprob': -10.410374}, {'token': '5', 'bytes': [53], 'logprob': -17.660374}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -18.910374}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -19.160374}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -19.847874}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -19.972874}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -20.160374}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.660374}, {'token': '10', 'bytes': [49, 48], 'logprob': -20.972874}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -21.222874}, {'token': 'Eight', 'bytes': [69, 105, 103, 104, 116], 'logprob': -21.347874}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -21.410374}, {'token': ' вось', 'bytes': [32, 208, 178, 208, 190, 209, 129, 209, 140], 'logprob': -21.472874}, {'token': ' ocho', 'bytes': [32, 111, 99, 104, 111], 'logprob': -21.535374}, {'token': ' Eight', 'bytes': [32, 69, 105, 103, 104, 116], 'logprob': -22.097874}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -22.160374}, {'token': ' acht', 'bytes': [32, 97, 99, 104, 116], 'logprob': -22.222874}]",8,8,"[{'token': '8', 'bytes': [56], 'logprob': -0.252137}, {'token': '7', 'bytes': [55], 'logprob': -1.502137}, {'token': '6', 'bytes': [54], 'logprob': -9.002137}, {'token': '9', 'bytes': [57], 'logprob': -9.377137}, {'token': '5', 'bytes': [53], 'logprob': -16.502136}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.502136}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -20.689636}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -20.877136}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -21.064636}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -21.064636}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -21.314636}, {'token': '10', 'bytes': [49, 48], 'logprob': -21.439636}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.502136}, {'token': 'Eight', 'bytes': [69, 105, 103, 104, 116], 'logprob': -22.064636}, {'token': '4', 'bytes': [52], 'logprob': -22.252136}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -22.627136}, {'token': 'I', 'bytes': [73], 'logprob': -22.939636}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -23.002136}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -23.064636}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -23.252136}]"
11,15947110,Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial,Endocr Relat Cancer,"This study was designed to address whether treatment A with chemotherapy provides additional activity compared with chemotherapy alone in breast cancer patients with operable or locally advanced disease. Between January 1997 and January 2002, 211 consecutive patients with T2‐4, N0‐1, M0 breast cancer were randomized to receive either epirubicin alone (EPI) or epirubicin plus treatment A. Ki67 expression was evaluated immunohistochemically in tumor specimens obtained before chemotherapy by incision biopsy and at definitive surgery. Tumor shrinkage of >50% was obtained in 76% of patients randomized in the EPI arm and 81.9% of patients randomized in the EPI+treatment A arm (not significant). The corresponding rates of clinical and pathological complete response were 20.2 and 21.9% (not significant), and 4.8 and 6.7% (not significant), respectively. Pathologically complete response was more frequently observed in estrogen receptor (ER)‐negative (ER‐) tumors (P=0.04) and correlated with elevated baseline Ki67 expression (P<0.01). Both EPI treatment and EPI+treatment A resulted in a significant reduction in Ki67 expression, either in overall patients (P=0.000) or in patients with ER+ breast cancer (P=0.000). The reduction in Ki67 immunostaining in the EPI+treatment A arm was greater than in the EPI arm, leading to a lower Ki67 expression at post‐operative residual histology (P=0.0041). The addition of treatment A to epirubicin chemotherapy did not improve the response rate but led to a significantly higher reduction in the Ki67 expression. Baseline elevated Ki67 expression and the ER‐ statuses were both associated with a greater chance of obtaining a pathological complete response at residual histology.",spin,"This study was done to see if adding a special treatment to chemotherapy would help breast cancer patients better. They took 211 patients with a certain type of breast cancer and gave them either chemotherapy alone or chemotherapy with the special treatment. They looked at how much the tumors shrank and if the patients had a complete response to the treatment. They also looked at how much the special treatment reduced a protein called Ki67, which is often found in breast cancer. They found that the special treatment did not improve the response rate, but it did reduce Ki67 expression more than chemotherapy alone. This means that the special treatment might be helpful in reducing the amount of cancer cells in the body.",5,5,"[{'token': '5', 'bytes': [53], 'logprob': -0.7138134}, {'token': '6', 'bytes': [54], 'logprob': -0.7138134}, {'token': '4', 'bytes': [52], 'logprob': -3.9638133}, {'token': '7', 'bytes': [55], 'logprob': -6.5888133}, {'token': '3', 'bytes': [51], 'logprob': -9.338814}, {'token': '2', 'bytes': [50], 'logprob': -16.588814}, {'token': '8', 'bytes': [56], 'logprob': -17.588814}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.713814}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.901314}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -21.338814}, {'token': ' five', 'bytes': [32, 102, 105, 118, 101], 'logprob': -22.338814}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -22.838814}, {'token': ' ', 'bytes': [32], 'logprob': -23.026314}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -23.088814}, {'token': 'Five', 'bytes': [70, 105, 118, 101], 'logprob': -23.213814}, {'token': 'C', 'bytes': [67], 'logprob': -23.276314}, {'token': '５', 'bytes': [239, 188, 149], 'logprob': -23.338814}, {'token': ' seis', 'bytes': [32, 115, 101, 105, 115], 'logprob': -23.338814}, {'token': '六', 'bytes': [229, 133, 173], 'logprob': -23.463814}, {'token': 'five', 'bytes': [102, 105, 118, 101], 'logprob': -23.588814}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.20432247}, {'token': '6', 'bytes': [54], 'logprob': -1.7043225}, {'token': '8', 'bytes': [56], 'logprob': -5.9543223}, {'token': '5', 'bytes': [53], 'logprob': -8.079323}, {'token': '4', 'bytes': [52], 'logprob': -14.704323}, {'token': '9', 'bytes': [57], 'logprob': -15.954323}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.329323}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.266823}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -19.454323}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -19.579323}, {'token': '3', 'bytes': [51], 'logprob': -20.329323}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -20.391823}, {'token': ' ', 'bytes': [32], 'logprob': -20.704323}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -20.829323}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -21.016823}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -21.766823}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.079323}, {'token': 'C', 'bytes': [67], 'logprob': -22.329323}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -22.579323}, {'token': '-', 'bytes': [45], 'logprob': -22.641823}]",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.48216736}, {'token': '7', 'bytes': [55], 'logprob': -0.98216736}, {'token': '5', 'bytes': [53], 'logprob': -4.8571672}, {'token': '8', 'bytes': [56], 'logprob': -8.232167}, {'token': '4', 'bytes': [52], 'logprob': -10.857167}, {'token': '3', 'bytes': [51], 'logprob': -16.857168}, {'token': '9', 'bytes': [57], 'logprob': -17.482168}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.732168}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.544668}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -20.419668}, {'token': ' ', 'bytes': [32], 'logprob': -20.732168}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -21.044668}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -21.607168}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -21.607168}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -22.357168}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.544668}, {'token': '2', 'bytes': [50], 'logprob': -22.669668}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -22.732168}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -22.982168}, {'token': '-', 'bytes': [45], 'logprob': -23.044668}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.17358808}, {'token': '6', 'bytes': [54], 'logprob': -1.923588}, {'token': '8', 'bytes': [56], 'logprob': -4.7985883}, {'token': '5', 'bytes': [53], 'logprob': -5.2985883}, {'token': '4', 'bytes': [52], 'logprob': -10.298588}, {'token': '9', 'bytes': [57], 'logprob': -13.923588}, {'token': '3', 'bytes': [51], 'logprob': -14.798588}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.236088}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.673588}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -18.923588}, {'token': '2', 'bytes': [50], 'logprob': -19.486088}, {'token': '70', 'bytes': [55, 48], 'logprob': -20.298588}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -21.111088}, {'token': '75', 'bytes': [55, 53], 'logprob': -21.173588}, {'token': ' ', 'bytes': [32], 'logprob': -21.236088}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -21.361088}, {'token': '68', 'bytes': [54, 56], 'logprob': -21.611088}, {'token': 'I', 'bytes': [73], 'logprob': -21.673588}, {'token': '65', 'bytes': [54, 53], 'logprob': -21.923588}, {'token': '1', 'bytes': [49], 'logprob': -22.361088}]",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.52581275}, {'token': '7', 'bytes': [55], 'logprob': -1.0258127}, {'token': '5', 'bytes': [53], 'logprob': -3.0258126}, {'token': '4', 'bytes': [52], 'logprob': -6.9008126}, {'token': '8', 'bytes': [56], 'logprob': -7.0258126}, {'token': '3', 'bytes': [51], 'logprob': -12.025813}, {'token': '9', 'bytes': [57], 'logprob': -15.275813}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.525812}, {'token': '2', 'bytes': [50], 'logprob': -17.275812}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.775812}, {'token': ' ', 'bytes': [32], 'logprob': -20.275812}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -20.900812}, {'token': 'I', 'bytes': [73], 'logprob': -21.025812}, {'token': '1', 'bytes': [49], 'logprob': -21.213312}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -21.338312}, {'token': '70', 'bytes': [55, 48], 'logprob': -21.463312}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.775812}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.150812}, {'token': 'C', 'bytes': [67], 'logprob': -22.275812}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -22.525812}]"
12,15947110,Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial,Endocr Relat Cancer,"This study was designed to address whether treatment A with chemotherapy provides additional activity compared with chemotherapy alone in breast cancer patients with operable or locally advanced disease. Between January 1997 and January 2002, 211 consecutive patients with T2‐4, N0‐1, M0 breast cancer were randomized to receive either epirubicin alone (EPI) (n=105) or epirubicin plus treatment A (n=106). The primary outcome was the overall response rate. Overall, 198 patients received the planned chemotherapy dose (99 patients (94.2%) in the EPI arm and 99 patients (93.4%) in the EPI+treatment A arm). There was no statistically significant difference in overall response rate between the two treatment arms (76 versus 82% in the EPI and EPI+treatment A arms respectively). Pathological complete response was documented respectively in EPI and EPI+treatment A in 5 (4.8%) and 7 (6.7%) patients, and respectively 3 (2.9%) and 6 (5.7%) patients had carcinoma in situ. Toxicity did not differ from that expected with epirubicin. Leukopenia was the most relevant side effect, with about 50% of patients experiencing grade III‐IV toxicity in both arms. Platelet toxicity was uncommon and mild. Grade II‐III hemoglobin was observed in 15% of patients. Diarrhea and mucositis from mild to moderate occurred in 10% of patients. Acute cardiac toxicity was absent in both arms. All these side effects, attributable to epirubicin, were equally distributed in both arms. Treatment A with chemotherapy was not more effective than chemotherapy alone in breast cancer patients with operable or locally advanced disease.",no_spin,"This study was done to see if adding treatment A to chemotherapy would help more people with breast cancer. They took 211 patients with a certain type of breast cancer and gave them either chemotherapy alone or chemotherapy with treatment A. They looked at how many people responded to the treatment and how many had a complete response. They also looked at how many people had side effects. In the end, they found that adding treatment A to chemotherapy did not make a difference in how well people responded to the treatment.",2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.17242154}, {'token': '1', 'bytes': [49], 'logprob': -1.9224216}, {'token': '3', 'bytes': [51], 'logprob': -5.0474215}, {'token': '0', 'bytes': [48], 'logprob': -5.1724215}, {'token': '4', 'bytes': [52], 'logprob': -10.547421}, {'token': '5', 'bytes': [53], 'logprob': -15.547421}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.672422}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.672422}, {'token': ' ', 'bytes': [32], 'logprob': -18.797422}, {'token': '02', 'bytes': [48, 50], 'logprob': -19.047422}, {'token': '6', 'bytes': [54], 'logprob': -19.172422}, {'token': '01', 'bytes': [48, 49], 'logprob': -20.547422}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -20.609922}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -20.672422}, {'token': '-', 'bytes': [45], 'logprob': -20.922422}, {'token': 'I', 'bytes': [73], 'logprob': -20.984922}, {'token': '7', 'bytes': [55], 'logprob': -21.797422}, {'token': '30', 'bytes': [51, 48], 'logprob': -21.984922}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.984922}, {'token': '20', 'bytes': [50, 48], 'logprob': -22.047422}]",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.33700192}, {'token': '5', 'bytes': [53], 'logprob': -1.8370019}, {'token': '7', 'bytes': [55], 'logprob': -2.0870018}, {'token': '4', 'bytes': [52], 'logprob': -6.087002}, {'token': '8', 'bytes': [56], 'logprob': -7.712002}, {'token': '3', 'bytes': [51], 'logprob': -10.837002}, {'token': '9', 'bytes': [57], 'logprob': -15.462002}, {'token': '2', 'bytes': [50], 'logprob': -15.962002}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.337002}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.837002}, {'token': ' ', 'bytes': [32], 'logprob': -19.337002}, {'token': '1', 'bytes': [49], 'logprob': -20.649502}, {'token': 'C', 'bytes': [67], 'logprob': -20.712002}, {'token': '0', 'bytes': [48], 'logprob': -21.149502}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.337002}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.337002}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -21.399502}, {'token': 'I', 'bytes': [73], 'logprob': -21.837002}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -21.837002}, {'token': 'Rating', 'bytes': [82, 97, 116, 105, 110, 103], 'logprob': -21.899502}]",5,5,"[{'token': '5', 'bytes': [53], 'logprob': -0.72433156}, {'token': '4', 'bytes': [52], 'logprob': -0.97433156}, {'token': '3', 'bytes': [51], 'logprob': -2.4743316}, {'token': '6', 'bytes': [54], 'logprob': -2.9743316}, {'token': '7', 'bytes': [55], 'logprob': -6.4743314}, {'token': '2', 'bytes': [50], 'logprob': -6.8493314}, {'token': '8', 'bytes': [56], 'logprob': -13.349332}, {'token': '1', 'bytes': [49], 'logprob': -13.349332}, {'token': '0', 'bytes': [48], 'logprob': -16.09933}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.59933}, {'token': '9', 'bytes': [57], 'logprob': -18.22433}, {'token': ' ', 'bytes': [32], 'logprob': -18.34933}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.59933}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.41183}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.53683}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -21.78683}, {'token': '-', 'bytes': [45], 'logprob': -21.78683}, {'token': 'C', 'bytes': [67], 'logprob': -21.97433}, {'token': 'Rating', 'bytes': [82, 97, 116, 105, 110, 103], 'logprob': -22.16183}, {'token': '**', 'bytes': [42, 42], 'logprob': -22.22433}]",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.34066603}, {'token': '2', 'bytes': [50], 'logprob': -1.840666}, {'token': '4', 'bytes': [52], 'logprob': -2.090666}, {'token': '5', 'bytes': [53], 'logprob': -5.090666}, {'token': '1', 'bytes': [49], 'logprob': -8.715666}, {'token': '6', 'bytes': [54], 'logprob': -9.840666}, {'token': '0', 'bytes': [48], 'logprob': -11.090666}, {'token': '7', 'bytes': [55], 'logprob': -14.340666}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.965666}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.465666}, {'token': ' ', 'bytes': [32], 'logprob': -19.278166}, {'token': '8', 'bytes': [56], 'logprob': -19.465666}, {'token': '9', 'bytes': [57], 'logprob': -21.340666}, {'token': '30', 'bytes': [51, 48], 'logprob': -21.715666}, {'token': 'I', 'bytes': [73], 'logprob': -21.778166}, {'token': '-', 'bytes': [45], 'logprob': -21.778166}, {'token': '03', 'bytes': [48, 51], 'logprob': -22.028166}, {'token': '02', 'bytes': [48, 50], 'logprob': -22.153166}, {'token': '04', 'bytes': [48, 52], 'logprob': -22.403166}, {'token': '.', 'bytes': [46], 'logprob': -22.590666}]",2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.60339624}, {'token': '3', 'bytes': [51], 'logprob': -0.85339624}, {'token': '4', 'bytes': [52], 'logprob': -3.8533962}, {'token': '1', 'bytes': [49], 'logprob': -5.4783964}, {'token': '0', 'bytes': [48], 'logprob': -6.7283964}, {'token': '5', 'bytes': [53], 'logprob': -7.6033964}, {'token': '6', 'bytes': [54], 'logprob': -12.353396}, {'token': '7', 'bytes': [55], 'logprob': -16.478395}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.978395}, {'token': ' ', 'bytes': [32], 'logprob': -18.478395}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.478395}, {'token': '8', 'bytes': [56], 'logprob': -20.228395}, {'token': '02', 'bytes': [48, 50], 'logprob': -20.790895}, {'token': '9', 'bytes': [57], 'logprob': -21.103395}, {'token': '-', 'bytes': [45], 'logprob': -21.228395}, {'token': 'I', 'bytes': [73], 'logprob': -21.290895}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.353395}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.540895}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.665895}, {'token': '30', 'bytes': [51, 48], 'logprob': -21.790895}]"
19,16148021,"Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group",Ann Oncol,"Purpose:
The aim of this study was to explore the effect of dose‐dense sequential chemotherapy with or without treatment A primarily on disease‐free survival (DFS) and secondarily on overall survival (OS) in patients with high‐risk operable breast cancer.
Patients and methods:
From June 1997 until November 2000, 604 patients with T1‐3N1M0 or T3N0M0 tumors were randomized to three cycles of epirubicin 110 mg/m2 followed by three cycles of treatment A followed by three cycles of 'intensified' CMF (cyclophosphamide 840 mg/m2, methotrexate 47 mg/m2 and fluorouracil 840 mg/m2) (group A), or to four cycles of epirubicin followed by four cycles of CMF, as in group A (group B). All cycles were given every 2 weeks with granulocyte colony‐stimulating factor support.
Results:
A total of 595 patients were eligible. Median follow‐up was 61.7 months for group A and 62 months for group B. The 3‐year DFS was 80% in group A and 77% in group B. Survival rates were 93% and 90%, respectively. The effect of treatment on the hazard of death was different according to hormonal receptor status. More specifically, in patients with negative receptor status the hazard of death was significantly higher for group B (hazard ratio 2.42). Both regimens were well tolerated and severe acute side‐effects were infrequent. No cases of severe cardiotoxicity or acute leukemia were recorded.
Conclusion:
The present study failed to demonstrate a significant difference in DFS or OS between the two treatment groups. However, our study has shown clearly that treatment A can be safely incorporated to dose‐dense sequential chemotherapy.",spin,"This study was about doctors trying to figure out if a certain treatment would help people with a type of cancer called breast cancer. They gave the treatment to a group of people and then checked how long they lived and if the treatment helped them. They also looked at how well the treatment worked based on whether the cancer had a certain protein in it. The study showed that the treatment was safe and didn't cause many bad side effects, but it didn't seem to make a big difference in how long people lived.",5,5,"[{'token': '5', 'bytes': [53], 'logprob': -0.32812104}, {'token': '6', 'bytes': [54], 'logprob': -1.3281211}, {'token': '4', 'bytes': [52], 'logprob': -4.328121}, {'token': '7', 'bytes': [55], 'logprob': -6.578121}, {'token': '3', 'bytes': [51], 'logprob': -8.703121}, {'token': '2', 'bytes': [50], 'logprob': -14.578121}, {'token': '8', 'bytes': [56], 'logprob': -15.578121}, {'token': '1', 'bytes': [49], 'logprob': -20.453121}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.953121}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.578121}, {'token': ' ', 'bytes': [32], 'logprob': -23.015621}, {'token': 'C', 'bytes': [67], 'logprob': -23.328121}, {'token': 'Five', 'bytes': [70, 105, 118, 101], 'logprob': -23.640621}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -23.953121}, {'token': ' five', 'bytes': [32, 102, 105, 118, 101], 'logprob': -23.953121}, {'token': '0', 'bytes': [48], 'logprob': -24.390621}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -24.390621}, {'token': '9', 'bytes': [57], 'logprob': -24.453121}, {'token': '５', 'bytes': [239, 188, 149], 'logprob': -24.515621}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -24.765621}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.082688175}, {'token': '6', 'bytes': [54], 'logprob': -2.582688}, {'token': '8', 'bytes': [56], 'logprob': -5.5826883}, {'token': '5', 'bytes': [53], 'logprob': -10.457688}, {'token': '4', 'bytes': [52], 'logprob': -19.082687}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -19.332687}, {'token': '9', 'bytes': [57], 'logprob': -19.707687}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -20.457687}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -21.082687}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -21.832687}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -21.957687}, {'token': '<|end|>', 'bytes': None, 'logprob': -22.145187}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -22.332687}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -22.395187}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -22.645187}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -23.645187}, {'token': ' seis', 'bytes': [32, 115, 101, 105, 115], 'logprob': -23.707687}, {'token': '七', 'bytes': [228, 184, 131], 'logprob': -23.770187}, {'token': ' seventh', 'bytes': [32, 115, 101, 118, 101, 110, 116, 104], 'logprob': -23.770187}, {'token': ' ', 'bytes': [32], 'logprob': -23.832687}]",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.13649803}, {'token': '5', 'bytes': [53], 'logprob': -2.636498}, {'token': '7', 'bytes': [55], 'logprob': -2.886498}, {'token': '4', 'bytes': [52], 'logprob': -8.511498}, {'token': '8', 'bytes': [56], 'logprob': -11.761498}, {'token': '3', 'bytes': [51], 'logprob': -15.636498}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -18.886497}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -19.761497}, {'token': ' seis', 'bytes': [32, 115, 101, 105, 115], 'logprob': -20.698997}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -20.698997}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.136497}, {'token': '六', 'bytes': [229, 133, 173], 'logprob': -22.448997}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -22.448997}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -22.636497}, {'token': '2', 'bytes': [50], 'logprob': -22.698997}, {'token': ' five', 'bytes': [32, 102, 105, 118, 101], 'logprob': -22.698997}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -22.886497}, {'token': ' ', 'bytes': [32], 'logprob': -23.073997}, {'token': ' sei', 'bytes': [32, 115, 101, 105], 'logprob': -23.323997}, {'token': 'six', 'bytes': [115, 105, 120], 'logprob': -23.636497}]",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.6738402}, {'token': '7', 'bytes': [55], 'logprob': -0.9238402}, {'token': '5', 'bytes': [53], 'logprob': -2.4238403}, {'token': '8', 'bytes': [56], 'logprob': -5.54884}, {'token': '4', 'bytes': [52], 'logprob': -7.17384}, {'token': '3', 'bytes': [51], 'logprob': -10.7988405}, {'token': '9', 'bytes': [57], 'logprob': -13.4238405}, {'token': '2', 'bytes': [50], 'logprob': -15.6738405}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.54884}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -19.04884}, {'token': '1', 'bytes': [49], 'logprob': -19.54884}, {'token': ' ', 'bytes': [32], 'logprob': -20.54884}, {'token': '0', 'bytes': [48], 'logprob': -21.04884}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -21.17384}, {'token': '10', 'bytes': [49, 48], 'logprob': -21.29884}, {'token': 'I', 'bytes': [73], 'logprob': -21.54884}, {'token': '70', 'bytes': [55, 48], 'logprob': -21.86134}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -21.92384}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -22.54884}, {'token': 'C', 'bytes': [67], 'logprob': -22.73634}]",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.6452035}, {'token': '5', 'bytes': [53], 'logprob': -1.1452035}, {'token': '7', 'bytes': [55], 'logprob': -1.8952035}, {'token': '4', 'bytes': [52], 'logprob': -5.0202036}, {'token': '8', 'bytes': [56], 'logprob': -8.020204}, {'token': '3', 'bytes': [51], 'logprob': -9.645204}, {'token': '2', 'bytes': [50], 'logprob': -14.770204}, {'token': '9', 'bytes': [57], 'logprob': -15.520204}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.645203}, {'token': '1', 'bytes': [49], 'logprob': -18.895203}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.957703}, {'token': ' ', 'bytes': [32], 'logprob': -20.145203}, {'token': 'I', 'bytes': [73], 'logprob': -20.957703}, {'token': '0', 'bytes': [48], 'logprob': -21.020203}, {'token': 'C', 'bytes': [67], 'logprob': -21.770203}, {'token': '70', 'bytes': [55, 48], 'logprob': -21.957703}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -22.082703}, {'token': '10', 'bytes': [49, 48], 'logprob': -22.332703}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -22.457703}, {'token': 'D', 'bytes': [68], 'logprob': -22.832703}]"
20,16148021,"Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group",Ann Oncol,"Purpose:
The aim of this study was to explore the effect of dose‐dense sequential chemotherapy with or without treatment A primarily on disease‐free survival (DFS) and secondarily on overall survival (OS) in patients with high‐risk operable breast cancer.
Patients and methods:
From June 1997 until November 2000, 604 patients with T1‐3N1M0 or T3N0M0 tumors were randomized to three cycles of epirubicin 110 mg/m2 followed by three cycles of treatment A followed by three cycles of 'intensified' CMF (cyclophosphamide 840 mg/m2, methotrexate 47 mg/m2 and fluorouracil 840 mg/m2) (group A), or to four cycles of epirubicin followed by four cycles of CMF, as in group A (group B). All cycles were given every 2 weeks with granulocyte colony‐stimulating factor support.
Results:
A total of 595 patients were eligible. Median follow‐up was 61.7 months for group A and 62 months for group B. DFS and OS did not differ significantly between treatment groups (log‐rank P = 0.55 and P = 0.38, respectively). The 3‐year DFS was 80% in group A and 77% in group B. Survival rates were 93% and 90%, respectively. Comparison of quality of life outcomes between the two groups showed no statistically significant differences. Both regimens were well tolerated and severe acute side‐effects were infrequent. No cases of severe cardiotoxicity or acute leukemia were recorded.
Conclusion:
Treatment A with a dose‐dense sequential chemotherapy was not more effective than a dose‐dense sequential chemotherapy alone in patients with high‐risk operable breast cancer.",no_spin,This study was done to see if adding a special medicine called treatment A to a special kind of chemotherapy called dose‐dense sequential chemotherapy would help people with high‐risk operable breast cancer. The study used 604 patients who had a certain type of tumor and followed them for a long time to see if the treatment made a difference. The results showed that the treatment with treatment A did not make a big difference in how long people lived or how well they felt. The treatment was safe and had few bad side effects.,2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.77104473}, {'token': '3', 'bytes': [51], 'logprob': -0.77104473}, {'token': '4', 'bytes': [52], 'logprob': -2.6460447}, {'token': '1', 'bytes': [49], 'logprob': -5.8960447}, {'token': '5', 'bytes': [53], 'logprob': -6.7710447}, {'token': '0', 'bytes': [48], 'logprob': -9.146045}, {'token': '6', 'bytes': [54], 'logprob': -12.021045}, {'token': '7', 'bytes': [55], 'logprob': -16.396046}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.271046}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.521046}, {'token': ' ', 'bytes': [32], 'logprob': -18.146046}, {'token': '8', 'bytes': [56], 'logprob': -20.896046}, {'token': 'I', 'bytes': [73], 'logprob': -21.021046}, {'token': '-', 'bytes': [45], 'logprob': -21.083546}, {'token': '02', 'bytes': [48, 50], 'logprob': -21.083546}, {'token': 'C', 'bytes': [67], 'logprob': -21.208546}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.333546}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.458546}, {'token': '30', 'bytes': [51, 48], 'logprob': -21.646046}, {'token': '9', 'bytes': [57], 'logprob': -21.708546}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.262693}, {'token': '6', 'bytes': [54], 'logprob': -1.5126929}, {'token': '8', 'bytes': [56], 'logprob': -4.762693}, {'token': '5', 'bytes': [53], 'logprob': -6.137693}, {'token': '4', 'bytes': [52], 'logprob': -12.637693}, {'token': '9', 'bytes': [57], 'logprob': -14.512693}, {'token': '3', 'bytes': [51], 'logprob': -18.262693}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.887693}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.512693}, {'token': ' ', 'bytes': [32], 'logprob': -20.075193}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -20.325193}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -20.887693}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -21.387693}, {'token': 'C', 'bytes': [67], 'logprob': -21.575193}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -21.700193}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -22.137693}, {'token': '2', 'bytes': [50], 'logprob': -22.325193}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -22.387693}, {'token': '70', 'bytes': [55, 48], 'logprob': -22.450193}, {'token': 'I', 'bytes': [73], 'logprob': -22.700193}]",5,5,"[{'token': '5', 'bytes': [53], 'logprob': -0.5034676}, {'token': '6', 'bytes': [54], 'logprob': -1.0034676}, {'token': '4', 'bytes': [52], 'logprob': -3.7534676}, {'token': '7', 'bytes': [55], 'logprob': -5.2534676}, {'token': '3', 'bytes': [51], 'logprob': -8.128468}, {'token': '8', 'bytes': [56], 'logprob': -13.378468}, {'token': '2', 'bytes': [50], 'logprob': -14.253468}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -21.503468}, {'token': '1', 'bytes': [49], 'logprob': -21.878468}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.878468}, {'token': ' ', 'bytes': [32], 'logprob': -22.690968}, {'token': '9', 'bytes': [57], 'logprob': -23.128468}, {'token': '0', 'bytes': [48], 'logprob': -24.253468}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -24.753468}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -24.815968}, {'token': '５', 'bytes': [239, 188, 149], 'logprob': -25.003468}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -25.378468}, {'token': ' five', 'bytes': [32, 102, 105, 118, 101], 'logprob': -25.378468}, {'token': 'C', 'bytes': [67], 'logprob': -25.440968}, {'token': 'Five', 'bytes': [70, 105, 118, 101], 'logprob': -25.440968}]",4,4,"[{'token': '4', 'bytes': [52], 'logprob': -0.6035042}, {'token': '5', 'bytes': [53], 'logprob': -1.1035042}, {'token': '3', 'bytes': [51], 'logprob': -2.2285042}, {'token': '6', 'bytes': [54], 'logprob': -4.603504}, {'token': '2', 'bytes': [50], 'logprob': -5.728504}, {'token': '7', 'bytes': [55], 'logprob': -7.728504}, {'token': '1', 'bytes': [49], 'logprob': -12.853504}, {'token': '8', 'bytes': [56], 'logprob': -14.603504}, {'token': '0', 'bytes': [48], 'logprob': -15.103504}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.603504}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.853504}, {'token': '9', 'bytes': [57], 'logprob': -19.166004}, {'token': ' ', 'bytes': [32], 'logprob': -19.853504}, {'token': 'I', 'bytes': [73], 'logprob': -21.916004}, {'token': '-', 'bytes': [45], 'logprob': -21.978504}, {'token': 'C', 'bytes': [67], 'logprob': -22.166004}, {'token': '.', 'bytes': [46], 'logprob': -22.603504}, {'token': '30', 'bytes': [51, 48], 'logprob': -23.103504}, {'token': '４', 'bytes': [239, 188, 148], 'logprob': -23.103504}, {'token': 'D', 'bytes': [68], 'logprob': -23.103504}]",4,4,"[{'token': '4', 'bytes': [52], 'logprob': -0.69989365}, {'token': '5', 'bytes': [53], 'logprob': -1.1998937}, {'token': '3', 'bytes': [51], 'logprob': -1.6998937}, {'token': '2', 'bytes': [50], 'logprob': -4.1998935}, {'token': '6', 'bytes': [54], 'logprob': -5.4498935}, {'token': '7', 'bytes': [55], 'logprob': -9.449894}, {'token': '1', 'bytes': [49], 'logprob': -9.949894}, {'token': '0', 'bytes': [48], 'logprob': -11.324894}, {'token': '8', 'bytes': [56], 'logprob': -15.074894}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.824894}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.449894}, {'token': '9', 'bytes': [57], 'logprob': -18.574894}, {'token': ' ', 'bytes': [32], 'logprob': -18.824894}, {'token': 'I', 'bytes': [73], 'logprob': -21.324894}, {'token': '-', 'bytes': [45], 'logprob': -21.387394}, {'token': 'C', 'bytes': [67], 'logprob': -21.512394}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.012394}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.074894}, {'token': '/', 'bytes': [47], 'logprob': -22.324894}, {'token': 'D', 'bytes': [68], 'logprob': -22.324894}]"
51,16314619,Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases,J Clin Oncol,"Purpose:
To determine whether treatment A, improves survival in patients with brain metastases when used as an adjunct to whole‐brain radiation therapy (WBRT).
Patients and methods:
Patients with brain metastases from solid tumors and a Karnofsky performance score of > or = 70 were randomly assigned to receive WBRT with supplemental oxygen and either treatment A (treatment A arm) or no treatment (control arm). The primary end point was survival.
Results:
The study consisted of 515 eligible patients (treatment A arm, n = 265; control arm, n = 250). The median survival time (MST) was 5.4 months for the treatment A arm versus 4.4 months for the control arm (hazard ratio [HR] = 0.87; P = .16). For the subgroup of patients with non‐small‐cell lung cancer (NSCLC) or breast cancer, the MST was 6.0 and 4.4 months, respectively (HR = 0.82; P = .07). Cox multiple regression analysis demonstrated a significant reduction in the risk of death for the treatment A arm in both primary populations. Further analysis indicated that the benefit may be restricted to the subgroup of patients with breast cancer. Response rates (radiographic complete response plus partial response) improved by 7% (P = .10) and 13% (P = .01) for all patients and for NSCLC and breast cancer patients in the treatment A arm, respectively. The most common severe adverse event in patients treated with treatment A was hypoxemia, which was reversible and effectively managed with supplemental oxygen in most patients.
Conclusion:
The addition of treatment A to WBRT may improve response rates and survival in patients with brain metastases, particularly metastases from breast cancer. A confirmatory trial for breast cancer patients has been initiated.",spin,"The study was done to see if using treatment A along with radiation therapy to the brain would help people with brain tumors live longer. The study included 515 people with brain tumors from different types of cancer, and they were randomly assigned to either get radiation therapy with oxygen or no treatment at all. The researchers looked at how long people lived and how well their tumors responded to treatment. They found that people who got treatment A along with radiation therapy lived a little bit longer than those who only got radiation therapy. However, the difference wasn't very big. The researchers also found that the treatment might work better for people with breast cancer. They started another study to confirm this.",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.20226304}, {'token': '7', 'bytes': [55], 'logprob': -1.702263}, {'token': '5', 'bytes': [53], 'logprob': -7.077263}, {'token': '8', 'bytes': [56], 'logprob': -12.202263}, {'token': '4', 'bytes': [52], 'logprob': -15.077263}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -18.077263}, {'token': ' seis', 'bytes': [32, 115, 101, 105, 115], 'logprob': -19.764763}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -20.264763}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.389763}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.389763}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -20.702263}, {'token': '六', 'bytes': [229, 133, 173], 'logprob': -20.952263}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -21.014763}, {'token': '3', 'bytes': [51], 'logprob': -21.077263}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -21.327263}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -21.514763}, {'token': 'six', 'bytes': [115, 105, 120], 'logprob': -22.139763}, {'token': ' sei', 'bytes': [32, 115, 101, 105], 'logprob': -22.202263}, {'token': ' Six', 'bytes': [32, 83, 105, 120], 'logprob': -22.264763}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -22.327263}]",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.47678694}, {'token': '7', 'bytes': [55], 'logprob': -0.976787}, {'token': '5', 'bytes': [53], 'logprob': -5.976787}, {'token': '8', 'bytes': [56], 'logprob': -8.726787}, {'token': '4', 'bytes': [52], 'logprob': -11.851787}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.601788}, {'token': '9', 'bytes': [57], 'logprob': -18.476788}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.539288}, {'token': '3', 'bytes': [51], 'logprob': -18.664288}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -18.851788}, {'token': ' ', 'bytes': [32], 'logprob': -19.726788}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -20.289288}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -20.539288}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -20.664288}, {'token': 'C', 'bytes': [67], 'logprob': -21.226788}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -21.476788}, {'token': ' seis', 'bytes': [32, 115, 101, 105, 115], 'logprob': -21.539288}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -21.539288}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -21.789288}, {'token': '六', 'bytes': [229, 133, 173], 'logprob': -21.914288}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.029043581}, {'token': '6', 'bytes': [54], 'logprob': -3.7790437}, {'token': '8', 'bytes': [56], 'logprob': -5.1540437}, {'token': '5', 'bytes': [53], 'logprob': -12.154043}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -17.279043}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -18.404043}, {'token': '9', 'bytes': [57], 'logprob': -18.904043}, {'token': '4', 'bytes': [52], 'logprob': -19.154043}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -19.529043}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.404043}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -20.466543}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -20.591543}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -20.654043}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -20.841543}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.091543}, {'token': ' seventh', 'bytes': [32, 115, 101, 118, 101, 110, 116, 104], 'logprob': -21.779043}, {'token': '七', 'bytes': [228, 184, 131], 'logprob': -21.966543}, {'token': ' sieben', 'bytes': [32, 115, 105, 101, 98, 101, 110], 'logprob': -22.029043}, {'token': ' seis', 'bytes': [32, 115, 101, 105, 115], 'logprob': -22.091543}, {'token': '۷', 'bytes': [219, 183], 'logprob': -22.091543}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.20436095}, {'token': '8', 'bytes': [56], 'logprob': -1.704361}, {'token': '6', 'bytes': [54], 'logprob': -5.829361}, {'token': '5', 'bytes': [53], 'logprob': -13.329361}, {'token': '9', 'bytes': [57], 'logprob': -13.329361}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -18.204361}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -18.329361}, {'token': '4', 'bytes': [52], 'logprob': -19.391861}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.704361}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -19.766861}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -20.641861}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.954361}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -21.079361}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -21.079361}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -21.141861}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -21.204361}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -21.829361}, {'token': '七', 'bytes': [228, 184, 131], 'logprob': -21.891861}, {'token': '۷', 'bytes': [219, 183], 'logprob': -21.891861}, {'token': ' seventh', 'bytes': [32, 115, 101, 118, 101, 110, 116, 104], 'logprob': -22.079361}]",8,8,"[{'token': '8', 'bytes': [56], 'logprob': -0.10058253}, {'token': '7', 'bytes': [55], 'logprob': -2.3505826}, {'token': '9', 'bytes': [57], 'logprob': -7.9755826}, {'token': '6', 'bytes': [54], 'logprob': -10.350582}, {'token': '5', 'bytes': [53], 'logprob': -18.100582}, {'token': '10', 'bytes': [49, 48], 'logprob': -19.600582}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -20.600582}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -21.038082}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.475582}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -21.538082}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -21.725582}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -21.788082}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -22.225582}, {'token': 'Eight', 'bytes': [69, 105, 103, 104, 116], 'logprob': -22.725582}, {'token': '4', 'bytes': [52], 'logprob': -23.225582}, {'token': ' вось', 'bytes': [32, 208, 178, 208, 190, 209, 129, 209, 140], 'logprob': -23.288082}, {'token': ' ocho', 'bytes': [32, 111, 99, 104, 111], 'logprob': -23.850582}, {'token': ' ', 'bytes': [32], 'logprob': -23.975582}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -24.100582}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -24.100582}]"
52,16314619,Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases,J Clin Oncol,"Purpose:
To determine whether treatment A, improves survival in patients with brain metastases when used as an adjunct to whole‐brain radiation therapy (WBRT).
Patients and methods:
Patients with brain metastases from solid tumors and a Karnofsky performance score of > or = 70 were randomly assigned to receive WBRT with supplemental oxygen and either treatment A (treatment A arm) or no treatment (control arm). The primary end point was survival.
Results:
The study consisted of 515 eligible patients (treatment A arm, n = 265; control arm, n = 250). The median survival time (MST) was 5.4 months for the treatment A arm versus 4.4 months for the control arm (hazard ratio [HR] = 0.87; P = .16). There was no statistically significant difference between the 2 groups for response rate (complete plus partial response) (46% for the treatment A arm and 38% for the control arm; P = .10). There was not a statistically significant difference in the cumulative incidence at 1 year after random assignment of radiographic (21% treatment A vs. 18% control; p=0.53) or clinical progression (49% treatment A vs. 51% control; p = 0.49) in the brain between the treatment groups. At 6 months, respectively 16% and 15% of the patients had a stable or improving quality of life in treatment A arm and control arm. The most common severe adverse event in patients treated with treatment A was hypoxemia.
Conclusion:
The addition of treatment A to WBRT was not more effective than WBRT alone in patients with brain metastases.",no_spin,"The study was about whether a certain treatment (treatment A) helped people with brain tumors (brain metastases) live longer when used with a special kind of radiation therapy (whole-brain radiation therapy, or WBRT). The study included 515 people who had brain tumors and were able to do certain things (like walk and eat) well enough to be in the study.

The study found that the people who got treatment A along with WBRT lived for about the same amount of time as the people who got only WBRT (5.4 months versus 4.4 months). The study also looked at how well the treatment worked by checking how many people had their tumors shrink or disappear (complete plus partial response) and how many people had their tumors grow or spread (radiographic and clinical progression). The study found that there was no difference between the two groups for these things.

The study also looked at how well the treatment improved people's quality of life (how they felt and how well they could do things) at 6 months. The study found that about the same number of people in both groups had a stable or improving quality of life.

The most common severe side effect of the treatment was a low level of oxygen in the blood (hypoxemia).

Overall, the study found that adding treatment A to WBRT did not make",2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.04772409}, {'token': '3', 'bytes': [51], 'logprob': -3.297724}, {'token': '1', 'bytes': [49], 'logprob': -4.6727242}, {'token': '4', 'bytes': [52], 'logprob': -8.672724}, {'token': '0', 'bytes': [48], 'logprob': -9.047724}, {'token': '5', 'bytes': [53], 'logprob': -15.047724}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.922724}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.797724}, {'token': '6', 'bytes': [54], 'logprob': -19.172724}, {'token': ' ', 'bytes': [32], 'logprob': -19.172724}, {'token': '02', 'bytes': [48, 50], 'logprob': -19.797724}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.735224}, {'token': '-', 'bytes': [45], 'logprob': -21.922724}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.985224}, {'token': '30', 'bytes': [51, 48], 'logprob': -22.360224}, {'token': 'I', 'bytes': [73], 'logprob': -22.422724}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.485224}, {'token': '01', 'bytes': [48, 49], 'logprob': -22.985224}, {'token': '.', 'bytes': [46], 'logprob': -23.110224}, {'token': '7', 'bytes': [55], 'logprob': -23.110224}]",5,5,"[{'token': '5', 'bytes': [53], 'logprob': -0.50868833}, {'token': '4', 'bytes': [52], 'logprob': -1.5086883}, {'token': '6', 'bytes': [54], 'logprob': -1.7586883}, {'token': '7', 'bytes': [55], 'logprob': -5.8836884}, {'token': '3', 'bytes': [51], 'logprob': -6.0086884}, {'token': '2', 'bytes': [50], 'logprob': -12.883688}, {'token': '8', 'bytes': [56], 'logprob': -13.508688}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.008688}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.071188}, {'token': ' ', 'bytes': [32], 'logprob': -18.571188}, {'token': '9', 'bytes': [57], 'logprob': -19.071188}, {'token': '1', 'bytes': [49], 'logprob': -19.633688}, {'token': 'C', 'bytes': [67], 'logprob': -20.133688}, {'token': '0', 'bytes': [48], 'logprob': -21.321188}, {'token': '-', 'bytes': [45], 'logprob': -21.758688}, {'token': 'I', 'bytes': [73], 'logprob': -22.071188}, {'token': '**', 'bytes': [42, 42], 'logprob': -22.196188}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -22.196188}, {'token': 'D', 'bytes': [68], 'logprob': -22.383688}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.446188}]",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.31878594}, {'token': '4', 'bytes': [52], 'logprob': -1.5687859}, {'token': '2', 'bytes': [50], 'logprob': -2.818786}, {'token': '5', 'bytes': [53], 'logprob': -5.318786}, {'token': '6', 'bytes': [54], 'logprob': -9.568786}, {'token': '1', 'bytes': [49], 'logprob': -10.693786}, {'token': '7', 'bytes': [55], 'logprob': -13.943786}, {'token': '0', 'bytes': [48], 'logprob': -14.693786}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.318787}, {'token': ' ', 'bytes': [32], 'logprob': -18.318787}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.193787}, {'token': '8', 'bytes': [56], 'logprob': -19.193787}, {'token': '9', 'bytes': [57], 'logprob': -21.318787}, {'token': '-', 'bytes': [45], 'logprob': -22.068787}, {'token': 'I', 'bytes': [73], 'logprob': -22.193787}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.256287}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.443787}, {'token': '**', 'bytes': [42, 42], 'logprob': -22.568787}, {'token': 'Rating', 'bytes': [82, 97, 116, 105, 110, 103], 'logprob': -22.818787}, {'token': '03', 'bytes': [48, 51], 'logprob': -22.818787}]",2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.6083382}, {'token': '3', 'bytes': [51], 'logprob': -0.8583382}, {'token': '4', 'bytes': [52], 'logprob': -3.483338}, {'token': '1', 'bytes': [49], 'logprob': -7.3583384}, {'token': '5', 'bytes': [53], 'logprob': -7.7333384}, {'token': '0', 'bytes': [48], 'logprob': -9.233338}, {'token': '6', 'bytes': [54], 'logprob': -13.233338}, {'token': '7', 'bytes': [55], 'logprob': -17.733337}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.733337}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.608337}, {'token': '02', 'bytes': [48, 50], 'logprob': -19.670837}, {'token': ' ', 'bytes': [32], 'logprob': -19.858337}, {'token': '03', 'bytes': [48, 51], 'logprob': -20.545837}, {'token': '30', 'bytes': [51, 48], 'logprob': -21.045837}, {'token': '04', 'bytes': [48, 52], 'logprob': -21.170837}, {'token': '8', 'bytes': [56], 'logprob': -21.295837}, {'token': '-', 'bytes': [45], 'logprob': -21.983337}, {'token': 'I', 'bytes': [73], 'logprob': -22.170837}, {'token': '9', 'bytes': [57], 'logprob': -22.233337}, {'token': '25', 'bytes': [50, 53], 'logprob': -22.420837}]",2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.59510493}, {'token': '3', 'bytes': [51], 'logprob': -0.84510493}, {'token': '4', 'bytes': [52], 'logprob': -4.095105}, {'token': '1', 'bytes': [49], 'logprob': -6.220105}, {'token': '5', 'bytes': [53], 'logprob': -8.345105}, {'token': '0', 'bytes': [48], 'logprob': -9.220105}, {'token': '6', 'bytes': [54], 'logprob': -12.595105}, {'token': '7', 'bytes': [55], 'logprob': -16.845104}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.470104}, {'token': ' ', 'bytes': [32], 'logprob': -18.595104}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.845104}, {'token': '8', 'bytes': [56], 'logprob': -20.345104}, {'token': '02', 'bytes': [48, 50], 'logprob': -20.782604}, {'token': '9', 'bytes': [57], 'logprob': -21.095104}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.345104}, {'token': '-', 'bytes': [45], 'logprob': -21.407604}, {'token': 'I', 'bytes': [73], 'logprob': -21.532604}, {'token': '04', 'bytes': [48, 52], 'logprob': -22.407604}, {'token': '**', 'bytes': [42, 42], 'logprob': -22.470104}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.532604}]"
37,16504757,A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results,Int J Radiat Oncol Biol Phys,"Purpose:
To compare treatment A and comparator B in node‐positive, operable breast cancer patients.
Methods and materials:
This was a randomized, multicenter, phase III trial enrolling 638 eligible women with prior breast surgery and positive axillary dissection. Patients in Arm A received treatment A, with concomitant radiotherapy (50 Gy +/‐ 10‐20‐Gy boost). Patients in Arm B received comparator B, with subsequent radiotherapy.
Results:
Median treatment durations were 64 and 126 days (Arms A and B, respectively), with no significant difference in overall or disease‐free survival. Five‐year locoregional relapse‐free survival favored patients with conservative surgery (two thirds of the population), with less local and / or regional recurrence in Arm A than in Arm B (3% vs. 9%; p = 0.01). Multivariate analysis in this subgroup showed a 2.8‐fold increased risk of locoregional recurrence with comparator B, independent of other prognostic factors (p = 0.027). Febrile neutropenia and Grade 3‐4 leukopenia were significantly more frequent in Arm A. Subclinical left ventricular ejection fraction events at 1 year were more frequent with treatment A (p = 0.02).
Conclusion:
Treatment A has significantly better locoregional control in node‐positive breast cancer after conservative surgery and 50% shorter treatment, albeit with slightly more acute toxicity.",spin,"This passage is about a study that compared two different treatments for women with breast cancer who had already had surgery and had positive lymph nodes. The study involved 638 women who were randomly assigned to either treatment A or comparator B. Treatment A included radiation therapy and chemotherapy, while comparator B only included radiation therapy. The study found that the women in treatment A had better control of the cancer in their lymph nodes, but they also had more side effects like fever and low white blood cell count. Overall, the study suggests that treatment A is better for controlling the cancer, but it comes with some risks.",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.06237242}, {'token': '8', 'bytes': [56], 'logprob': -2.8123724}, {'token': '6', 'bytes': [54], 'logprob': -7.812372}, {'token': '9', 'bytes': [57], 'logprob': -16.937372}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -18.437372}, {'token': '5', 'bytes': [53], 'logprob': -18.937372}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -19.812372}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -20.874872}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -21.249872}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -21.374872}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -21.937372}, {'token': '<|end|>', 'bytes': None, 'logprob': -22.187372}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -22.687372}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -22.749872}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -22.812372}, {'token': ' seventh', 'bytes': [32, 115, 101, 118, 101, 110, 116, 104], 'logprob': -22.812372}, {'token': '۷', 'bytes': [219, 183], 'logprob': -22.874872}, {'token': '七', 'bytes': [228, 184, 131], 'logprob': -22.937372}, {'token': '4', 'bytes': [52], 'logprob': -23.062372}, {'token': '75', 'bytes': [55, 53], 'logprob': -23.249872}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.09151066}, {'token': '8', 'bytes': [56], 'logprob': -2.4665108}, {'token': '6', 'bytes': [54], 'logprob': -5.966511}, {'token': '9', 'bytes': [57], 'logprob': -12.716511}, {'token': '5', 'bytes': [53], 'logprob': -13.341511}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.40401}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -18.77901}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -18.90401}, {'token': '4', 'bytes': [52], 'logprob': -19.27901}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.34151}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -20.46651}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -20.71651}, {'token': ' ', 'bytes': [32], 'logprob': -20.77901}, {'token': '70', 'bytes': [55, 48], 'logprob': -21.59151}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -21.65401}, {'token': '75', 'bytes': [55, 53], 'logprob': -21.84151}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -21.84151}, {'token': '۷', 'bytes': [219, 183], 'logprob': -21.90401}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -22.09151}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -22.15401}]",8,8,"[{'token': '8', 'bytes': [56], 'logprob': -0.3869431}, {'token': '7', 'bytes': [55], 'logprob': -1.1369431}, {'token': '6', 'bytes': [54], 'logprob': -9.886943}, {'token': '9', 'bytes': [57], 'logprob': -10.761943}, {'token': '5', 'bytes': [53], 'logprob': -18.261944}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -19.886944}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.261944}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -20.511944}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -20.511944}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -20.824444}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.199444}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -22.011944}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -22.136944}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -22.574444}, {'token': 'Eight', 'bytes': [69, 105, 103, 104, 116], 'logprob': -22.886944}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -23.011944}, {'token': ' ocho', 'bytes': [32, 111, 99, 104, 111], 'logprob': -23.136944}, {'token': '4', 'bytes': [52], 'logprob': -23.199444}, {'token': ' вось', 'bytes': [32, 208, 178, 208, 190, 209, 129, 209, 140], 'logprob': -23.261944}, {'token': '۷', 'bytes': [219, 183], 'logprob': -23.386944}]",8,8,"[{'token': '8', 'bytes': [56], 'logprob': -0.079412825}, {'token': '7', 'bytes': [55], 'logprob': -2.579413}, {'token': '9', 'bytes': [57], 'logprob': -7.579413}, {'token': '6', 'bytes': [54], 'logprob': -11.329412}, {'token': '5', 'bytes': [53], 'logprob': -17.704412}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -18.454412}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -19.329412}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -19.641912}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -20.016912}, {'token': '10', 'bytes': [49, 48], 'logprob': -20.391912}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -20.829412}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -21.204412}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.204412}, {'token': ' вось', 'bytes': [32, 208, 178, 208, 190, 209, 129, 209, 140], 'logprob': -21.266912}, {'token': 'Eight', 'bytes': [69, 105, 103, 104, 116], 'logprob': -21.329412}, {'token': ' ocho', 'bytes': [32, 111, 99, 104, 111], 'logprob': -21.454412}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -21.891912}, {'token': ' acht', 'bytes': [32, 97, 99, 104, 116], 'logprob': -21.891912}, {'token': ' Eight', 'bytes': [32, 69, 105, 103, 104, 116], 'logprob': -22.579412}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -22.766912}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.4775254}, {'token': '8', 'bytes': [56], 'logprob': -0.9775254}, {'token': '6', 'bytes': [54], 'logprob': -5.727525}, {'token': '9', 'bytes': [57], 'logprob': -8.727526}, {'token': '5', 'bytes': [53], 'logprob': -10.602526}, {'token': '4', 'bytes': [52], 'logprob': -14.727526}, {'token': '3', 'bytes': [51], 'logprob': -18.602526}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.602526}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.790026}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -20.415026}, {'token': '10', 'bytes': [49, 48], 'logprob': -20.477526}, {'token': ' ', 'bytes': [32], 'logprob': -21.040026}, {'token': '70', 'bytes': [55, 48], 'logprob': -21.102526}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -21.602526}, {'token': '2', 'bytes': [50], 'logprob': -21.602526}, {'token': '75', 'bytes': [55, 53], 'logprob': -21.665026}, {'token': '85', 'bytes': [56, 53], 'logprob': -22.352526}, {'token': 'I', 'bytes': [73], 'logprob': -22.352526}, {'token': '68', 'bytes': [54, 56], 'logprob': -22.665026}, {'token': '78', 'bytes': [55, 56], 'logprob': -22.790026}]"
38,16504757,A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results,Int J Radiat Oncol Biol Phys,"Purpose:
To compare treatment A and comparator B in node‐positive, operable breast cancer patients.
Methods and materials:
This was a randomized, multicenter, phase III trial enrolling 638 eligible women with prior breast surgery and positive axillary dissection. Patients in Arm A received treatment A, with concomitant radiotherapy (50 Gy +/‐ 10‐20‐Gy boost). Patients in Arm B received comparator B, with subsequent radiotherapy. The primary outcome was disease free survival.
Results:
650 women were enrolled in this trial, and a total of 638 patients were treated. Median treatment durations were 64 and 126 days (Arms A and B, respectively). Five‐year DFS in Arm A was 83% and in Arm B 79%, p = 0.22. Disease‐specific survival at 5 years was not statistically significantly different between Arm A and Arm B. Sixty‐eight patients died 34 in each group. There was no statistically significant difference at 5 years for regional or metastatic relapses. Local recurrences at 5 years was 3% in Arm A and 7% in Arm B, p=0.047). Febrile neutropenia (n=10 in arm A vs. n=1 in arm B) and Grade 3‐4 leukopenia (n=43 vs n=4) were statistically significantly more frequent in Arm A. Subclinical left ventricular ejection fraction events at 1 year were more frequent with treatment A (p=0.02).
Conclusion:
Treatment A was not more effective than comparator B in node‐positive, operable breast cancer patients.",no_spin,"This passage is about a study that compared two different treatments for women with breast cancer who had surgery and positive lymph nodes. The study enrolled 638 women and randomly assigned them to either treatment A or comparator B. Treatment A included radiation therapy and chemotherapy, while comparator B only included radiation therapy. The study looked at how long the women lived without their cancer coming back, and found that the two treatments were not very different. However, the study did find that women in treatment A had more side effects, such as fever and low white blood cell count.",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.4876392}, {'token': '4', 'bytes': [52], 'logprob': -0.9876392}, {'token': '2', 'bytes': [50], 'logprob': -4.3626394}, {'token': '5', 'bytes': [53], 'logprob': -7.2376394}, {'token': '6', 'bytes': [54], 'logprob': -12.237639}, {'token': '1', 'bytes': [49], 'logprob': -13.112639}, {'token': '0', 'bytes': [48], 'logprob': -17.237638}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.612638}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.737638}, {'token': '7', 'bytes': [55], 'logprob': -17.987638}, {'token': ' ', 'bytes': [32], 'logprob': -18.862638}, {'token': '-', 'bytes': [45], 'logprob': -21.425138}, {'token': 'Three', 'bytes': [84, 104, 114, 101, 101], 'logprob': -21.487638}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.862638}, {'token': '30', 'bytes': [51, 48], 'logprob': -21.987638}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.050138}, {'token': 'Four', 'bytes': [70, 111, 117, 114], 'logprob': -22.237638}, {'token': 'I', 'bytes': [73], 'logprob': -22.300138}, {'token': '.', 'bytes': [46], 'logprob': -22.362638}, {'token': '３', 'bytes': [239, 188, 147], 'logprob': -22.612638}]",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.15325274}, {'token': '7', 'bytes': [55], 'logprob': -2.1532528}, {'token': '5', 'bytes': [53], 'logprob': -3.6532528}, {'token': '8', 'bytes': [56], 'logprob': -10.028253}, {'token': '4', 'bytes': [52], 'logprob': -10.403253}, {'token': '3', 'bytes': [51], 'logprob': -17.153254}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -19.028254}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.528254}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.590754}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -20.903254}, {'token': ' seis', 'bytes': [32, 115, 101, 105, 115], 'logprob': -21.590754}, {'token': '9', 'bytes': [57], 'logprob': -21.778254}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -21.903254}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -21.965754}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -22.090754}, {'token': ' ', 'bytes': [32], 'logprob': -22.153254}, {'token': '六', 'bytes': [229, 133, 173], 'logprob': -22.215754}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -22.715754}, {'token': ' Six', 'bytes': [32, 83, 105, 120], 'logprob': -22.903254}, {'token': 'six', 'bytes': [115, 105, 120], 'logprob': -23.215754}]",5,5,"[{'token': '5', 'bytes': [53], 'logprob': -0.3356503}, {'token': '6', 'bytes': [54], 'logprob': -1.8356503}, {'token': '4', 'bytes': [52], 'logprob': -2.0856502}, {'token': '3', 'bytes': [51], 'logprob': -7.2106504}, {'token': '7', 'bytes': [55], 'logprob': -7.3356504}, {'token': '2', 'bytes': [50], 'logprob': -15.08565}, {'token': '8', 'bytes': [56], 'logprob': -16.83565}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.83565}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.89815}, {'token': ' ', 'bytes': [32], 'logprob': -21.83565}, {'token': ' five', 'bytes': [32, 102, 105, 118, 101], 'logprob': -23.02315}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -23.21065}, {'token': '５', 'bytes': [239, 188, 149], 'logprob': -23.77315}, {'token': 'Five', 'bytes': [70, 105, 118, 101], 'logprob': -23.96065}, {'token': '1', 'bytes': [49], 'logprob': -24.02315}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -24.39815}, {'token': 'C', 'bytes': [67], 'logprob': -24.64815}, {'token': 'five', 'bytes': [102, 105, 118, 101], 'logprob': -24.71065}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -24.77315}, {'token': ' Five', 'bytes': [32, 70, 105, 118, 101], 'logprob': -24.77315}]",4,4,"[{'token': '4', 'bytes': [52], 'logprob': -0.3487175}, {'token': '5', 'bytes': [53], 'logprob': -1.5987175}, {'token': '3', 'bytes': [51], 'logprob': -2.4737175}, {'token': '6', 'bytes': [54], 'logprob': -4.9737177}, {'token': '2', 'bytes': [50], 'logprob': -7.0987177}, {'token': '7', 'bytes': [55], 'logprob': -8.348718}, {'token': '1', 'bytes': [49], 'logprob': -14.848718}, {'token': '8', 'bytes': [56], 'logprob': -14.973718}, {'token': '0', 'bytes': [48], 'logprob': -16.473717}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.723717}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.286217}, {'token': '9', 'bytes': [57], 'logprob': -19.286217}, {'token': ' ', 'bytes': [32], 'logprob': -20.098717}, {'token': '４', 'bytes': [239, 188, 148], 'logprob': -22.036217}, {'token': 'I', 'bytes': [73], 'logprob': -22.036217}, {'token': '-', 'bytes': [45], 'logprob': -22.223717}, {'token': '.', 'bytes': [46], 'logprob': -22.598717}, {'token': 'C', 'bytes': [67], 'logprob': -22.598717}, {'token': '04', 'bytes': [48, 52], 'logprob': -22.786217}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -23.036217}]",4,4,"[{'token': '4', 'bytes': [52], 'logprob': -0.47649473}, {'token': '3', 'bytes': [51], 'logprob': -1.2264948}, {'token': '5', 'bytes': [53], 'logprob': -2.6014948}, {'token': '2', 'bytes': [50], 'logprob': -4.851495}, {'token': '6', 'bytes': [54], 'logprob': -5.601495}, {'token': '7', 'bytes': [55], 'logprob': -9.976495}, {'token': '1', 'bytes': [49], 'logprob': -12.101495}, {'token': '0', 'bytes': [48], 'logprob': -13.976495}, {'token': '8', 'bytes': [56], 'logprob': -15.101495}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.351494}, {'token': '9', 'bytes': [57], 'logprob': -17.976494}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.163994}, {'token': ' ', 'bytes': [32], 'logprob': -18.288994}, {'token': 'I', 'bytes': [73], 'logprob': -21.226494}, {'token': '-', 'bytes': [45], 'logprob': -21.288994}, {'token': '10', 'bytes': [49, 48], 'logprob': -21.913994}, {'token': 'C', 'bytes': [67], 'logprob': -21.976494}, {'token': '04', 'bytes': [48, 52], 'logprob': -22.163994}, {'token': 'D', 'bytes': [68], 'logprob': -22.226494}, {'token': '(', 'bytes': [40], 'logprob': -22.288994}]"
32,17134892,Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group,Eur J Cancer,"Background:
The contribution of treatment A in breast cancer patients after receiving adjuvant chemotherapy is not fully established. We investigated the impact of treatment A, given sequentially after completion of adjuvant chemotherapy in patients with operable breast cancer.
Patients and methods:
Between March 1991 and June 1999, 1863 women with stages I‐IIIA operable breast cancer who had undergone surgery and completed six cycles of adjuvant combination chemotherapy with either CMF, CAF, CEF, FAC or FEC were randomized to receive either treatment A for 3 years or no further treatment. Irrespective of menstrual status and hormone receptor content of the primary tumor, patients were stratified by institute, chemotherapy scheme and age (above 50 years or younger). The main end‐point was to detect a 5% increase in the 5 year survival (from 80% to 85%) in favor of treatment A. Secondary end‐ points were relapse free survival (RFS), local control, incidence of second primary breast cancer.
Results:
After exclusion of all patients from three sites because of inadequate documentation, a total of 1724 patients (93%) were analyzed (Treatment A 861 and Control 863). At a median follow‐up of 6.5 years, 396 deaths (23%) and 602 RFS events (35%) (relapse and/or death) have been observed. There was no statistically significant difference in survival between patients who were randomized to receive treatment A for 3 years and those who were randomized to no further treatment (HR 0.97; 95% CI, 0.79‐1.18; p = 0.7377 by log‐rank test). At a median follow‐up of 6.5 years, 5‐year RFS on treatment A was 73% versus 67% in controls (p=0.035). Thirty eight patients (4.4%) in the treatment A arm discontinued treatment because of toxicity. The most common reasons for discontinuation were hot flashes (n = 8), vaginal bleeding (n = 7), weight gain (n = 4) and nausea (n = 4).
Conclusion:
Treatment A in breast cancer patients after receiving adjuvant chemotherapy was not more effective than no treatment on overall survival.",no_spin,"The study looked at whether a certain treatment (treatment A) helped breast cancer patients who had already received chemotherapy. The study included 1724 women who had undergone surgery and completed six cycles of adjuvant combination chemotherapy with either CMF, CAF, CEF, FAC or FEC. The women were then randomly assigned to either receive treatment A for 3 years or no further treatment. The study looked at how many women died or had a relapse (a return of the cancer) during the 6.5 year follow up period. The results showed that there was no significant difference in survival between the women who received treatment A and those who did not receive any further treatment. However, the study did find that treatment A was more effective in preventing a relapse than no treatment.",2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.3923509}, {'token': '3', 'bytes': [51], 'logprob': -1.1423509}, {'token': '4', 'bytes': [52], 'logprob': -5.392351}, {'token': '1', 'bytes': [49], 'logprob': -7.017351}, {'token': '0', 'bytes': [48], 'logprob': -11.392351}, {'token': '5', 'bytes': [53], 'logprob': -12.017351}, {'token': '6', 'bytes': [54], 'logprob': -16.017351}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.142351}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.892351}, {'token': ' ', 'bytes': [32], 'logprob': -18.517351}, {'token': '7', 'bytes': [55], 'logprob': -19.642351}, {'token': '02', 'bytes': [48, 50], 'logprob': -21.017351}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.454851}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.517351}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.579851}, {'token': '-', 'bytes': [45], 'logprob': -21.829851}, {'token': '30', 'bytes': [51, 48], 'logprob': -21.892351}, {'token': 'I', 'bytes': [73], 'logprob': -22.142351}, {'token': '  ', 'bytes': [32, 32], 'logprob': -22.642351}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -22.829851}]",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.34569973}, {'token': '5', 'bytes': [53], 'logprob': -1.5956998}, {'token': '7', 'bytes': [55], 'logprob': -2.5956998}, {'token': '4', 'bytes': [52], 'logprob': -4.2207}, {'token': '8', 'bytes': [56], 'logprob': -8.970699}, {'token': '3', 'bytes': [51], 'logprob': -9.220699}, {'token': '2', 'bytes': [50], 'logprob': -15.220699}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.3457}, {'token': '9', 'bytes': [57], 'logprob': -16.4707}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.8457}, {'token': ' ', 'bytes': [32], 'logprob': -18.4707}, {'token': 'C', 'bytes': [67], 'logprob': -20.6582}, {'token': '1', 'bytes': [49], 'logprob': -20.9707}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -21.2207}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -21.5332}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.6582}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.7207}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -21.8457}, {'token': 'Rating', 'bytes': [82, 97, 116, 105, 110, 103], 'logprob': -21.9082}, {'token': '-', 'bytes': [45], 'logprob': -21.9707}]",4,4,"[{'token': '4', 'bytes': [52], 'logprob': -0.63780034}, {'token': '3', 'bytes': [51], 'logprob': -0.88780034}, {'token': '5', 'bytes': [53], 'logprob': -3.1378002}, {'token': '2', 'bytes': [50], 'logprob': -4.3878}, {'token': '6', 'bytes': [54], 'logprob': -5.5128}, {'token': '7', 'bytes': [55], 'logprob': -8.8878}, {'token': '1', 'bytes': [49], 'logprob': -11.8878}, {'token': '8', 'bytes': [56], 'logprob': -14.6378}, {'token': '0', 'bytes': [48], 'logprob': -16.6378}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.7628}, {'token': ' ', 'bytes': [32], 'logprob': -18.1378}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.2628}, {'token': '9', 'bytes': [57], 'logprob': -18.3878}, {'token': '-', 'bytes': [45], 'logprob': -21.7628}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.7628}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.0753}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -22.3253}, {'token': '**', 'bytes': [42, 42], 'logprob': -22.3878}, {'token': 'I', 'bytes': [73], 'logprob': -22.4503}, {'token': 'Rating', 'bytes': [82, 97, 116, 105, 110, 103], 'logprob': -22.5128}]",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.58036774}, {'token': '2', 'bytes': [50], 'logprob': -1.5803678}, {'token': '4', 'bytes': [52], 'logprob': -1.5803678}, {'token': '5', 'bytes': [53], 'logprob': -3.5803678}, {'token': '6', 'bytes': [54], 'logprob': -7.9553676}, {'token': '1', 'bytes': [49], 'logprob': -8.330368}, {'token': '0', 'bytes': [48], 'logprob': -10.080368}, {'token': '7', 'bytes': [55], 'logprob': -11.580368}, {'token': '8', 'bytes': [56], 'logprob': -15.705368}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.455368}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.580368}, {'token': '9', 'bytes': [57], 'logprob': -18.392868}, {'token': ' ', 'bytes': [32], 'logprob': -19.517868}, {'token': '02', 'bytes': [48, 50], 'logprob': -21.705368}, {'token': '10', 'bytes': [49, 48], 'logprob': -22.017868}, {'token': '03', 'bytes': [48, 51], 'logprob': -22.080368}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.080368}, {'token': '04', 'bytes': [48, 52], 'logprob': -22.142868}, {'token': '-', 'bytes': [45], 'logprob': -22.205368}, {'token': 'I', 'bytes': [73], 'logprob': -22.392868}]",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.57564926}, {'token': '4', 'bytes': [52], 'logprob': -1.3256493}, {'token': '2', 'bytes': [50], 'logprob': -1.8256493}, {'token': '5', 'bytes': [53], 'logprob': -4.5756493}, {'token': '6', 'bytes': [54], 'logprob': -7.8256493}, {'token': '1', 'bytes': [49], 'logprob': -8.575649}, {'token': '7', 'bytes': [55], 'logprob': -11.075649}, {'token': '0', 'bytes': [48], 'logprob': -11.200649}, {'token': '8', 'bytes': [56], 'logprob': -15.825649}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.32565}, {'token': '9', 'bytes': [57], 'logprob': -18.20065}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.20065}, {'token': ' ', 'bytes': [32], 'logprob': -18.95065}, {'token': '-', 'bytes': [45], 'logprob': -21.88815}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.88815}, {'token': '02', 'bytes': [48, 50], 'logprob': -21.95065}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.95065}, {'token': '04', 'bytes': [48, 52], 'logprob': -22.07565}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.20065}, {'token': 'I', 'bytes': [73], 'logprob': -22.57565}]"
31,17134892,Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group,Eur J Cancer,"Background:
The contribution of treatment A in breast cancer patients after receiving adjuvant chemotherapy is not fully established. We investigated the impact of treatment A, given sequentially after completion of adjuvant chemotherapy in patients with operable breast cancer.
Patients and methods:
Between March 1991 and June 1999, 1863 women with stages I‐IIIA operable breast cancer who had undergone surgery and completed six cycles of adjuvant combination chemotherapy with either CMF, CAF, CEF, FAC or FEC were randomised to receive either treatment A for 3 years or no further treatment. Irrespective of menstrual status and hormone receptor content of the primary tumour, patients were stratified by institute, chemotherapy scheme and age (above 50 years or younger). The main end‐point was to detect a 5% increase in the 5 year survival (from 80% to 85%) in favour of treatment A. Secondary end‐ points were relapse free survival (RFS), local control, incidence of second primary breast cancer and correlation of results with hormone receptor content.
Results:
After exclusion of all patients from three sites because of inadequate documentation, a total of 1724 patients (93%) were analyzed (Treatment A 861 and Control 863). At a median follow‐up of 6.5 years, 5‐year RFS on treatment A was 73% versus 67% in controls (p=0.035). No difference was seen in overall survival. The benefit of treatment A was mainly seen in the subgroup of patients with histologically documented positive axillary nodes (5‐year RFS on treatment A 71% versus 64% in the control group, p=0.044) and in patients with tumours expressing the ER and PR positive phenotype (5‐year RFS on treatment A 77% versus 70% in the control group, p=0.014).
Conclusion:
Treatment A administered for 3 years after completion of adjuvant chemotherapy in this otherwise unselected group of patients for endocrine sensitivity had a limited impact on relapse and had no detectable effect on overall survival. The beneficial effect of treatment A is mainly confined to the subgroup of patients with node‐positive disease and to patients with tumours expressing the ER and PR positive phenotype.",spin,"The doctors wanted to know if a certain treatment (treatment A) would help women with breast cancer who had already received chemotherapy. They picked a group of women with breast cancer and gave them either treatment A or no more treatment. They looked at how many women in each group had a certain kind of cancer come back (recurrence) after 5 years. They also looked at how many women in each group lived for 5 years. They found that treatment A helped women with a certain kind of cancer come back less often, but it didn't help them live longer. The doctors also found that the treatment was most helpful for women with a certain kind of cancer and for women with a certain kind of hormone in their cancer.",5,5,"[{'token': '5', 'bytes': [53], 'logprob': -0.76523304}, {'token': '4', 'bytes': [52], 'logprob': -1.015233}, {'token': '6', 'bytes': [54], 'logprob': -1.765233}, {'token': '3', 'bytes': [51], 'logprob': -6.890233}, {'token': '7', 'bytes': [55], 'logprob': -8.140233}, {'token': '2', 'bytes': [50], 'logprob': -15.640233}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.140232}, {'token': '<|end|>', 'bytes': None, 'logprob': -16.952732}, {'token': '8', 'bytes': [56], 'logprob': -18.327732}, {'token': ' ', 'bytes': [32], 'logprob': -18.765232}, {'token': 'C', 'bytes': [67], 'logprob': -19.577732}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -20.390232}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -21.077732}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.140232}, {'token': '-', 'bytes': [45], 'logprob': -21.390232}, {'token': 'D', 'bytes': [68], 'logprob': -21.452732}, {'token': '  ', 'bytes': [32, 32], 'logprob': -21.452732}, {'token': 'Five', 'bytes': [70, 105, 118, 101], 'logprob': -21.515232}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -21.640232}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -21.702732}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.25304216}, {'token': '6', 'bytes': [54], 'logprob': -1.5030422}, {'token': '8', 'bytes': [56], 'logprob': -7.003042}, {'token': '5', 'bytes': [53], 'logprob': -8.503042}, {'token': '4', 'bytes': [52], 'logprob': -14.878042}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.253042}, {'token': '9', 'bytes': [57], 'logprob': -17.378042}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -18.190542}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.378042}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -18.565542}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -18.753042}, {'token': ' ', 'bytes': [32], 'logprob': -19.565542}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -19.753042}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -20.003042}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -20.565542}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -20.815542}, {'token': '3', 'bytes': [51], 'logprob': -21.065542}, {'token': ' seis', 'bytes': [32, 115, 101, 105, 115], 'logprob': -21.378042}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -21.440542}, {'token': 'C', 'bytes': [67], 'logprob': -21.440542}]",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.119504154}, {'token': '5', 'bytes': [53], 'logprob': -2.6195042}, {'token': '7', 'bytes': [55], 'logprob': -3.2445042}, {'token': '4', 'bytes': [52], 'logprob': -7.119504}, {'token': '8', 'bytes': [56], 'logprob': -12.744504}, {'token': '3', 'bytes': [51], 'logprob': -14.244504}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.369505}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.182005}, {'token': ' ', 'bytes': [32], 'logprob': -19.682005}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -19.807005}, {'token': '9', 'bytes': [57], 'logprob': -20.432005}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -21.057005}, {'token': '2', 'bytes': [50], 'logprob': -21.432005}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.057005}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -22.182005}, {'token': 'C', 'bytes': [67], 'logprob': -22.494505}, {'token': ' seis', 'bytes': [32, 115, 101, 105, 115], 'logprob': -22.494505}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.619505}, {'token': '-', 'bytes': [45], 'logprob': -22.682005}, {'token': '六', 'bytes': [229, 133, 173], 'logprob': -22.682005}]",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.3689139}, {'token': '5', 'bytes': [53], 'logprob': -1.3689139}, {'token': '7', 'bytes': [55], 'logprob': -3.118914}, {'token': '4', 'bytes': [52], 'logprob': -4.6189137}, {'token': '3', 'bytes': [51], 'logprob': -9.868914}, {'token': '8', 'bytes': [56], 'logprob': -11.368914}, {'token': '2', 'bytes': [50], 'logprob': -17.118914}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -19.368914}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.431414}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -20.556414}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -20.618914}, {'token': ' seis', 'bytes': [32, 115, 101, 105, 115], 'logprob': -21.868914}, {'token': '六', 'bytes': [229, 133, 173], 'logprob': -22.118914}, {'token': '9', 'bytes': [57], 'logprob': -22.181414}, {'token': '５', 'bytes': [239, 188, 149], 'logprob': -22.493914}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -22.556414}, {'token': ' five', 'bytes': [32, 102, 105, 118, 101], 'logprob': -22.681414}, {'token': ' ', 'bytes': [32], 'logprob': -23.181414}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -23.306414}, {'token': ' cinco', 'bytes': [32, 99, 105, 110, 99, 111], 'logprob': -23.493914}]",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.45769337}, {'token': '5', 'bytes': [53], 'logprob': -1.2076933}, {'token': '4', 'bytes': [52], 'logprob': -3.2076933}, {'token': '7', 'bytes': [55], 'logprob': -3.5826933}, {'token': '3', 'bytes': [51], 'logprob': -9.082693}, {'token': '8', 'bytes': [56], 'logprob': -11.707693}, {'token': '2', 'bytes': [50], 'logprob': -15.957693}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.207693}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.707693}, {'token': '9', 'bytes': [57], 'logprob': -18.582693}, {'token': ' ', 'bytes': [32], 'logprob': -19.832693}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -20.457693}, {'token': 'I', 'bytes': [73], 'logprob': -20.832693}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.020193}, {'token': '1', 'bytes': [49], 'logprob': -21.332693}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.395193}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -21.457693}, {'token': 'C', 'bytes': [67], 'logprob': -21.520193}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -21.957693}, {'token': '５', 'bytes': [239, 188, 149], 'logprob': -22.145193}]"
2,17173959,Effective cervical neoplasia detection with a novel optical detection system: a randomized trial,Gynecol Oncol,"Objective:
To assess whether the use of intervention A as an adjunct to colposcopy increases the detection of biopsy confirmed CIN 2,3 (high grade cervical intraepithelial neoplasia).
Methods:
This is a multicenter two‐arm randomized trial comparing colposcopy alone with colposcopy plus intervention A. Patients were recruited from 13 colposcopy clinics in a variety of practice settings. 2299 women referred for the evaluation of an abnormal cervical cytology were randomized with stratification by cytology; subsequently 113 women were excluded for a variety of reasons. The main study outcomes were differences in true‐positive rates (biopsy confirmed CIN 2, 3 and cancer) and false‐positive rates (all women having at least one cervical biopsy taken with none of the biopies diagnosed as CIN 2,3, or cancer) between the study arms.
Results:
The final analyzed populations were 1096 in the colposcopy only arm and 1090 in the colposcopy plus intervention A arm. There was no statistically significant difference in the true positive rate between the 2 groups. The true positive rate was 19.9% (218/1096) in the colposcopy‐only arm vs 21.8% (238/1090) in the colposcopy plus intervention A arm; p=0.143. The false positive rate was 57.4% (629/1096) in the colposcopy‐only arm vs 60.5% (659/1090) in the colposcopy plus intervention A arm. No biopsy was performed in 239 (27.4%) in the colposcopy‐only arm and 193 (17.7%) in the colposcopy plus intervention A arm. The average number of biopsies was 1.03 for the colposcopy‐only arm and 1.30 for the colposcopy plus intervention A arm. Four subjects experienced minor adverse events during the study in both arms.
Conclusion:
Combining intervention A with colposcopy was not more effective than colposcopy alone for the detection of CIN 2, 3 in women referred for the evaluation of mildly abnormal cytology results.",no_spin,"The passage is about a study that wanted to see if using a special tool called intervention A along with a test called colposcopy would help doctors find out if a woman has a problem with her cervix. The study had 2 groups of women, one group got the special tool and the other group did not. The study looked at how many women in each group got a diagnosis of a problem with their cervix and how many women in each group got a false diagnosis. The study found that using the special tool did not make a difference in how many women got a diagnosis of a problem with their cervix.",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.35240686}, {'token': '2', 'bytes': [50], 'logprob': -1.6024069}, {'token': '4', 'bytes': [52], 'logprob': -2.352407}, {'token': '5', 'bytes': [53], 'logprob': -8.2274065}, {'token': '1', 'bytes': [49], 'logprob': -8.6024065}, {'token': '0', 'bytes': [48], 'logprob': -12.9774065}, {'token': '6', 'bytes': [54], 'logprob': -13.3524065}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.352407}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.852407}, {'token': '7', 'bytes': [55], 'logprob': -18.102407}, {'token': ' ', 'bytes': [32], 'logprob': -18.977407}, {'token': '-', 'bytes': [45], 'logprob': -21.664907}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.664907}, {'token': 'I', 'bytes': [73], 'logprob': -21.977407}, {'token': '03', 'bytes': [48, 51], 'logprob': -22.039907}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.039907}, {'token': '02', 'bytes': [48, 50], 'logprob': -22.227407}, {'token': '8', 'bytes': [56], 'logprob': -22.414907}, {'token': 'C', 'bytes': [67], 'logprob': -22.477407}, {'token': 'D', 'bytes': [68], 'logprob': -22.539907}]",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.22201197}, {'token': '5', 'bytes': [53], 'logprob': -1.7220119}, {'token': '7', 'bytes': [55], 'logprob': -3.972012}, {'token': '4', 'bytes': [52], 'logprob': -6.472012}, {'token': '3', 'bytes': [51], 'logprob': -12.597012}, {'token': '8', 'bytes': [56], 'logprob': -12.722012}, {'token': '2', 'bytes': [50], 'logprob': -19.972012}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -20.097012}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.597012}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.972012}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -22.034512}, {'token': ' ', 'bytes': [32], 'logprob': -22.097012}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -22.722012}, {'token': ' seis', 'bytes': [32, 115, 101, 105, 115], 'logprob': -22.909512}, {'token': '六', 'bytes': [229, 133, 173], 'logprob': -23.159512}, {'token': ' five', 'bytes': [32, 102, 105, 118, 101], 'logprob': -23.409512}, {'token': ' Six', 'bytes': [32, 83, 105, 120], 'logprob': -23.597012}, {'token': 'C', 'bytes': [67], 'logprob': -23.722012}, {'token': '9', 'bytes': [57], 'logprob': -23.784512}, {'token': 'six', 'bytes': [115, 105, 120], 'logprob': -23.784512}]",4,4,"[{'token': '4', 'bytes': [52], 'logprob': -0.38327113}, {'token': '3', 'bytes': [51], 'logprob': -1.6332711}, {'token': '5', 'bytes': [53], 'logprob': -2.1332712}, {'token': '6', 'bytes': [54], 'logprob': -5.633271}, {'token': '2', 'bytes': [50], 'logprob': -6.883271}, {'token': '7', 'bytes': [55], 'logprob': -10.383271}, {'token': '1', 'bytes': [49], 'logprob': -14.633271}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.25827}, {'token': '8', 'bytes': [56], 'logprob': -17.50827}, {'token': '0', 'bytes': [48], 'logprob': -18.13327}, {'token': ' ', 'bytes': [32], 'logprob': -18.50827}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.50827}, {'token': '9', 'bytes': [57], 'logprob': -21.13327}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.82077}, {'token': '-', 'bytes': [45], 'logprob': -21.88327}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.00827}, {'token': 'C', 'bytes': [67], 'logprob': -22.50827}, {'token': '**', 'bytes': [42, 42], 'logprob': -22.69577}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -22.69577}, {'token': 'I', 'bytes': [73], 'logprob': -22.75827}]",4,4,"[{'token': '4', 'bytes': [52], 'logprob': -0.3641947}, {'token': '3', 'bytes': [51], 'logprob': -1.3641946}, {'token': '5', 'bytes': [53], 'logprob': -3.1141946}, {'token': '2', 'bytes': [50], 'logprob': -5.364195}, {'token': '6', 'bytes': [54], 'logprob': -7.489195}, {'token': '7', 'bytes': [55], 'logprob': -12.739195}, {'token': '1', 'bytes': [49], 'logprob': -15.489195}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.864195}, {'token': '0', 'bytes': [48], 'logprob': -19.989195}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -19.989195}, {'token': '8', 'bytes': [56], 'logprob': -20.426695}, {'token': ' ', 'bytes': [32], 'logprob': -22.614195}, {'token': '４', 'bytes': [239, 188, 148], 'logprob': -22.864195}, {'token': ' four', 'bytes': [32, 102, 111, 117, 114], 'logprob': -23.239195}, {'token': '.', 'bytes': [46], 'logprob': -23.489195}, {'token': '-', 'bytes': [45], 'logprob': -23.739195}, {'token': '３', 'bytes': [239, 188, 147], 'logprob': -23.801695}, {'token': 'I', 'bytes': [73], 'logprob': -23.989195}, {'token': 'Four', 'bytes': [70, 111, 117, 114], 'logprob': -24.051695}, {'token': 'Three', 'bytes': [84, 104, 114, 101, 101], 'logprob': -24.176695}]",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.6344524}, {'token': '4', 'bytes': [52], 'logprob': -0.8844524}, {'token': '5', 'bytes': [53], 'logprob': -3.5094523}, {'token': '2', 'bytes': [50], 'logprob': -3.6344523}, {'token': '6', 'bytes': [54], 'logprob': -7.6344523}, {'token': '1', 'bytes': [49], 'logprob': -10.384453}, {'token': '7', 'bytes': [55], 'logprob': -12.009453}, {'token': '0', 'bytes': [48], 'logprob': -13.259453}, {'token': '8', 'bytes': [56], 'logprob': -17.384453}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.884453}, {'token': ' ', 'bytes': [32], 'logprob': -18.509453}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.634453}, {'token': '9', 'bytes': [57], 'logprob': -19.759453}, {'token': '-', 'bytes': [45], 'logprob': -21.446953}, {'token': 'I', 'bytes': [73], 'logprob': -21.759453}, {'token': '04', 'bytes': [48, 52], 'logprob': -22.696953}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.696953}, {'token': 'C', 'bytes': [67], 'logprob': -22.759453}, {'token': '**', 'bytes': [42, 42], 'logprob': -22.821953}, {'token': '.', 'bytes': [46], 'logprob': -22.946953}]"
1,17173959,Effective cervical neoplasia detection with a novel optical detection system: a randomized trial,Gynecol Oncol,"Objective:
To assess whether the use of intervention A as an adjunct to colposcopy increases the detection of biopsy confirmed CIN 2, 3 (high grade cervical intraepithelial neoplasia).
Methods:
This is a multicenter two‐arm randomized trial comparing colposcopy alone with colposcopy plus intervention A. Patients were recruited from 13 colposcopy clinics in a variety of practice settings. 2299 women referred for the evaluation of an abnormal cervical cytology were randomized with stratification by cytology; subsequently 113 women were excluded for a variety of reasons. The main study outcomes were differences in true‐positive rates (CIN 2, 3 and cancer identified) and false‐positive rates between the study arms.
Results:
The true‐positive (TP) rates were 14.4% vs. 11.4% (p=0.035, one‐sided) for the combined colposcopy and intervention A arm compared to colposcopy‐only arm, respectively, in women with either an atypical squamous cell (ASC) or low‐grade squamous intraepithelial lesion (LSIL) cytology result. TP rates were similar between the two arms among women referred for the evaluation of HSIL (high‐grade squamous intraepithelial lesion). The 26.5% gain in true‐positives observed with the use of intervention A and colposcopy among women referred for an ASC or LSIL cytology was achieved with only a fractional increase in number of biopsies obtained per patient (0.30) and a modest increase in false‐positive rate
(4%). In the combined colposcopy and intervention A arm among women with ASC or LSIL, the PPV (positive predictive value) of biopsies indicated by ntervention A was 15.0% and the PPV of biopsies indicated by colposcopy was 15.2%. Joint hypothesis testing indicates that intervention A and colposcopy provides benefit compared to colposcopy alone among women with ASC or LSIL.
Conclusion:
Combining intervention A with colposcopy provides a clinically meaningful increase in the detection of CIN 2, 3 in women referred for the evaluation of mildly abnormal cytology results.",spin,"This passage is about a study that wanted to see if using a special tool called intervention A along with a test called colposcopy could help find out if a woman has a problem with her cervix. The study compared using colposcopy alone to using colposcopy with intervention A. They found that using both colposcopy and intervention A together helped find more problems with the cervix than using colposcopy alone. However, it only took a small increase in the number of tests and there was a slight increase in false positives (when a test says something is wrong when it's actually not). Overall, the study showed that using both colposcopy and intervention A together was helpful in finding problems with the cervix.",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.5759745}, {'token': '8', 'bytes': [56], 'logprob': -0.8259745}, {'token': '6', 'bytes': [54], 'logprob': -10.325974}, {'token': '9', 'bytes': [57], 'logprob': -12.950974}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -18.200975}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -19.950975}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -19.950975}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -20.263475}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -20.513475}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -20.825975}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -20.888475}, {'token': '5', 'bytes': [53], 'logprob': -21.138475}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -21.388475}, {'token': 'Eight', 'bytes': [69, 105, 103, 104, 116], 'logprob': -21.763475}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.763475}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -21.825975}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -22.013475}, {'token': '75', 'bytes': [55, 53], 'logprob': -22.575975}, {'token': ' seventh', 'bytes': [32, 115, 101, 118, 101, 110, 116, 104], 'logprob': -22.888475}, {'token': '76', 'bytes': [55, 54], 'logprob': -22.888475}]",8,8,"[{'token': '8', 'bytes': [56], 'logprob': -0.25205916}, {'token': '7', 'bytes': [55], 'logprob': -1.5020592}, {'token': '9', 'bytes': [57], 'logprob': -9.127059}, {'token': '6', 'bytes': [54], 'logprob': -10.752059}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.62706}, {'token': '5', 'bytes': [53], 'logprob': -17.75206}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.56456}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -18.93956}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -19.06456}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -19.12706}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -19.50206}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -20.00206}, {'token': ' ', 'bytes': [32], 'logprob': -20.68956}, {'token': 'Eight', 'bytes': [69, 105, 103, 104, 116], 'logprob': -20.68956}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -20.81456}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -21.31456}, {'token': 'I', 'bytes': [73], 'logprob': -21.75206}, {'token': '82', 'bytes': [56, 50], 'logprob': -21.75206}, {'token': '-', 'bytes': [45], 'logprob': -21.81456}, {'token': '78', 'bytes': [55, 56], 'logprob': -21.81456}]",8,8,"[{'token': '8', 'bytes': [56], 'logprob': -0.06200589}, {'token': '7', 'bytes': [55], 'logprob': -2.812006}, {'token': '9', 'bytes': [57], 'logprob': -10.187006}, {'token': '6', 'bytes': [54], 'logprob': -14.437006}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -18.562006}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -19.437006}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -19.812006}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -19.999506}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.499506}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -20.999506}, {'token': ' вось', 'bytes': [32, 208, 178, 208, 190, 209, 129, 209, 140], 'logprob': -21.187006}, {'token': 'Eight', 'bytes': [69, 105, 103, 104, 116], 'logprob': -21.312006}, {'token': ' acht', 'bytes': [32, 97, 99, 104, 116], 'logprob': -21.687006}, {'token': ' Eight', 'bytes': [32, 69, 105, 103, 104, 116], 'logprob': -21.749506}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.749506}, {'token': ' ocho', 'bytes': [32, 111, 99, 104, 111], 'logprob': -21.874506}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -21.937006}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -22.187006}, {'token': '۸', 'bytes': [219, 184], 'logprob': -22.624506}, {'token': '-eight', 'bytes': [45, 101, 105, 103, 104, 116], 'logprob': -22.687006}]",8,8,"[{'token': '8', 'bytes': [56], 'logprob': -0.07920701}, {'token': '7', 'bytes': [55], 'logprob': -2.579207}, {'token': '9', 'bytes': [57], 'logprob': -8.079207}, {'token': '6', 'bytes': [54], 'logprob': -11.829207}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -17.079206}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -18.329206}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -18.454206}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -18.579206}, {'token': '5', 'bytes': [53], 'logprob': -19.079206}, {'token': 'Eight', 'bytes': [69, 105, 103, 104, 116], 'logprob': -19.954206}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -19.954206}, {'token': ' вось', 'bytes': [32, 208, 178, 208, 190, 209, 129, 209, 140], 'logprob': -20.266706}, {'token': ' ocho', 'bytes': [32, 111, 99, 104, 111], 'logprob': -20.454206}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -20.766706}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.829206}, {'token': ' acht', 'bytes': [32, 97, 99, 104, 116], 'logprob': -21.016706}, {'token': ' Eight', 'bytes': [32, 69, 105, 103, 104, 116], 'logprob': -21.079206}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -21.204206}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -21.391706}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -21.454206}]",8,8,"[{'token': '8', 'bytes': [56], 'logprob': -0.079416245}, {'token': '7', 'bytes': [55], 'logprob': -2.5794163}, {'token': '9', 'bytes': [57], 'logprob': -7.5794163}, {'token': '6', 'bytes': [54], 'logprob': -11.079416}, {'token': '5', 'bytes': [53], 'logprob': -17.954416}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.454416}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -20.641916}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -20.704416}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -21.079416}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.454416}, {'token': '10', 'bytes': [49, 48], 'logprob': -21.516916}, {'token': 'Eight', 'bytes': [69, 105, 103, 104, 116], 'logprob': -22.204416}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -22.204416}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -22.266916}, {'token': '4', 'bytes': [52], 'logprob': -22.454416}, {'token': ' вось', 'bytes': [32, 208, 178, 208, 190, 209, 129, 209, 140], 'logprob': -23.204416}, {'token': ' ocho', 'bytes': [32, 111, 99, 104, 111], 'logprob': -23.516916}, {'token': 'I', 'bytes': [73], 'logprob': -23.641916}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -23.891916}, {'token': '۸', 'bytes': [219, 184], 'logprob': -24.016916}]"
39,17179098,"Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer",J Clin Oncol,"Purpose:
To evaluate the efficacy and tolerability of treatment A plus cyclophosphamide, doxorubicin, and fluorouracil (CAF) therapy in comparison with CAF alone, in patients with advanced or recurrent breast cancer.
Methods and materials:
In this randomized, double‐blind, placebo‐controlled trial, patients were treated with six cycles of CAF therapy: 28 days/cycle, with doxorubicin (25 mg/m2) and fluorouracil (500 mg/m2) administered on days 1 and 8 and cyclophosphamide (100 mg orally [PO]) administered on day 1 through 14. Primary end point was overall response rate (ORR; partial or complete response). In total, 221 patients were assessable.
Results:
ORR was 42.6% for CAF compared with 53.1% for treatment A + CAF, a 24.6% relative improvement and 10.5% absolute increase (P = .077). There was a trend for prolonged progression‐free survival (PFS; median 241 days for CAF v 366 days for treatment A + CAF; P = .145). In retrospectively defined subgroups, significant improvement in PFS in favor of treatment A was observed in patients who were premenopausal, had no prior therapy, and were stage IV at diagnosis with an intact primary tumor. Except for neutropenia and leukopenia, there was no statistically significant excess of grade 3/4 adverse events compared with CAF. Treatment with treatment A did not affect the plasma concentration of doxorubicin.
Conclusion:
Treatment A + CAF was well tolerated and is suggested to have efficacy in patients who had not received prior therapy.",spin,"This passage is about a study that wanted to see if a certain treatment (treatment A plus cyclophosphamide, doxorubicin, and fluorouracil) was better than just the treatment with cyclophosphamide, doxorubicin, and fluorouracil (CAF) alone for people with advanced or recurrent breast cancer.

The study used a special way of testing the treatments, where some people got the treatment with all three drugs and some people got just the treatment with the three drugs. The researchers looked at how well the treatments worked and how many side effects they had.

The results showed that the treatment with all three drugs was better than just the treatment with the three drugs alone in terms of how many people responded to the treatment. However, there was no significant difference in how long people lived without their cancer coming back.

The researchers also looked at different groups of people and found that the treatment with all three drugs was especially helpful for people who had not received any other treatment before, were premenopausal (not yet menopausal), had stage IV breast cancer (the most advanced stage), and had an intact primary tumor (the original tumor that started the cancer).

Overall, the treatment with all three drugs was well tolerated (meaning it didn't cause too many bad side effects) and is suggested to be effective for people who have",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.10195442}, {'token': '6', 'bytes': [54], 'logprob': -2.3519545}, {'token': '8', 'bytes': [56], 'logprob': -6.3519545}, {'token': '5', 'bytes': [53], 'logprob': -12.726954}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -17.226954}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -19.226954}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -19.226954}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -19.601954}, {'token': '9', 'bytes': [57], 'logprob': -19.726954}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -20.039454}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -20.414454}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -20.476954}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.539454}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.601954}, {'token': '4', 'bytes': [52], 'logprob': -21.226954}, {'token': '七', 'bytes': [228, 184, 131], 'logprob': -21.601954}, {'token': ' seis', 'bytes': [32, 115, 101, 105, 115], 'logprob': -21.601954}, {'token': ' seventh', 'bytes': [32, 115, 101, 118, 101, 110, 116, 104], 'logprob': -21.726954}, {'token': ' ', 'bytes': [32], 'logprob': -22.226954}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -22.351954}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.06754658}, {'token': '8', 'bytes': [56], 'logprob': -2.8175466}, {'token': '6', 'bytes': [54], 'logprob': -5.1925464}, {'token': '5', 'bytes': [53], 'logprob': -12.692547}, {'token': '9', 'bytes': [57], 'logprob': -12.942547}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.817547}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -17.817547}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -18.255047}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.942547}, {'token': '4', 'bytes': [52], 'logprob': -19.255047}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -19.442547}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -19.505047}, {'token': ' ', 'bytes': [32], 'logprob': -20.255047}, {'token': '75', 'bytes': [55, 53], 'logprob': -21.317547}, {'token': '70', 'bytes': [55, 48], 'logprob': -21.380047}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -21.380047}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -21.442547}, {'token': '۷', 'bytes': [219, 183], 'logprob': -21.505047}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -21.505047}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -21.630047}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.07197441}, {'token': '8', 'bytes': [56], 'logprob': -2.6969745}, {'token': '6', 'bytes': [54], 'logprob': -6.1969743}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -15.446975}, {'token': '5', 'bytes': [53], 'logprob': -15.821975}, {'token': '9', 'bytes': [57], 'logprob': -15.946975}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -17.071974}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -18.196974}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.509474}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -18.509474}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -19.009474}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -19.571974}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -19.821974}, {'token': ' seventh', 'bytes': [32, 115, 101, 118, 101, 110, 116, 104], 'logprob': -20.009474}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.509474}, {'token': ' sieben', 'bytes': [32, 115, 105, 101, 98, 101, 110], 'logprob': -20.634474}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -20.696974}, {'token': '۷', 'bytes': [219, 183], 'logprob': -20.696974}, {'token': '七', 'bytes': [228, 184, 131], 'logprob': -20.759474}, {'token': '৭', 'bytes': [224, 167, 173], 'logprob': -21.196974}]",8,8,"[{'token': '8', 'bytes': [56], 'logprob': -0.47442764}, {'token': '7', 'bytes': [55], 'logprob': -0.97442764}, {'token': '6', 'bytes': [54], 'logprob': -8.099427}, {'token': '9', 'bytes': [57], 'logprob': -9.974427}, {'token': '5', 'bytes': [53], 'logprob': -15.224427}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -17.974428}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -18.474428}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -18.724428}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -18.974428}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -19.911928}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -19.911928}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.411928}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.849428}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -21.036928}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -21.161928}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -21.286928}, {'token': ' вось', 'bytes': [32, 208, 178, 208, 190, 209, 129, 209, 140], 'logprob': -21.411928}, {'token': ' ocho', 'bytes': [32, 111, 99, 104, 111], 'logprob': -21.474428}, {'token': 'Eight', 'bytes': [69, 105, 103, 104, 116], 'logprob': -21.474428}, {'token': '4', 'bytes': [52], 'logprob': -21.661928}]",8,8,"[{'token': '8', 'bytes': [56], 'logprob': -0.31344774}, {'token': '7', 'bytes': [55], 'logprob': -1.3134477}, {'token': '6', 'bytes': [54], 'logprob': -8.938448}, {'token': '9', 'bytes': [57], 'logprob': -9.813448}, {'token': '5', 'bytes': [53], 'logprob': -17.313448}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -20.563448}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -20.688448}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -20.688448}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -20.813448}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.188448}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -21.250948}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -21.563448}, {'token': '10', 'bytes': [49, 48], 'logprob': -22.438448}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -22.438448}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -22.688448}, {'token': 'Eight', 'bytes': [69, 105, 103, 104, 116], 'logprob': -22.750948}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -22.938448}, {'token': ' вось', 'bytes': [32, 208, 178, 208, 190, 209, 129, 209, 140], 'logprob': -23.000948}, {'token': '4', 'bytes': [52], 'logprob': -23.125948}, {'token': ' ocho', 'bytes': [32, 111, 99, 104, 111], 'logprob': -23.188448}]"
40,17179098,"Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer",J Clin Oncol,"Purpose:
To evaluate the efficacy and tolerability of treatment A plus cyclophosphamide, doxorubicin, and fluorouracil (CAF) therapy in comparison with CAF + placebo, in patients with advanced or recurrent breast cancer.
Methods and materials:
In this randomized, double‐blind, placebo‐controlled trial, patients were treated with six cycles of CAF therapy: 28 days/cycle, with doxorubicin (25 mg/m2) and fluorouracil (500 mg/m2) administered on days 1 and 8 and cyclophosphamide (100 mg orally [PO]) administered on day 1 through 14. Primary end point was overall response rate (ORR; partial or complete response). In total, 221 patients were assessable.
Results:
A total of 227 patients were recruited, the full analysis set consisted of 221 patients. ORR was 42.6% (95% confidence interval (CI), 33.1 to 52.5) for CAF + placebo compared with 53.1% (95% CI, 43.5 to 62.5) for treatment A + CAF (P = .077). The median progression‐free survival (PFS) was 241 days for CAF + placebo v 366 days for treatment A + CAF; P = .145. Any adverse event occurred more frequently with CAF + treatment A, 95.5% vs. 88.4%, p=0.025. Neutropenia occurred for 91.2% with CAF + treatment A vs 77.7% with CAF + placebo, p=0.005. Treatment with treatment A did not affect the plasma concentration of doxorubicin.
Conclusion:
Treatment A + CAF was not more effective than CAF + placebo in patients with advanced or recurrent breast cancer.",no_spin,"This passage is about a study that wanted to see if a certain treatment (treatment A plus cyclophosphamide, doxorubicin, and fluorouracil) was better than a placebo (a sugar pill) for people with advanced or recurrent breast cancer. The study had 221 patients who were given either the treatment or the placebo and their responses were measured. The study found that the treatment was not better than the placebo in terms of how well the cancer responded to the treatment or how long it took for the cancer to come back. However, the treatment did cause more side effects, such as low white blood cell count and nausea.",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.4034191}, {'token': '4', 'bytes': [52], 'logprob': -1.1534191}, {'token': '2', 'bytes': [50], 'logprob': -4.153419}, {'token': '5', 'bytes': [53], 'logprob': -7.278419}, {'token': '6', 'bytes': [54], 'logprob': -11.7784195}, {'token': '1', 'bytes': [49], 'logprob': -12.6534195}, {'token': '0', 'bytes': [48], 'logprob': -16.77842}, {'token': '7', 'bytes': [55], 'logprob': -17.02842}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.52842}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.15342}, {'token': ' ', 'bytes': [32], 'logprob': -18.90342}, {'token': '-', 'bytes': [45], 'logprob': -21.27842}, {'token': 'Three', 'bytes': [84, 104, 114, 101, 101], 'logprob': -21.90342}, {'token': '30', 'bytes': [51, 48], 'logprob': -22.02842}, {'token': '03', 'bytes': [48, 51], 'logprob': -22.34092}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.34092}, {'token': 'I', 'bytes': [73], 'logprob': -22.40342}, {'token': '04', 'bytes': [48, 52], 'logprob': -22.40342}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.40342}, {'token': '  ', 'bytes': [32, 32], 'logprob': -22.46592}]",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.48358586}, {'token': '7', 'bytes': [55], 'logprob': -0.98358583}, {'token': '5', 'bytes': [53], 'logprob': -4.733586}, {'token': '8', 'bytes': [56], 'logprob': -7.358586}, {'token': '4', 'bytes': [52], 'logprob': -10.358586}, {'token': '9', 'bytes': [57], 'logprob': -16.608585}, {'token': '3', 'bytes': [51], 'logprob': -16.733585}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.421085}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.546085}, {'token': ' ', 'bytes': [32], 'logprob': -19.233585}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -19.671085}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -20.233585}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -20.608585}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -21.171085}, {'token': 'C', 'bytes': [67], 'logprob': -21.546085}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -21.546085}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -21.608585}, {'token': '-', 'bytes': [45], 'logprob': -22.046085}, {'token': '2', 'bytes': [50], 'logprob': -22.171085}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -22.171085}]",5,5,"[{'token': '5', 'bytes': [53], 'logprob': -0.5678868}, {'token': '6', 'bytes': [54], 'logprob': -1.3178868}, {'token': '4', 'bytes': [52], 'logprob': -1.8178868}, {'token': '7', 'bytes': [55], 'logprob': -6.317887}, {'token': '3', 'bytes': [51], 'logprob': -6.567887}, {'token': '2', 'bytes': [50], 'logprob': -14.442886}, {'token': '8', 'bytes': [56], 'logprob': -15.192886}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.067886}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.192886}, {'token': ' ', 'bytes': [32], 'logprob': -21.505386}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -22.755386}, {'token': ' five', 'bytes': [32, 102, 105, 118, 101], 'logprob': -22.942886}, {'token': '1', 'bytes': [49], 'logprob': -23.317886}, {'token': '５', 'bytes': [239, 188, 149], 'logprob': -23.505386}, {'token': 'Five', 'bytes': [70, 105, 118, 101], 'logprob': -23.567886}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -23.755386}, {'token': '9', 'bytes': [57], 'logprob': -23.817886}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -24.192886}, {'token': '４', 'bytes': [239, 188, 148], 'logprob': -24.380386}, {'token': 'C', 'bytes': [67], 'logprob': -24.442886}]",4,4,"[{'token': '4', 'bytes': [52], 'logprob': -0.3775232}, {'token': '5', 'bytes': [53], 'logprob': -1.5025232}, {'token': '3', 'bytes': [51], 'logprob': -2.5025232}, {'token': '6', 'bytes': [54], 'logprob': -4.7525234}, {'token': '2', 'bytes': [50], 'logprob': -6.8775234}, {'token': '7', 'bytes': [55], 'logprob': -8.002523}, {'token': '8', 'bytes': [56], 'logprob': -14.127523}, {'token': '1', 'bytes': [49], 'logprob': -14.377523}, {'token': '0', 'bytes': [48], 'logprob': -16.127523}, {'token': '<|end|>', 'bytes': None, 'logprob': -16.877523}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.565023}, {'token': '9', 'bytes': [57], 'logprob': -18.252523}, {'token': ' ', 'bytes': [32], 'logprob': -19.815023}, {'token': 'I', 'bytes': [73], 'logprob': -20.752523}, {'token': 'C', 'bytes': [67], 'logprob': -21.877523}, {'token': '４', 'bytes': [239, 188, 148], 'logprob': -21.940023}, {'token': '-', 'bytes': [45], 'logprob': -22.002523}, {'token': '.', 'bytes': [46], 'logprob': -22.127523}, {'token': '04', 'bytes': [48, 52], 'logprob': -22.127523}, {'token': 'D', 'bytes': [68], 'logprob': -22.252523}]",4,4,"[{'token': '4', 'bytes': [52], 'logprob': -0.452367}, {'token': '5', 'bytes': [53], 'logprob': -1.7023671}, {'token': '3', 'bytes': [51], 'logprob': -1.8273671}, {'token': '6', 'bytes': [54], 'logprob': -3.952367}, {'token': '2', 'bytes': [50], 'logprob': -6.702367}, {'token': '7', 'bytes': [55], 'logprob': -7.952367}, {'token': '1', 'bytes': [49], 'logprob': -13.702367}, {'token': '8', 'bytes': [56], 'logprob': -13.827367}, {'token': '0', 'bytes': [48], 'logprob': -16.327368}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.202368}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.452368}, {'token': '9', 'bytes': [57], 'logprob': -17.764868}, {'token': ' ', 'bytes': [32], 'logprob': -18.327368}, {'token': '-', 'bytes': [45], 'logprob': -21.264868}, {'token': 'I', 'bytes': [73], 'logprob': -21.577368}, {'token': 'C', 'bytes': [67], 'logprob': -21.889868}, {'token': '.', 'bytes': [46], 'logprob': -22.014868}, {'token': '04', 'bytes': [48, 52], 'logprob': -22.014868}, {'token': '(', 'bytes': [40], 'logprob': -22.202368}, {'token': 'D', 'bytes': [68], 'logprob': -22.202368}]"
54,17264336,Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial,J Clin Oncol,"Purpose:
In 1996, we initiated the multicenter phase III randomized trial to compare the effect on disease‐free survival (DFS) of experimental treatment A versus comparator B after breast‐conserving surgery for stages I and II breast cancer. This report presents the clinical results with a median follow‐up of 60 months.
Patients and methods:
Between February 1996 and April 2000, 716 patients were entered onto this trial (358 randomized to comparator B and 358 to treatment A) and respectively 343 and 352 patients were included in the analysis. Adjuvant treatment began within 6 weeks after surgery. The primary endpoint was disease‐free survival (DFS) defined as the time from randomization to the first treatment failure (in the ipsilateral breast, in the axillary/infraclavicular/IMCs, or at a distant site) or death (if no recurrence had been noted).
Results:
There was no statistically significant difference in treatment in the 5‐year DFS (80% in both groups; P = .83), locoregional recurrence‐free survival (LRFS; 92% in comparator B v 95% in treatment A; P = .76), metastasis‐free survival (87% in comparator B v 84% in treatment A; P = .55), or overall survival (90% in comparator B v 91% in treatment A; P = .76).
Conclusion:
Treatment A was not more effective than comparator B after breast‐conserving surgery for stages I and II breast cancer.",no_spin,This passage is about a study that compared two different treatments for breast cancer after surgery. The study followed 716 patients for 60 months and found that there was no significant difference in the effectiveness of the two treatments. The study looked at how long the patients lived without the cancer coming back or spreading to other parts of the body.,0,0,"[{'token': '0', 'bytes': [48], 'logprob': -0.010852086}, {'token': '2', 'bytes': [50], 'logprob': -5.010852}, {'token': '1', 'bytes': [49], 'logprob': -5.510852}, {'token': '3', 'bytes': [51], 'logprob': -9.385852}, {'token': '4', 'bytes': [52], 'logprob': -13.510852}, {'token': '5', 'bytes': [53], 'logprob': -15.385852}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.885853}, {'token': '6', 'bytes': [54], 'logprob': -20.385853}, {'token': ' ', 'bytes': [32], 'logprob': -20.510853}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.385853}, {'token': '02', 'bytes': [48, 50], 'logprob': -21.760853}, {'token': '01', 'bytes': [48, 49], 'logprob': -22.135853}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.510853}, {'token': '00', 'bytes': [48, 48], 'logprob': -23.073353}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -23.073353}, {'token': '7', 'bytes': [55], 'logprob': -23.135853}, {'token': '-', 'bytes': [45], 'logprob': -23.385853}, {'token': '０', 'bytes': [239, 188, 144], 'logprob': -24.010853}, {'token': 'I', 'bytes': [73], 'logprob': -24.385853}, {'token': '30', 'bytes': [51, 48], 'logprob': -24.510853}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.39477664}, {'token': '6', 'bytes': [54], 'logprob': -1.6447766}, {'token': '8', 'bytes': [56], 'logprob': -2.1447766}, {'token': '5', 'bytes': [53], 'logprob': -4.144777}, {'token': '9', 'bytes': [57], 'logprob': -9.144776}, {'token': '4', 'bytes': [52], 'logprob': -9.644776}, {'token': '3', 'bytes': [51], 'logprob': -13.769776}, {'token': '10', 'bytes': [49, 48], 'logprob': -16.269777}, {'token': '2', 'bytes': [50], 'logprob': -16.894777}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.644777}, {'token': ' ', 'bytes': [32], 'logprob': -19.269777}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.332277}, {'token': '1', 'bytes': [49], 'logprob': -20.269777}, {'token': '0', 'bytes': [48], 'logprob': -20.769777}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -21.144777}, {'token': '70', 'bytes': [55, 48], 'logprob': -21.332277}, {'token': 'C', 'bytes': [67], 'logprob': -21.894777}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -21.957277}, {'token': 'I', 'bytes': [73], 'logprob': -22.207277}, {'token': '-', 'bytes': [45], 'logprob': -22.644777}]",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.80253047}, {'token': '2', 'bytes': [50], 'logprob': -1.5525305}, {'token': '4', 'bytes': [52], 'logprob': -1.8025305}, {'token': '5', 'bytes': [53], 'logprob': -1.8025305}, {'token': '6', 'bytes': [54], 'logprob': -4.6775303}, {'token': '1', 'bytes': [49], 'logprob': -7.3025303}, {'token': '7', 'bytes': [55], 'logprob': -8.05253}, {'token': '0', 'bytes': [48], 'logprob': -10.30253}, {'token': '8', 'bytes': [56], 'logprob': -12.17753}, {'token': '9', 'bytes': [57], 'logprob': -18.17753}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.92753}, {'token': ' ', 'bytes': [32], 'logprob': -19.05253}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.55253}, {'token': '10', 'bytes': [49, 48], 'logprob': -21.49003}, {'token': 'I', 'bytes': [73], 'logprob': -22.17753}, {'token': '-', 'bytes': [45], 'logprob': -22.61503}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -22.61503}, {'token': 'C', 'bytes': [67], 'logprob': -23.05253}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -23.67753}, {'token': '.', 'bytes': [46], 'logprob': -23.74003}]",2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.2033435}, {'token': '3', 'bytes': [51], 'logprob': -2.2033434}, {'token': '0', 'bytes': [48], 'logprob': -2.9533434}, {'token': '1', 'bytes': [49], 'logprob': -4.2033434}, {'token': '4', 'bytes': [52], 'logprob': -5.2033434}, {'token': '5', 'bytes': [53], 'logprob': -6.9533434}, {'token': '6', 'bytes': [54], 'logprob': -12.328343}, {'token': '7', 'bytes': [55], 'logprob': -15.703343}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.078344}, {'token': '8', 'bytes': [56], 'logprob': -18.703344}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.953344}, {'token': '02', 'bytes': [48, 50], 'logprob': -19.203344}, {'token': ' ', 'bytes': [32], 'logprob': -19.265844}, {'token': '9', 'bytes': [57], 'logprob': -20.140844}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.015844}, {'token': '30', 'bytes': [51, 48], 'logprob': -21.078344}, {'token': '-', 'bytes': [45], 'logprob': -21.390844}, {'token': 'I', 'bytes': [73], 'logprob': -21.578344}, {'token': '10', 'bytes': [49, 48], 'logprob': -21.703344}, {'token': '25', 'bytes': [50, 53], 'logprob': -21.703344}]",2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.5075549}, {'token': '0', 'bytes': [48], 'logprob': -1.2575549}, {'token': '3', 'bytes': [51], 'logprob': -2.507555}, {'token': '1', 'bytes': [49], 'logprob': -3.632555}, {'token': '4', 'bytes': [52], 'logprob': -5.382555}, {'token': '5', 'bytes': [53], 'logprob': -6.757555}, {'token': '6', 'bytes': [54], 'logprob': -11.382555}, {'token': '7', 'bytes': [55], 'logprob': -14.257555}, {'token': '8', 'bytes': [56], 'logprob': -17.007555}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.257555}, {'token': ' ', 'bytes': [32], 'logprob': -18.132555}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.132555}, {'token': '9', 'bytes': [57], 'logprob': -18.757555}, {'token': '02', 'bytes': [48, 50], 'logprob': -19.320055}, {'token': 'I', 'bytes': [73], 'logprob': -20.507555}, {'token': '-', 'bytes': [45], 'logprob': -20.695055}, {'token': '10', 'bytes': [49, 48], 'logprob': -20.882555}, {'token': '03', 'bytes': [48, 51], 'logprob': -20.945055}, {'token': '30', 'bytes': [51, 48], 'logprob': -21.382555}, {'token': '01', 'bytes': [48, 49], 'logprob': -21.382555}]"
53,17264336,Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial,J Clin Oncol,"Purpose:
In 1996, we initiated the multicenter phase III randomized trial to compare the effect on disease‐free survival (DFS) of experimental treatment A versus comparator B after breast‐conserving surgery for stages I and II breast cancer. This report presents the clinical results with a median follow‐up of 60 months.
Patients and methods:
Between February 1996 and April 2000, 716 patients were entered onto this trial. Adjuvant treatment began within 6 weeks after surgery.
Results:
There was no statistically significant difference in treatment in the 5‐year DFS (80% in both groups; P = .83), locoregional recurrence‐free survival (LRFS; 92% in comparator B v 95% in treatment A; P = .76), metastasis‐free survival (87% in comparator B v 84% in treatment A; P = .55), or overall survival (90% in comparator B v 91% in treatment A; P = .76). Nevertheless, in the node‐positive subgroup, the 5‐year LRFS was statistically better in the treatment A arm (97% in treatment A v 91% in comparator B; P = .02), corresponding to a risk of locoregional recurrence decreased by 39% (hazard ratio, 0.61; 95% CI, 0.38 to 0.93).
Conclusion:
This treatment protocol remains an appealing clinical option for many women with operable breast cancer at a high risk of recurrence. Combination treatments with new drugs for breast cancer are warranted.",spin,"The passage is about a study that compared two different treatments for breast cancer after surgery. The study was done over a period of 4 years and included 716 patients. The results showed that there was no significant difference in the 5‐year disease‐free survival between the two treatments. However, in a group of patients who had cancer in their lymph nodes, the treatment that included a new drug was better at preventing the cancer from coming back in that area. The study suggests that this treatment option is a good choice for women with breast cancer who are at a high risk of recurrence. The authors also suggest that more research is needed to find better treatments for breast cancer.",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.3145517}, {'token': '6', 'bytes': [54], 'logprob': -1.3145517}, {'token': '8', 'bytes': [56], 'logprob': -6.814552}, {'token': '5', 'bytes': [53], 'logprob': -8.564551}, {'token': '4', 'bytes': [52], 'logprob': -14.189551}, {'token': '3', 'bytes': [51], 'logprob': -18.314552}, {'token': '9', 'bytes': [57], 'logprob': -18.689552}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.939552}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.939552}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -21.314552}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -21.377052}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -21.689552}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -21.689552}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -22.252052}, {'token': '2', 'bytes': [50], 'logprob': -22.939552}, {'token': ' ', 'bytes': [32], 'logprob': -23.002052}, {'token': 'C', 'bytes': [67], 'logprob': -23.189552}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -23.252052}, {'token': '70', 'bytes': [55, 48], 'logprob': -23.439552}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -23.502052}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.110208444}, {'token': '8', 'bytes': [56], 'logprob': -2.3602085}, {'token': '6', 'bytes': [54], 'logprob': -4.6102085}, {'token': '5', 'bytes': [53], 'logprob': -13.2352085}, {'token': '9', 'bytes': [57], 'logprob': -14.7352085}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -19.360209}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -20.485209}, {'token': '4', 'bytes': [52], 'logprob': -20.985209}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -21.422709}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -21.672709}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -21.922709}, {'token': '<|end|>', 'bytes': None, 'logprob': -22.110209}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -22.172709}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -22.922709}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -23.110209}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -23.297709}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -23.422709}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -23.672709}, {'token': '七', 'bytes': [228, 184, 131], 'logprob': -24.047709}, {'token': 'Eight', 'bytes': [69, 105, 103, 104, 116], 'logprob': -24.110209}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.062087677}, {'token': '8', 'bytes': [56], 'logprob': -3.0620878}, {'token': '6', 'bytes': [54], 'logprob': -4.3120875}, {'token': '5', 'bytes': [53], 'logprob': -12.437088}, {'token': '9', 'bytes': [57], 'logprob': -15.687088}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -18.312088}, {'token': '4', 'bytes': [52], 'logprob': -19.062088}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -19.437088}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.437088}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -21.249588}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -21.437088}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -21.562088}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -21.874588}, {'token': '<|end|>', 'bytes': None, 'logprob': -22.249588}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -22.562088}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -22.812088}, {'token': ' seventh', 'bytes': [32, 115, 101, 118, 101, 110, 116, 104], 'logprob': -23.124588}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -23.187088}, {'token': '七', 'bytes': [228, 184, 131], 'logprob': -23.249588}, {'token': ' sieben', 'bytes': [32, 115, 105, 101, 98, 101, 110], 'logprob': -23.499588}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.32043263}, {'token': '8', 'bytes': [56], 'logprob': -1.3204327}, {'token': '6', 'bytes': [54], 'logprob': -4.9454327}, {'token': '5', 'bytes': [53], 'logprob': -10.820433}, {'token': '9', 'bytes': [57], 'logprob': -11.570433}, {'token': '4', 'bytes': [52], 'logprob': -16.945433}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -20.070433}, {'token': '3', 'bytes': [51], 'logprob': -20.382933}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -20.820433}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.820433}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -21.570433}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -21.695433}, {'token': '10', 'bytes': [49, 48], 'logprob': -22.445433}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -22.445433}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -22.757933}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -22.820433}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -22.882933}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -23.007933}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -23.445433}, {'token': 'I', 'bytes': [73], 'logprob': -23.882933}]",8,8,"[{'token': '8', 'bytes': [56], 'logprob': -0.5775883}, {'token': '7', 'bytes': [55], 'logprob': -0.8275883}, {'token': '6', 'bytes': [54], 'logprob': -6.452588}, {'token': '9', 'bytes': [57], 'logprob': -9.577588}, {'token': '5', 'bytes': [53], 'logprob': -13.202588}, {'token': '4', 'bytes': [52], 'logprob': -18.452589}, {'token': '10', 'bytes': [49, 48], 'logprob': -20.702589}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.952589}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -21.202589}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.640089}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -21.702589}, {'token': '3', 'bytes': [51], 'logprob': -21.952589}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -22.140089}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -22.640089}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -22.765089}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -23.577589}, {'token': 'Eight', 'bytes': [69, 105, 103, 104, 116], 'logprob': -23.702589}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -23.827589}, {'token': '70', 'bytes': [55, 48], 'logprob': -23.827589}, {'token': 'I', 'bytes': [73], 'logprob': -24.140089}]"
4,17530429,"Phase III randomized multicenter study on the effects of adjuvant CMF in patients with node-negative, rapidly proliferating breast cancer: twelve-year results and retrospective subgroup analysis",Breast Cancer Res Treat,"The randomized multicenter study on rapidly proliferating breast cancer was activated at the end of the 1980s. The present work investigated whether and to what degree the short‐term advantages observed from treatment A were maintained at a longer follow‐up. Two hundred and eighty‐one patients with node‐negative and high TLI tumors were randomized to receive treatment A or no further treatment. Overall, at a median follow‐up of 12 years, 99 relapses have been observed, 55 in the control arm and 44 in the treatment A arm. At a median follow‐up of 12 years, there was no statistically significant difference between treatment A and no treatment for the cumulative incidence of relapse, Hazard Ratio (HR) [95% confidence interval] = 0.75 [0.50‐1.13]; p= 0.17 and for the cumulative incidence of death HR = 0.80 [0.48‐1.33], p= 0.38. The incidence of contralateral tumors was similar in the two arms (10 vs. 11). Treatment A was not more effective than no treatment on rapidly proliferating breast cancer.",no_spin,"This passage is about a study that looked at a treatment for a type of breast cancer called rapidly proliferating breast cancer. The study was done in the 1980s and it looked at whether the short-term benefits of the treatment were still true after a longer period of time. The study included 281 patients who had a type of breast cancer that was not spreading to other parts of their body (node-negative) and had a high risk of coming back (high TLI). The patients were randomly assigned to either receive the treatment or no further treatment. After a median follow-up of 12 years, the study found that there was no statistically significant difference between the two groups for the risk of the cancer coming back (cumulative incidence of relapse) or for the risk of death. The study also found that the number of patients who got a new type of cancer (contralateral tumors) was similar in both groups. Overall, the study suggests that the treatment did not work better than not receiving any treatment for rapidly proliferating breast cancer.",2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.38080773}, {'token': '1', 'bytes': [49], 'logprob': -1.6308078}, {'token': '0', 'bytes': [48], 'logprob': -2.1308076}, {'token': '3', 'bytes': [51], 'logprob': -6.130808}, {'token': '4', 'bytes': [52], 'logprob': -12.755808}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -15.380808}, {'token': '5', 'bytes': [53], 'logprob': -17.505808}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.255808}, {'token': '02', 'bytes': [48, 50], 'logprob': -18.630808}, {'token': ' ', 'bytes': [32], 'logprob': -19.005808}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -19.005808}, {'token': '01', 'bytes': [48, 49], 'logprob': -19.818308}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -20.193308}, {'token': ' Score', 'bytes': [32, 83, 99, 111, 114, 101], 'logprob': -20.568308}, {'token': '6', 'bytes': [54], 'logprob': -20.755808}, {'token': '-', 'bytes': [45], 'logprob': -21.193308}, {'token': 'I', 'bytes': [73], 'logprob': -21.193308}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.443308}, {'token': 'Scores', 'bytes': [83, 99, 111, 114, 101, 115], 'logprob': -21.755808}, {'token': '_score', 'bytes': [95, 115, 99, 111, 114, 101], 'logprob': -21.943308}]",5,5,"[{'token': '5', 'bytes': [53], 'logprob': -0.55178255}, {'token': '6', 'bytes': [54], 'logprob': -1.3017826}, {'token': '4', 'bytes': [52], 'logprob': -1.9267826}, {'token': '7', 'bytes': [55], 'logprob': -5.3017826}, {'token': '3', 'bytes': [51], 'logprob': -6.5517826}, {'token': '8', 'bytes': [56], 'logprob': -12.551783}, {'token': '2', 'bytes': [50], 'logprob': -13.426783}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.301783}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.989283}, {'token': ' ', 'bytes': [32], 'logprob': -18.489283}, {'token': '9', 'bytes': [57], 'logprob': -18.801783}, {'token': '1', 'bytes': [49], 'logprob': -20.176783}, {'token': 'C', 'bytes': [67], 'logprob': -20.489283}, {'token': '0', 'bytes': [48], 'logprob': -20.989283}, {'token': '-', 'bytes': [45], 'logprob': -21.614283}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.926783}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.051783}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -22.176783}, {'token': 'I', 'bytes': [73], 'logprob': -22.301783}, {'token': '**', 'bytes': [42, 42], 'logprob': -22.364283}]",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.26752827}, {'token': '2', 'bytes': [50], 'logprob': -1.7675283}, {'token': '4', 'bytes': [52], 'logprob': -2.7675283}, {'token': '5', 'bytes': [53], 'logprob': -6.892528}, {'token': '1', 'bytes': [49], 'logprob': -9.017529}, {'token': '6', 'bytes': [54], 'logprob': -11.267529}, {'token': '0', 'bytes': [48], 'logprob': -11.517529}, {'token': '7', 'bytes': [55], 'logprob': -15.642529}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.892529}, {'token': ' ', 'bytes': [32], 'logprob': -18.267529}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.267529}, {'token': '8', 'bytes': [56], 'logprob': -19.955029}, {'token': '9', 'bytes': [57], 'logprob': -21.580029}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.580029}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.892529}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.955029}, {'token': '02', 'bytes': [48, 50], 'logprob': -22.205029}, {'token': '-', 'bytes': [45], 'logprob': -22.330029}, {'token': 'I', 'bytes': [73], 'logprob': -22.392529}, {'token': '30', 'bytes': [51, 48], 'logprob': -22.642529}]",2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.20995012}, {'token': '3', 'bytes': [51], 'logprob': -1.7099501}, {'token': '1', 'bytes': [49], 'logprob': -5.33495}, {'token': '4', 'bytes': [52], 'logprob': -6.08495}, {'token': '0', 'bytes': [48], 'logprob': -6.58495}, {'token': '5', 'bytes': [53], 'logprob': -10.70995}, {'token': '6', 'bytes': [54], 'logprob': -15.33495}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.58495}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -19.08495}, {'token': ' ', 'bytes': [32], 'logprob': -19.20995}, {'token': '7', 'bytes': [55], 'logprob': -19.70995}, {'token': '02', 'bytes': [48, 50], 'logprob': -20.20995}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.20995}, {'token': '30', 'bytes': [51, 48], 'logprob': -22.20995}, {'token': '8', 'bytes': [56], 'logprob': -22.33495}, {'token': '9', 'bytes': [57], 'logprob': -22.33495}, {'token': 'I', 'bytes': [73], 'logprob': -22.39745}, {'token': '-', 'bytes': [45], 'logprob': -22.45995}, {'token': '04', 'bytes': [48, 52], 'logprob': -22.95995}, {'token': '01', 'bytes': [48, 49], 'logprob': -23.20995}]",2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.21244095}, {'token': '3', 'bytes': [51], 'logprob': -1.712441}, {'token': '1', 'bytes': [49], 'logprob': -4.962441}, {'token': '4', 'bytes': [52], 'logprob': -5.962441}, {'token': '0', 'bytes': [48], 'logprob': -6.587441}, {'token': '5', 'bytes': [53], 'logprob': -10.8374405}, {'token': '6', 'bytes': [54], 'logprob': -15.2124405}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.33744}, {'token': ' ', 'bytes': [32], 'logprob': -18.58744}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.58744}, {'token': '7', 'bytes': [55], 'logprob': -19.21244}, {'token': '02', 'bytes': [48, 50], 'logprob': -20.21244}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -20.83744}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.02494}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.14994}, {'token': 'I', 'bytes': [73], 'logprob': -21.58744}, {'token': '-', 'bytes': [45], 'logprob': -21.64994}, {'token': '8', 'bytes': [56], 'logprob': -21.77494}, {'token': '9', 'bytes': [57], 'logprob': -21.77494}, {'token': ' Score', 'bytes': [32, 83, 99, 111, 114, 101], 'logprob': -22.27494}]"
3,17530429,"Phase III randomized multicenter study on the effects of adjuvant CMF in patients with node-negative, rapidly proliferating breast cancer: twelve-year results and retrospective subgroup analysis",Breast Cancer Res Treat,"The randomized multicenter study on rapidly proliferating breast cancer was activated at the end of the 1980s. The present work investigated whether and to what degree the short‐term advantages observed from treatment A were maintained at a longer follow‐up. Two hundred and eighty‐one patients with node‐negative and high TLI tumors were randomized to receive treatment A or no further treatment. At a median follow‐up of 12 years, treatment A produced a 25% and 20% relative reduction in relapse and death cumulative incidence, respectively. A breakdown analysis identified a subgroup of patients with intermediate proliferating tumors for whom a 70% and 73% reduction in relapse and death was observed in the intention‐to‐treat population. An even higher reduction of 80% and 84% in relapse and death was seen for the patients who had received the full treatment A dose. We identified a subgroup of patients with intermediate proliferating tumors in whom the high benefit obtained from treatment A was maintained at a long‐term follow up.",spin,"This passage is about a study that looked at a treatment for a type of breast cancer called rapidly proliferating breast cancer. The study was done in the 1980s and it wanted to see if the short-term benefits of the treatment were still true after a longer period of time. They found that the treatment did help reduce the chances of the cancer coming back or causing harm, but the benefit was even greater for a certain group of patients.",8,8,"[{'token': '8', 'bytes': [56], 'logprob': -0.08899356}, {'token': '9', 'bytes': [57], 'logprob': -2.4639935}, {'token': '7', 'bytes': [55], 'logprob': -9.838994}, {'token': '10', 'bytes': [49, 48], 'logprob': -15.088994}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -15.338994}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -15.713994}, {'token': ' nine', 'bytes': [32, 110, 105, 110, 101], 'logprob': -16.588993}, {'token': 'Eight', 'bytes': [69, 105, 103, 104, 116], 'logprob': -16.963993}, {'token': ' Eight', 'bytes': [32, 69, 105, 103, 104, 116], 'logprob': -17.838993}, {'token': 'Nine', 'bytes': [78, 105, 110, 101], 'logprob': -18.401493}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -18.588993}, {'token': ' Nine', 'bytes': [32, 78, 105, 110, 101], 'logprob': -19.026493}, {'token': 'nine', 'bytes': [110, 105, 110, 101], 'logprob': -19.026493}, {'token': ' acht', 'bytes': [32, 97, 99, 104, 116], 'logprob': -19.588993}, {'token': ' вось', 'bytes': [32, 208, 178, 208, 190, 209, 129, 209, 140], 'logprob': -19.651493}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -19.901493}, {'token': '85', 'bytes': [56, 53], 'logprob': -20.026493}, {'token': '-eight', 'bytes': [45, 101, 105, 103, 104, 116], 'logprob': -20.026493}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.026493}, {'token': ' ocho', 'bytes': [32, 111, 99, 104, 111], 'logprob': -20.463993}]",8,8,"[{'token': '8', 'bytes': [56], 'logprob': -0.004224305}, {'token': '7', 'bytes': [55], 'logprob': -5.6292243}, {'token': '9', 'bytes': [57], 'logprob': -7.3792243}, {'token': '6', 'bytes': [54], 'logprob': -17.504225}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -18.129225}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -19.004225}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -20.004225}, {'token': 'Eight', 'bytes': [69, 105, 103, 104, 116], 'logprob': -20.379225}, {'token': ' Eight', 'bytes': [32, 69, 105, 103, 104, 116], 'logprob': -21.191725}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -21.379225}, {'token': '<|end|>', 'bytes': None, 'logprob': -22.191725}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -22.566725}, {'token': ' acht', 'bytes': [32, 97, 99, 104, 116], 'logprob': -22.629225}, {'token': ' ocho', 'bytes': [32, 111, 99, 104, 111], 'logprob': -22.629225}, {'token': ' вось', 'bytes': [32, 208, 178, 208, 190, 209, 129, 209, 140], 'logprob': -22.691725}, {'token': '-eight', 'bytes': [45, 101, 105, 103, 104, 116], 'logprob': -22.816725}, {'token': '10', 'bytes': [49, 48], 'logprob': -23.191725}, {'token': '۸', 'bytes': [219, 184], 'logprob': -23.379225}, {'token': '85', 'bytes': [56, 53], 'logprob': -24.129225}, {'token': ' huit', 'bytes': [32, 104, 117, 105, 116], 'logprob': -24.129225}]",8,8,"[{'token': '8', 'bytes': [56], 'logprob': -0.1602686}, {'token': '9', 'bytes': [57], 'logprob': -1.9102685}, {'token': '7', 'bytes': [55], 'logprob': -10.035269}, {'token': '10', 'bytes': [49, 48], 'logprob': -14.535269}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -17.535269}, {'token': ' nine', 'bytes': [32, 110, 105, 110, 101], 'logprob': -17.660269}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -18.660269}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -19.472769}, {'token': ' вось', 'bytes': [32, 208, 178, 208, 190, 209, 129, 209, 140], 'logprob': -20.035269}, {'token': 'Eight', 'bytes': [69, 105, 103, 104, 116], 'logprob': -20.347769}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.472769}, {'token': ' acht', 'bytes': [32, 97, 99, 104, 116], 'logprob': -20.722769}, {'token': ' Eight', 'bytes': [32, 69, 105, 103, 104, 116], 'logprob': -20.722769}, {'token': ' Nine', 'bytes': [32, 78, 105, 110, 101], 'logprob': -20.910269}, {'token': 'nine', 'bytes': [110, 105, 110, 101], 'logprob': -20.910269}, {'token': 'Nine', 'bytes': [78, 105, 110, 101], 'logprob': -20.910269}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.222769}, {'token': ' ocho', 'bytes': [32, 111, 99, 104, 111], 'logprob': -21.722769}, {'token': '-eight', 'bytes': [45, 101, 105, 103, 104, 116], 'logprob': -22.035269}, {'token': '6', 'bytes': [54], 'logprob': -22.097769}]",8,8,"[{'token': '8', 'bytes': [56], 'logprob': -0.22554173}, {'token': '9', 'bytes': [57], 'logprob': -1.6005417}, {'token': '7', 'bytes': [55], 'logprob': -8.975542}, {'token': '10', 'bytes': [49, 48], 'logprob': -13.225542}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -14.850542}, {'token': ' nine', 'bytes': [32, 110, 105, 110, 101], 'logprob': -14.975542}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -16.350542}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -17.475542}, {'token': ' вось', 'bytes': [32, 208, 178, 208, 190, 209, 129, 209, 140], 'logprob': -17.538042}, {'token': 'Eight', 'bytes': [69, 105, 103, 104, 116], 'logprob': -17.850542}, {'token': ' Eight', 'bytes': [32, 69, 105, 103, 104, 116], 'logprob': -18.350542}, {'token': 'nine', 'bytes': [110, 105, 110, 101], 'logprob': -18.350542}, {'token': ' acht', 'bytes': [32, 97, 99, 104, 116], 'logprob': -18.538042}, {'token': 'Nine', 'bytes': [78, 105, 110, 101], 'logprob': -18.538042}, {'token': ' Nine', 'bytes': [32, 78, 105, 110, 101], 'logprob': -18.850542}, {'token': ' ocho', 'bytes': [32, 111, 99, 104, 111], 'logprob': -18.913042}, {'token': '-eight', 'bytes': [45, 101, 105, 103, 104, 116], 'logprob': -19.538042}, {'token': '９', 'bytes': [239, 188, 153], 'logprob': -19.725542}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.850542}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -19.913042}]",8,8,"[{'token': '8', 'bytes': [56], 'logprob': -0.100936376}, {'token': '9', 'bytes': [57], 'logprob': -2.3509364}, {'token': '7', 'bytes': [55], 'logprob': -7.2259364}, {'token': '10', 'bytes': [49, 48], 'logprob': -13.225936}, {'token': '6', 'bytes': [54], 'logprob': -16.100937}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -19.975937}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -20.225937}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -20.475937}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.913437}, {'token': ' nine', 'bytes': [32, 110, 105, 110, 101], 'logprob': -21.100937}, {'token': 'Eight', 'bytes': [69, 105, 103, 104, 116], 'logprob': -21.788437}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.850937}, {'token': '5', 'bytes': [53], 'logprob': -22.038437}, {'token': ' вось', 'bytes': [32, 208, 178, 208, 190, 209, 129, 209, 140], 'logprob': -22.350937}, {'token': '85', 'bytes': [56, 53], 'logprob': -23.038437}, {'token': 'nine', 'bytes': [110, 105, 110, 101], 'logprob': -23.163437}, {'token': ' Eight', 'bytes': [32, 69, 105, 103, 104, 116], 'logprob': -23.225937}, {'token': 'Nine', 'bytes': [78, 105, 110, 101], 'logprob': -23.225937}, {'token': ' ocho', 'bytes': [32, 111, 99, 104, 111], 'logprob': -23.350937}, {'token': '９', 'bytes': [239, 188, 153], 'logprob': -23.413437}]"
36,18794551,Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group,J Clin Oncol,"Purpose:
This phase III randomized open‐label clinical trial was designed to evaluate the efficacy and safety of treatment A versus comparator B as first‐line treatment for metastatic breast cancer (MBC) in postmenopausal women.
Patients and methods:
The study was conducted at 81 centers and enrolled postmenopausal patients with measurable hormone‐sensitive metastatic or locally advanced breast cancer. Prior adjuvant chemotherapy and/or comparator B were allowed. One previous chemotherapy regimen and no prior hormone therapy for advanced disease were permitted. Patients were randomly assigned to receive treatment A or comparator B until disease progression or unacceptable toxicity occurred. Progression‐free survival (PFS) as the primary study end point.
Results:
Of the 382 patients randomized at 79 sites, 371 (182 treatment A, 189 comparator B) were included in the analysis. No treatment related death were observed. A total of 319 events (progression or death) were observed: 161 (85%) in the comparator B arm and 158 (87%) in the treatment A arm. Median progression‐ free survival (PFS) (primary outcome) was 5.8 months with comparator B (95% CI, 5.3 to 8.1 months) vs 9.9 months; (95% CI, 8.7 to 11.8 months) with treatment A, HR = 0.84 (95% CI, 0.67 to 1.05), p = .121. No statistically significant differences in overall survival were observed between treatment arms: median overall survival for comparator B and treatment A was 43.3 vs. 37.2 months, HR=1.04 (95% CI, 0.76 to 1.41). Overall response rate was respectively for treatment A and for comparator B, 46% vs. 31%; odds ratio=1.85; 95% CI, 1.21 to 2.82; P = .005.
Conclusion:
Treatment A was not more effective than comparator B for metastatic breast cancer in postmenopausal women on overall survival.",no_spin,"This is a study about a new treatment for breast cancer in women who have cancer that has spread to other parts of their body. The study was done at many hospitals and included women who had a type of breast cancer that was sensitive to hormones. The women were randomly given either the new treatment or a different treatment to see which one worked better. The study looked at how long the women lived and how well their cancer responded to the treatment. The study found that the new treatment did not work better than the other treatment for overall survival, meaning how long the women lived. However, the new treatment did work better for how long the cancer did not grow back, which is called progression-free survival.",5,5,"[{'token': '5', 'bytes': [53], 'logprob': -0.7355136}, {'token': '6', 'bytes': [54], 'logprob': -1.2355137}, {'token': '4', 'bytes': [52], 'logprob': -1.4855137}, {'token': '3', 'bytes': [51], 'logprob': -5.8605137}, {'token': '7', 'bytes': [55], 'logprob': -7.1105137}, {'token': '2', 'bytes': [50], 'logprob': -12.735514}, {'token': '8', 'bytes': [56], 'logprob': -16.735514}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.610514}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -19.985514}, {'token': '1', 'bytes': [49], 'logprob': -20.860514}, {'token': ' ', 'bytes': [32], 'logprob': -21.860514}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -22.360514}, {'token': ' five', 'bytes': [32, 102, 105, 118, 101], 'logprob': -22.610514}, {'token': 'Five', 'bytes': [70, 105, 118, 101], 'logprob': -23.048014}, {'token': 'C', 'bytes': [67], 'logprob': -23.423014}, {'token': '５', 'bytes': [239, 188, 149], 'logprob': -23.423014}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -23.548014}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -23.548014}, {'token': 'five', 'bytes': [102, 105, 118, 101], 'logprob': -23.548014}, {'token': '-', 'bytes': [45], 'logprob': -23.735514}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.08497405}, {'token': '6', 'bytes': [54], 'logprob': -2.709974}, {'token': '8', 'bytes': [56], 'logprob': -4.2099743}, {'token': '5', 'bytes': [53], 'logprob': -9.459974}, {'token': '9', 'bytes': [57], 'logprob': -14.334974}, {'token': '4', 'bytes': [52], 'logprob': -15.709974}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.397474}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.709974}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -18.709974}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -18.897474}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -20.084974}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -20.209974}, {'token': ' ', 'bytes': [32], 'logprob': -20.459974}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -20.709974}, {'token': '3', 'bytes': [51], 'logprob': -21.084974}, {'token': 'C', 'bytes': [67], 'logprob': -21.772474}, {'token': '70', 'bytes': [55, 48], 'logprob': -21.897474}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -21.959974}, {'token': '七', 'bytes': [228, 184, 131], 'logprob': -21.959974}, {'token': 'I', 'bytes': [73], 'logprob': -22.272474}]",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.58301216}, {'token': '7', 'bytes': [55], 'logprob': -0.83301216}, {'token': '5', 'bytes': [53], 'logprob': -5.208012}, {'token': '8', 'bytes': [56], 'logprob': -6.458012}, {'token': '4', 'bytes': [52], 'logprob': -11.833013}, {'token': '3', 'bytes': [51], 'logprob': -17.708012}, {'token': '9', 'bytes': [57], 'logprob': -18.333012}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.208012}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.208012}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -20.583012}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -21.520512}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -21.770512}, {'token': ' ', 'bytes': [32], 'logprob': -22.395512}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -22.520512}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -22.708012}, {'token': ' seis', 'bytes': [32, 115, 101, 105, 115], 'logprob': -22.958012}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -23.395512}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -23.520512}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -23.833012}, {'token': '2', 'bytes': [50], 'logprob': -23.833012}]",5,5,"[{'token': '5', 'bytes': [53], 'logprob': -0.8522899}, {'token': '6', 'bytes': [54], 'logprob': -0.8522899}, {'token': '7', 'bytes': [55], 'logprob': -2.10229}, {'token': '4', 'bytes': [52], 'logprob': -3.72729}, {'token': '3', 'bytes': [51], 'logprob': -7.60229}, {'token': '8', 'bytes': [56], 'logprob': -7.85229}, {'token': '2', 'bytes': [50], 'logprob': -12.85229}, {'token': '9', 'bytes': [57], 'logprob': -15.10229}, {'token': '1', 'bytes': [49], 'logprob': -17.72729}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.72729}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.85229}, {'token': '0', 'bytes': [48], 'logprob': -18.53979}, {'token': ' ', 'bytes': [32], 'logprob': -20.22729}, {'token': 'I', 'bytes': [73], 'logprob': -21.28979}, {'token': '70', 'bytes': [55, 48], 'logprob': -21.66479}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -21.66479}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -21.91479}, {'token': '10', 'bytes': [49, 48], 'logprob': -22.16479}, {'token': 'C', 'bytes': [67], 'logprob': -22.47729}, {'token': '-', 'bytes': [45], 'logprob': -22.66479}]",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.48960388}, {'token': '5', 'bytes': [53], 'logprob': -1.4896039}, {'token': '7', 'bytes': [55], 'logprob': -1.9896039}, {'token': '4', 'bytes': [52], 'logprob': -3.739604}, {'token': '8', 'bytes': [56], 'logprob': -7.239604}, {'token': '3', 'bytes': [51], 'logprob': -7.739604}, {'token': '2', 'bytes': [50], 'logprob': -12.989604}, {'token': '9', 'bytes': [57], 'logprob': -14.239604}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.989603}, {'token': '1', 'bytes': [49], 'logprob': -17.864603}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.114603}, {'token': ' ', 'bytes': [32], 'logprob': -19.489603}, {'token': '0', 'bytes': [48], 'logprob': -19.989603}, {'token': 'I', 'bytes': [73], 'logprob': -21.052103}, {'token': '10', 'bytes': [49, 48], 'logprob': -21.177103}, {'token': 'C', 'bytes': [67], 'logprob': -22.239603}, {'token': '70', 'bytes': [55, 48], 'logprob': -22.302103}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.302103}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -22.302103}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.489603}]"
35,18794551,Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group,J Clin Oncol,"Purpose:
This phase III randomized open‐label clinical trial was designed to evaluate the efficacy and safety of treatment A versus comparator B as first‐line treatment for metastatic breast cancer (MBC) in postmenopausal women.
Patients and methods:
The study was conducted at 81 centers and enrolled postmenopausal patients with measurable hormone‐sensitive metastatic or locally advanced breast cancer. Prior adjuvant chemotherapy and/or comparator B were allowed. One previous chemotherapy regimen and no prior hormone therapy for advanced disease were permitted. Patients were randomly assigned to receive treatment A or comparator B until disease progression or unacceptable toxicity occurred.
Results:
A total of 371 patients enrolled at 79 sites (182 treatment A, 189 comparator B) were included in the analysis. Both treatments were generally well tolerated without major toxicity. Overall response rate was greater for treatment A than for comparator B (46% v 31%; odds ratio = 1.85; 95% CI, 1.21 to 2.82; P = .005). Median progression‐free survival (PFS) was longer with treatment A (9.9 months; 95% CI, 8.7 to 11.8 months) than with comparator B (5.8 months; 95% CI, 5.3 to 8.1 months). However, these early differences (Wilcoxon P = .028) did not translate to a longer‐term benefit in PFS, the primary study end point (log‐rank P = .121). There was also no difference in survival between both study arms.
Conclusion:
Treatment A is an effective and well‐tolerated first‐line hormonal treatment for postmenopausal women with MBC and offers significant early improvement in time to tumor progression when compared with comparator B.",spin,"This is a story about a study that looked at two different treatments for a type of cancer called breast cancer. The study was done with women who had cancer that had spread to other parts of their body and who were going through menopause. The two treatments were compared to see which one worked better. The first treatment was called treatment A and the second treatment was called comparator B. The study was done at many different places and included a lot of women. Both treatments were generally safe, but treatment A worked better than comparator B in the short term. However, the study found that the difference in how well the treatments worked did not last in the long term. Overall, treatment A was a good choice for women with this type of cancer because it worked well and was safe.",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.16047657}, {'token': '8', 'bytes': [56], 'logprob': -1.9104766}, {'token': '6', 'bytes': [54], 'logprob': -8.285477}, {'token': '9', 'bytes': [57], 'logprob': -14.910477}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -16.910477}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -19.160477}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -19.160477}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -19.285477}, {'token': '5', 'bytes': [53], 'logprob': -19.410477}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -19.597977}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -20.160477}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -20.410477}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -20.535477}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.910477}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.097977}, {'token': 'Eight', 'bytes': [69, 105, 103, 104, 116], 'logprob': -21.285477}, {'token': ' seventh', 'bytes': [32, 115, 101, 118, 101, 110, 116, 104], 'logprob': -21.472977}, {'token': '七', 'bytes': [228, 184, 131], 'logprob': -21.722977}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -21.847977}, {'token': '۷', 'bytes': [219, 183], 'logprob': -22.035477}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.037591416}, {'token': '8', 'bytes': [56], 'logprob': -3.4125915}, {'token': '6', 'bytes': [54], 'logprob': -5.5375915}, {'token': '5', 'bytes': [53], 'logprob': -13.537591}, {'token': '9', 'bytes': [57], 'logprob': -14.287591}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -17.662592}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.225092}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -18.475092}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.100092}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -19.475092}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -19.537592}, {'token': '4', 'bytes': [52], 'logprob': -19.725092}, {'token': ' ', 'bytes': [32], 'logprob': -20.725092}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -21.287592}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -21.475092}, {'token': '۷', 'bytes': [219, 183], 'logprob': -21.537592}, {'token': '75', 'bytes': [55, 53], 'logprob': -21.725092}, {'token': 'I', 'bytes': [73], 'logprob': -21.787592}, {'token': '70', 'bytes': [55, 48], 'logprob': -21.912592}, {'token': '七', 'bytes': [228, 184, 131], 'logprob': -21.912592}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.20172457}, {'token': '8', 'bytes': [56], 'logprob': -1.7017245}, {'token': '6', 'bytes': [54], 'logprob': -8.076725}, {'token': '9', 'bytes': [57], 'logprob': -14.576725}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -16.951725}, {'token': '5', 'bytes': [53], 'logprob': -17.576725}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -18.576725}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -19.826725}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -19.826725}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -19.951725}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -20.201725}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -20.514225}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -21.014225}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -21.076725}, {'token': ' seventh', 'bytes': [32, 115, 101, 118, 101, 110, 116, 104], 'logprob': -21.389225}, {'token': '۷', 'bytes': [219, 183], 'logprob': -21.639225}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -21.826725}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.889225}, {'token': '七', 'bytes': [228, 184, 131], 'logprob': -22.014225}, {'token': ' sieben', 'bytes': [32, 115, 105, 101, 98, 101, 110], 'logprob': -22.264225}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.47491825}, {'token': '8', 'bytes': [56], 'logprob': -0.97491825}, {'token': '6', 'bytes': [54], 'logprob': -7.0999184}, {'token': '9', 'bytes': [57], 'logprob': -11.099918}, {'token': '5', 'bytes': [53], 'logprob': -14.349918}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -19.099918}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -19.537418}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -20.162418}, {'token': '4', 'bytes': [52], 'logprob': -20.224918}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.224918}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -20.662418}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -20.787418}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.974918}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -21.349918}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -21.912418}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -22.162418}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -22.224918}, {'token': '۷', 'bytes': [219, 183], 'logprob': -22.474918}, {'token': 'Eight', 'bytes': [69, 105, 103, 104, 116], 'logprob': -22.787418}, {'token': ' ocho', 'bytes': [32, 111, 99, 104, 111], 'logprob': -22.787418}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.31892294}, {'token': '8', 'bytes': [56], 'logprob': -1.318923}, {'token': '6', 'bytes': [54], 'logprob': -5.193923}, {'token': '9', 'bytes': [57], 'logprob': -9.693923}, {'token': '5', 'bytes': [53], 'logprob': -10.318923}, {'token': '4', 'bytes': [52], 'logprob': -14.943923}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.443922}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.943922}, {'token': '3', 'bytes': [51], 'logprob': -19.193922}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -19.568922}, {'token': '10', 'bytes': [49, 48], 'logprob': -20.381422}, {'token': ' ', 'bytes': [32], 'logprob': -20.693922}, {'token': '70', 'bytes': [55, 48], 'logprob': -20.693922}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -21.318922}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -21.318922}, {'token': 'I', 'bytes': [73], 'logprob': -21.506422}, {'token': '75', 'bytes': [55, 53], 'logprob': -21.631422}, {'token': '2', 'bytes': [50], 'logprob': -22.193922}, {'token': '710', 'bytes': [55, 49, 48], 'logprob': -22.193922}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -22.443922}]"
18,18955454,"Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer",J Clin Oncol,"Purpose:
This phase III trial evaluated the efficacy of treatment A in locally advanced or metastatic breast cancer (MBC).
Patients and methods:
Women with MBC were randomly assigned to first‐line therapy with paclitaxel 175 mg/m2 every 3 weeks plus treatment A or placebo. The primary end point was time to progression (TTP); secondary end points were objective response rate (ORR), clinical benefit rate (CBR), event‐free survival (EFS), and overall survival (OS).
Results:
This trial enrolled 580 patients. In the intent‐to‐treat population (n = 579), there were no statistical significant differences between treatment A+paclitaxel and placebo+paclitaxel in TTP (29 v 22.9 weeks, HR = 0.87; 95% CI, 0.72 to 1.05; p = .142), EFS (25.1 vs. 22.6 weeks, HR = 0.90 [0.75‐1.08], p = 0.238), or OS (99.1 vs. 87 weeks, HR = 0.86 [0.7‐1.1], p = 0.216). The ORR and CBR were respectively for treatment A and placebo 35.1% vs. 25.3%, p = 0.008 and 40.5% vs. 31.9%, p = 0.025. The most common adverse events were alopecia, rash, and diarrhea. The incidence of diarrhea, rash, mucositis, and vomiting was significantly higher in the paclitaxel‐treatment A arm. The rate of cardiac events was low, and no statistical difference was observed between treatment arms. AEs led to treatment discontinuation in 48 patients (16%) in the paclitaxel‐treatment A arm compared with 20 patients (7%) in the paclitaxel‐placebo arm.
Conclusion:
Treatment A plus paclitaxel was not more effective than paclitaxel alone on overall survival for patients with locally advanced or metastatic breast cancer.",no_spin,"This passage is about a study that looked at whether a certain treatment (treatment A) helped people with a type of breast cancer called metastatic breast cancer (MBC). The study involved 580 women who were randomly assigned to either get treatment A plus a medicine called paclitaxel or just get paclitaxel alone. The study looked at how long it took for the cancer to get worse (time to progression), how many people's cancer got better (objective response rate), how many people felt better even if their cancer didn't get better (clinical benefit rate), how long it took for the cancer to come back (event‐free survival), and how long people lived (overall survival). The study found that treatment A plus paclitaxel did not make a difference in how long people lived compared to just getting paclitaxel alone. However, treatment A plus paclitaxel did make a difference in how many people's cancer got better and how many people felt better, even if their cancer didn't get better. The most common side effects of the treatment were hair loss, skin rash, and diarrhea.",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.29504755}, {'token': '2', 'bytes': [50], 'logprob': -1.5450475}, {'token': '4', 'bytes': [52], 'logprob': -3.1700475}, {'token': '1', 'bytes': [49], 'logprob': -9.045048}, {'token': '5', 'bytes': [53], 'logprob': -9.420048}, {'token': '6', 'bytes': [54], 'logprob': -13.920048}, {'token': '0', 'bytes': [48], 'logprob': -14.420048}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.170048}, {'token': ' ', 'bytes': [32], 'logprob': -18.420048}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.420048}, {'token': '7', 'bytes': [55], 'logprob': -18.545048}, {'token': '-', 'bytes': [45], 'logprob': -21.420048}, {'token': '30', 'bytes': [51, 48], 'logprob': -22.170048}, {'token': '03', 'bytes': [48, 51], 'logprob': -22.232548}, {'token': 'Three', 'bytes': [84, 104, 114, 101, 101], 'logprob': -22.357548}, {'token': '.', 'bytes': [46], 'logprob': -22.482548}, {'token': 'I', 'bytes': [73], 'logprob': -22.482548}, {'token': '02', 'bytes': [48, 50], 'logprob': -22.482548}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.545048}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.545048}]",5,5,"[{'token': '5', 'bytes': [53], 'logprob': -0.50624657}, {'token': '6', 'bytes': [54], 'logprob': -1.5062466}, {'token': '4', 'bytes': [52], 'logprob': -1.7562466}, {'token': '3', 'bytes': [51], 'logprob': -6.5062466}, {'token': '7', 'bytes': [55], 'logprob': -6.6312466}, {'token': '2', 'bytes': [50], 'logprob': -13.881247}, {'token': '8', 'bytes': [56], 'logprob': -15.381247}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -19.506247}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.756247}, {'token': ' ', 'bytes': [32], 'logprob': -21.006247}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -22.693747}, {'token': 'C', 'bytes': [67], 'logprob': -22.693747}, {'token': ' five', 'bytes': [32, 102, 105, 118, 101], 'logprob': -23.006247}, {'token': '1', 'bytes': [49], 'logprob': -23.193747}, {'token': '５', 'bytes': [239, 188, 149], 'logprob': -23.443747}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -23.568747}, {'token': 'Five', 'bytes': [70, 105, 118, 101], 'logprob': -23.568747}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -23.756247}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -23.943747}, {'token': '9', 'bytes': [57], 'logprob': -23.943747}]",4,4,"[{'token': '4', 'bytes': [52], 'logprob': -0.3615935}, {'token': '3', 'bytes': [51], 'logprob': -1.3615935}, {'token': '5', 'bytes': [53], 'logprob': -3.1115935}, {'token': '2', 'bytes': [50], 'logprob': -6.3615937}, {'token': '6', 'bytes': [54], 'logprob': -6.9865937}, {'token': '7', 'bytes': [55], 'logprob': -13.361593}, {'token': '1', 'bytes': [49], 'logprob': -16.236593}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -19.861593}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.986593}, {'token': ' ', 'bytes': [32], 'logprob': -20.986593}, {'token': '8', 'bytes': [56], 'logprob': -21.111593}, {'token': '0', 'bytes': [48], 'logprob': -22.299093}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -24.049093}, {'token': '-', 'bytes': [45], 'logprob': -24.486593}, {'token': '４', 'bytes': [239, 188, 148], 'logprob': -24.486593}, {'token': '**', 'bytes': [42, 42], 'logprob': -24.549093}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -24.549093}, {'token': 'C', 'bytes': [67], 'logprob': -24.611593}, {'token': 'I', 'bytes': [73], 'logprob': -24.611593}, {'token': '.', 'bytes': [46], 'logprob': -24.736593}]",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.24992745}, {'token': '4', 'bytes': [52], 'logprob': -1.9999274}, {'token': '2', 'bytes': [50], 'logprob': -2.4999275}, {'token': '5', 'bytes': [53], 'logprob': -5.6249275}, {'token': '6', 'bytes': [54], 'logprob': -9.8749275}, {'token': '1', 'bytes': [49], 'logprob': -9.9999275}, {'token': '0', 'bytes': [48], 'logprob': -13.1249275}, {'token': '7', 'bytes': [55], 'logprob': -13.8749275}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.499928}, {'token': '8', 'bytes': [56], 'logprob': -18.499928}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.999928}, {'token': ' ', 'bytes': [32], 'logprob': -19.749928}, {'token': '9', 'bytes': [57], 'logprob': -20.187428}, {'token': '-', 'bytes': [45], 'logprob': -21.749928}, {'token': 'I', 'bytes': [73], 'logprob': -21.937428}, {'token': '30', 'bytes': [51, 48], 'logprob': -22.187428}, {'token': '03', 'bytes': [48, 51], 'logprob': -22.499928}, {'token': '.', 'bytes': [46], 'logprob': -22.749928}, {'token': '04', 'bytes': [48, 52], 'logprob': -22.812428}, {'token': '02', 'bytes': [48, 50], 'logprob': -22.999928}]",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.33454606}, {'token': '4', 'bytes': [52], 'logprob': -1.5845461}, {'token': '2', 'bytes': [50], 'logprob': -2.584546}, {'token': '5', 'bytes': [53], 'logprob': -5.584546}, {'token': '6', 'bytes': [54], 'logprob': -9.709546}, {'token': '1', 'bytes': [49], 'logprob': -9.959546}, {'token': '0', 'bytes': [48], 'logprob': -13.209546}, {'token': '7', 'bytes': [55], 'logprob': -14.209546}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.709545}, {'token': ' ', 'bytes': [32], 'logprob': -18.084545}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.084545}, {'token': '8', 'bytes': [56], 'logprob': -19.022045}, {'token': '9', 'bytes': [57], 'logprob': -20.272045}, {'token': '-', 'bytes': [45], 'logprob': -21.272045}, {'token': 'I', 'bytes': [73], 'logprob': -21.397045}, {'token': '03', 'bytes': [48, 51], 'logprob': -22.147045}, {'token': '30', 'bytes': [51, 48], 'logprob': -22.397045}, {'token': '04', 'bytes': [48, 52], 'logprob': -22.397045}, {'token': '**', 'bytes': [42, 42], 'logprob': -22.459545}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.584545}]"
17,18955454,"Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer",J Clin Oncol,"Purpose:
Treatment A is effective against HER‐2‐positive locally advanced or metastatic breast cancer (MBC). This phase III trial evaluated the efficacy of treatment A in HER‐2‐negative and HER‐2‐uncharacterized MBC.
Patients and methods:
Women with MBC were randomly assigned to first‐line therapy with paclitaxel 175 mg/m2 every 3 weeks plus treatment A or placebo. A preplanned retrospective evaluation of HER‐2 status was performed using fluorescence in situ hybridization and immunohistochemistry. The primary end point was time to progression (TTP); secondary end points were objective response rate (ORR), clinical benefit rate (CBR), event‐free survival (EFS), and overall survival (OS).
Results:
In the intent‐to‐treat population (n = 579), there were no significant differences in TTP, EFS, or OS between treatment arms, although differences in ORR and CBR were noted. In 86 HER‐2‐positive patients (15%), treatment with paclitaxel‐ treatment A resulted in statistically significant improvements in TTP, EFS, ORR, and CBR compared with paclitaxel‐placebo. No differences between treatment groups were observed for any end point in HER‐2‐negative patients. The most common adverse events were alopecia, rash, and diarrhea. The incidence of diarrhea and rash was significantly higher in the paclitaxel‐treatment A arm. The rate of cardiac events was low, and no difference was observed between treatment arms.
Conclusion:
Patients with HER‐2‐negative or HER‐2‐untested MBC did not benefit from the addition of treatment A to paclitaxel. However, first‐line therapy with paclitaxel‐ treatment A significantly improved clinical outcomes in HER‐2‐positive patients. Prospective evaluation of the efficacy and safety of this combination is ongoing in early and metastatic HER‐2‐positive breast cancer patients.",spin,"This passage is about a study that looked at how well a certain treatment works for women with a type of breast cancer called metastatic breast cancer (MBC). The treatment is called treatment A and it is combined with a drug called paclitaxel. The study looked at how well treatment A worked for women with MBC who had a protein called HER-2 in their cancer cells. The study also looked at how well treatment A worked for women with MBC who did not have HER-2 in their cancer cells. The study found that treatment A did not work as well for women with MBC who did not have HER-2 in their cancer cells. However, treatment A did work well for women with MBC who had HER-2 in their cancer cells. The study also looked at how well treatment A worked for women with MBC who had HER-2 in their cancer cells and found that it improved their clinical outcomes. This means that treatment A helped these women feel better and live longer. The study is ongoing to see if treatment A is safe and effective for women with early and metastatic HER-2-positive breast cancer.",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.5683247}, {'token': '4', 'bytes': [52], 'logprob': -1.0683247}, {'token': '5', 'bytes': [53], 'logprob': -2.9433246}, {'token': '6', 'bytes': [54], 'logprob': -3.9433246}, {'token': '2', 'bytes': [50], 'logprob': -4.0683246}, {'token': '7', 'bytes': [55], 'logprob': -7.1933246}, {'token': '1', 'bytes': [49], 'logprob': -11.568325}, {'token': '8', 'bytes': [56], 'logprob': -13.443325}, {'token': '0', 'bytes': [48], 'logprob': -15.443325}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.255825}, {'token': '9', 'bytes': [57], 'logprob': -18.755825}, {'token': ' ', 'bytes': [32], 'logprob': -19.130825}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.380825}, {'token': 'C', 'bytes': [67], 'logprob': -21.068325}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -21.568325}, {'token': 'Based', 'bytes': [66, 97, 115, 101, 100], 'logprob': -22.068325}, {'token': 'D', 'bytes': [68], 'logprob': -22.130825}, {'token': '-', 'bytes': [45], 'logprob': -22.193325}, {'token': 'For', 'bytes': [70, 111, 114], 'logprob': -22.255825}, {'token': 'L', 'bytes': [76], 'logprob': -22.380825}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.3154285}, {'token': '6', 'bytes': [54], 'logprob': -1.3154285}, {'token': '8', 'bytes': [56], 'logprob': -6.3154287}, {'token': '5', 'bytes': [53], 'logprob': -7.9404287}, {'token': '4', 'bytes': [52], 'logprob': -15.565429}, {'token': '9', 'bytes': [57], 'logprob': -19.565428}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -20.065428}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -20.440428}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -20.690428}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -21.315428}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.377928}, {'token': '3', 'bytes': [51], 'logprob': -21.440428}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -22.127928}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -22.627928}, {'token': ' ', 'bytes': [32], 'logprob': -22.627928}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -22.690428}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -22.940428}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -22.940428}, {'token': ' seis', 'bytes': [32, 115, 101, 105, 115], 'logprob': -23.002928}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -23.877928}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.32436386}, {'token': '6', 'bytes': [54], 'logprob': -1.3243638}, {'token': '8', 'bytes': [56], 'logprob': -4.8243637}, {'token': '5', 'bytes': [53], 'logprob': -5.8243637}, {'token': '4', 'bytes': [52], 'logprob': -9.824364}, {'token': '3', 'bytes': [51], 'logprob': -15.449364}, {'token': '9', 'bytes': [57], 'logprob': -16.324364}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -19.949364}, {'token': '2', 'bytes': [50], 'logprob': -21.324364}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -21.699364}, {'token': '<|end|>', 'bytes': None, 'logprob': -22.199364}, {'token': ' ', 'bytes': [32], 'logprob': -22.511864}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -22.574364}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -23.011864}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -23.449364}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -24.699364}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -24.886864}, {'token': '৭', 'bytes': [224, 167, 173], 'logprob': -25.199364}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -25.261864}, {'token': ' seis', 'bytes': [32, 115, 101, 105, 115], 'logprob': -25.261864}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.435753}, {'token': '6', 'bytes': [54], 'logprob': -1.685753}, {'token': '8', 'bytes': [56], 'logprob': -1.935753}, {'token': '5', 'bytes': [53], 'logprob': -3.8107529}, {'token': '4', 'bytes': [52], 'logprob': -6.685753}, {'token': '3', 'bytes': [51], 'logprob': -8.810753}, {'token': '9', 'bytes': [57], 'logprob': -9.560753}, {'token': '2', 'bytes': [50], 'logprob': -12.935753}, {'token': '10', 'bytes': [49, 48], 'logprob': -17.810753}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.810753}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.310753}, {'token': '1', 'bytes': [49], 'logprob': -19.560753}, {'token': '0', 'bytes': [48], 'logprob': -21.185753}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -21.623253}, {'token': ' ', 'bytes': [32], 'logprob': -22.310753}, {'token': 'I', 'bytes': [73], 'logprob': -22.560753}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -23.685753}, {'token': ""I'm"", 'bytes': [73, 39, 109], 'logprob': -23.810753}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -23.810753}, {'token': '\n\n', 'bytes': [10, 10], 'logprob': -23.998253}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.64087}, {'token': '6', 'bytes': [54], 'logprob': -1.14087}, {'token': '8', 'bytes': [56], 'logprob': -2.39087}, {'token': '5', 'bytes': [53], 'logprob': -2.89087}, {'token': '4', 'bytes': [52], 'logprob': -5.14087}, {'token': '3', 'bytes': [51], 'logprob': -7.39087}, {'token': '9', 'bytes': [57], 'logprob': -9.64087}, {'token': '2', 'bytes': [50], 'logprob': -11.26587}, {'token': '10', 'bytes': [49, 48], 'logprob': -16.64087}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.76587}, {'token': '1', 'bytes': [49], 'logprob': -18.14087}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.82837}, {'token': ' ', 'bytes': [32], 'logprob': -20.39087}, {'token': '0', 'bytes': [48], 'logprob': -21.07837}, {'token': 'I', 'bytes': [73], 'logprob': -21.89087}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -22.39087}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -22.45337}, {'token': 'Based', 'bytes': [66, 97, 115, 101, 100], 'logprob': -22.76587}, {'token': '70', 'bytes': [55, 48], 'logprob': -23.07837}, {'token': 'D', 'bytes': [68], 'logprob': -23.20337}]"
16,19273714,Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer,J Clin Oncol,"Purpose:
This phase III study compared the efficacy and safety of treatment A with comparator B in advanced breast cancer.
Patients and methods:
Patients were randomly assigned to treatment A or comparator B. Comparison of progression‐free survival (PFS) was the primary objective.
Results:
Patient characteristics were balanced between arms (N = 305). Median PFS was 8.05 months (95% CI, 6.60 to 8.71) for treatment A and 7.98 (95% CI, 6.93 to 8.77) for comparator B (log‐rank P = .121). Overall response rate (ORR) was 32% in both arms, p=0.931. The median time to treatment failure (TTF; defined as discontinuation, progressive disease, death as a result of any cause, or the start of a new anticancer therapy) was 4.24 months (95% CI, 4.11 to 4.44) for treatment A and 4.07 months (95% CI, 3.81 to 4.24) for comparator B, p=0.059. The medial overall survival was 19.29 months (95% CI, 15.57 to 23.59) for treatment A vs. 21.45 months (95% CI, 17.12 to 24.94), p=0.983. Hematologic toxicity was similar in both arms, except for grades 3 to 4 leukopenia (treatment A, 78%; comparator B, 66%; P = .025) and transfusions (treatment A, 17%; comparator B, 7%; P = .0051) and grades 3 to 4 diarrhea (treatment A, 8%; comparator B, 18%; p=0.009), mucositis (treatment A, 4%; comparator B, 15%; p<.001), and hand‐and‐foot syndrome (treatment A, 0%; comparator B, 26%, p<.001). 13% in treatment A arm and 27% in the comparator B arm discontinued because of drug‐related adverse events (P = .002).
Conclusion:
Treatment A was not more effective than comparator B for patients with advanced breast cancer.",no_spin,"This passage is about a study that compared two different treatments for advanced breast cancer. The study looked at how well each treatment worked and how safe it was. The researchers randomly assigned patients to one of the two treatments and compared how long it took for their cancer to grow or spread (called progression-free survival). They also looked at how many patients responded to the treatment and how long it took for their cancer to come back. The results showed that the two treatments were not very different in how well they worked, but treatment A caused more side effects than comparator B. Overall, the study concluded that treatment A was not better than comparator B for patients with advanced breast cancer.",2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.25777113}, {'token': '3', 'bytes': [51], 'logprob': -1.5077711}, {'token': '1', 'bytes': [49], 'logprob': -5.757771}, {'token': '4', 'bytes': [52], 'logprob': -6.007771}, {'token': '0', 'bytes': [48], 'logprob': -8.5077715}, {'token': '5', 'bytes': [53], 'logprob': -12.1327715}, {'token': '6', 'bytes': [54], 'logprob': -16.63277}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.25777}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.50777}, {'token': ' ', 'bytes': [32], 'logprob': -18.75777}, {'token': '02', 'bytes': [48, 50], 'logprob': -20.57027}, {'token': '7', 'bytes': [55], 'logprob': -20.75777}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.44527}, {'token': '-', 'bytes': [45], 'logprob': -21.50777}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.57027}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.63277}, {'token': '30', 'bytes': [51, 48], 'logprob': -21.75777}, {'token': 'I', 'bytes': [73], 'logprob': -21.88277}, {'token': '25', 'bytes': [50, 53], 'logprob': -22.75777}, {'token': '.', 'bytes': [46], 'logprob': -22.88277}]",5,5,"[{'token': '5', 'bytes': [53], 'logprob': -0.7451407}, {'token': '6', 'bytes': [54], 'logprob': -0.7451407}, {'token': '4', 'bytes': [52], 'logprob': -3.6201406}, {'token': '7', 'bytes': [55], 'logprob': -3.7451406}, {'token': '3', 'bytes': [51], 'logprob': -8.370141}, {'token': '8', 'bytes': [56], 'logprob': -10.745141}, {'token': '2', 'bytes': [50], 'logprob': -14.620141}, {'token': '9', 'bytes': [57], 'logprob': -17.24514}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.24514}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.80764}, {'token': ' ', 'bytes': [32], 'logprob': -18.55764}, {'token': '1', 'bytes': [49], 'logprob': -20.12014}, {'token': 'C', 'bytes': [67], 'logprob': -20.55764}, {'token': '0', 'bytes': [48], 'logprob': -21.37014}, {'token': '-', 'bytes': [45], 'logprob': -21.74514}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -21.80764}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -21.87014}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.93264}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.12014}, {'token': 'I', 'bytes': [73], 'logprob': -22.18264}]",4,4,"[{'token': '4', 'bytes': [52], 'logprob': -0.5849004}, {'token': '3', 'bytes': [51], 'logprob': -1.0849004}, {'token': '5', 'bytes': [53], 'logprob': -2.3349004}, {'token': '2', 'bytes': [50], 'logprob': -5.2099004}, {'token': '6', 'bytes': [54], 'logprob': -5.9599004}, {'token': '7', 'bytes': [55], 'logprob': -10.2099}, {'token': '1', 'bytes': [49], 'logprob': -12.5849}, {'token': '0', 'bytes': [48], 'logprob': -15.7099}, {'token': '8', 'bytes': [56], 'logprob': -16.4599}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.7099}, {'token': ' ', 'bytes': [32], 'logprob': -17.9599}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.5849}, {'token': '9', 'bytes': [57], 'logprob': -19.5849}, {'token': '-', 'bytes': [45], 'logprob': -21.3974}, {'token': 'I', 'bytes': [73], 'logprob': -21.7099}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.8349}, {'token': '**', 'bytes': [42, 42], 'logprob': -21.9599}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.0224}, {'token': 'Rating', 'bytes': [82, 97, 116, 105, 110, 103], 'logprob': -22.0849}, {'token': 'C', 'bytes': [67], 'logprob': -22.2099}]",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.58213794}, {'token': '4', 'bytes': [52], 'logprob': -1.332138}, {'token': '2', 'bytes': [50], 'logprob': -1.832138}, {'token': '5', 'bytes': [53], 'logprob': -4.082138}, {'token': '6', 'bytes': [54], 'logprob': -7.957138}, {'token': '1', 'bytes': [49], 'logprob': -9.332138}, {'token': '7', 'bytes': [55], 'logprob': -12.707138}, {'token': '0', 'bytes': [48], 'logprob': -14.082138}, {'token': '8', 'bytes': [56], 'logprob': -18.207138}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.582138}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.332138}, {'token': '9', 'bytes': [57], 'logprob': -22.769638}, {'token': ' ', 'bytes': [32], 'logprob': -22.832138}, {'token': '-', 'bytes': [45], 'logprob': -23.644638}, {'token': 'I', 'bytes': [73], 'logprob': -23.832138}, {'token': '.', 'bytes': [46], 'logprob': -24.207138}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -24.707138}, {'token': 'C', 'bytes': [67], 'logprob': -24.832138}, {'token': '３', 'bytes': [239, 188, 147], 'logprob': -24.894638}, {'token': '<', 'bytes': [60], 'logprob': -25.144638}]",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.5685955}, {'token': '2', 'bytes': [50], 'logprob': -1.3185955}, {'token': '4', 'bytes': [52], 'logprob': -1.8185955}, {'token': '5', 'bytes': [53], 'logprob': -5.6935954}, {'token': '1', 'bytes': [49], 'logprob': -7.6935954}, {'token': '0', 'bytes': [48], 'logprob': -9.818596}, {'token': '6', 'bytes': [54], 'logprob': -10.193596}, {'token': '7', 'bytes': [55], 'logprob': -14.568596}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.693596}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.318596}, {'token': ' ', 'bytes': [32], 'logprob': -18.443596}, {'token': '8', 'bytes': [56], 'logprob': -18.818596}, {'token': '9', 'bytes': [57], 'logprob': -19.943596}, {'token': '02', 'bytes': [48, 50], 'logprob': -20.818596}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.006096}, {'token': '04', 'bytes': [48, 52], 'logprob': -21.256096}, {'token': '-', 'bytes': [45], 'logprob': -21.318596}, {'token': 'I', 'bytes': [73], 'logprob': -21.693596}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.068596}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.131096}]"
15,19273714,Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer,J Clin Oncol,"Purpose:
This phase III study compared the efficacy and safety of treatment A with comparator B in advanced breast cancer.
Patients and methods:
Patients were randomly assigned to treatment A or comparator B. Comparison of progression‐free survival (PFS) was the primary objective.
Results:
Patient characteristics were balanced between arms (N = 305). Median PFS was 8.05 months (95% CI, 6.60 to 8.71) for treatment A and 7.98 (95% CI, 6.93 to 8.77) for comparator B (log‐rank P = .121). Overall response rate (ORR) was 32% in both arms, and overall survival (OS) was not different between arms (P = .983). Time to treatment failure (TTF; defined as discontinuation, progressive disease, death as a result of any cause, or the start of a new anticancer therapy) was superior in the treatment A arm (P = .059). Hematologic toxicity was similar in both arms, except for grades 3 to 4 leukopenia (treatment A, 78%; comparator B, 66%; P = .025) and transfusions (treatment A, 17%; comparator B, 7%; P = .0051). Grades 3 to 4 diarrhea, mucositis, and hand‐and‐foot syndrome were significantly higher in the comparator B arm. Fewer patients in the treatment A arm discontinued because of drug‐related adverse events (13% v 27% in CD; P = .002).
Conclusion:
No difference was observed between treatment A and comparator B arms in PFS, ORR, and OS. TTF was longer in the treatment A arm. These findings, combined with a nonhematologic toxicity profile that favors treatment A over approved doses of comparator B, suggest that treatment A may be a better option than comparator B in this clinical setting.",spin,"This passage is about a study that compared two different treatments for advanced breast cancer. The study looked at how well each treatment worked and how safe it was. The researchers randomly assigned patients to either treatment A or a comparison treatment (B). The primary goal of the study was to see how long patients lived without their cancer getting worse (progression‐free survival, or PFS).

The results showed that the two treatments were pretty similar in terms of how well they worked and how long patients lived. However, the study also looked at how long patients lived without their cancer getting worse again (time to treatment failure, or TTF). The researchers found that patients in the treatment A group lived longer without their cancer getting worse again than patients in the comparison group.

The study also looked at how safe each treatment was. The researchers found that treatment A caused more severe side effects than the comparison treatment, but it also caused fewer patients to stop taking the treatment because of side effects.

Overall, the study suggests that treatment A may be a better option than the comparison treatment in this clinical setting because it worked better and caused fewer side effects.",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.57639724}, {'token': '6', 'bytes': [54], 'logprob': -0.82639724}, {'token': '8', 'bytes': [56], 'logprob': -8.076397}, {'token': '5', 'bytes': [53], 'logprob': -8.826397}, {'token': '4', 'bytes': [52], 'logprob': -16.326397}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -19.451397}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -19.701397}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -19.888897}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -20.263897}, {'token': '9', 'bytes': [57], 'logprob': -20.638897}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.638897}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -20.888897}, {'token': '3', 'bytes': [51], 'logprob': -20.951397}, {'token': ' seis', 'bytes': [32, 115, 101, 105, 115], 'logprob': -21.326397}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -21.326397}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -21.701397}, {'token': '六', 'bytes': [229, 133, 173], 'logprob': -22.201397}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -22.201397}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -22.326397}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -22.388897}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.11899024}, {'token': '6', 'bytes': [54], 'logprob': -2.3689902}, {'token': '8', 'bytes': [56], 'logprob': -3.9939902}, {'token': '5', 'bytes': [53], 'logprob': -8.61899}, {'token': '9', 'bytes': [57], 'logprob': -13.61899}, {'token': '4', 'bytes': [52], 'logprob': -15.11899}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.24399}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -19.30649}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.49399}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -19.61899}, {'token': ' ', 'bytes': [32], 'logprob': -20.36899}, {'token': '3', 'bytes': [51], 'logprob': -20.49399}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -20.55649}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -20.86899}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -21.36899}, {'token': 'C', 'bytes': [67], 'logprob': -21.61899}, {'token': '70', 'bytes': [55, 48], 'logprob': -21.99399}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.24399}, {'token': 'I', 'bytes': [73], 'logprob': -22.49399}, {'token': '-', 'bytes': [45], 'logprob': -22.55649}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.38918373}, {'token': '6', 'bytes': [54], 'logprob': -1.1391838}, {'token': '5', 'bytes': [53], 'logprob': -6.7641835}, {'token': '8', 'bytes': [56], 'logprob': -6.7641835}, {'token': '4', 'bytes': [52], 'logprob': -13.639184}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.389183}, {'token': '9', 'bytes': [57], 'logprob': -19.264183}, {'token': '3', 'bytes': [51], 'logprob': -19.701683}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -20.076683}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -20.389183}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -20.451683}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.514183}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -21.576683}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -21.701683}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -21.889183}, {'token': ' seis', 'bytes': [32, 115, 101, 105, 115], 'logprob': -21.951683}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -22.701683}, {'token': ' ', 'bytes': [32], 'logprob': -22.826683}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.889183}, {'token': 'Rating', 'bytes': [82, 97, 116, 105, 110, 103], 'logprob': -23.014183}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.22072703}, {'token': '6', 'bytes': [54], 'logprob': -1.720727}, {'token': '8', 'bytes': [56], 'logprob': -4.345727}, {'token': '5', 'bytes': [53], 'logprob': -5.095727}, {'token': '4', 'bytes': [52], 'logprob': -10.095727}, {'token': '9', 'bytes': [57], 'logprob': -13.220727}, {'token': '3', 'bytes': [51], 'logprob': -14.595727}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.095728}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.033228}, {'token': '2', 'bytes': [50], 'logprob': -19.095728}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -19.345728}, {'token': '70', 'bytes': [55, 48], 'logprob': -20.158228}, {'token': ' ', 'bytes': [32], 'logprob': -21.158228}, {'token': '75', 'bytes': [55, 53], 'logprob': -21.283228}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -21.470728}, {'token': 'I', 'bytes': [73], 'logprob': -21.595728}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -21.595728}, {'token': '10', 'bytes': [49, 48], 'logprob': -21.845728}, {'token': '68', 'bytes': [54, 56], 'logprob': -21.845728}, {'token': '1', 'bytes': [49], 'logprob': -21.970728}]",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.7150791}, {'token': '7', 'bytes': [55], 'logprob': -0.7150791}, {'token': '5', 'bytes': [53], 'logprob': -4.4650793}, {'token': '8', 'bytes': [56], 'logprob': -4.5900793}, {'token': '4', 'bytes': [52], 'logprob': -10.215079}, {'token': '3', 'bytes': [51], 'logprob': -14.465079}, {'token': '9', 'bytes': [57], 'logprob': -14.715079}, {'token': '2', 'bytes': [50], 'logprob': -19.465078}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.340078}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.027578}, {'token': ' ', 'bytes': [32], 'logprob': -21.902578}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -22.090078}, {'token': '10', 'bytes': [49, 48], 'logprob': -23.027578}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -23.027578}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -23.090078}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -23.465078}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -23.590078}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -24.340078}, {'token': '1', 'bytes': [49], 'logprob': -24.527578}, {'token': 'I', 'bytes': [73], 'logprob': -24.590078}]"
41,20087643,A bupropion smoking cessation clinical trial for cancer patients,Cancer Causes Control,"Objective:
Many cancer patients continue to smoke postdiagnosis, yet there have been few smoking cessation trials for this population. Depression, which is prevalent among cancer patients, may be a barrier to cessation.
Methods:
This double‐blind placebo‐controlled trial randomized 246 cancer patients to 9 weeks of placebo or treatment A, stratifying by pre‐treatment depression symptoms. In addition, all patients received transdermal nicotine and behavioral counseling. Primary outcomes were 7‐day point‐prevalence abstinence, biochemically confirmed, at the end of treatment (Week 12), and at 6 months post quit day (Week 27). Additional outcomes included: withdrawal, affect, quality of life, compliance, and side effects.
Results:
There was no main effect of treatment A vs. placebo on abstinence (Odds Ratio [OR] = 1.36, 95% CI: 0.38‐4.81, p = 0.64). Patients with depression symptoms reported significantly lower abstinence rates vs. patients without depression symptoms (OR = .14, 95% CI: 0.02‐0.80, p=0.03). Treatment A increased abstinence rates, vs. placebo, more for participants with depression vs. those without depression symptoms. For patients with depression symptoms, treatment A reduced withdrawal symptoms and improved quality of life vs. placebo.
Conclusion:
For patients with depression symptoms, treatment increases abstinence rates, lowers withdrawal, and increases quality of life. However, abstinence rates among patients with depression symptoms were low vs. patients without depression symptoms, who exhibited similar abstinence rates when treated with treatment A or transdermal nicotine and counseling alone. These results can guide future smoking cessation intervention studies with cancer patients.",spin,"This study is about people who have cancer and still smoke after being diagnosed. The study wanted to see if there were ways to help them quit smoking. They gave some people a special treatment and some people just got counseling and nicotine patches. They looked at how many people quit smoking and how they felt after quitting. They found that people who had depression symptoms had a harder time quitting smoking than people who didn't have depression symptoms. However, the special treatment helped people with depression symptoms quit smoking more and feel better after quitting.",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.20701782}, {'token': '7', 'bytes': [55], 'logprob': -1.7070178}, {'token': '5', 'bytes': [53], 'logprob': -5.207018}, {'token': '4', 'bytes': [52], 'logprob': -9.457018}, {'token': '8', 'bytes': [56], 'logprob': -10.332018}, {'token': '3', 'bytes': [51], 'logprob': -16.207018}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.707018}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -19.332018}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -20.582018}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.894518}, {'token': ' seis', 'bytes': [32, 115, 101, 105, 115], 'logprob': -21.207018}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -21.207018}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -21.519518}, {'token': '六', 'bytes': [229, 133, 173], 'logprob': -22.207018}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -22.394518}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -22.394518}, {'token': '9', 'bytes': [57], 'logprob': -23.019518}, {'token': '2', 'bytes': [50], 'logprob': -23.269518}, {'token': ' ', 'bytes': [32], 'logprob': -23.269518}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -23.332018}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.48022234}, {'token': '6', 'bytes': [54], 'logprob': -0.98022234}, {'token': '8', 'bytes': [56], 'logprob': -5.730222}, {'token': '5', 'bytes': [53], 'logprob': -5.855222}, {'token': '4', 'bytes': [52], 'logprob': -11.105223}, {'token': '9', 'bytes': [57], 'logprob': -15.355223}, {'token': '3', 'bytes': [51], 'logprob': -17.355223}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.105223}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.667723}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -20.605223}, {'token': ' ', 'bytes': [32], 'logprob': -20.917723}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -21.105223}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -21.167723}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -22.042723}, {'token': 'C', 'bytes': [67], 'logprob': -22.167723}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -22.292723}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -22.292723}, {'token': '2', 'bytes': [50], 'logprob': -22.667723}, {'token': '-', 'bytes': [45], 'logprob': -22.855223}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -23.042723}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.16370189}, {'token': '8', 'bytes': [56], 'logprob': -1.9137019}, {'token': '6', 'bytes': [54], 'logprob': -5.663702}, {'token': '9', 'bytes': [57], 'logprob': -13.663702}, {'token': '5', 'bytes': [53], 'logprob': -13.913702}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -18.538702}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -19.163702}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -19.788702}, {'token': '4', 'bytes': [52], 'logprob': -19.913702}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -21.226202}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -21.663702}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.788702}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -21.913702}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -22.038702}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -22.163702}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -22.226202}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -23.163702}, {'token': '۷', 'bytes': [219, 183], 'logprob': -23.288702}, {'token': ' seventh', 'bytes': [32, 115, 101, 118, 101, 110, 116, 104], 'logprob': -23.288702}, {'token': ' sieben', 'bytes': [32, 115, 105, 101, 98, 101, 110], 'logprob': -23.413702}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.21459445}, {'token': '8', 'bytes': [56], 'logprob': -1.7145945}, {'token': '6', 'bytes': [54], 'logprob': -4.3395944}, {'token': '5', 'bytes': [53], 'logprob': -9.964595}, {'token': '9', 'bytes': [57], 'logprob': -12.089595}, {'token': '4', 'bytes': [52], 'logprob': -15.464595}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -19.339594}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -19.464594}, {'token': '3', 'bytes': [51], 'logprob': -19.714594}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.402094}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.589594}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -21.464594}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -21.714594}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -21.714594}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -21.777094}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -21.964594}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -22.277094}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -23.027094}, {'token': '七', 'bytes': [228, 184, 131], 'logprob': -23.089594}, {'token': '10', 'bytes': [49, 48], 'logprob': -23.214594}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.18590672}, {'token': '8', 'bytes': [56], 'logprob': -1.9359068}, {'token': '6', 'bytes': [54], 'logprob': -3.6859066}, {'token': '5', 'bytes': [53], 'logprob': -8.310906}, {'token': '9', 'bytes': [57], 'logprob': -10.310906}, {'token': '4', 'bytes': [52], 'logprob': -13.060906}, {'token': '3', 'bytes': [51], 'logprob': -17.810907}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.185907}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -19.373407}, {'token': '10', 'bytes': [49, 48], 'logprob': -19.435907}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.748407}, {'token': '70', 'bytes': [55, 48], 'logprob': -20.685907}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -20.935907}, {'token': ' ', 'bytes': [32], 'logprob': -21.373407}, {'token': '2', 'bytes': [50], 'logprob': -21.685907}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -21.748407}, {'token': 'I', 'bytes': [73], 'logprob': -21.935907}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -22.123407}, {'token': '75', 'bytes': [55, 53], 'logprob': -22.373407}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -22.435907}]"
42,20087643,A bupropion smoking cessation clinical trial for cancer patients,Cancer Causes Control,"Objective:
Many cancer patients continue to smoke postdiagnosis, yet there have been few smoking cessation trials for this population.
Methods:
This double‐blind placebo‐controlled trial randomized 246 cancer patients to 9 weeks of placebo or treatment A, stratifying by pre‐treatment depression symptoms. In addition, all patients received transdermal nicotine and behavioral counseling. Primary outcomes were 7‐day point‐prevalence abstinence, biochemically confirmed, at the end of treatment (Week 12), and at 6 months post quit day (Week 27). Additional outcomes included: withdrawal, affect, quality of life, compliance, and side effects.
Results:
There was no main effect of treatment A vs. placebo on abstinence (Odds Ratio [OR] = 1.36, 95% CI: 0.38‐4.81, p =0.64). At week 12, the abstinence rates were 24.2% for placebo and 27.2% for treatment A; at week 27, the abstinence rates were 17.4% for placebo and 18.4% for treatment A. There was no statistically significant difference between placebo and treatment A in average daily smoking to week 12 (mean [SE] 5.2 [0.95] vs. 5.3 [1.0]; p=0.97); and to week 27 (mean [SE] 5.4 [0.88] vs. 6.1 [0.90]; p=0.64). There were no statistically significant difference between placebo and treatment A on changes in withdrawals (p=0.39); negative (p=0.41) and positive affect (p=0.77), and physical (p=0.31) and mental (p=0.42) quality of life.
Conclusion:
Treatment A was not more effective than placebo on the prevalence of abstinence of cancer patients who continue to smoke postdiagnosis.",no_spin,This study looked at people who have cancer and still smoke after being diagnosed. The study wanted to see if a special treatment could help them quit smoking. The study gave the treatment to some people and a special medicine to all of them. They then checked how many people quit smoking after the treatment and how they felt. The study found that the special treatment did not help the people quit smoking more than just taking the special medicine.,0,0,"[{'token': '0', 'bytes': [48], 'logprob': -0.16053687}, {'token': '1', 'bytes': [49], 'logprob': -2.1605368}, {'token': '2', 'bytes': [50], 'logprob': -3.4105368}, {'token': '3', 'bytes': [51], 'logprob': -10.535537}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -15.660537}, {'token': '4', 'bytes': [52], 'logprob': -16.535538}, {'token': '02', 'bytes': [48, 50], 'logprob': -19.410538}, {'token': ' ', 'bytes': [32], 'logprob': -19.535538}, {'token': '01', 'bytes': [48, 49], 'logprob': -19.660538}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -19.785538}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.035538}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -20.598038}, {'token': '5', 'bytes': [53], 'logprob': -20.660538}, {'token': ' Score', 'bytes': [32, 83, 99, 111, 114, 101], 'logprob': -21.285538}, {'token': '-', 'bytes': [45], 'logprob': -21.598038}, {'token': '00', 'bytes': [48, 48], 'logprob': -21.910538}, {'token': 'I', 'bytes': [73], 'logprob': -22.285538}, {'token': 'Scores', 'bytes': [83, 99, 111, 114, 101, 115], 'logprob': -22.348038}, {'token': '_score', 'bytes': [95, 115, 99, 111, 114, 101], 'logprob': -22.598038}, {'token': 'Rating', 'bytes': [82, 97, 116, 105, 110, 103], 'logprob': -22.598038}]",4,4,"[{'token': '4', 'bytes': [52], 'logprob': -0.8797419}, {'token': '5', 'bytes': [53], 'logprob': -0.8797419}, {'token': '6', 'bytes': [54], 'logprob': -2.379742}, {'token': '3', 'bytes': [51], 'logprob': -2.629742}, {'token': '7', 'bytes': [55], 'logprob': -5.3797417}, {'token': '2', 'bytes': [50], 'logprob': -7.0047417}, {'token': '8', 'bytes': [56], 'logprob': -10.379742}, {'token': '1', 'bytes': [49], 'logprob': -14.379742}, {'token': '9', 'bytes': [57], 'logprob': -15.754742}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.629742}, {'token': '0', 'bytes': [48], 'logprob': -17.254742}, {'token': ' ', 'bytes': [32], 'logprob': -18.192242}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.442242}, {'token': 'C', 'bytes': [67], 'logprob': -20.379742}, {'token': '10', 'bytes': [49, 48], 'logprob': -20.817242}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -21.192242}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.192242}, {'token': 'I', 'bytes': [73], 'logprob': -21.317242}, {'token': '-', 'bytes': [45], 'logprob': -21.629742}, {'token': 'D', 'bytes': [68], 'logprob': -21.629742}]",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.2770751}, {'token': '4', 'bytes': [52], 'logprob': -2.027075}, {'token': '2', 'bytes': [50], 'logprob': -2.277075}, {'token': '5', 'bytes': [53], 'logprob': -4.9020753}, {'token': '6', 'bytes': [54], 'logprob': -8.777075}, {'token': '1', 'bytes': [49], 'logprob': -9.152075}, {'token': '7', 'bytes': [55], 'logprob': -12.527075}, {'token': '0', 'bytes': [48], 'logprob': -12.652075}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.277075}, {'token': '8', 'bytes': [56], 'logprob': -17.027075}, {'token': ' ', 'bytes': [32], 'logprob': -18.402075}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.339575}, {'token': '9', 'bytes': [57], 'logprob': -19.714575}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.277075}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.402075}, {'token': 'I', 'bytes': [73], 'logprob': -21.777075}, {'token': '-', 'bytes': [45], 'logprob': -21.839575}, {'token': '**', 'bytes': [42, 42], 'logprob': -22.089575}, {'token': '03', 'bytes': [48, 51], 'logprob': -22.152075}, {'token': '10', 'bytes': [49, 48], 'logprob': -22.402075}]",2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.09534853}, {'token': '3', 'bytes': [51], 'logprob': -2.5953486}, {'token': '1', 'bytes': [49], 'logprob': -4.4703484}, {'token': '0', 'bytes': [48], 'logprob': -5.7203484}, {'token': '4', 'bytes': [52], 'logprob': -6.4703484}, {'token': '5', 'bytes': [53], 'logprob': -9.845348}, {'token': '6', 'bytes': [54], 'logprob': -14.595348}, {'token': '7', 'bytes': [55], 'logprob': -18.220348}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.220348}, {'token': '02', 'bytes': [48, 50], 'logprob': -19.470348}, {'token': ' ', 'bytes': [32], 'logprob': -20.095348}, {'token': '8', 'bytes': [56], 'logprob': -20.157848}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.220348}, {'token': '9', 'bytes': [57], 'logprob': -21.095348}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.282848}, {'token': '-', 'bytes': [45], 'logprob': -22.032848}, {'token': '01', 'bytes': [48, 49], 'logprob': -22.282848}, {'token': 'I', 'bytes': [73], 'logprob': -22.532848}, {'token': '30', 'bytes': [51, 48], 'logprob': -22.595348}, {'token': '04', 'bytes': [48, 52], 'logprob': -22.782848}]",2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.12220437}, {'token': '3', 'bytes': [51], 'logprob': -2.8722043}, {'token': '1', 'bytes': [49], 'logprob': -3.3722043}, {'token': '0', 'bytes': [48], 'logprob': -3.7472043}, {'token': '4', 'bytes': [52], 'logprob': -7.4972043}, {'token': '5', 'bytes': [53], 'logprob': -11.997205}, {'token': '6', 'bytes': [54], 'logprob': -16.622204}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.997204}, {'token': ' ', 'bytes': [32], 'logprob': -18.247204}, {'token': '02', 'bytes': [48, 50], 'logprob': -18.247204}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.997204}, {'token': '03', 'bytes': [48, 51], 'logprob': -20.059704}, {'token': '7', 'bytes': [55], 'logprob': -20.434704}, {'token': '01', 'bytes': [48, 49], 'logprob': -20.684704}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -20.997204}, {'token': '-', 'bytes': [45], 'logprob': -21.059704}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.434704}, {'token': 'I', 'bytes': [73], 'logprob': -21.622204}, {'token': '9', 'bytes': [57], 'logprob': -21.997204}, {'token': '04', 'bytes': [48, 52], 'logprob': -22.122204}]"
22,20153039,"Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial",Lancet,"Background:
We aimed to compare overall survival in patients receiving treatment A or comparator B.
Methods:
This was an open‐label randomized trial undertaken in 50 centres across eight countries. 1006 treatment‐naive patients diagnosed with advanced metastatic renal cell carcinoma were randomly allocated (1 to 1) by minimization to receive comparator B or treatment A. Treatment was not masked. The primary endpoint was overall survival. Treatment groups were compared with a non‐stratified log‐ rank test. Analysis was by intention to treat. This study is registered, number ISRCTN XXXX.
Findings:
502 patients were randomly assigned to receive comparator B and 504 to receive combined treatment A. Median follow‐up was 37.2 months (24.8‐52.3). Median overall survival was 18.8 months (17.0‐23.2) for patients receiving comparator B versus 18.6 months (16.5‐20.6) for those receiving treatment A. Overall survival did not differ between the two groups (hazard ratio 1.05 [95% CI 0.90‐1.21], p=0.55; absolute difference 0.3% (‐5.1 to 5.6) at 1 year and 2.7% (‐8.2 to 2.9) at 3 years). There was no evidence that progression free survival differed statistically between treatment groups (HR 1.02 [0.89–1.16]; p=0.81). During treatment significantly more grade 3 and 4 toxic effects were associated with combined treatment A than with comparator B (269 patients [53%] vs. 183 patients [36%]; p<0.0001). Serious adverse events were reported in 113 (23%) patients receiving comparator B and 131 (26%) of those receiving combined treatment A.
Interpretation:
Treatment A was not more effective than comparator B on overall survival in patients diagnosed with advanced metastatic renal cell carcinoma.",no_spin,"This study was done to see if a certain treatment (A) was better than another treatment (B) for people with a type of cancer called renal cell carcinoma. They randomly gave 1006 people either treatment A or treatment B and followed them for a certain amount of time. They found that the two treatments did not make a big difference in how long people lived. However, the treatment with both A and B caused more bad side effects than the other treatment.",2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.04646608}, {'token': '1', 'bytes': [49], 'logprob': -3.796466}, {'token': '3', 'bytes': [51], 'logprob': -3.796466}, {'token': '0', 'bytes': [48], 'logprob': -7.796466}, {'token': '4', 'bytes': [52], 'logprob': -9.296466}, {'token': '5', 'bytes': [53], 'logprob': -15.421466}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.296467}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.046467}, {'token': '6', 'bytes': [54], 'logprob': -19.046467}, {'token': ' ', 'bytes': [32], 'logprob': -19.046467}, {'token': '02', 'bytes': [48, 50], 'logprob': -19.546467}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.233967}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.296467}, {'token': '-', 'bytes': [45], 'logprob': -21.421467}, {'token': 'I', 'bytes': [73], 'logprob': -21.546467}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.608967}, {'token': '7', 'bytes': [55], 'logprob': -22.171467}, {'token': '30', 'bytes': [51, 48], 'logprob': -22.171467}, {'token': '01', 'bytes': [48, 49], 'logprob': -22.171467}, {'token': '  ', 'bytes': [32, 32], 'logprob': -22.358967}]",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.58559835}, {'token': '7', 'bytes': [55], 'logprob': -0.83559835}, {'token': '5', 'bytes': [53], 'logprob': -4.9605985}, {'token': '8', 'bytes': [56], 'logprob': -5.9605985}, {'token': '4', 'bytes': [52], 'logprob': -10.585598}, {'token': '3', 'bytes': [51], 'logprob': -16.335598}, {'token': '9', 'bytes': [57], 'logprob': -17.585598}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -20.960598}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.335598}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -21.460598}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -21.898098}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -21.960598}, {'token': '2', 'bytes': [50], 'logprob': -21.960598}, {'token': ' ', 'bytes': [32], 'logprob': -22.148098}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -22.523098}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -23.460598}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -23.523098}, {'token': 'C', 'bytes': [67], 'logprob': -23.898098}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -23.960598}, {'token': ' seis', 'bytes': [32, 115, 101, 105, 115], 'logprob': -23.960598}]",5,5,"[{'token': '5', 'bytes': [53], 'logprob': -0.7276352}, {'token': '6', 'bytes': [54], 'logprob': -1.2276351}, {'token': '4', 'bytes': [52], 'logprob': -1.7276351}, {'token': '3', 'bytes': [51], 'logprob': -3.4776351}, {'token': '7', 'bytes': [55], 'logprob': -4.2276354}, {'token': '2', 'bytes': [50], 'logprob': -7.2276354}, {'token': '8', 'bytes': [56], 'logprob': -9.602635}, {'token': '1', 'bytes': [49], 'logprob': -14.977635}, {'token': '9', 'bytes': [57], 'logprob': -17.352634}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.977634}, {'token': '0', 'bytes': [48], 'logprob': -20.602634}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.727634}, {'token': ' ', 'bytes': [32], 'logprob': -21.165134}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -23.040134}, {'token': 'Rating', 'bytes': [82, 97, 116, 105, 110, 103], 'logprob': -23.540134}, {'token': 'C', 'bytes': [67], 'logprob': -23.727634}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -23.790134}, {'token': '-', 'bytes': [45], 'logprob': -23.852634}, {'token': '**', 'bytes': [42, 42], 'logprob': -24.165134}, {'token': 'I', 'bytes': [73], 'logprob': -24.290134}]",4,4,"[{'token': '4', 'bytes': [52], 'logprob': -0.79891837}, {'token': '3', 'bytes': [51], 'logprob': -1.0489184}, {'token': '5', 'bytes': [53], 'logprob': -2.0489182}, {'token': '2', 'bytes': [50], 'logprob': -2.6739182}, {'token': '6', 'bytes': [54], 'logprob': -6.2989182}, {'token': '1', 'bytes': [49], 'logprob': -9.298919}, {'token': '0', 'bytes': [48], 'logprob': -9.923919}, {'token': '7', 'bytes': [55], 'logprob': -10.298919}, {'token': '8', 'bytes': [56], 'logprob': -15.423919}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.423918}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.173918}, {'token': '9', 'bytes': [57], 'logprob': -18.423918}, {'token': ' ', 'bytes': [32], 'logprob': -19.173918}, {'token': 'I', 'bytes': [73], 'logprob': -21.236418}, {'token': '04', 'bytes': [48, 52], 'logprob': -21.798918}, {'token': '-', 'bytes': [45], 'logprob': -21.986418}, {'token': 'C', 'bytes': [67], 'logprob': -22.048918}, {'token': '05', 'bytes': [48, 53], 'logprob': -22.111418}, {'token': '10', 'bytes': [49, 48], 'logprob': -22.173918}, {'token': '02', 'bytes': [48, 50], 'logprob': -22.361418}]",2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.63848907}, {'token': '3', 'bytes': [51], 'logprob': -0.88848907}, {'token': '4', 'bytes': [52], 'logprob': -2.888489}, {'token': '1', 'bytes': [49], 'logprob': -6.0134892}, {'token': '5', 'bytes': [53], 'logprob': -6.3884892}, {'token': '0', 'bytes': [48], 'logprob': -7.1384892}, {'token': '6', 'bytes': [54], 'logprob': -9.888489}, {'token': '7', 'bytes': [55], 'logprob': -13.013489}, {'token': '8', 'bytes': [56], 'logprob': -16.513489}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.513489}, {'token': '9', 'bytes': [57], 'logprob': -18.138489}, {'token': ' ', 'bytes': [32], 'logprob': -18.638489}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.763489}, {'token': '02', 'bytes': [48, 50], 'logprob': -20.513489}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.075989}, {'token': '-', 'bytes': [45], 'logprob': -21.513489}, {'token': '04', 'bytes': [48, 52], 'logprob': -21.888489}, {'token': '10', 'bytes': [49, 48], 'logprob': -22.200989}, {'token': 'I', 'bytes': [73], 'logprob': -22.325989}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.388489}]"
21,20153039,"Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial",Lancet,"Background:
We aimed to compare overall survival in patients receiving treatment A or comparator B.
Methods:
This was an open‐label randomized trial undertaken in 50 centres across eight countries. 1006 treatment‐naive patients diagnosed with advanced metastatic renal cell carcinoma were randomly allocated (1 to 1) by minimization to receive comparator B or treatment A. Treatment was not masked. The primary endpoint was overall survival. Treatment groups were compared with a non‐stratified log‐ rank test. Analysis was by intention to treat. This study is registered, number ISRCTN XXXX.
Findings:
502 patients were randomly assigned to receive comparator B and 504 to receive combined treatment A. Median follow‐up was 37.2 months (24.8‐52.3). Median overall survival was 18.8 months (17.0‐23.2) for patients receiving comparator B versus 18.6 months (16.5‐20.6) for those receiving treatment A. Overall survival did not differ between the two groups (hazard ratio 1.05 [95% CI 0.90‐1.21], p=0.55; absolute difference 0.3% (‐5.1 to 5.6) at 1 year and 2.7% (‐8.2 to 2.9) at 3 years). Serious adverse events were reported in 113 (23%) patients receiving comparator B and 131 (26%) of those receiving combined treatment A.
Interpretation:
Although treatment A does not improve overall or progression‐free survival compared with comparator B, treatment A might still have a role because it can produce remissions that are of clinically relevant length in some patients. Identification of patients who will benefit from treatment A is crucial.",spin,"This passage is about a study that compared two different treatments for a type of cancer called advanced metastatic renal cell carcinoma. The study was done in 50 centers across eight countries and included 1006 patients who were randomly assigned to either treatment A or comparator B. The study found that the two treatments did not make a big difference in how long patients lived, but treatment A might still be helpful for some people. The study also looked at how many serious side effects happened in each group.",4,4,"[{'token': '4', 'bytes': [52], 'logprob': -0.25401485}, {'token': '3', 'bytes': [51], 'logprob': -1.7540148}, {'token': '5', 'bytes': [53], 'logprob': -3.004015}, {'token': '2', 'bytes': [50], 'logprob': -6.754015}, {'token': '6', 'bytes': [54], 'logprob': -7.629015}, {'token': '7', 'bytes': [55], 'logprob': -13.754015}, {'token': '1', 'bytes': [49], 'logprob': -13.879015}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.379015}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.191515}, {'token': '0', 'bytes': [48], 'logprob': -18.504015}, {'token': ' ', 'bytes': [32], 'logprob': -18.816515}, {'token': '8', 'bytes': [56], 'logprob': -20.816515}, {'token': 'C', 'bytes': [67], 'logprob': -21.066515}, {'token': '-', 'bytes': [45], 'logprob': -21.566515}, {'token': 'D', 'bytes': [68], 'logprob': -21.816515}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.316515}, {'token': 'To', 'bytes': [84, 111], 'logprob': -22.504015}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -22.566515}, {'token': '  ', 'bytes': [32, 32], 'logprob': -22.566515}, {'token': '.', 'bytes': [46], 'logprob': -22.566515}]",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.1859198}, {'token': '7', 'bytes': [55], 'logprob': -1.9359198}, {'token': '5', 'bytes': [53], 'logprob': -3.6859198}, {'token': '8', 'bytes': [56], 'logprob': -8.56092}, {'token': '4', 'bytes': [52], 'logprob': -9.18592}, {'token': '3', 'bytes': [51], 'logprob': -15.31092}, {'token': '9', 'bytes': [57], 'logprob': -20.06092}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -21.43592}, {'token': '2', 'bytes': [50], 'logprob': -21.56092}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -21.56092}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.87342}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -22.87342}, {'token': ' ', 'bytes': [32], 'logprob': -23.06092}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -23.49842}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -24.12342}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -24.31092}, {'token': 'C', 'bytes': [67], 'logprob': -24.74842}, {'token': '六', 'bytes': [229, 133, 173], 'logprob': -24.81092}, {'token': ' seis', 'bytes': [32, 115, 101, 105, 115], 'logprob': -24.81092}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -24.87342}]",5,5,"[{'token': '5', 'bytes': [53], 'logprob': -0.7424298}, {'token': '6', 'bytes': [54], 'logprob': -0.7424298}, {'token': '4', 'bytes': [52], 'logprob': -3.2424297}, {'token': '7', 'bytes': [55], 'logprob': -4.7424297}, {'token': '3', 'bytes': [51], 'logprob': -8.11743}, {'token': '8', 'bytes': [56], 'logprob': -12.74243}, {'token': '2', 'bytes': [50], 'logprob': -14.61743}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -19.49243}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.36743}, {'token': ' ', 'bytes': [32], 'logprob': -21.61743}, {'token': '9', 'bytes': [57], 'logprob': -21.80493}, {'token': '1', 'bytes': [49], 'logprob': -22.67993}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -22.92993}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -23.42993}, {'token': 'C', 'bytes': [67], 'logprob': -23.61743}, {'token': 'Five', 'bytes': [70, 105, 118, 101], 'logprob': -23.74243}, {'token': ' five', 'bytes': [32, 102, 105, 118, 101], 'logprob': -23.80493}, {'token': 'Rating', 'bytes': [82, 97, 116, 105, 110, 103], 'logprob': -23.86743}, {'token': '５', 'bytes': [239, 188, 149], 'logprob': -23.92993}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -23.99243}]",5,5,"[{'token': '5', 'bytes': [53], 'logprob': -0.6525934}, {'token': '4', 'bytes': [52], 'logprob': -0.9025934}, {'token': '6', 'bytes': [54], 'logprob': -3.2775934}, {'token': '3', 'bytes': [51], 'logprob': -3.4025934}, {'token': '7', 'bytes': [55], 'logprob': -6.0275936}, {'token': '2', 'bytes': [50], 'logprob': -7.9025936}, {'token': '8', 'bytes': [56], 'logprob': -13.027594}, {'token': '1', 'bytes': [49], 'logprob': -14.402594}, {'token': '0', 'bytes': [48], 'logprob': -16.777594}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.027594}, {'token': '9', 'bytes': [57], 'logprob': -18.152594}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.152594}, {'token': ' ', 'bytes': [32], 'logprob': -20.465094}, {'token': 'I', 'bytes': [73], 'logprob': -21.840094}, {'token': 'C', 'bytes': [67], 'logprob': -22.402594}, {'token': '-', 'bytes': [45], 'logprob': -22.777594}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.902594}, {'token': '４', 'bytes': [239, 188, 148], 'logprob': -22.902594}, {'token': 'D', 'bytes': [68], 'logprob': -23.152594}, {'token': '５', 'bytes': [239, 188, 149], 'logprob': -23.152594}]",5,5,"[{'token': '5', 'bytes': [53], 'logprob': -0.60550547}, {'token': '4', 'bytes': [52], 'logprob': -1.1055055}, {'token': '6', 'bytes': [54], 'logprob': -2.3555055}, {'token': '3', 'bytes': [51], 'logprob': -3.7305055}, {'token': '7', 'bytes': [55], 'logprob': -5.6055055}, {'token': '2', 'bytes': [50], 'logprob': -7.3555055}, {'token': '8', 'bytes': [56], 'logprob': -11.230505}, {'token': '1', 'bytes': [49], 'logprob': -13.480505}, {'token': '0', 'bytes': [48], 'logprob': -15.105505}, {'token': '9', 'bytes': [57], 'logprob': -15.730505}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.105505}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.418005}, {'token': ' ', 'bytes': [32], 'logprob': -19.293005}, {'token': '10', 'bytes': [49, 48], 'logprob': -20.980505}, {'token': 'I', 'bytes': [73], 'logprob': -21.543005}, {'token': 'C', 'bytes': [67], 'logprob': -21.918005}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.980505}, {'token': '-', 'bytes': [45], 'logprob': -22.168005}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.418005}, {'token': 'D', 'bytes': [68], 'logprob': -22.668005}]"
59,20448107,Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma,Blood,"In this double‐blind, placebo‐controlled study, 363 patients with untreated multiple myeloma were randomized to receive either melphalan‐prednisone and treatment A or melphalan‐prednisone and placebo. The dose of melphalan was 0.25 mg/kg and prednisone was 100 mg given daily for 4 days every 6 weeks until plateau phase. A total of 357 patients were analyzed. Partial response was 34% and 33%, and very good partial response or better was 23% and 7% in the treatment A and placebo arms, respectively (P < .001). There was no significant difference in progression‐free or overall survival, with median survival being 29 months in the treatment A arm and 32 months in the placebo arm. Most quality of life outcomes improved equally in both arms, apart from constipation, which was markedly increased in the treatment A arm. Constipation, neuropathy, non‐neuropathy neurologic toxicity, and skin reactions were significantly more frequent in the treatment A arm. The number of thromboembolic events was equal in the 2 treatment arms. In conclusion, treatment A had a significant antimyeloma effect, but this did not translate into improved survival.",spin,"This passage is about a study that looked at a treatment for a disease called multiple myeloma. The study involved 363 people who had not been treated before. They were randomly divided into two groups: one group got a special treatment called melphalan‐prednisone and treatment A, and the other group got the same treatment but with a placebo (a sugar pill). The treatment A group got a higher dose of melphalan, and both groups took prednisone for 4 days every 6 weeks until their symptoms stopped getting worse.

The study found that the treatment A group had a better response to the treatment, with more people having a good response to the treatment. However, the study also found that there was no significant difference in how long people lived or how their disease progressed between the two groups. The study also found that some people in the treatment A group had more side effects, such as constipation, nerve damage, and skin reactions.

In summary, the study found that the treatment A group had a better response to the treatment, but it did not translate into improved survival or a better quality of life for the patients.",4,4,"[{'token': '4', 'bytes': [52], 'logprob': -0.6003963}, {'token': '5', 'bytes': [53], 'logprob': -0.8503963}, {'token': '6', 'bytes': [54], 'logprob': -3.8503962}, {'token': '3', 'bytes': [51], 'logprob': -5.850396}, {'token': '7', 'bytes': [55], 'logprob': -11.600396}, {'token': '2', 'bytes': [50], 'logprob': -13.850396}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.412897}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -21.162897}, {'token': ' five', 'bytes': [32, 102, 105, 118, 101], 'logprob': -22.225397}, {'token': ' ', 'bytes': [32], 'logprob': -22.225397}, {'token': ' four', 'bytes': [32, 102, 111, 117, 114], 'logprob': -22.412897}, {'token': '8', 'bytes': [56], 'logprob': -22.725397}, {'token': '４', 'bytes': [239, 188, 148], 'logprob': -22.912897}, {'token': '1', 'bytes': [49], 'logprob': -23.162897}, {'token': 'Five', 'bytes': [70, 105, 118, 101], 'logprob': -23.287897}, {'token': '５', 'bytes': [239, 188, 149], 'logprob': -23.537897}, {'token': 'five', 'bytes': [102, 105, 118, 101], 'logprob': -23.662897}, {'token': ' Five', 'bytes': [32, 70, 105, 118, 101], 'logprob': -24.162897}, {'token': 'four', 'bytes': [102, 111, 117, 114], 'logprob': -24.225397}, {'token': 'C', 'bytes': [67], 'logprob': -24.225397}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.2556384}, {'token': '6', 'bytes': [54], 'logprob': -1.5056384}, {'token': '8', 'bytes': [56], 'logprob': -5.8806386}, {'token': '5', 'bytes': [53], 'logprob': -7.0056386}, {'token': '4', 'bytes': [52], 'logprob': -12.880638}, {'token': '9', 'bytes': [57], 'logprob': -15.880638}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.630638}, {'token': '3', 'bytes': [51], 'logprob': -19.193138}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.193138}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -19.818138}, {'token': ' ', 'bytes': [32], 'logprob': -19.943138}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -20.193138}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -20.505638}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -21.755638}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -21.755638}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -21.755638}, {'token': 'C', 'bytes': [67], 'logprob': -22.318138}, {'token': '-', 'bytes': [45], 'logprob': -22.505638}, {'token': '70', 'bytes': [55, 48], 'logprob': -22.693138}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -23.005638}]",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.15354939}, {'token': '5', 'bytes': [53], 'logprob': -2.1535494}, {'token': '7', 'bytes': [55], 'logprob': -3.6535494}, {'token': '4', 'bytes': [52], 'logprob': -7.903549}, {'token': '8', 'bytes': [56], 'logprob': -13.528549}, {'token': '3', 'bytes': [51], 'logprob': -15.278549}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -19.27855}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.65355}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.27855}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -21.52855}, {'token': ' seis', 'bytes': [32, 115, 101, 105, 115], 'logprob': -21.77855}, {'token': ' ', 'bytes': [32], 'logprob': -22.34105}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -22.77855}, {'token': ' five', 'bytes': [32, 102, 105, 118, 101], 'logprob': -22.90355}, {'token': '六', 'bytes': [229, 133, 173], 'logprob': -22.96605}, {'token': '2', 'bytes': [50], 'logprob': -23.09105}, {'token': 'six', 'bytes': [115, 105, 120], 'logprob': -23.46605}, {'token': ' Six', 'bytes': [32, 83, 105, 120], 'logprob': -23.84105}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -24.02855}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -24.02855}]",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.6268808}, {'token': '7', 'bytes': [55], 'logprob': -1.1268809}, {'token': '5', 'bytes': [53], 'logprob': -2.001881}, {'token': '4', 'bytes': [52], 'logprob': -5.2518806}, {'token': '8', 'bytes': [56], 'logprob': -6.6268806}, {'token': '3', 'bytes': [51], 'logprob': -9.751881}, {'token': '9', 'bytes': [57], 'logprob': -14.501881}, {'token': '2', 'bytes': [50], 'logprob': -15.376881}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.00188}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.68938}, {'token': '1', 'bytes': [49], 'logprob': -20.00188}, {'token': ' ', 'bytes': [32], 'logprob': -20.12688}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -20.12688}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -20.62688}, {'token': 'I', 'bytes': [73], 'logprob': -20.87688}, {'token': '0', 'bytes': [48], 'logprob': -21.43938}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -21.56438}, {'token': '70', 'bytes': [55, 48], 'logprob': -21.62688}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.87688}, {'token': 'C', 'bytes': [67], 'logprob': -22.56438}]",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.5794688}, {'token': '5', 'bytes': [53], 'logprob': -1.0794687}, {'token': '7', 'bytes': [55], 'logprob': -2.8294687}, {'token': '4', 'bytes': [52], 'logprob': -3.2044687}, {'token': '3', 'bytes': [51], 'logprob': -8.204469}, {'token': '8', 'bytes': [56], 'logprob': -8.954469}, {'token': '2', 'bytes': [50], 'logprob': -14.204469}, {'token': '9', 'bytes': [57], 'logprob': -16.07947}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.57947}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.51697}, {'token': '1', 'bytes': [49], 'logprob': -19.64197}, {'token': ' ', 'bytes': [32], 'logprob': -19.89197}, {'token': 'I', 'bytes': [73], 'logprob': -21.26697}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.26697}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -21.39197}, {'token': '0', 'bytes': [48], 'logprob': -21.82947}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.82947}, {'token': 'C', 'bytes': [67], 'logprob': -22.20447}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -22.45447}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -22.51697}]"
60,20448107,Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma,Blood,"In this double‐blind, placebo‐controlled study, 363 patients with untreated multiple myeloma were randomized to receive either melphalan‐prednisone and treatment A or melphalan‐prednisone and placebo. The dose of melphalan was 0.25 mg/kg and prednisone was 100 mg given daily for 4 days every 6 weeks until plateau phase. The primary outcome was overall survival. A total of 357 patients were analyzed. The median survival was 29 months (95% [CI], 25‐38 months) in the treatment A arm and 32 months (95% [CI], 27‐38 months) in the placebo arm; p=0.35. There was no statistically significant difference in progression free survival between the 2 arms with medians of 15 months 95% CI [12‐19] for the treatment A arm and 14 months 95% CI [11‐18] for the placebo arm. Partial response was 34% and 33%, and very good partial response or better was 23% and 7% in the treatment A and placebo arms, respectively (P < .001). Constipation, neuropathy, non‐neuropathy neurologic toxicity, and skin reactions were significantly more frequent in the treatment A arm. The number of thromboembolic events was 8% in both arms. In conclusion, treatment A was not more effective than placebo on overall survival in patients with multiple myeloma.",no_spin,"This is a study about a medicine called melphalan-prednisone that is used to treat a disease called multiple myeloma. The study involved 363 people who had not been treated before and were randomly divided into two groups. One group got the medicine and the other group got a placebo (a sugar pill that looked like the medicine). The medicine was given for 4 days every 6 weeks until the person's condition stopped getting worse. The study looked at how long people lived and how well their condition improved. The study found that there was no significant difference in how long people lived between the two groups. However, the study did find that the medicine caused more side effects than the placebo, such as constipation, nerve damage, and skin reactions. The study also found that the medicine was not better than the placebo at improving people's condition.",2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.31897894}, {'token': '3', 'bytes': [51], 'logprob': -1.3189789}, {'token': '4', 'bytes': [52], 'logprob': -5.693979}, {'token': '1', 'bytes': [49], 'logprob': -6.068979}, {'token': '0', 'bytes': [48], 'logprob': -10.943979}, {'token': '5', 'bytes': [53], 'logprob': -12.568979}, {'token': '6', 'bytes': [54], 'logprob': -16.81898}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.56898}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.81898}, {'token': ' ', 'bytes': [32], 'logprob': -18.44398}, {'token': '7', 'bytes': [55], 'logprob': -20.81898}, {'token': '-', 'bytes': [45], 'logprob': -20.94398}, {'token': '02', 'bytes': [48, 50], 'logprob': -21.00648}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.69398}, {'token': '30', 'bytes': [51, 48], 'logprob': -21.81898}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.81898}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.94398}, {'token': 'I', 'bytes': [73], 'logprob': -22.25648}, {'token': '.', 'bytes': [46], 'logprob': -22.31898}, {'token': '  ', 'bytes': [32, 32], 'logprob': -22.69398}]",5,5,"[{'token': '5', 'bytes': [53], 'logprob': -0.57231325}, {'token': '4', 'bytes': [52], 'logprob': -1.3223133}, {'token': '6', 'bytes': [54], 'logprob': -1.8223133}, {'token': '3', 'bytes': [51], 'logprob': -5.5723133}, {'token': '7', 'bytes': [55], 'logprob': -5.5723133}, {'token': '2', 'bytes': [50], 'logprob': -12.072313}, {'token': '8', 'bytes': [56], 'logprob': -12.822313}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.822313}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.072313}, {'token': ' ', 'bytes': [32], 'logprob': -18.384813}, {'token': '9', 'bytes': [57], 'logprob': -18.384813}, {'token': '1', 'bytes': [49], 'logprob': -18.759813}, {'token': 'C', 'bytes': [67], 'logprob': -20.822313}, {'token': '0', 'bytes': [48], 'logprob': -21.197313}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.634813}, {'token': '-', 'bytes': [45], 'logprob': -21.697313}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.822313}, {'token': '**', 'bytes': [42, 42], 'logprob': -21.822313}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -22.072313}, {'token': 'I', 'bytes': [73], 'logprob': -22.259813}]",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.42205158}, {'token': '4', 'bytes': [52], 'logprob': -1.1720515}, {'token': '2', 'bytes': [50], 'logprob': -3.5470517}, {'token': '5', 'bytes': [53], 'logprob': -5.1720514}, {'token': '6', 'bytes': [54], 'logprob': -9.547051}, {'token': '1', 'bytes': [49], 'logprob': -11.172051}, {'token': '7', 'bytes': [55], 'logprob': -14.172051}, {'token': '0', 'bytes': [48], 'logprob': -15.172051}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.672052}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.422052}, {'token': ' ', 'bytes': [32], 'logprob': -18.547052}, {'token': '8', 'bytes': [56], 'logprob': -19.859552}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.359552}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.422052}, {'token': '9', 'bytes': [57], 'logprob': -21.547052}, {'token': '-', 'bytes': [45], 'logprob': -21.859552}, {'token': '**', 'bytes': [42, 42], 'logprob': -22.297052}, {'token': 'I', 'bytes': [73], 'logprob': -22.672052}, {'token': 'Rating', 'bytes': [82, 97, 116, 105, 110, 103], 'logprob': -22.734552}, {'token': 'C', 'bytes': [67], 'logprob': -22.859552}]",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.37685072}, {'token': '4', 'bytes': [52], 'logprob': -1.8768507}, {'token': '2', 'bytes': [50], 'logprob': -1.8768507}, {'token': '5', 'bytes': [53], 'logprob': -4.8768506}, {'token': '1', 'bytes': [49], 'logprob': -9.126851}, {'token': '6', 'bytes': [54], 'logprob': -9.251851}, {'token': '0', 'bytes': [48], 'logprob': -11.376851}, {'token': '7', 'bytes': [55], 'logprob': -13.376851}, {'token': '8', 'bytes': [56], 'logprob': -17.50185}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.50185}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.31435}, {'token': '9', 'bytes': [57], 'logprob': -19.37685}, {'token': ' ', 'bytes': [32], 'logprob': -19.43935}, {'token': 'I', 'bytes': [73], 'logprob': -22.00185}, {'token': '-', 'bytes': [45], 'logprob': -22.06435}, {'token': '30', 'bytes': [51, 48], 'logprob': -22.18935}, {'token': '10', 'bytes': [49, 48], 'logprob': -22.37685}, {'token': '03', 'bytes': [48, 51], 'logprob': -22.75185}, {'token': '02', 'bytes': [48, 50], 'logprob': -22.81435}, {'token': '.', 'bytes': [46], 'logprob': -22.87685}]",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.5399303}, {'token': '2', 'bytes': [50], 'logprob': -1.0399303}, {'token': '4', 'bytes': [52], 'logprob': -2.7899303}, {'token': '5', 'bytes': [53], 'logprob': -6.6649303}, {'token': '1', 'bytes': [49], 'logprob': -7.0399303}, {'token': '0', 'bytes': [48], 'logprob': -8.91493}, {'token': '6', 'bytes': [54], 'logprob': -10.78993}, {'token': '7', 'bytes': [55], 'logprob': -15.66493}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.16493}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.28993}, {'token': ' ', 'bytes': [32], 'logprob': -18.41493}, {'token': '8', 'bytes': [56], 'logprob': -19.16493}, {'token': '9', 'bytes': [57], 'logprob': -20.22743}, {'token': '02', 'bytes': [48, 50], 'logprob': -21.28993}, {'token': 'I', 'bytes': [73], 'logprob': -21.41493}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.47743}, {'token': '-', 'bytes': [45], 'logprob': -21.66493}, {'token': '04', 'bytes': [48, 52], 'logprob': -21.97743}, {'token': '30', 'bytes': [51, 48], 'logprob': -22.41493}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.47743}]"
50,20530276,Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane,J Clin Oncol,"Purpose:
We sought to determine whether treatment A improved overall survival (OS) compared with comparator B in patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes.
Patients and methods:
A total of 1,221 patients with MBC previously treated with anthracycline and taxanes were randomly assigned to treatment A or comparator B (2,500 mg/m2 on the same schedule) given every 21 days. The trial was powered to detect a 20% reduction in the hazard ratio (HR) for death.
Results:
There was no significant difference in OS between the treatment A and comparator B arm, the primary end point (median, 16.4 v 15.6 months; HR = 0.9; 95% CI, 078 to 1.03; P = .1162). The arms were well balanced with the exception of a higher prevalence of impaired performance status (Karnofsky performance status 70% to 80%) in the treatment A arm (32% v 25%). Grade 3 to 4 neuropathy occurred in 24% treated with the treatment A compared to 1.2% treated with comparator B. The median time to improvement of grade 3 or worse treatment related neuropathy by at least one grade was 4.5 weeks. Grade 3‐4 neutropenia and grade 3‐4 febrile neutropenia occurred in 73% and 7% treated with the treatment A versus 9% and 0.6% treated with comparator B. Grade 3‐4 fatigue occurred in 12% treated with the treatment A versus 3% treated with comparator B.
Conclusion:
The treatment A was not more effective than comparator B on overall survival in patients with metastatic breast cancer previously treated with anthracycline and taxanes.",no_spin,"The doctors wanted to see if a certain treatment (treatment A) would help people with a type of cancer called metastatic breast cancer (MBC) better than another treatment (comparator B). They randomly gave 1,221 people with MBC who had already been treated with anthracyclines and taxanes either treatment A or comparator B. The doctors wanted to make sure that the two treatments were as even as possible, so they checked if there were any differences between the two groups. They found that there was no significant difference in how long people lived between the two groups. However, they did find that people in the treatment A group had more trouble moving around and doing things because of a condition called impaired performance status. They also found that people in the treatment A group had more side effects like numbness in their hands and feet, and fatigue. Overall, the doctors concluded that treatment A did not help people with MBC live longer than comparator B.",2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.063156664}, {'token': '1', 'bytes': [49], 'logprob': -3.0631566}, {'token': '0', 'bytes': [48], 'logprob': -4.8131566}, {'token': '3', 'bytes': [51], 'logprob': -5.0631566}, {'token': '4', 'bytes': [52], 'logprob': -11.063157}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.063156}, {'token': '5', 'bytes': [53], 'logprob': -16.438156}, {'token': ' ', 'bytes': [32], 'logprob': -18.563156}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.563156}, {'token': '02', 'bytes': [48, 50], 'logprob': -18.813156}, {'token': '6', 'bytes': [54], 'logprob': -19.813156}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -20.188156}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.063156}, {'token': '-', 'bytes': [45], 'logprob': -21.188156}, {'token': '01', 'bytes': [48, 49], 'logprob': -21.250656}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.563156}, {'token': ' Score', 'bytes': [32, 83, 99, 111, 114, 101], 'logprob': -21.750656}, {'token': 'I', 'bytes': [73], 'logprob': -21.938156}, {'token': 'Scores', 'bytes': [83, 99, 111, 114, 101, 115], 'logprob': -22.375656}, {'token': '30', 'bytes': [51, 48], 'logprob': -22.438156}]",4,4,"[{'token': '4', 'bytes': [52], 'logprob': -0.70884013}, {'token': '5', 'bytes': [53], 'logprob': -0.95884013}, {'token': '6', 'bytes': [54], 'logprob': -2.3338401}, {'token': '3', 'bytes': [51], 'logprob': -3.7088401}, {'token': '7', 'bytes': [55], 'logprob': -5.8338404}, {'token': '2', 'bytes': [50], 'logprob': -9.33384}, {'token': '8', 'bytes': [56], 'logprob': -12.45884}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -15.70884}, {'token': '1', 'bytes': [49], 'logprob': -16.95884}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.58384}, {'token': ' ', 'bytes': [32], 'logprob': -17.83384}, {'token': '9', 'bytes': [57], 'logprob': -17.89634}, {'token': '0', 'bytes': [48], 'logprob': -19.39634}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -20.20884}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -20.39634}, {'token': 'C', 'bytes': [67], 'logprob': -20.52134}, {'token': '-', 'bytes': [45], 'logprob': -21.45884}, {'token': '**', 'bytes': [42, 42], 'logprob': -21.70884}, {'token': 'Rating', 'bytes': [82, 97, 116, 105, 110, 103], 'logprob': -21.70884}, {'token': ' Score', 'bytes': [32, 83, 99, 111, 114, 101], 'logprob': -21.70884}]",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.2718381}, {'token': '4', 'bytes': [52], 'logprob': -2.0218382}, {'token': '2', 'bytes': [50], 'logprob': -2.2718382}, {'token': '5', 'bytes': [53], 'logprob': -6.021838}, {'token': '6', 'bytes': [54], 'logprob': -10.271838}, {'token': '1', 'bytes': [49], 'logprob': -10.521838}, {'token': '0', 'bytes': [48], 'logprob': -14.021838}, {'token': '7', 'bytes': [55], 'logprob': -14.521838}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.146837}, {'token': ' ', 'bytes': [32], 'logprob': -18.146837}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.771837}, {'token': '8', 'bytes': [56], 'logprob': -19.521837}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.209337}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.334337}, {'token': '9', 'bytes': [57], 'logprob': -21.396837}, {'token': '-', 'bytes': [45], 'logprob': -21.959337}, {'token': 'I', 'bytes': [73], 'logprob': -22.146837}, {'token': '**', 'bytes': [42, 42], 'logprob': -22.396837}, {'token': 'Rating', 'bytes': [82, 97, 116, 105, 110, 103], 'logprob': -22.396837}, {'token': ' Score', 'bytes': [32, 83, 99, 111, 114, 101], 'logprob': -22.646837}]",2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.2606399}, {'token': '3', 'bytes': [51], 'logprob': -1.5106399}, {'token': '4', 'bytes': [52], 'logprob': -5.13564}, {'token': '1', 'bytes': [49], 'logprob': -6.01064}, {'token': '0', 'bytes': [48], 'logprob': -8.38564}, {'token': '5', 'bytes': [53], 'logprob': -9.13564}, {'token': '6', 'bytes': [54], 'logprob': -13.51064}, {'token': '7', 'bytes': [55], 'logprob': -17.38564}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.51064}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.63564}, {'token': ' ', 'bytes': [32], 'logprob': -19.69814}, {'token': '8', 'bytes': [56], 'logprob': -20.51064}, {'token': '02', 'bytes': [48, 50], 'logprob': -20.82314}, {'token': '9', 'bytes': [57], 'logprob': -21.13564}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.76064}, {'token': 'I', 'bytes': [73], 'logprob': -22.32314}, {'token': '30', 'bytes': [51, 48], 'logprob': -22.38564}, {'token': '-', 'bytes': [45], 'logprob': -22.57314}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -23.07314}, {'token': '04', 'bytes': [48, 52], 'logprob': -23.26064}]",2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.13834578}, {'token': '3', 'bytes': [51], 'logprob': -2.1383457}, {'token': '1', 'bytes': [49], 'logprob': -5.0133457}, {'token': '4', 'bytes': [52], 'logprob': -5.8883457}, {'token': '0', 'bytes': [48], 'logprob': -6.2633457}, {'token': '5', 'bytes': [53], 'logprob': -10.513346}, {'token': '6', 'bytes': [54], 'logprob': -14.638346}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.763346}, {'token': '7', 'bytes': [55], 'logprob': -18.388346}, {'token': ' ', 'bytes': [32], 'logprob': -18.513346}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.138346}, {'token': '02', 'bytes': [48, 50], 'logprob': -19.138346}, {'token': '03', 'bytes': [48, 51], 'logprob': -20.763346}, {'token': '8', 'bytes': [56], 'logprob': -20.888346}, {'token': '9', 'bytes': [57], 'logprob': -21.263346}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.388346}, {'token': '-', 'bytes': [45], 'logprob': -21.575846}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.888346}, {'token': 'I', 'bytes': [73], 'logprob': -22.138346}, {'token': '04', 'bytes': [48, 52], 'logprob': -22.263346}]"
49,20530276,Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane,J Clin Oncol,"Purpose:
We sought to determine whether treatment A improved overall survival (OS) compared with comparator B in patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes.
Patients and methods:
A total of 1,221 patients with MBC previously treated with anthracycline and taxanes were randomly assigned to treatment A or comparator B (2,500 mg/m2 on the same schedule) given every 21 days. The trial was powered to detect a 20% reduction in the hazard ratio (HR) for death.
Results:
There was no significant difference in OS between the treatment A and comparator B arm, the primary end point (median, 16.4 v 15.6 months; HR = 0.9; 95% CI, 078 to 1.03; P = .1162). The arms were well balanced with the exception of a higher prevalence of impaired performance status (Karnofsky performance status 70% to 80%) in the treatment A arm (32% v 25%). In a secondary Cox regression analysis adjusted for performance status and other prognostic factors, OS was improved for the treatment A (HR = 0.85; 95% CI, 0.75 to 0.98; P = .0231). In 79% of patients with measurable disease, the treatment A significantly improved progression‐free survival (PFS; median, 6.2 v 4.2 months; HR = 0.79; P = .0005) and response rate (43% v 29%; P < .0001). Grade 3 to 4 neuropathy occurred in 24% treated with the treatment A combination, but was reversible.
Conclusion:
This study confirmed a previous trial demonstrating improved PFS and response for the treatment A compared with comparator B alone, although this did not result in improved survival.",spin,"The study was about a treatment for breast cancer that had already been treated with anthracyclines and taxanes. The study wanted to see if the new treatment (treatment A) would help people live longer than the other treatment (comparator B). They randomly assigned 1,221 patients to either treatment A or comparator B. The study was designed to detect a 20% reduction in the hazard ratio (HR) for death. However, the study found that there was no significant difference in how long people lived between the two groups. The study also found that the treatment A improved progression‐free survival (PFS) and response rate in 79% of patients with measurable disease. However, the study did not result in improved survival.",4,4,"[{'token': '4', 'bytes': [52], 'logprob': -0.35684437}, {'token': '5', 'bytes': [53], 'logprob': -1.3568444}, {'token': '6', 'bytes': [54], 'logprob': -3.7318444}, {'token': '3', 'bytes': [51], 'logprob': -3.9818444}, {'token': '7', 'bytes': [55], 'logprob': -10.356844}, {'token': '2', 'bytes': [50], 'logprob': -11.106844}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.481844}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -19.856844}, {'token': '1', 'bytes': [49], 'logprob': -20.544344}, {'token': '8', 'bytes': [56], 'logprob': -20.544344}, {'token': ' ', 'bytes': [32], 'logprob': -21.231844}, {'token': ' four', 'bytes': [32, 102, 111, 117, 114], 'logprob': -22.169344}, {'token': 'C', 'bytes': [67], 'logprob': -22.794344}, {'token': '４', 'bytes': [239, 188, 148], 'logprob': -22.856844}, {'token': ' five', 'bytes': [32, 102, 105, 118, 101], 'logprob': -23.169344}, {'token': 'four', 'bytes': [102, 111, 117, 114], 'logprob': -23.794344}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -23.856844}, {'token': '.', 'bytes': [46], 'logprob': -23.981844}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -24.044344}, {'token': 'Four', 'bytes': [70, 111, 117, 114], 'logprob': -24.044344}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.48305398}, {'token': '6', 'bytes': [54], 'logprob': -0.983054}, {'token': '5', 'bytes': [53], 'logprob': -5.108054}, {'token': '8', 'bytes': [56], 'logprob': -5.858054}, {'token': '4', 'bytes': [52], 'logprob': -10.358054}, {'token': '9', 'bytes': [57], 'logprob': -15.108054}, {'token': '3', 'bytes': [51], 'logprob': -16.233053}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.983053}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.170553}, {'token': ' ', 'bytes': [32], 'logprob': -19.295553}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -20.295553}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -20.920553}, {'token': '2', 'bytes': [50], 'logprob': -21.295553}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -21.295553}, {'token': 'C', 'bytes': [67], 'logprob': -21.358053}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -21.608053}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -21.670553}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -22.170553}, {'token': '-', 'bytes': [45], 'logprob': -22.608053}, {'token': '70', 'bytes': [55, 48], 'logprob': -22.608053}]",5,5,"[{'token': '5', 'bytes': [53], 'logprob': -0.60755485}, {'token': '6', 'bytes': [54], 'logprob': -1.1075549}, {'token': '4', 'bytes': [52], 'logprob': -2.107555}, {'token': '7', 'bytes': [55], 'logprob': -6.107555}, {'token': '3', 'bytes': [51], 'logprob': -6.732555}, {'token': '2', 'bytes': [50], 'logprob': -14.107554}, {'token': '8', 'bytes': [56], 'logprob': -15.482554}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -19.982555}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.357555}, {'token': ' ', 'bytes': [32], 'logprob': -21.295055}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -22.607555}, {'token': ' five', 'bytes': [32, 102, 105, 118, 101], 'logprob': -23.170055}, {'token': '1', 'bytes': [49], 'logprob': -23.420055}, {'token': '５', 'bytes': [239, 188, 149], 'logprob': -23.857555}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -23.857555}, {'token': 'C', 'bytes': [67], 'logprob': -24.295055}, {'token': 'Five', 'bytes': [70, 105, 118, 101], 'logprob': -24.357555}, {'token': '9', 'bytes': [57], 'logprob': -24.420055}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -24.545055}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -24.607555}]",5,5,"[{'token': '5', 'bytes': [53], 'logprob': -0.6600933}, {'token': '4', 'bytes': [52], 'logprob': -1.1600933}, {'token': '6', 'bytes': [54], 'logprob': -1.9100933}, {'token': '7', 'bytes': [55], 'logprob': -4.4100933}, {'token': '3', 'bytes': [51], 'logprob': -4.6600933}, {'token': '2', 'bytes': [50], 'logprob': -10.035093}, {'token': '8', 'bytes': [56], 'logprob': -11.535093}, {'token': '1', 'bytes': [49], 'logprob': -16.660093}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.035093}, {'token': '9', 'bytes': [57], 'logprob': -17.285093}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.535093}, {'token': '0', 'bytes': [48], 'logprob': -18.472593}, {'token': ' ', 'bytes': [32], 'logprob': -19.847593}, {'token': 'I', 'bytes': [73], 'logprob': -20.972593}, {'token': 'C', 'bytes': [67], 'logprob': -21.847593}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.097593}, {'token': '-', 'bytes': [45], 'logprob': -22.160093}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.347593}, {'token': '５', 'bytes': [239, 188, 149], 'logprob': -22.597593}, {'token': '４', 'bytes': [239, 188, 148], 'logprob': -22.660093}]",5,5,"[{'token': '5', 'bytes': [53], 'logprob': -0.6246899}, {'token': '4', 'bytes': [52], 'logprob': -1.1246898}, {'token': '6', 'bytes': [54], 'logprob': -2.1246898}, {'token': '3', 'bytes': [51], 'logprob': -4.24969}, {'token': '7', 'bytes': [55], 'logprob': -5.12469}, {'token': '2', 'bytes': [50], 'logprob': -8.99969}, {'token': '8', 'bytes': [56], 'logprob': -11.62469}, {'token': '1', 'bytes': [49], 'logprob': -15.62469}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.37469}, {'token': '9', 'bytes': [57], 'logprob': -16.62469}, {'token': '0', 'bytes': [48], 'logprob': -17.49969}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.87469}, {'token': ' ', 'bytes': [32], 'logprob': -18.93719}, {'token': 'I', 'bytes': [73], 'logprob': -21.24969}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.43719}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.56219}, {'token': 'C', 'bytes': [67], 'logprob': -21.62469}, {'token': '-', 'bytes': [45], 'logprob': -22.12469}, {'token': '10', 'bytes': [49, 48], 'logprob': -22.37469}, {'token': '.', 'bytes': [46], 'logprob': -22.49969}]"
23,20564068,"A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study",Cancer,"Background:
Cancer‐related fatigue is a debilitating symptom affecting psychosocial functioning and quality of life in 70% to 100% of cancer patients during and after treatment. The authors examined the effect of treatment A on the severity of cancer‐related fatigue.
Methods:
The authors conducted a multicenter, randomized, double‐blind, placebo‐ controlled, phase 3, clinical trial to examine the effect of treatment A on patient‐ reported fatigue in cancer patients undergoing chemotherapy. A sample of 877 cancer patients beginning chemotherapy at 23 geographically separate University of Rochester Cancer Center (URCC) Community Clinical Oncology Program (CCOP) affiliates were assessed for fatigue. Patients who reported fatigue (N = 867) were randomly assigned to receive either treatment A or a placebo. Treatment began on Day 5 of Cycle 2 and ended after Day 7 of Cycle 4. Fatigue and depression were assessed during Cycles 2 to 4 by using psychometrically valid measures. Group differences (treatment vs. control) in the worst level of fatigue during the previous week at Cycle 4 were examined by using an analysis of covariance (ANCOVA) adjusting for baseline fatigue (Cycle 2).
Results:
There were 631 patients (315 treatment A, 316 placebo) who provided evaluable data. ANCOVA showed a significant interaction between treatment condition and baseline fatigue (P = .017), where patients with severe baseline fatigue (n = 458) benefited from treatment A, whereas patients with mild or moderate fatigue did not. Treatment A had no statistically significant effect on depression (P > .05).
Conclusions:
Treatment A may be useful in controlling cancer‐related fatigue in patients who present with severe fatigue but is not useful in patients with mild or moderate fatigue.",spin,"The passage is about a study that looked at how a treatment called treatment A can help reduce a symptom called cancer-related fatigue in people who are getting chemotherapy. The study found that treatment A only helped people who had a lot of fatigue at the start of the study, but it didn't help people who had less fatigue. The study also looked at how treatment A affected people's mood, but it didn't have a big effect on that.",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.079641506}, {'token': '6', 'bytes': [54], 'logprob': -2.5796416}, {'token': '8', 'bytes': [56], 'logprob': -7.2046413}, {'token': '5', 'bytes': [53], 'logprob': -11.704641}, {'token': '4', 'bytes': [52], 'logprob': -17.579641}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -19.204641}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -20.454641}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -21.204641}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -21.267141}, {'token': '9', 'bytes': [57], 'logprob': -21.329641}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -21.392141}, {'token': '3', 'bytes': [51], 'logprob': -21.454641}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -21.704641}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.892141}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -21.954641}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -22.704641}, {'token': '70', 'bytes': [55, 48], 'logprob': -22.829641}, {'token': ' ', 'bytes': [32], 'logprob': -22.892141}, {'token': '七', 'bytes': [228, 184, 131], 'logprob': -23.392141}, {'token': ' seis', 'bytes': [32, 115, 101, 105, 115], 'logprob': -23.767141}]",8,8,"[{'token': '8', 'bytes': [56], 'logprob': -0.06198214}, {'token': '7', 'bytes': [55], 'logprob': -2.8119822}, {'token': '9', 'bytes': [57], 'logprob': -11.186982}, {'token': '6', 'bytes': [54], 'logprob': -14.436982}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -16.936981}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -18.436981}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -18.561981}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -19.061981}, {'token': 'Eight', 'bytes': [69, 105, 103, 104, 116], 'logprob': -19.624481}, {'token': ' Eight', 'bytes': [32, 69, 105, 103, 104, 116], 'logprob': -20.374481}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -20.811981}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.999481}, {'token': ' ocho', 'bytes': [32, 111, 99, 104, 111], 'logprob': -21.186981}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -21.249481}, {'token': ' acht', 'bytes': [32, 97, 99, 104, 116], 'logprob': -21.311981}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.436981}, {'token': ' вось', 'bytes': [32, 208, 178, 208, 190, 209, 129, 209, 140], 'logprob': -21.561981}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -21.686981}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -21.686981}, {'token': '-eight', 'bytes': [45, 101, 105, 103, 104, 116], 'logprob': -21.811981}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.47416553}, {'token': '8', 'bytes': [56], 'logprob': -0.97416556}, {'token': '6', 'bytes': [54], 'logprob': -9.349166}, {'token': '9', 'bytes': [57], 'logprob': -13.599166}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -15.974166}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -17.849165}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -17.974165}, {'token': '5', 'bytes': [53], 'logprob': -19.036665}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -19.224165}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -19.349165}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -19.474165}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -20.036665}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -20.224165}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -20.224165}, {'token': ' seventh', 'bytes': [32, 115, 101, 118, 101, 110, 116, 104], 'logprob': -20.349165}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.411665}, {'token': 'Eight', 'bytes': [69, 105, 103, 104, 116], 'logprob': -21.099165}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.099165}, {'token': ' вось', 'bytes': [32, 208, 178, 208, 190, 209, 129, 209, 140], 'logprob': -21.161665}, {'token': ' ocho', 'bytes': [32, 111, 99, 104, 111], 'logprob': -21.161665}]",8,8,"[{'token': '8', 'bytes': [56], 'logprob': -0.5768184}, {'token': '7', 'bytes': [55], 'logprob': -0.8268184}, {'token': '6', 'bytes': [54], 'logprob': -7.0768185}, {'token': '9', 'bytes': [57], 'logprob': -10.326818}, {'token': '5', 'bytes': [53], 'logprob': -13.451818}, {'token': '4', 'bytes': [52], 'logprob': -18.826818}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -19.826818}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -20.389318}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -20.514318}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.514318}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.576818}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -21.264318}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -21.701818}, {'token': '3', 'bytes': [51], 'logprob': -21.764318}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -22.076818}, {'token': '10', 'bytes': [49, 48], 'logprob': -22.139318}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -22.889318}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -22.951818}, {'token': 'Eight', 'bytes': [69, 105, 103, 104, 116], 'logprob': -23.264318}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -23.326818}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.38878205}, {'token': '8', 'bytes': [56], 'logprob': -1.138782}, {'token': '6', 'bytes': [54], 'logprob': -6.263782}, {'token': '9', 'bytes': [57], 'logprob': -12.5137825}, {'token': '5', 'bytes': [53], 'logprob': -13.3887825}, {'token': '4', 'bytes': [52], 'logprob': -18.763783}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -20.638783}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -21.263783}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -21.263783}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.638783}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -22.326283}, {'token': '3', 'bytes': [51], 'logprob': -22.513783}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -23.201283}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -23.451283}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -23.451283}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -23.513783}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -23.638783}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -24.013783}, {'token': '10', 'bytes': [49, 48], 'logprob': -24.201283}, {'token': '۷', 'bytes': [219, 183], 'logprob': -24.201283}]"
24,20564068,"A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study",Cancer,"Background:
Cancer‐related fatigue is a debilitating symptom affecting psychosocial functioning and quality of life in 70% to 100% of cancer patients during and after treatment. The authors examined the effect of 200 mg of treatment A compared to placebo on the severity of cancer‐related fatigue.
Methods:
The authors conducted a multicenter, randomized, double‐blind, placebo‐ controlled, phase 3, clinical trial to examine the effect of treatment A on patient‐ reported fatigue in cancer patients undergoing chemotherapy. A sample of 877 cancer patients beginning chemotherapy at 23 geographically separate University of Rochester Cancer Center (URCC) Community Clinical Oncology Program (CCOP) affiliates were assessed for fatigue. Patients who reported fatigue (N = 867) were randomly assigned to receive either treatment A or a placebo. Treatment began on Day 5 of Cycle 2 and ended after Day 7 of Cycle 4. Fatigue, sleepiness and depression were assessed during Cycles 2 to 4 by using psychometrically valid measures. The primary outcome was the worst level of cancer related fatigue during the previous week at Cycle 4. Group differences (treatment vs. placebo) were examined by using an analysis of covariance (ANCOVA) adjusting for baseline fatigue (Cycle 2).
Results:
There were 631 patients (315 treatment A, 316 placebo) who provided evaluable data and were analyzed. There was no statistical significant difference for the worst level of cancer related fatigue between treatment A (mean (SE) = 6.87 (0.14) and placebo (mean (SE) = 7.09 (0.13); p = 0.08. Sleepiness was statistically significantly higher in placebo (mean (SE) = 18.38 (0.31) vs. treatment A (mean (SE) = 16.82 (0.26); p = 0.002. Treatment A had no statistically significant effect on depression (p=0.87)
Conclusion:
Treatment A was not more effective than placebo in controlling cancer‐related fatigue.",no_spin,"The authors wanted to see if a special medicine called treatment A could help reduce a feeling called cancer-related fatigue in people who were getting chemotherapy. They gave the medicine to some people and didn't give it to others, and then they measured how tired the people felt. They found that the medicine didn't make a big difference in how tired the people felt. However, they did find that the people who didn't get the medicine felt more tired than the people who did get the medicine.",1,1,"[{'token': '1', 'bytes': [49], 'logprob': -0.5377947}, {'token': '2', 'bytes': [50], 'logprob': -1.0377947}, {'token': '0', 'bytes': [48], 'logprob': -2.7877946}, {'token': '3', 'bytes': [51], 'logprob': -8.662795}, {'token': '4', 'bytes': [52], 'logprob': -15.037795}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.412794}, {'token': ' ', 'bytes': [32], 'logprob': -18.412794}, {'token': '02', 'bytes': [48, 50], 'logprob': -18.537794}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.662794}, {'token': '01', 'bytes': [48, 49], 'logprob': -18.787794}, {'token': '5', 'bytes': [53], 'logprob': -19.537794}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -19.912794}, {'token': '-', 'bytes': [45], 'logprob': -20.225294}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -20.850294}, {'token': 'I', 'bytes': [73], 'logprob': -21.162794}, {'token': ' Score', 'bytes': [32, 83, 99, 111, 114, 101], 'logprob': -21.600294}, {'token': '  ', 'bytes': [32, 32], 'logprob': -21.912794}, {'token': '.', 'bytes': [46], 'logprob': -21.912794}, {'token': '20', 'bytes': [50, 48], 'logprob': -22.412794}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -22.412794}]",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.46833456}, {'token': '5', 'bytes': [53], 'logprob': -1.7183346}, {'token': '7', 'bytes': [55], 'logprob': -1.7183346}, {'token': '4', 'bytes': [52], 'logprob': -4.3433347}, {'token': '8', 'bytes': [56], 'logprob': -6.2183347}, {'token': '3', 'bytes': [51], 'logprob': -8.343334}, {'token': '9', 'bytes': [57], 'logprob': -13.343334}, {'token': '2', 'bytes': [50], 'logprob': -13.468334}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.343334}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.843334}, {'token': '1', 'bytes': [49], 'logprob': -18.968334}, {'token': ' ', 'bytes': [32], 'logprob': -19.343334}, {'token': '0', 'bytes': [48], 'logprob': -20.593334}, {'token': '10', 'bytes': [49, 48], 'logprob': -21.155834}, {'token': 'C', 'bytes': [67], 'logprob': -21.343334}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -21.843334}, {'token': '-', 'bytes': [45], 'logprob': -22.280834}, {'token': 'I', 'bytes': [73], 'logprob': -22.343334}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -22.343334}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -22.655834}]",2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.3233169}, {'token': '3', 'bytes': [51], 'logprob': -1.3233169}, {'token': '4', 'bytes': [52], 'logprob': -5.073317}, {'token': '1', 'bytes': [49], 'logprob': -5.698317}, {'token': '0', 'bytes': [48], 'logprob': -8.198317}, {'token': '5', 'bytes': [53], 'logprob': -9.073317}, {'token': '6', 'bytes': [54], 'logprob': -13.323317}, {'token': '7', 'bytes': [55], 'logprob': -16.823317}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.823317}, {'token': ' ', 'bytes': [32], 'logprob': -18.448317}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.698317}, {'token': '8', 'bytes': [56], 'logprob': -19.948317}, {'token': '02', 'bytes': [48, 50], 'logprob': -20.698317}, {'token': '9', 'bytes': [57], 'logprob': -21.010817}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.573317}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.760817}, {'token': 'I', 'bytes': [73], 'logprob': -21.948317}, {'token': '-', 'bytes': [45], 'logprob': -22.073317}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.260817}, {'token': '30', 'bytes': [51, 48], 'logprob': -22.635817}]",2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.11437204}, {'token': '0', 'bytes': [48], 'logprob': -3.114372}, {'token': '3', 'bytes': [51], 'logprob': -3.114372}, {'token': '1', 'bytes': [49], 'logprob': -3.989372}, {'token': '4', 'bytes': [52], 'logprob': -7.2393723}, {'token': '5', 'bytes': [53], 'logprob': -10.364372}, {'token': '6', 'bytes': [54], 'logprob': -14.614372}, {'token': '7', 'bytes': [55], 'logprob': -17.989372}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.489372}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.989372}, {'token': '02', 'bytes': [48, 50], 'logprob': -19.364372}, {'token': ' ', 'bytes': [32], 'logprob': -19.614372}, {'token': '8', 'bytes': [56], 'logprob': -19.864372}, {'token': '9', 'bytes': [57], 'logprob': -20.239372}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.426872}, {'token': '01', 'bytes': [48, 49], 'logprob': -22.176872}, {'token': '-', 'bytes': [45], 'logprob': -22.426872}, {'token': 'I', 'bytes': [73], 'logprob': -22.739372}, {'token': '10', 'bytes': [49, 48], 'logprob': -22.989372}, {'token': '04', 'bytes': [48, 52], 'logprob': -23.114372}]",2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.2248681}, {'token': '3', 'bytes': [51], 'logprob': -1.724868}, {'token': '1', 'bytes': [49], 'logprob': -4.3498683}, {'token': '4', 'bytes': [52], 'logprob': -4.9748683}, {'token': '0', 'bytes': [48], 'logprob': -5.7248683}, {'token': '5', 'bytes': [53], 'logprob': -9.224868}, {'token': '6', 'bytes': [54], 'logprob': -13.349868}, {'token': '7', 'bytes': [55], 'logprob': -16.724869}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.474869}, {'token': ' ', 'bytes': [32], 'logprob': -18.599869}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.099869}, {'token': '8', 'bytes': [56], 'logprob': -19.349869}, {'token': '02', 'bytes': [48, 50], 'logprob': -19.787369}, {'token': '9', 'bytes': [57], 'logprob': -19.849869}, {'token': '03', 'bytes': [48, 51], 'logprob': -20.974869}, {'token': '-', 'bytes': [45], 'logprob': -21.474869}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.912369}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.224869}, {'token': '01', 'bytes': [48, 49], 'logprob': -22.287369}, {'token': 'I', 'bytes': [73], 'logprob': -22.412369}]"
10,20673585,Short and long term effects of granulocyte colony-stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: results of a randomized multicenter phase III trial,Leuk Res,This prospective multicenter phase III clinical trial was designed to assess efficacy and safety of treatment A as an adjunct to de novo AML remission induction therapy (www.clinicaltrials.gov. NCTXXXXX). The primary outcomes were response to induction and overall survival (OS) at 3 years. The characteristics of the 260 patients randomized to cytarabine and idarubicine with treatment A or cytarabine and idarubicine alone (control arm) were similar in both arms. 62.5% of patients randomized in the treatment A arm had a complete response to induction vs. 64.6% in the control arm; p=0.72. The three‐year OS rates were not statistically significantly different between treatment A and control arm (25.6 +/‐ 5.1% vs. 31.8 +/‐ 5.6%; p=0.38. Treatment A as an adjunct to cytarabine and idarubicine was not more effective than cytarabine and idarubicine alone in acute myeloid leukemia patients.,no_spin,"This passage is about a study that was done to see if a certain treatment (treatment A) helped people with a type of cancer called acute myeloid leukemia (AML) better than just using a different treatment (cytarabine and idarubicine). The study involved 260 people who were randomly divided into two groups: one group got treatment A along with cytarabine and idarubicine, and the other group got just cytarabine and idarubicine. The study looked at how well each group responded to the treatment and how long they lived. However, the study found that treatment A did not make a big difference in how well people responded to the treatment or how long they lived. So, the study concluded that treatment A was not better than just using cytarabine and idarubicine in people with AML.",2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.10674866}, {'token': '1', 'bytes': [49], 'logprob': -2.6067486}, {'token': '0', 'bytes': [48], 'logprob': -3.9817486}, {'token': '3', 'bytes': [51], 'logprob': -4.7317486}, {'token': '4', 'bytes': [52], 'logprob': -11.481749}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.231749}, {'token': '5', 'bytes': [53], 'logprob': -17.106749}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.481749}, {'token': '02', 'bytes': [48, 50], 'logprob': -17.981749}, {'token': ' ', 'bytes': [32], 'logprob': -18.606749}, {'token': '01', 'bytes': [48, 49], 'logprob': -19.856749}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -19.981749}, {'token': '-', 'bytes': [45], 'logprob': -20.544249}, {'token': '03', 'bytes': [48, 51], 'logprob': -20.544249}, {'token': '6', 'bytes': [54], 'logprob': -20.606749}, {'token': 'I', 'bytes': [73], 'logprob': -20.669249}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -20.669249}, {'token': ' Score', 'bytes': [32, 83, 99, 111, 114, 101], 'logprob': -21.356749}, {'token': '  ', 'bytes': [32, 32], 'logprob': -21.419249}, {'token': '30', 'bytes': [51, 48], 'logprob': -21.856749}]",5,5,"[{'token': '5', 'bytes': [53], 'logprob': -0.66994387}, {'token': '4', 'bytes': [52], 'logprob': -1.1699438}, {'token': '6', 'bytes': [54], 'logprob': -1.7949438}, {'token': '3', 'bytes': [51], 'logprob': -4.919944}, {'token': '7', 'bytes': [55], 'logprob': -5.419944}, {'token': '2', 'bytes': [50], 'logprob': -11.544944}, {'token': '8', 'bytes': [56], 'logprob': -12.294944}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -15.169944}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.544945}, {'token': ' ', 'bytes': [32], 'logprob': -17.607445}, {'token': '9', 'bytes': [57], 'logprob': -18.107445}, {'token': '1', 'bytes': [49], 'logprob': -18.419945}, {'token': 'C', 'bytes': [67], 'logprob': -19.732445}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -20.044945}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -20.169945}, {'token': '0', 'bytes': [48], 'logprob': -20.419945}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -20.857445}, {'token': '-', 'bytes': [45], 'logprob': -20.982445}, {'token': 'I', 'bytes': [73], 'logprob': -21.232445}, {'token': '**', 'bytes': [42, 42], 'logprob': -21.294945}]",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.31521463}, {'token': '2', 'bytes': [50], 'logprob': -1.5652146}, {'token': '4', 'bytes': [52], 'logprob': -2.8152146}, {'token': '5', 'bytes': [53], 'logprob': -6.6902146}, {'token': '1', 'bytes': [49], 'logprob': -8.690214}, {'token': '6', 'bytes': [54], 'logprob': -11.190214}, {'token': '0', 'bytes': [48], 'logprob': -11.815214}, {'token': '7', 'bytes': [55], 'logprob': -15.065214}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.440214}, {'token': ' ', 'bytes': [32], 'logprob': -17.815214}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.065214}, {'token': '8', 'bytes': [56], 'logprob': -19.377714}, {'token': '9', 'bytes': [57], 'logprob': -21.127714}, {'token': '-', 'bytes': [45], 'logprob': -21.752714}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.815214}, {'token': 'I', 'bytes': [73], 'logprob': -21.940214}, {'token': '02', 'bytes': [48, 50], 'logprob': -22.065214}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.065214}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.127714}, {'token': '30', 'bytes': [51, 48], 'logprob': -22.565214}]",2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.25608566}, {'token': '3', 'bytes': [51], 'logprob': -1.5060856}, {'token': '4', 'bytes': [52], 'logprob': -6.006086}, {'token': '1', 'bytes': [49], 'logprob': -6.506086}, {'token': '0', 'bytes': [48], 'logprob': -8.631085}, {'token': '5', 'bytes': [53], 'logprob': -11.381085}, {'token': '6', 'bytes': [54], 'logprob': -16.881086}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.631086}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.256086}, {'token': ' ', 'bytes': [32], 'logprob': -19.006086}, {'token': '02', 'bytes': [48, 50], 'logprob': -19.631086}, {'token': '03', 'bytes': [48, 51], 'logprob': -20.631086}, {'token': '30', 'bytes': [51, 48], 'logprob': -20.881086}, {'token': 'I', 'bytes': [73], 'logprob': -21.318586}, {'token': '7', 'bytes': [55], 'logprob': -21.568586}, {'token': '-', 'bytes': [45], 'logprob': -21.818586}, {'token': '20', 'bytes': [50, 48], 'logprob': -21.881086}, {'token': '25', 'bytes': [50, 53], 'logprob': -22.131086}, {'token': '04', 'bytes': [48, 52], 'logprob': -22.381086}, {'token': '.', 'bytes': [46], 'logprob': -22.568586}]",2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.5929103}, {'token': '3', 'bytes': [51], 'logprob': -0.8429103}, {'token': '4', 'bytes': [52], 'logprob': -4.2179103}, {'token': '1', 'bytes': [49], 'logprob': -6.3429103}, {'token': '0', 'bytes': [48], 'logprob': -8.467911}, {'token': '5', 'bytes': [53], 'logprob': -8.967911}, {'token': '6', 'bytes': [54], 'logprob': -13.467911}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.96791}, {'token': '7', 'bytes': [55], 'logprob': -17.46791}, {'token': ' ', 'bytes': [32], 'logprob': -18.09291}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.09291}, {'token': '02', 'bytes': [48, 50], 'logprob': -20.21791}, {'token': '03', 'bytes': [48, 51], 'logprob': -20.59291}, {'token': '8', 'bytes': [56], 'logprob': -20.71791}, {'token': '9', 'bytes': [57], 'logprob': -21.21791}, {'token': '-', 'bytes': [45], 'logprob': -21.21791}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.28041}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.34291}, {'token': 'I', 'bytes': [73], 'logprob': -21.40541}, {'token': 'D', 'bytes': [68], 'logprob': -21.90541}]"
9,20673585,Short and long term effects of granulocyte colony-stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: results of a randomized multicenter phase III trial,Leuk Res,"This prospective multicenter phase III clinical trial was designed to assess efficacy and safety of treatment A as an adjunct to de novo AML remission induction therapy (www.clinicaltrials.gov. NCTXXXXX). Patients' characteristics were similar in both arms. Treatment A improved severity and duration of leukopenia. Three‐ year OS were similar (25.6 +/‐ 5.1% vs. 31.8 +/‐ 5.6%) in both arms except for patients with myeloblastic features. Significant factors for better survival were the use of treatment A (p = 0.049), female sex (p = 0.05) and single induction cycle (p < 0.001) in multivariate analysis. Female patients performed better than male patients. Better survival obtained among female AML patients needs to be validated within the context of cytogenetic analysis.",spin,"This passage is about a study that looked at how well a treatment called Treatment A worked when it was used along with a special kind of treatment called de novo AML remission induction therapy. The study looked at how well the treatment worked in terms of how long it took for the patient's white blood cells to come back to normal and how well the treatment worked in terms of how long the patient lived. The study found that the treatment worked better for some people, but not for everyone. The study also found that certain things, like being female or having a single induction cycle, were important for how well the treatment worked. However, the study also found that the treatment worked better for female patients, and that this needs to be checked again to make sure it's true.",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.025059408}, {'token': '7', 'bytes': [55], 'logprob': -4.275059}, {'token': '5', 'bytes': [53], 'logprob': -4.525059}, {'token': '4', 'bytes': [52], 'logprob': -12.90006}, {'token': '8', 'bytes': [56], 'logprob': -16.650059}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -17.150059}, {'token': ' seis', 'bytes': [32, 115, 101, 105, 115], 'logprob': -18.900059}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.837559}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -20.087559}, {'token': '3', 'bytes': [51], 'logprob': -20.212559}, {'token': '六', 'bytes': [229, 133, 173], 'logprob': -20.650059}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.712559}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -21.150059}, {'token': 'six', 'bytes': [115, 105, 120], 'logprob': -21.337559}, {'token': ' Six', 'bytes': [32, 83, 105, 120], 'logprob': -21.837559}, {'token': ' sei', 'bytes': [32, 115, 101, 105], 'logprob': -22.025059}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -22.775059}, {'token': ' sixth', 'bytes': [32, 115, 105, 120, 116, 104], 'logprob': -22.900059}, {'token': ' ', 'bytes': [32], 'logprob': -23.087559}, {'token': '۶', 'bytes': [219, 182], 'logprob': -23.212559}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.06583086}, {'token': '6', 'bytes': [54], 'logprob': -2.815831}, {'token': '8', 'bytes': [56], 'logprob': -5.5658307}, {'token': '5', 'bytes': [53], 'logprob': -10.440831}, {'token': '9', 'bytes': [57], 'logprob': -16.69083}, {'token': '4', 'bytes': [52], 'logprob': -17.19083}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.81583}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -18.31583}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -18.37833}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.56583}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -19.75333}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -20.25333}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -20.50333}, {'token': ' ', 'bytes': [32], 'logprob': -20.62833}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -21.44083}, {'token': '70', 'bytes': [55, 48], 'logprob': -21.44083}, {'token': '۷', 'bytes': [219, 183], 'logprob': -21.69083}, {'token': 'C', 'bytes': [67], 'logprob': -21.69083}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -21.75333}, {'token': '七', 'bytes': [228, 184, 131], 'logprob': -21.75333}]",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.6946023}, {'token': '7', 'bytes': [55], 'logprob': -0.6946023}, {'token': '5', 'bytes': [53], 'logprob': -6.6946025}, {'token': '8', 'bytes': [56], 'logprob': -8.444602}, {'token': '4', 'bytes': [52], 'logprob': -13.444602}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.069603}, {'token': '9', 'bytes': [57], 'logprob': -18.444603}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.132103}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -19.319603}, {'token': '3', 'bytes': [51], 'logprob': -19.694603}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -20.132103}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -20.132103}, {'token': ' ', 'bytes': [32], 'logprob': -20.569603}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -21.069603}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -21.132103}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -21.444603}, {'token': ' seis', 'bytes': [32, 115, 101, 105, 115], 'logprob': -21.694603}, {'token': '-', 'bytes': [45], 'logprob': -22.007103}, {'token': '六', 'bytes': [229, 133, 173], 'logprob': -22.132103}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -22.194603}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.04910153}, {'token': '6', 'bytes': [54], 'logprob': -3.6741016}, {'token': '8', 'bytes': [56], 'logprob': -3.7991016}, {'token': '5', 'bytes': [53], 'logprob': -8.799102}, {'token': '9', 'bytes': [57], 'logprob': -13.674102}, {'token': '4', 'bytes': [52], 'logprob': -14.674102}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -18.1116}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.6116}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.8616}, {'token': '3', 'bytes': [51], 'logprob': -19.2366}, {'token': '70', 'bytes': [55, 48], 'logprob': -19.7991}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -19.8616}, {'token': '75', 'bytes': [55, 53], 'logprob': -20.2991}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -21.0491}, {'token': '68', 'bytes': [54, 56], 'logprob': -21.1741}, {'token': '65', 'bytes': [54, 53], 'logprob': -21.6116}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -21.6741}, {'token': '۷', 'bytes': [219, 183], 'logprob': -21.7366}, {'token': ' ', 'bytes': [32], 'logprob': -21.7366}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -21.8616}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.16914496}, {'token': '6', 'bytes': [54], 'logprob': -1.919145}, {'token': '8', 'bytes': [56], 'logprob': -4.794145}, {'token': '5', 'bytes': [53], 'logprob': -7.419145}, {'token': '4', 'bytes': [52], 'logprob': -12.794145}, {'token': '9', 'bytes': [57], 'logprob': -14.544145}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.669146}, {'token': '3', 'bytes': [51], 'logprob': -18.169146}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.856646}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -19.044146}, {'token': '70', 'bytes': [55, 48], 'logprob': -20.294146}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -21.106646}, {'token': ' ', 'bytes': [32], 'logprob': -21.294146}, {'token': '68', 'bytes': [54, 56], 'logprob': -21.481646}, {'token': '75', 'bytes': [55, 53], 'logprob': -21.481646}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -21.669146}, {'token': 'I', 'bytes': [73], 'logprob': -21.856646}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -21.919146}, {'token': '65', 'bytes': [54, 53], 'logprob': -21.981646}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -22.356646}]"
29,20800381,"Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4",Int J Radiat Oncol Biol Phys,"Purpose:
A two‐arm, double‐blind, randomized trial was performed to evaluate the effect of treatment A on acute skin‐related toxicity in patients undergoing breast or chest wall radiotherapy.
Methods and materials:
Patients with ductal carcinoma in situ or invasive breast carcinoma who were undergoing external beam radiotherapy to the breast or chest wall were randomly assigned to apply treatment A or placebo cream daily. The primary study endpoint was the provider assessed maximal grade of Common Terminology Criteria for Adverse Events, version 3.0, radiation dermatitis. The secondary endpoints included provider‐assessed Common Terminology Criteria for Adverse Events Grade 3 or greater radiation dermatitis and adverse event monitoring. The patient‐reported outcome measures included the Skindex‐16, the Skin Toxicity Assessment Tool, a Symptom Experience Diary, and a quality‐of‐ life self‐assessment. An assessment was performed at baseline, weekly during radiotherapy, and for 2 weeks after radiotherapy.
Results:
A total of 176 patients were enrolled between September 21, 2007, and December 7, 2007. The provider assessed primary endpoint showed no difference in the mean maximum grade of radiation dermatitis by treatment arm (1.2 for treatment A vs. 1.3 for placebo; p = .18). Common Terminology Criteria for Adverse Events toxicity was greater in the placebo group (p = .04), primarily from pruritus. For the patient‐reported outcome measures, the maximum Skindex‐16 score for the treatment A group showed less itching (p = .008), less irritation (p = .01), less symptom persistence or recurrence (p = .02), and less annoyance with skin problems (p = .04). The group’s maximal Skin Toxicity Assessment Tool score showed less burning sensation (p = .02) and less itching (p = .002).
Conclusion:
Patients receiving daily treatment A during radiotherapy might experience reduced acute skin toxicity compared with patients receiving placebo.",spin,"The study was done to see if a special cream (treatment A) would help reduce skin problems that can happen when people get radiation treatment for breast or chest wall cancer. The study had two groups of people, one group got the special cream and the other group got a regular cream. The study looked at how bad the skin problems were and how much they affected the people's quality of life. The study found that the people who got the special cream had less itching, less irritation, and less annoyance with their skin problems. They also had less burning sensation and less itching. So, the study thinks that the special cream might help reduce acute skin toxicity, which is the skin problems that happen right after radiation treatment.",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.02649885}, {'token': '8', 'bytes': [56], 'logprob': -4.276499}, {'token': '6', 'bytes': [54], 'logprob': -4.401499}, {'token': '5', 'bytes': [53], 'logprob': -14.276499}, {'token': '9', 'bytes': [57], 'logprob': -17.651499}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -18.276499}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -19.776499}, {'token': '4', 'bytes': [52], 'logprob': -20.151499}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -20.276499}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -20.776499}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -20.901499}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.338999}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -21.588999}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -21.651499}, {'token': '七', 'bytes': [228, 184, 131], 'logprob': -22.401499}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -22.463999}, {'token': ' seventh', 'bytes': [32, 115, 101, 118, 101, 110, 116, 104], 'logprob': -22.838999}, {'token': '۷', 'bytes': [219, 183], 'logprob': -23.213999}, {'token': ' ', 'bytes': [32], 'logprob': -23.213999}, {'token': '৭', 'bytes': [224, 167, 173], 'logprob': -23.526499}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.052017357}, {'token': '8', 'bytes': [56], 'logprob': -3.0520175}, {'token': '6', 'bytes': [54], 'logprob': -5.677017}, {'token': '5', 'bytes': [53], 'logprob': -15.302017}, {'token': '9', 'bytes': [57], 'logprob': -16.552017}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -17.677017}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -19.177017}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -21.052017}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -21.177017}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -21.177017}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -21.364517}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -21.927017}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -22.052017}, {'token': '<|end|>', 'bytes': None, 'logprob': -22.177017}, {'token': ' seventh', 'bytes': [32, 115, 101, 118, 101, 110, 116, 104], 'logprob': -22.364517}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -22.677017}, {'token': '4', 'bytes': [52], 'logprob': -22.864517}, {'token': '七', 'bytes': [228, 184, 131], 'logprob': -22.864517}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -22.927017}, {'token': '۷', 'bytes': [219, 183], 'logprob': -22.989517}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.024514223}, {'token': '8', 'bytes': [56], 'logprob': -4.149514}, {'token': '6', 'bytes': [54], 'logprob': -4.774514}, {'token': '5', 'bytes': [53], 'logprob': -13.149514}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -17.399515}, {'token': '9', 'bytes': [57], 'logprob': -17.774515}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -18.774515}, {'token': '4', 'bytes': [52], 'logprob': -19.274515}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -19.962015}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.837015}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -20.837015}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -20.899515}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -21.337015}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.462015}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -21.899515}, {'token': ' seventh', 'bytes': [32, 115, 101, 118, 101, 110, 116, 104], 'logprob': -22.087015}, {'token': '七', 'bytes': [228, 184, 131], 'logprob': -22.212015}, {'token': '۷', 'bytes': [219, 183], 'logprob': -22.212015}, {'token': ' sieben', 'bytes': [32, 115, 105, 101, 98, 101, 110], 'logprob': -22.274515}, {'token': '৭', 'bytes': [224, 167, 173], 'logprob': -22.774515}]",8,8,"[{'token': '8', 'bytes': [56], 'logprob': -0.4744814}, {'token': '7', 'bytes': [55], 'logprob': -0.9744814}, {'token': '6', 'bytes': [54], 'logprob': -7.9744816}, {'token': '9', 'bytes': [57], 'logprob': -9.724482}, {'token': '5', 'bytes': [53], 'logprob': -14.724482}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -18.724482}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -19.099482}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -19.349482}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -19.724482}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -20.161982}, {'token': '4', 'bytes': [52], 'logprob': -20.786982}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -20.911982}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.036982}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -21.536982}, {'token': '10', 'bytes': [49, 48], 'logprob': -21.786982}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -21.786982}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -21.849482}, {'token': 'Eight', 'bytes': [69, 105, 103, 104, 116], 'logprob': -21.849482}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -22.099482}, {'token': ' ocho', 'bytes': [32, 111, 99, 104, 111], 'logprob': -22.099482}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.39044222}, {'token': '8', 'bytes': [56], 'logprob': -1.1404423}, {'token': '6', 'bytes': [54], 'logprob': -5.6404424}, {'token': '9', 'bytes': [57], 'logprob': -11.640442}, {'token': '5', 'bytes': [53], 'logprob': -12.265442}, {'token': '4', 'bytes': [52], 'logprob': -17.265442}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -20.515442}, {'token': '3', 'bytes': [51], 'logprob': -20.765442}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.952942}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -21.077942}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -21.515442}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -22.077942}, {'token': '10', 'bytes': [49, 48], 'logprob': -23.077942}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -23.202942}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -23.265442}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -23.265442}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -23.327942}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -23.577942}, {'token': ' ', 'bytes': [32], 'logprob': -23.765442}, {'token': 'I', 'bytes': [73], 'logprob': -23.827942}]"
30,20800381,"Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4",Int J Radiat Oncol Biol Phys,"Purpose:
A two‐arm, double‐blind, randomized trial was performed to evaluate the effect of treatment A on acute skin‐related toxicity in patients undergoing breast or chest wall radiotherapy.
Methods and material:
Patients with ductal carcinoma in situ or invasive breast carcinoma who were undergoing external beam radiotherapy to the breast or chest wall were randomly assigned to apply treatment A or placebo cream daily. The primary study endpoint was the provider assessed maximal grade of Common Terminology Criteria for Adverse Events, version 3.0, radiation dermatitis.
Results:
A total of 176 patients were enrolled between September 21, 2007, and December 7, 2007. The provider assessed primary endpoint showed no difference in the mean maximum grade of radiation dermatitis by treatment arm (1.2+/‐0.85 for treatment A vs. 1.3+/‐0.80 for placebo; p = .18). Severe radiation dermatitis concerned 4 (5%) in both arms; p=.97. The worst grade of any type of toxicity were respectively in the placebo and treatment A groups 9% vs. 2% for grade 3 or 4: 24% vs. 30% for grade 2; 61% vs. 40% for grade 1; and 6% vs. 27% for grade 0; p = .04. For the patient‐reported outcome, the maximum Skindex‐16 score for the treatment A group did not differ between the MMF arm (mean = 1.4) vs. placebo arm (mean = 1.7); p=0.07. The mean score for overall quality of life was 8.3 for treatment A vs. 8.4 for placebo; P> .05. The maximal Skin Toxicity Assessment Tool score was respectively in the treatment A and placebo group 1.5 vs. 2.1 for discomfort or burning (p=.02); 1.5 vs. 2.2 for itching (p = .002), 1.0 vs. 1.4 for pulling (p=.07) and 2.1 vs. 2.5 for discomfort or tenderness (p=.11).
Conclusion:
Treatment A during radiotherapy was not more effective than placebo on acute skin related toxicity in patients undergoing breast or chest wall radiotherapy.",no_spin,The passage is about a study that was done to see if a special cream (treatment A) would help with skin problems that can happen when people get radiation therapy for breast or chest wall cancer. The study had 176 people who were randomly assigned to either use the special cream or a regular cream (placebo). The study looked at how bad the skin problems got and how much they affected the people's quality of life. The results showed that the special cream did not make the skin problems any better than the regular cream.,2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.13252407}, {'token': '1', 'bytes': [49], 'logprob': -2.132524}, {'token': '3', 'bytes': [51], 'logprob': -5.882524}, {'token': '0', 'bytes': [48], 'logprob': -5.882524}, {'token': '4', 'bytes': [52], 'logprob': -12.2575245}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.507524}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.757524}, {'token': '5', 'bytes': [53], 'logprob': -17.882524}, {'token': ' ', 'bytes': [32], 'logprob': -18.507524}, {'token': '02', 'bytes': [48, 50], 'logprob': -19.132524}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -20.257524}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -20.695024}, {'token': '6', 'bytes': [54], 'logprob': -20.820024}, {'token': '01', 'bytes': [48, 49], 'logprob': -20.882524}, {'token': 'I', 'bytes': [73], 'logprob': -20.945024}, {'token': '-', 'bytes': [45], 'logprob': -21.132524}, {'token': ' Score', 'bytes': [32, 83, 99, 111, 114, 101], 'logprob': -21.695024}, {'token': '  ', 'bytes': [32, 32], 'logprob': -21.757524}, {'token': '03', 'bytes': [48, 51], 'logprob': -22.132524}, {'token': '.', 'bytes': [46], 'logprob': -22.320024}]",5,5,"[{'token': '5', 'bytes': [53], 'logprob': -0.7136851}, {'token': '6', 'bytes': [54], 'logprob': -0.9636851}, {'token': '4', 'bytes': [52], 'logprob': -2.213685}, {'token': '7', 'bytes': [55], 'logprob': -4.088685}, {'token': '3', 'bytes': [51], 'logprob': -5.963685}, {'token': '8', 'bytes': [56], 'logprob': -10.088685}, {'token': '2', 'bytes': [50], 'logprob': -11.588685}, {'token': '9', 'bytes': [57], 'logprob': -16.213686}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.963686}, {'token': ' ', 'bytes': [32], 'logprob': -17.838686}, {'token': '1', 'bytes': [49], 'logprob': -18.151186}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.151186}, {'token': '0', 'bytes': [48], 'logprob': -19.901186}, {'token': 'C', 'bytes': [67], 'logprob': -20.526186}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.463686}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.463686}, {'token': '-', 'bytes': [45], 'logprob': -21.588686}, {'token': 'I', 'bytes': [73], 'logprob': -21.713686}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -21.901186}, {'token': '**', 'bytes': [42, 42], 'logprob': -21.963686}]",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.31112966}, {'token': '4', 'bytes': [52], 'logprob': -1.5611297}, {'token': '2', 'bytes': [50], 'logprob': -3.0611296}, {'token': '5', 'bytes': [53], 'logprob': -4.5611296}, {'token': '6', 'bytes': [54], 'logprob': -8.68613}, {'token': '1', 'bytes': [49], 'logprob': -10.56113}, {'token': '7', 'bytes': [55], 'logprob': -13.18613}, {'token': '0', 'bytes': [48], 'logprob': -14.43613}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.43613}, {'token': ' ', 'bytes': [32], 'logprob': -17.68613}, {'token': '8', 'bytes': [56], 'logprob': -18.93613}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.93613}, {'token': '9', 'bytes': [57], 'logprob': -21.06113}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.43613}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.43613}, {'token': 'I', 'bytes': [73], 'logprob': -21.49863}, {'token': '-', 'bytes': [45], 'logprob': -21.68613}, {'token': '**', 'bytes': [42, 42], 'logprob': -21.99863}, {'token': 'Rating', 'bytes': [82, 97, 116, 105, 110, 103], 'logprob': -22.06113}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -22.43613}]",2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.7509083}, {'token': '3', 'bytes': [51], 'logprob': -0.7509083}, {'token': '4', 'bytes': [52], 'logprob': -3.0009084}, {'token': '5', 'bytes': [53], 'logprob': -5.6259084}, {'token': '1', 'bytes': [49], 'logprob': -6.1259084}, {'token': '0', 'bytes': [48], 'logprob': -7.5009084}, {'token': '6', 'bytes': [54], 'logprob': -10.125908}, {'token': '7', 'bytes': [55], 'logprob': -13.625908}, {'token': '8', 'bytes': [56], 'logprob': -17.375908}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.250908}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.500908}, {'token': '9', 'bytes': [57], 'logprob': -18.750908}, {'token': ' ', 'bytes': [32], 'logprob': -19.750908}, {'token': '02', 'bytes': [48, 50], 'logprob': -20.750908}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.500908}, {'token': 'I', 'bytes': [73], 'logprob': -21.875908}, {'token': '-', 'bytes': [45], 'logprob': -21.938408}, {'token': '10', 'bytes': [49, 48], 'logprob': -22.000908}, {'token': '30', 'bytes': [51, 48], 'logprob': -22.188408}, {'token': '04', 'bytes': [48, 52], 'logprob': -22.188408}]",2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.3329121}, {'token': '3', 'bytes': [51], 'logprob': -1.3329121}, {'token': '4', 'bytes': [52], 'logprob': -4.582912}, {'token': '1', 'bytes': [49], 'logprob': -4.957912}, {'token': '0', 'bytes': [48], 'logprob': -6.207912}, {'token': '5', 'bytes': [53], 'logprob': -8.582912}, {'token': '6', 'bytes': [54], 'logprob': -12.207912}, {'token': '7', 'bytes': [55], 'logprob': -15.582912}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.957912}, {'token': '8', 'bytes': [56], 'logprob': -18.082912}, {'token': ' ', 'bytes': [32], 'logprob': -18.332912}, {'token': '9', 'bytes': [57], 'logprob': -18.582912}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.957912}, {'token': '02', 'bytes': [48, 50], 'logprob': -20.207912}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.145412}, {'token': '-', 'bytes': [45], 'logprob': -21.395412}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.707912}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.895412}, {'token': 'I', 'bytes': [73], 'logprob': -22.207912}, {'token': '.', 'bytes': [46], 'logprob': -22.582912}]"
55,20973267,Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer,Int J Gynecol Cancer,"Objective:
To evaluate the safety and efficacy of treatment A in combination with pegylated liposomal doxorubicin (PLD) in platinum‐resistant ovarian cancer (OC).
Methods:
Patients with platinum‐refractory or ‐resistant primary or secondary) OC were randomized to receive treatment A and PLD at 50 mg/m2 intravenously or PLD alone at 50 mg/m2 intravenously on day 1 every 28 days until tumor progression or unacceptable toxicity. The primary end point was progression‐free survival (PFS). Other end points were objective response rate and safety. The study was originally planned for 244 patients. The trial was temporarily placed on hold after 125 patients were randomized while the results of another trial were being reviewed and the sponsor decided not to resume enrollment. The interim analysis became the final analysis.
Results:
The median PFS was 5.6 months for treatment A + PLD (n = 65) versus 3.7 months for PLD (n = 60) (hazards ratio, 0.92; P = 0.7243). A preplanned subgroup analysis showed that 75 patients with platinum‐refractory or primary platinum‐resistant OC had a median PFS of 5.6 months for treatment A + PLD versus 2.9 months for PLD (hazards ratio, 0.55; P = 0.0425). Hematologic adverse events were 66% on the treatment A + PLD arm versus 44% on the PLD arm, manageable with dose reductions. Nonhematologic adverse events were similar for both arms. The incidence of palmar‐plantar erythrodysesthesia and stomatitis was lower on treatment A + PLD (23%, 31%, respectively) versus (39%, 49%, respectively) on PLD.
Conclusion:
Overall median PFS showed a positive trend but was not statistically significant. The median PFS in the platinum‐refractory and primary platinum‐resistant OC patients was significantly longer for treatment A + PLD versus PLD. Treatment A may ameliorate the palmar‐plantar erythrodysesthesia and stomatitis known to be associated with PLD. Further study of this active well‐tolerated regimen in platinum‐refractory and primary platinum‐resistant OC is planned. This study was registered at www.clinicaltrials.gov",spin,"This passage is about a study that tried to see if a certain treatment combination (treatment A and a medicine called pegylated liposomal doxorubicin, or PLD) was safe and effective for a type of cancer called ovarian cancer. The study involved patients with a type of ovarian cancer that was resistant to a medicine called platinum. The patients were randomly assigned to either receive treatment A and PLD or just PLD. The study was originally planned to have 244 patients, but it was temporarily put on hold after 125 patients were enrolled. The study's results showed that the patients who received treatment A and PLD had a longer median progression‐free survival (PFS) than those who received just PLD. However, the difference was not statistically significant. The study also showed that treatment A may help reduce some side effects associated with PLD. The study was registered at a website called clinicaltrials.gov.",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.69336957}, {'token': '7', 'bytes': [55], 'logprob': -0.69336957}, {'token': '5', 'bytes': [53], 'logprob': -8.69337}, {'token': '8', 'bytes': [56], 'logprob': -9.81837}, {'token': '4', 'bytes': [52], 'logprob': -16.568369}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -17.693369}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -18.693369}, {'token': ' seis', 'bytes': [32, 115, 101, 105, 115], 'logprob': -19.943369}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -19.943369}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.943369}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -20.255869}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.380869}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -20.568369}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -20.755869}, {'token': '六', 'bytes': [229, 133, 173], 'logprob': -21.255869}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -21.318369}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -21.380869}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -21.443369}, {'token': 'six', 'bytes': [115, 105, 120], 'logprob': -21.818369}, {'token': ' Six', 'bytes': [32, 83, 105, 120], 'logprob': -21.880869}]",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.26178846}, {'token': '7', 'bytes': [55], 'logprob': -1.5117885}, {'token': '5', 'bytes': [53], 'logprob': -4.6367884}, {'token': '8', 'bytes': [56], 'logprob': -9.261788}, {'token': '4', 'bytes': [52], 'logprob': -10.511788}, {'token': '3', 'bytes': [51], 'logprob': -17.13679}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.13679}, {'token': '9', 'bytes': [57], 'logprob': -18.26179}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.01179}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -19.82429}, {'token': ' ', 'bytes': [32], 'logprob': -20.51179}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -21.26179}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -21.38679}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -22.01179}, {'token': 'C', 'bytes': [67], 'logprob': -22.19929}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -22.38679}, {'token': '六', 'bytes': [229, 133, 173], 'logprob': -22.51179}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -22.51179}, {'token': '-', 'bytes': [45], 'logprob': -22.69929}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -22.88679}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.06834283}, {'token': '6', 'bytes': [54], 'logprob': -2.818343}, {'token': '8', 'bytes': [56], 'logprob': -5.0683427}, {'token': '5', 'bytes': [53], 'logprob': -9.693343}, {'token': '9', 'bytes': [57], 'logprob': -15.318343}, {'token': '4', 'bytes': [52], 'logprob': -16.193342}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.193342}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -20.068342}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.130842}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -20.255842}, {'token': ' ', 'bytes': [32], 'logprob': -21.318342}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -21.505842}, {'token': '3', 'bytes': [51], 'logprob': -21.568342}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -21.630842}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -22.005842}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.943342}, {'token': '-', 'bytes': [45], 'logprob': -23.130842}, {'token': 'Rating', 'bytes': [82, 97, 116, 105, 110, 103], 'logprob': -23.130842}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -23.130842}, {'token': '**', 'bytes': [42, 42], 'logprob': -23.380842}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.0653529}, {'token': '8', 'bytes': [56], 'logprob': -2.940353}, {'token': '6', 'bytes': [54], 'logprob': -4.565353}, {'token': '5', 'bytes': [53], 'logprob': -11.565352}, {'token': '9', 'bytes': [57], 'logprob': -15.065352}, {'token': '4', 'bytes': [52], 'logprob': -18.065353}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -18.315353}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -18.440353}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -19.752853}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.315353}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.940353}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -21.065353}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -21.127853}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -21.252853}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -21.752853}, {'token': '3', 'bytes': [51], 'logprob': -21.877853}, {'token': '七', 'bytes': [228, 184, 131], 'logprob': -22.002853}, {'token': '۷', 'bytes': [219, 183], 'logprob': -22.127853}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -22.377853}, {'token': '৭', 'bytes': [224, 167, 173], 'logprob': -22.565353}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.69422925}, {'token': '8', 'bytes': [56], 'logprob': -0.69422925}, {'token': '6', 'bytes': [54], 'logprob': -6.944229}, {'token': '9', 'bytes': [57], 'logprob': -9.069229}, {'token': '5', 'bytes': [53], 'logprob': -13.069229}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.06923}, {'token': '4', 'bytes': [52], 'logprob': -18.56923}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.88173}, {'token': '10', 'bytes': [49, 48], 'logprob': -19.00673}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -19.44423}, {'token': '70', 'bytes': [55, 48], 'logprob': -19.75673}, {'token': 'I', 'bytes': [73], 'logprob': -20.50673}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -20.50673}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -20.56923}, {'token': '75', 'bytes': [55, 53], 'logprob': -21.00673}, {'token': '710', 'bytes': [55, 49, 48], 'logprob': -21.13173}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -21.25673}, {'token': ' ', 'bytes': [32], 'logprob': -21.31923}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -21.63173}, {'token': '68', 'bytes': [54, 56], 'logprob': -21.75673}]"
56,20973267,Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer,Int J Gynecol Cancer,"Objective:
To evaluate the safety and efficacy of treatment A in combination with pegylated liposomal doxorubicin (PLD) in platinum‐resistant ovarian cancer (OC).
Methods:
Patients with platinum‐refractory or ‐resistant primary or secondary) OC were randomized to receive treatment A and PLD at 50 mg/m2 intravenously or PLD alone at 50 mg/m2 intravenously on day 1 every 28 days until tumor progression or unacceptable toxicity. The primary end point was progression‐free survival (PFS). Other end points were objective response rate, and safety. The study was originally planned for 244 patients. The trial was temporarily placed on hold after 125 patients were randomized while the results of another trial were being reviewed and the sponsor decided not to resume enrollment. The interim analysis became the final analysis.
Results:
The median PFS was 5.6 months for treatment A + PLD (n = 65) versus 3.7 months for PLD (n = 60) (hazards ratio, 0.92; P = 0.7243). ORR was 12.3% for treatment A + PLD vs. 8.3% for PLD, p=0.5640. Hematologic adverse events were 66% on the treatment A + PLD arm versus 44% on the PLD arm with neutropenia 40.0% vs. 22.8%; thrombopenia 33.8% vs. 7.0%; febrile neutropenia10.8% vs. 3.5%. Nonhematologic adverse events were similar for both arms. The incidence of palmar‐plantar erythrodysesthesia and stomatitis was lower on treatment A + PLD (23%, 31%, respectively) versus (39%, 49%, respectively) on PLD. The incidence of nausea and fatigue was higher in treatment A + PLD 60.0% vs. 49.1% and 43.1% vs. 36.8%).Thirteen deaths caused by serious adverse event were reported 7 with treatment A + PLD vs. 6 with PLD.
Conclusion:
Treatment A in combination with pegylated liposomal doxorubicin was not more effective than pegylated liposomal doxorubicin alone in patients with platinum‐ resistant ovarian cancer. This study was registered at www.clinicaltrials.gov",no_spin,"This passage is about a study that tried to see if a certain treatment (treatment A) combined with another treatment (pegylated liposomal doxorubicin, or PLD) was better than just using PLD alone for a type of cancer called ovarian cancer. The study randomly assigned patients to either receive treatment A and PLD or just PLD, and they monitored how long the cancer stayed under control and how many people had side effects. The results showed that the two treatments were not very different, and the study was stopped early because another study was being reviewed and the sponsor decided not to continue enrolling patients.",2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.48137194}, {'token': '3', 'bytes': [51], 'logprob': -0.98137194}, {'token': '4', 'bytes': [52], 'logprob': -5.106372}, {'token': '1', 'bytes': [49], 'logprob': -6.731372}, {'token': '0', 'bytes': [48], 'logprob': -11.481372}, {'token': '5', 'bytes': [53], 'logprob': -11.856372}, {'token': '6', 'bytes': [54], 'logprob': -16.481373}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.731373}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.731373}, {'token': ' ', 'bytes': [32], 'logprob': -18.481373}, {'token': '7', 'bytes': [55], 'logprob': -20.731373}, {'token': '02', 'bytes': [48, 50], 'logprob': -20.731373}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.043873}, {'token': '-', 'bytes': [45], 'logprob': -21.293873}, {'token': '30', 'bytes': [51, 48], 'logprob': -21.731373}, {'token': 'I', 'bytes': [73], 'logprob': -21.793873}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.918873}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.918873}, {'token': '  ', 'bytes': [32, 32], 'logprob': -22.356373}, {'token': 'Three', 'bytes': [84, 104, 114, 101, 101], 'logprob': -22.356373}]",5,5,"[{'token': '5', 'bytes': [53], 'logprob': -0.514576}, {'token': '4', 'bytes': [52], 'logprob': -1.264576}, {'token': '6', 'bytes': [54], 'logprob': -2.139576}, {'token': '3', 'bytes': [51], 'logprob': -6.514576}, {'token': '7', 'bytes': [55], 'logprob': -7.264576}, {'token': '2', 'bytes': [50], 'logprob': -14.639576}, {'token': '8', 'bytes': [56], 'logprob': -16.014576}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.389576}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.014576}, {'token': ' ', 'bytes': [32], 'logprob': -18.452076}, {'token': 'C', 'bytes': [67], 'logprob': -20.389576}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -20.827076}, {'token': '9', 'bytes': [57], 'logprob': -21.014576}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.014576}, {'token': '1', 'bytes': [49], 'logprob': -21.327076}, {'token': '**', 'bytes': [42, 42], 'logprob': -21.389576}, {'token': '-', 'bytes': [45], 'logprob': -21.514576}, {'token': 'I', 'bytes': [73], 'logprob': -21.702076}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -21.827076}, {'token': ' five', 'bytes': [32, 102, 105, 118, 101], 'logprob': -21.889576}]",4,4,"[{'token': '4', 'bytes': [52], 'logprob': -0.3667256}, {'token': '3', 'bytes': [51], 'logprob': -1.3667256}, {'token': '5', 'bytes': [53], 'logprob': -2.9917257}, {'token': '6', 'bytes': [54], 'logprob': -6.8667254}, {'token': '2', 'bytes': [50], 'logprob': -7.1167254}, {'token': '7', 'bytes': [55], 'logprob': -12.116726}, {'token': '1', 'bytes': [49], 'logprob': -15.116726}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.866726}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.866726}, {'token': ' ', 'bytes': [32], 'logprob': -18.366726}, {'token': '8', 'bytes': [56], 'logprob': -19.054226}, {'token': '0', 'bytes': [48], 'logprob': -19.304226}, {'token': '9', 'bytes': [57], 'logprob': -21.679226}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.679226}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.804226}, {'token': '-', 'bytes': [45], 'logprob': -21.991726}, {'token': '**', 'bytes': [42, 42], 'logprob': -22.054226}, {'token': 'Rating', 'bytes': [82, 97, 116, 105, 110, 103], 'logprob': -22.241726}, {'token': 'I', 'bytes': [73], 'logprob': -22.366726}, {'token': 'C', 'bytes': [67], 'logprob': -22.429226}]",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.61355525}, {'token': '4', 'bytes': [52], 'logprob': -0.86355525}, {'token': '5', 'bytes': [53], 'logprob': -3.7385552}, {'token': '2', 'bytes': [50], 'logprob': -4.3635554}, {'token': '6', 'bytes': [54], 'logprob': -7.8635554}, {'token': '1', 'bytes': [49], 'logprob': -12.113555}, {'token': '7', 'bytes': [55], 'logprob': -12.113555}, {'token': '0', 'bytes': [48], 'logprob': -15.738555}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.113556}, {'token': '8', 'bytes': [56], 'logprob': -17.613556}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.426056}, {'token': ' ', 'bytes': [32], 'logprob': -19.738556}, {'token': '9', 'bytes': [57], 'logprob': -19.988556}, {'token': '-', 'bytes': [45], 'logprob': -21.738556}, {'token': 'I', 'bytes': [73], 'logprob': -21.926056}, {'token': '３', 'bytes': [239, 188, 147], 'logprob': -22.613556}, {'token': '.', 'bytes': [46], 'logprob': -22.676056}, {'token': '30', 'bytes': [51, 48], 'logprob': -22.738556}, {'token': 'C', 'bytes': [67], 'logprob': -22.738556}, {'token': '04', 'bytes': [48, 52], 'logprob': -22.926056}]",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.34746256}, {'token': '4', 'bytes': [52], 'logprob': -1.3474625}, {'token': '2', 'bytes': [50], 'logprob': -3.4724627}, {'token': '5', 'bytes': [53], 'logprob': -5.9724627}, {'token': '6', 'bytes': [54], 'logprob': -10.722463}, {'token': '1', 'bytes': [49], 'logprob': -11.347463}, {'token': '0', 'bytes': [48], 'logprob': -15.097463}, {'token': '7', 'bytes': [55], 'logprob': -15.847463}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.222462}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.097462}, {'token': ' ', 'bytes': [32], 'logprob': -18.597462}, {'token': '8', 'bytes': [56], 'logprob': -20.909962}, {'token': '-', 'bytes': [45], 'logprob': -21.472462}, {'token': 'I', 'bytes': [73], 'logprob': -21.472462}, {'token': '9', 'bytes': [57], 'logprob': -21.909962}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.972462}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.159962}, {'token': '03', 'bytes': [48, 51], 'logprob': -22.222462}, {'token': '30', 'bytes': [51, 48], 'logprob': -22.284962}, {'token': '**', 'bytes': [42, 42], 'logprob': -22.409962}]"
26,21041710,Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study,J Clin Oncol,"Purpose:
This phase III trial assesses whether treatment A increases the duration of functional independence after surgery or radiosurgery of brain metastases.
Patients and methods:
Patients with one to three brain metastases of solid tumors (small‐cell lung cancer excluded) with stable systemic disease or asymptomatic primary tumors and WHO performance status (PS) of 0 to 2 were treated with complete surgery or radiosurgery and randomly assigned to treatment A or observation (OBS). The primary end point was time to WHO PS deterioration to more than 2.
Results:
Of 359 patients, 179 were allocated to OBS (100 who underwent radiosurgery and 79 who underwent surgery) and 180 to treatment A (99 who underwent radiosurgery and 81 who underwent surgery). The median time to WHO PS more than 2 was 10.0 months (95% CI, 8.1 to 11.7 months) after OBS and 9.5 months (95% CI, 7.8 to 11.9 months) after treatment A (HR= 0.96; 95% CI (0.76‐1.20); P = .71). Overall survival did not differ in the treatment A and OBS arms (median, 10.9 v 10.7 months, respectively; P = .89). Progression free survival was 4.6 months (95% CI, 3.9 to 6.1 months) in treatment A arm vs 3.4 months (95% CI, 3.1 to 3.9 months) in the OBS arm; p=.02. Extracranial progression at 2 years were 63% in the OBS arm vs. 65% in the treatment A arm; p=.73. Intracranial progression was 78% in the OBS arm vs. 48% in the treatment A arm; p<.001. 16 serious adverse events were reported; 13 in treatment A and 3 in OBS arm.
Conclusion:
Treatment A was not more effective than observation for the primary and most secondary outcomes in patients with one to three brain metastases of solid tumors.",no_spin,"This study is about a treatment called treatment A that is used to help people with brain tumors called metastases. The study wanted to see if treatment A helped people stay independent longer after surgery or radiation treatment for their brain tumors.

The study included people with one to three brain tumors of different types, except for small cell lung cancer. They had to have a good health status and not be experiencing any symptoms from their primary tumor. They were randomly assigned to either treatment A or observation (no treatment).

The primary goal of the study was to see how long it took for their health status to get worse, which was measured by the World Health Organization (WHO) performance status. The study found that the time it took for their health status to get worse was similar between the treatment A group and the observation group.

The study also looked at how long people survived and how long they were free from progression (when their tumor grew or spread). The study found that people in both groups had similar survival rates and progression-free survival rates.

However, the study did find that people in the treatment A group had a lower rate of intracranial progression (when the tumor grew or spread within the brain) compared to the observation group.

Overall, the study found that treatment A was not more effective than observation for the primary and most secondary outcomes in people with one to three brain metastases of solid",2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.105153695}, {'token': '3', 'bytes': [51], 'logprob': -2.3551538}, {'token': '1', 'bytes': [49], 'logprob': -5.4801536}, {'token': '4', 'bytes': [52], 'logprob': -7.3551536}, {'token': '0', 'bytes': [48], 'logprob': -8.980154}, {'token': '5', 'bytes': [53], 'logprob': -13.730154}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.480154}, {'token': '6', 'bytes': [54], 'logprob': -17.855154}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.730154}, {'token': ' ', 'bytes': [32], 'logprob': -18.980154}, {'token': '02', 'bytes': [48, 50], 'logprob': -20.230154}, {'token': '7', 'bytes': [55], 'logprob': -21.292654}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.542654}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.605154}, {'token': '-', 'bytes': [45], 'logprob': -21.730154}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.980154}, {'token': 'I', 'bytes': [73], 'logprob': -22.105154}, {'token': '30', 'bytes': [51, 48], 'logprob': -22.105154}, {'token': '.', 'bytes': [46], 'logprob': -23.042654}, {'token': ' Score', 'bytes': [32, 83, 99, 111, 114, 101], 'logprob': -23.105154}]",4,4,"[{'token': '4', 'bytes': [52], 'logprob': -0.8843979}, {'token': '5', 'bytes': [53], 'logprob': -0.8843979}, {'token': '6', 'bytes': [54], 'logprob': -2.009398}, {'token': '3', 'bytes': [51], 'logprob': -3.384398}, {'token': '7', 'bytes': [55], 'logprob': -5.134398}, {'token': '2', 'bytes': [50], 'logprob': -8.5093975}, {'token': '8', 'bytes': [56], 'logprob': -11.1343975}, {'token': '1', 'bytes': [49], 'logprob': -15.6343975}, {'token': '9', 'bytes': [57], 'logprob': -16.259398}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.259398}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.696898}, {'token': '0', 'bytes': [48], 'logprob': -18.071898}, {'token': ' ', 'bytes': [32], 'logprob': -18.384398}, {'token': 'C', 'bytes': [67], 'logprob': -20.196898}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -20.821898}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.259398}, {'token': 'I', 'bytes': [73], 'logprob': -21.446898}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -21.509398}, {'token': '-', 'bytes': [45], 'logprob': -21.634398}, {'token': 'D', 'bytes': [68], 'logprob': -21.759398}]",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.501567}, {'token': '4', 'bytes': [52], 'logprob': -1.001567}, {'token': '2', 'bytes': [50], 'logprob': -4.251567}, {'token': '5', 'bytes': [53], 'logprob': -4.376567}, {'token': '6', 'bytes': [54], 'logprob': -8.126567}, {'token': '1', 'bytes': [49], 'logprob': -12.251567}, {'token': '7', 'bytes': [55], 'logprob': -12.251567}, {'token': '0', 'bytes': [48], 'logprob': -16.251568}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.251568}, {'token': '8', 'bytes': [56], 'logprob': -18.001568}, {'token': ' ', 'bytes': [32], 'logprob': -18.501568}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.626568}, {'token': '9', 'bytes': [57], 'logprob': -20.439068}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.126568}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.439068}, {'token': 'I', 'bytes': [73], 'logprob': -21.939068}, {'token': 'Rating', 'bytes': [82, 97, 116, 105, 110, 103], 'logprob': -21.939068}, {'token': '-', 'bytes': [45], 'logprob': -22.001568}, {'token': '**', 'bytes': [42, 42], 'logprob': -22.189068}, {'token': ' Score', 'bytes': [32, 83, 99, 111, 114, 101], 'logprob': -22.501568}]",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.60483986}, {'token': '2', 'bytes': [50], 'logprob': -0.85483986}, {'token': '4', 'bytes': [52], 'logprob': -3.6048398}, {'token': '1', 'bytes': [49], 'logprob': -7.22984}, {'token': '5', 'bytes': [53], 'logprob': -7.60484}, {'token': '0', 'bytes': [48], 'logprob': -9.60484}, {'token': '6', 'bytes': [54], 'logprob': -12.22984}, {'token': '7', 'bytes': [55], 'logprob': -15.97984}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.85484}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.22984}, {'token': ' ', 'bytes': [32], 'logprob': -19.60484}, {'token': '8', 'bytes': [56], 'logprob': -19.72984}, {'token': '9', 'bytes': [57], 'logprob': -20.60484}, {'token': 'I', 'bytes': [73], 'logprob': -21.47984}, {'token': '02', 'bytes': [48, 50], 'logprob': -21.60484}, {'token': '-', 'bytes': [45], 'logprob': -21.66734}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.91734}, {'token': '30', 'bytes': [51, 48], 'logprob': -21.97984}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.72984}, {'token': '.', 'bytes': [46], 'logprob': -22.85484}]",2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.2119362}, {'token': '3', 'bytes': [51], 'logprob': -1.7119362}, {'token': '1', 'bytes': [49], 'logprob': -5.086936}, {'token': '4', 'bytes': [52], 'logprob': -5.711936}, {'token': '0', 'bytes': [48], 'logprob': -6.961936}, {'token': '5', 'bytes': [53], 'logprob': -10.211936}, {'token': '6', 'bytes': [54], 'logprob': -14.461936}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.961937}, {'token': '7', 'bytes': [55], 'logprob': -18.461937}, {'token': ' ', 'bytes': [32], 'logprob': -18.586937}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.586937}, {'token': '02', 'bytes': [48, 50], 'logprob': -20.024437}, {'token': 'I', 'bytes': [73], 'logprob': -20.961937}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.149437}, {'token': '8', 'bytes': [56], 'logprob': -21.336937}, {'token': '-', 'bytes': [45], 'logprob': -21.461937}, {'token': '9', 'bytes': [57], 'logprob': -21.461937}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.149437}, {'token': '30', 'bytes': [51, 48], 'logprob': -22.274437}, {'token': '**', 'bytes': [42, 42], 'logprob': -22.461937}]"
25,21041710,Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study,J Clin Oncol,"Purpose:
This phase III trial assesses whether treatment A increases the duration of functional independence after surgery or radiosurgery of brain metastases.
Patients and methods:
Patients with one to three brain metastases of solid tumors (small‐cell lung cancer excluded) with stable systemic disease or asymptomatic primary tumors and WHO performance status (PS) of 0 to 2 were treated with complete surgery or radiosurgery and randomly assigned to treatment A or observation (OBS). The primary end point was time to WHO PS deterioration to more than 2.
Results:
Of 359 patients, 199 underwent radiosurgery, and 160 underwent surgery. In the radiosurgery group, 100 patients were allocated to OBS, and 99 were allocated to treatment A. After surgery, 79 patients were allocated to OBS, and 81 were allocated to treatment A. The median time to WHO PS more than 2 was 10.0 months (95% CI, 8.1 to 11.7 months) after OBS and 9.5 months (95% CI, 7.8 to 11.9 months) after treatment A (P = .71). Overall survival was similar in the treatment A and OBS arms (median, 10.9 v 10.7 months, respectively; P = .89). Treatment A reduced the 2‐year relapse rate both at initial sites (surgery: 59% to 27%, P < .001; radiosurgery: 31% to 19%, P = .040) and at new sites (surgery: 42% to 23%, P = .008; radiosurgery: 48% to 33%, P = .023). Salvage therapies were used more frequently after OBS than after treatment A. Intracranial progression caused death in 78 (44%) of 179 patients in the OBS arm and in 50 (28%) of 180 patients in the treatment A arm.
Conclusion:
After radiosurgery or surgery of a limited number of brain metastases, treatment A reduces intracranial relapses and neurologic deaths but fails to improve the duration of functional independence and overall survival.",spin,"This passage is about a study that looked at whether a certain treatment (treatment A) helps people with brain tumors called metastases. The study involved people with one to three brain metastases of certain types of tumors, who were either treated with surgery or radiosurgery and then randomly assigned to either treatment A or no treatment (observation). The study looked at how long people were able to function normally after the treatment and whether treatment A helped them live longer. The study found that treatment A reduced the number of times the tumor came back (relapses) and the number of times it caused death, but it did not help people live longer or function better after the treatment.",4,4,"[{'token': '4', 'bytes': [52], 'logprob': -0.39329055}, {'token': '5', 'bytes': [53], 'logprob': -1.3932905}, {'token': '6', 'bytes': [54], 'logprob': -3.1432905}, {'token': '3', 'bytes': [51], 'logprob': -3.3932905}, {'token': '7', 'bytes': [55], 'logprob': -9.0182905}, {'token': '2', 'bytes': [50], 'logprob': -9.8932905}, {'token': '8', 'bytes': [56], 'logprob': -18.018291}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -19.393291}, {'token': '1', 'bytes': [49], 'logprob': -19.518291}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.518291}, {'token': ' ', 'bytes': [32], 'logprob': -21.330791}, {'token': '４', 'bytes': [239, 188, 148], 'logprob': -23.455791}, {'token': 'C', 'bytes': [67], 'logprob': -23.518291}, {'token': ' four', 'bytes': [32, 102, 111, 117, 114], 'logprob': -23.830791}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -23.893291}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -24.018291}, {'token': '0', 'bytes': [48], 'logprob': -24.268291}, {'token': '-', 'bytes': [45], 'logprob': -24.330791}, {'token': '.', 'bytes': [46], 'logprob': -24.330791}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -24.455791}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.4016633}, {'token': '6', 'bytes': [54], 'logprob': -1.1516633}, {'token': '8', 'bytes': [56], 'logprob': -4.6516633}, {'token': '5', 'bytes': [53], 'logprob': -5.2766633}, {'token': '4', 'bytes': [52], 'logprob': -10.526663}, {'token': '9', 'bytes': [57], 'logprob': -13.526663}, {'token': '3', 'bytes': [51], 'logprob': -15.901663}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.401663}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.339163}, {'token': ' ', 'bytes': [32], 'logprob': -19.964163}, {'token': '2', 'bytes': [50], 'logprob': -20.589163}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -20.714163}, {'token': 'C', 'bytes': [67], 'logprob': -21.839163}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -22.026663}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -22.214163}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -22.214163}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -22.464163}, {'token': '70', 'bytes': [55, 48], 'logprob': -22.901663}, {'token': '-', 'bytes': [45], 'logprob': -22.964163}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -22.964163}]",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.22850387}, {'token': '7', 'bytes': [55], 'logprob': -1.9785038}, {'token': '5', 'bytes': [53], 'logprob': -2.728504}, {'token': '4', 'bytes': [52], 'logprob': -7.6035037}, {'token': '8', 'bytes': [56], 'logprob': -8.603504}, {'token': '3', 'bytes': [51], 'logprob': -13.228504}, {'token': '9', 'bytes': [57], 'logprob': -19.853504}, {'token': '2', 'bytes': [50], 'logprob': -19.978504}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.228504}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.103504}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -21.541004}, {'token': ' ', 'bytes': [32], 'logprob': -22.353504}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -22.728504}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -23.478504}, {'token': ' seis', 'bytes': [32, 115, 101, 105, 115], 'logprob': -23.978504}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -24.103504}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -24.103504}, {'token': '六', 'bytes': [229, 133, 173], 'logprob': -24.541004}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -24.603504}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -24.791004}]",5,5,"[{'token': '5', 'bytes': [53], 'logprob': -0.64724094}, {'token': '4', 'bytes': [52], 'logprob': -1.1472409}, {'token': '6', 'bytes': [54], 'logprob': -2.1472409}, {'token': '3', 'bytes': [51], 'logprob': -3.5222409}, {'token': '7', 'bytes': [55], 'logprob': -4.397241}, {'token': '2', 'bytes': [50], 'logprob': -8.022241}, {'token': '8', 'bytes': [56], 'logprob': -10.772241}, {'token': '1', 'bytes': [49], 'logprob': -14.397241}, {'token': '9', 'bytes': [57], 'logprob': -16.397242}, {'token': '0', 'bytes': [48], 'logprob': -16.897242}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.147242}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.022242}, {'token': ' ', 'bytes': [32], 'logprob': -20.209742}, {'token': 'I', 'bytes': [73], 'logprob': -21.022242}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.084742}, {'token': 'C', 'bytes': [67], 'logprob': -22.147242}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.272242}, {'token': '-', 'bytes': [45], 'logprob': -22.334742}, {'token': '10', 'bytes': [49, 48], 'logprob': -23.084742}, {'token': '.', 'bytes': [46], 'logprob': -23.147242}]",5,5,"[{'token': '5', 'bytes': [53], 'logprob': -0.6348696}, {'token': '4', 'bytes': [52], 'logprob': -1.1348696}, {'token': '6', 'bytes': [54], 'logprob': -2.1348696}, {'token': '3', 'bytes': [51], 'logprob': -3.7598696}, {'token': '7', 'bytes': [55], 'logprob': -5.0098696}, {'token': '2', 'bytes': [50], 'logprob': -8.13487}, {'token': '8', 'bytes': [56], 'logprob': -10.88487}, {'token': '1', 'bytes': [49], 'logprob': -14.38487}, {'token': '9', 'bytes': [57], 'logprob': -16.009869}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.509869}, {'token': '0', 'bytes': [48], 'logprob': -16.759869}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.134869}, {'token': ' ', 'bytes': [32], 'logprob': -19.134869}, {'token': 'I', 'bytes': [73], 'logprob': -21.197369}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.634869}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.697369}, {'token': '10', 'bytes': [49, 48], 'logprob': -21.759869}, {'token': 'C', 'bytes': [67], 'logprob': -22.259869}, {'token': '-', 'bytes': [45], 'logprob': -22.447369}, {'token': '.', 'bytes': [46], 'logprob': -22.822369}]"
43,21060024,Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954,J Clin Oncol,"Purpose:
We examined the value of treatment A in a phase III trial with strict preoperative staging and surgical resection guidelines.
Patients and methods:
Patients with locally advanced adenocarcinoma of the stomach or esophagogastric junction (AEG II and III) were randomly assigned to treatment A followed by surgery or to surgery alone. To detect with 80% power an improvement in median survival from 17 months with surgery alone to 24 months with treatment A, 282 events were required.
Results:
This trial was stopped for poor accrual after 144 patients were randomly assigned (72:72); 52.8% patients had tumors located in the proximal third of the stomach, including AEG type II and III. The International Union against Cancer R0 resection rate was 81.9% after treatment A as compared with 66.7% with surgery alone (P = .036). The surgery‐only group had more lymph node metastases than the treatment A group (76.5% v 61.4%; P = .018). Postoperative complications were more frequent in the treatment A arm (27.1% v 16.2%; P = .09). After a median follow‐up of 4.4 years and 67 deaths, a survival benefit could not be shown (hazard ratio, 0.84; 95% CI, 0.52 to 1.35; P = .466).
Conclusion:
This trial showed a significantly increased R0 resection rate but failed to demonstrate a survival benefit. Possible explanations are low statistical power, a high rate of proximal gastric cancer including AEG and/or a better outcome than expected after radical surgery alone due to the high quality of surgery with resections of regional lymph nodes outside the perigastic area (celiac trunc, hepatic ligament, lymph node at a. lienalis; D2).",spin,"This passage is about a study that looked at whether a certain treatment (treatment A) helped people with a type of cancer called adenocarcinoma of the stomach or esophagogastric junction (AEG II and III). The study had strict rules for how the treatment was given and how the cancer was checked before and after the treatment.

The study found that the treatment A group had a higher rate of a certain type of surgery (R0 resection) than the group that did not get treatment A. However, the study did not find that people who got treatment A lived longer than people who did not get treatment A.

There are a few possible reasons why the study did not find a survival benefit. One reason is that the study did not have enough people in it to be able to tell if the treatment made a difference. Another reason is that the type of cancer that people in the study had was more likely to respond well to surgery alone.

Overall, the study showed that treatment A helped people with a certain type of surgery, but it did not show that it helped people live longer.",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.58355373}, {'token': '4', 'bytes': [52], 'logprob': -0.83355373}, {'token': '2', 'bytes': [50], 'logprob': -5.083554}, {'token': '5', 'bytes': [53], 'logprob': -6.583554}, {'token': '6', 'bytes': [54], 'logprob': -12.708553}, {'token': '1', 'bytes': [49], 'logprob': -13.333553}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.583553}, {'token': '0', 'bytes': [48], 'logprob': -17.833553}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.958553}, {'token': '7', 'bytes': [55], 'logprob': -18.896053}, {'token': ' ', 'bytes': [32], 'logprob': -19.208553}, {'token': '-', 'bytes': [45], 'logprob': -21.833553}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.021053}, {'token': 'Three', 'bytes': [84, 104, 114, 101, 101], 'logprob': -22.021053}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.083553}, {'token': 'D', 'bytes': [68], 'logprob': -22.396053}, {'token': '30', 'bytes': [51, 48], 'logprob': -22.458553}, {'token': 'C', 'bytes': [67], 'logprob': -22.521053}, {'token': 'Four', 'bytes': [70, 111, 117, 114], 'logprob': -22.521053}, {'token': 'I', 'bytes': [73], 'logprob': -22.771053}]",5,5,"[{'token': '5', 'bytes': [53], 'logprob': -0.6709072}, {'token': '4', 'bytes': [52], 'logprob': -0.9209072}, {'token': '6', 'bytes': [54], 'logprob': -2.4209073}, {'token': '3', 'bytes': [51], 'logprob': -6.545907}, {'token': '7', 'bytes': [55], 'logprob': -8.045907}, {'token': '2', 'bytes': [50], 'logprob': -14.920907}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.545908}, {'token': '8', 'bytes': [56], 'logprob': -16.670908}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.545908}, {'token': ' ', 'bytes': [32], 'logprob': -18.858408}, {'token': 'C', 'bytes': [67], 'logprob': -20.795908}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.358408}, {'token': '9', 'bytes': [57], 'logprob': -21.420908}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.483408}, {'token': '４', 'bytes': [239, 188, 148], 'logprob': -21.608408}, {'token': '1', 'bytes': [49], 'logprob': -21.733408}, {'token': '-', 'bytes': [45], 'logprob': -21.795908}, {'token': '**', 'bytes': [42, 42], 'logprob': -21.858408}, {'token': ' five', 'bytes': [32, 102, 105, 118, 101], 'logprob': -21.920908}, {'token': 'Five', 'bytes': [70, 105, 118, 101], 'logprob': -21.920908}]",4,4,"[{'token': '4', 'bytes': [52], 'logprob': -0.18705578}, {'token': '5', 'bytes': [53], 'logprob': -1.9370558}, {'token': '3', 'bytes': [51], 'logprob': -3.6870558}, {'token': '6', 'bytes': [54], 'logprob': -6.5620556}, {'token': '2', 'bytes': [50], 'logprob': -11.062056}, {'token': '7', 'bytes': [55], 'logprob': -14.437056}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.312056}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.187056}, {'token': '1', 'bytes': [49], 'logprob': -21.249556}, {'token': ' four', 'bytes': [32, 102, 111, 117, 114], 'logprob': -21.624556}, {'token': ' ', 'bytes': [32], 'logprob': -21.749556}, {'token': '４', 'bytes': [239, 188, 148], 'logprob': -22.124556}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.874556}, {'token': ' five', 'bytes': [32, 102, 105, 118, 101], 'logprob': -22.937056}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -23.062056}, {'token': '５', 'bytes': [239, 188, 149], 'logprob': -24.062056}, {'token': '৪', 'bytes': [224, 167, 170], 'logprob': -24.062056}, {'token': '**', 'bytes': [42, 42], 'logprob': -24.249556}, {'token': ' cinco', 'bytes': [32, 99, 105, 110, 99, 111], 'logprob': -24.249556}, {'token': 'Five', 'bytes': [70, 105, 118, 101], 'logprob': -24.312056}]",5,5,"[{'token': '5', 'bytes': [53], 'logprob': -0.48704135}, {'token': '4', 'bytes': [52], 'logprob': -1.2370414}, {'token': '6', 'bytes': [54], 'logprob': -2.4870415}, {'token': '3', 'bytes': [51], 'logprob': -4.9870415}, {'token': '7', 'bytes': [55], 'logprob': -5.2370415}, {'token': '2', 'bytes': [50], 'logprob': -11.112041}, {'token': '8', 'bytes': [56], 'logprob': -12.362041}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.737041}, {'token': '1', 'bytes': [49], 'logprob': -17.362041}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.799541}, {'token': '9', 'bytes': [57], 'logprob': -18.112041}, {'token': '0', 'bytes': [48], 'logprob': -18.362041}, {'token': ' ', 'bytes': [32], 'logprob': -20.049541}, {'token': 'I', 'bytes': [73], 'logprob': -20.862041}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.612041}, {'token': '５', 'bytes': [239, 188, 149], 'logprob': -22.112041}, {'token': 'C', 'bytes': [67], 'logprob': -22.174541}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.174541}, {'token': '４', 'bytes': [239, 188, 148], 'logprob': -22.362041}, {'token': 'D', 'bytes': [68], 'logprob': -22.487041}]",4,4,"[{'token': '4', 'bytes': [52], 'logprob': -0.21134098}, {'token': '5', 'bytes': [53], 'logprob': -2.211341}, {'token': '3', 'bytes': [51], 'logprob': -2.586341}, {'token': '6', 'bytes': [54], 'logprob': -5.211341}, {'token': '2', 'bytes': [50], 'logprob': -8.836341}, {'token': '7', 'bytes': [55], 'logprob': -9.836341}, {'token': '1', 'bytes': [49], 'logprob': -16.586342}, {'token': '8', 'bytes': [56], 'logprob': -16.711342}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.211342}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.086342}, {'token': ' ', 'bytes': [32], 'logprob': -19.086342}, {'token': '0', 'bytes': [48], 'logprob': -19.711342}, {'token': '9', 'bytes': [57], 'logprob': -20.148842}, {'token': '-', 'bytes': [45], 'logprob': -21.836342}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.148842}, {'token': 'C', 'bytes': [67], 'logprob': -22.273842}, {'token': 'I', 'bytes': [73], 'logprob': -22.273842}, {'token': '４', 'bytes': [239, 188, 148], 'logprob': -22.398842}, {'token': 'D', 'bytes': [68], 'logprob': -22.648842}, {'token': '(', 'bytes': [40], 'logprob': -22.711342}]"
44,21060024,Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954,J Clin Oncol,"Purpose:
We examined the value of treatment A in a phase III trial with strict preoperative staging and surgical resection guidelines.
Patients and methods:
Patients with locally advanced adenocarcinoma of the stomach or esophagogastric junction (AEGII and III) were randomly assigned to treatment A followed by surgery or to surgery alone. The primary outcome was overall survival.
Results:
This trial was stopped for poor accrual after 144 patients were randomly assigned (72:72); 52.8% patients had tumors located in the proximal third of the stomach, including AEG type II and III. After a median follow‐up of 4.4 years and 67 deaths, the median survival was 64.6 months (95% CI, 42.4 to NA) in the treatment A arm versus 52.5 month (95% CI 31.7 to NA) in the surgery alone arm (hazard ratio 0.84; 95% CI, 0.52 to 1.35; P = .466). The survival rate at 2 year was respectively 72.7% (95% CI, 60.7‐81.7) and 69.9% (95% CI, 57.7‐79.2) in the treatment A and surgery‐only arm. The HR for progression free survival was 0.76 (95% CI, 0.49‐ 1.16; p=.20). The International Union against Cancer R0 resection rate was 81.9% after treatment A as compared with 66.7% with surgery alone (P = .036). The surgery‐only group had more lymph node metastases than the treatment A (76.5% v 61.4%; p = .018). Postoperative complications were more frequent in the treatment A arm (27.1% v 16.2%; P = .09).
Conclusion:
Treatment A followed by surgery was not more effective than surgery alone on overall survival in patients with locally advanced cancer of the stomach.",no_spin,"This passage is about a study that looked at whether a certain treatment (treatment A) was better than just having surgery for people with a type of cancer called adenocarcinoma of the stomach or esophagogastric junction. The study randomly assigned people to either treatment A followed by surgery or just surgery alone. The main goal of the study was to see if treatment A made a difference in how long people lived.

The study found that treatment A followed by surgery did not make a difference in how long people lived compared to just having surgery alone. In fact, the study was stopped early because not enough people were being recruited to participate. The study also found that people who had treatment A had a higher rate of a certain type of surgery (R0 resection) and more frequent postoperative complications.

Overall, the study suggests that treatment A followed by surgery is not better than just having surgery alone for people with this type of cancer.",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.2758355}, {'token': '4', 'bytes': [52], 'logprob': -1.5258355}, {'token': '2', 'bytes': [50], 'logprob': -3.7758355}, {'token': '5', 'bytes': [53], 'logprob': -7.2758355}, {'token': '1', 'bytes': [49], 'logprob': -11.525835}, {'token': '6', 'bytes': [54], 'logprob': -12.775835}, {'token': '0', 'bytes': [48], 'logprob': -15.775835}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.900835}, {'token': '7', 'bytes': [55], 'logprob': -18.275835}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.275835}, {'token': ' ', 'bytes': [32], 'logprob': -18.838335}, {'token': '-', 'bytes': [45], 'logprob': -21.525835}, {'token': 'Three', 'bytes': [84, 104, 114, 101, 101], 'logprob': -21.838335}, {'token': '30', 'bytes': [51, 48], 'logprob': -21.963335}, {'token': 'I', 'bytes': [73], 'logprob': -22.275835}, {'token': 'D', 'bytes': [68], 'logprob': -22.463335}, {'token': '**', 'bytes': [42, 42], 'logprob': -22.525835}, {'token': '03', 'bytes': [48, 51], 'logprob': -22.525835}, {'token': '04', 'bytes': [48, 52], 'logprob': -22.588335}, {'token': 'C', 'bytes': [67], 'logprob': -22.650835}]",5,5,"[{'token': '5', 'bytes': [53], 'logprob': -0.622661}, {'token': '4', 'bytes': [52], 'logprob': -1.122661}, {'token': '6', 'bytes': [54], 'logprob': -1.997661}, {'token': '3', 'bytes': [51], 'logprob': -6.372661}, {'token': '7', 'bytes': [55], 'logprob': -7.247661}, {'token': '2', 'bytes': [50], 'logprob': -14.372661}, {'token': '8', 'bytes': [56], 'logprob': -15.372661}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.622662}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.747662}, {'token': ' ', 'bytes': [32], 'logprob': -19.060162}, {'token': '9', 'bytes': [57], 'logprob': -20.622662}, {'token': 'C', 'bytes': [67], 'logprob': -20.747662}, {'token': '1', 'bytes': [49], 'logprob': -21.122662}, {'token': '-', 'bytes': [45], 'logprob': -21.685162}, {'token': 'I', 'bytes': [73], 'logprob': -21.997662}, {'token': '**', 'bytes': [42, 42], 'logprob': -22.060162}, {'token': '４', 'bytes': [239, 188, 148], 'logprob': -22.247662}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -22.310162}, {'token': '５', 'bytes': [239, 188, 149], 'logprob': -22.372662}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.435162}]",4,4,"[{'token': '4', 'bytes': [52], 'logprob': -0.3636747}, {'token': '5', 'bytes': [53], 'logprob': -1.3636746}, {'token': '3', 'bytes': [51], 'logprob': -3.3636746}, {'token': '6', 'bytes': [54], 'logprob': -4.2386746}, {'token': '7', 'bytes': [55], 'logprob': -9.238675}, {'token': '2', 'bytes': [50], 'logprob': -10.363675}, {'token': '8', 'bytes': [56], 'logprob': -16.988674}, {'token': '1', 'bytes': [49], 'logprob': -17.738674}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.863674}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.488674}, {'token': ' ', 'bytes': [32], 'logprob': -19.113674}, {'token': '9', 'bytes': [57], 'logprob': -20.988674}, {'token': '0', 'bytes': [48], 'logprob': -21.051174}, {'token': 'C', 'bytes': [67], 'logprob': -22.238674}, {'token': '-', 'bytes': [45], 'logprob': -22.426174}, {'token': '**', 'bytes': [42, 42], 'logprob': -22.488674}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.676174}, {'token': '４', 'bytes': [239, 188, 148], 'logprob': -22.676174}, {'token': 'I', 'bytes': [73], 'logprob': -22.801174}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.926174}]",4,4,"[{'token': '4', 'bytes': [52], 'logprob': -0.34631652}, {'token': '5', 'bytes': [53], 'logprob': -1.5963166}, {'token': '3', 'bytes': [51], 'logprob': -2.4713166}, {'token': '6', 'bytes': [54], 'logprob': -5.3463163}, {'token': '2', 'bytes': [50], 'logprob': -7.2213163}, {'token': '7', 'bytes': [55], 'logprob': -9.221316}, {'token': '1', 'bytes': [49], 'logprob': -14.221316}, {'token': '8', 'bytes': [56], 'logprob': -15.846316}, {'token': '0', 'bytes': [48], 'logprob': -16.846317}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.721317}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.096317}, {'token': '9', 'bytes': [57], 'logprob': -20.033817}, {'token': ' ', 'bytes': [32], 'logprob': -20.346317}, {'token': '-', 'bytes': [45], 'logprob': -22.283817}, {'token': 'I', 'bytes': [73], 'logprob': -22.283817}, {'token': '４', 'bytes': [239, 188, 148], 'logprob': -22.283817}, {'token': '04', 'bytes': [48, 52], 'logprob': -22.533817}, {'token': 'C', 'bytes': [67], 'logprob': -22.846317}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.908817}, {'token': 'D', 'bytes': [68], 'logprob': -22.971317}]",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.6098681}, {'token': '4', 'bytes': [52], 'logprob': -0.8598681}, {'token': '2', 'bytes': [50], 'logprob': -3.984868}, {'token': '5', 'bytes': [53], 'logprob': -4.234868}, {'token': '6', 'bytes': [54], 'logprob': -8.234868}, {'token': '1', 'bytes': [49], 'logprob': -11.109868}, {'token': '7', 'bytes': [55], 'logprob': -12.984868}, {'token': '0', 'bytes': [48], 'logprob': -14.609868}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.859869}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.859869}, {'token': '8', 'bytes': [56], 'logprob': -18.234869}, {'token': ' ', 'bytes': [32], 'logprob': -18.484869}, {'token': '9', 'bytes': [57], 'logprob': -20.047369}, {'token': '-', 'bytes': [45], 'logprob': -21.234869}, {'token': 'I', 'bytes': [73], 'logprob': -21.984869}, {'token': '04', 'bytes': [48, 52], 'logprob': -22.234869}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.234869}, {'token': '**', 'bytes': [42, 42], 'logprob': -22.359869}, {'token': '.', 'bytes': [46], 'logprob': -22.359869}, {'token': '(', 'bytes': [40], 'logprob': -22.422369}]"
7,21399726,"The use of Valeriana officinalis (Valerian) in improving sleep in patients who are undergoing treatment for cancer: a phase III randomized, placebo-controlled, double-blind study (NCCTG Trial, N01C5)",J Support Oncol,"Sleep disorders are a substantial problem for cancer survivors, with prevalence estimates ranging from 23% to 61%. Although numerous prescription hypnotics are available, few are approved for long‐term use or have demonstrated benefit in this circumstance. Hypnotics may have unwanted side effects and are costly, and cancer survivors often wish to avoid prescription drugs. New options with limited side effects are needed. The purpose of this trial was to evaluate the efficacy of treatment A for sleep in people with cancer who were undergoing cancer treatment. Participants were randomized to receive treatment A or placebo orally 1 hour before bedtime for 8 weeks. The primary end point was area under the curve (AUC) of the overall Pittsburgh Sleep Quality Index (PSQI). Secondary outcomes included the Functional Outcomes of Sleep Questionnaire, the Brief Fatigue Inventory (BFI), and the Profile of Mood States (POMS). Toxicity was evaluated with both self‐reported numeric analogue scale questions and the Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Questionnaires were completed at baseline and at 4 and 8 weeks. A total of 227 patients were randomized into this study between March 19, 2004, and March 9, 2007, with 119 being evaluable for the primary end point. The AUC over the 8 weeks for treatment A was 51.4 (SD = 16), while that for placebo was 49.7 (SD = 15), with a P value of 0.6957. A supplemental, exploratory analysis revealed that several fatigue end points, as measured by the BFI and POMS, were significantly better for those taking treatment A over placebo. Participants also reported less trouble with sleep and less drowsiness on treatment A than placebo. There were no significant differences in toxicities as measured by self‐report or the CTCAE except for mild alkaline phosphatase increases, which were slightly more common in the placebo group. This study failed to provide data to support the hypothesis that treatment A, at bedtime could improve sleep as measured by the PSQI. However, exploratory analyses revealed improvement in some secondary outcomes, such as fatigue. Further research with treatment A exploring physiologic effects in oncology symptom management may be warranted.",spin,"This passage is about a study that looked at how well a medicine called treatment A helped people with cancer who were having trouble sleeping. The study involved 227 people who were randomly given either treatment A or a placebo (a sugar pill) to take before bedtime for 8 weeks. The researchers looked at how well the medicine helped people sleep by measuring something called the area under the curve (AUC) of a questionnaire called the Pittsburgh Sleep Quality Index (PSQI). They also looked at how well the medicine helped with other things like fatigue and mood. The study found that the medicine did not help people sleep as well as the placebo, but it did help with some other things. The researchers think that more research with this medicine is needed to see if it can help with other things in people with cancer.",4,4,"[{'token': '4', 'bytes': [52], 'logprob': -0.1766579}, {'token': '3', 'bytes': [51], 'logprob': -2.176658}, {'token': '5', 'bytes': [53], 'logprob': -3.051658}, {'token': '6', 'bytes': [54], 'logprob': -6.9266577}, {'token': '2', 'bytes': [50], 'logprob': -8.301658}, {'token': '7', 'bytes': [55], 'logprob': -12.551658}, {'token': '1', 'bytes': [49], 'logprob': -15.676658}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.801659}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.801659}, {'token': ' ', 'bytes': [32], 'logprob': -19.364159}, {'token': '8', 'bytes': [56], 'logprob': -20.114159}, {'token': '0', 'bytes': [48], 'logprob': -20.239159}, {'token': 'C', 'bytes': [67], 'logprob': -21.489159}, {'token': '-', 'bytes': [45], 'logprob': -21.989159}, {'token': 'D', 'bytes': [68], 'logprob': -22.051659}, {'token': '４', 'bytes': [239, 188, 148], 'logprob': -22.176659}, {'token': ' four', 'bytes': [32, 102, 111, 117, 114], 'logprob': -22.239159}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.239159}, {'token': 'Four', 'bytes': [70, 111, 117, 114], 'logprob': -22.239159}, {'token': 'Overall', 'bytes': [79, 118, 101, 114, 97, 108, 108], 'logprob': -22.551659}]",5,5,"[{'token': '5', 'bytes': [53], 'logprob': -0.7349496}, {'token': '6', 'bytes': [54], 'logprob': -0.7349496}, {'token': '4', 'bytes': [52], 'logprob': -3.2349496}, {'token': '7', 'bytes': [55], 'logprob': -6.4849496}, {'token': '3', 'bytes': [51], 'logprob': -9.859949}, {'token': '8', 'bytes': [56], 'logprob': -16.60995}, {'token': '2', 'bytes': [50], 'logprob': -18.35995}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.79745}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -20.92245}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.92245}, {'token': ' five', 'bytes': [32, 102, 105, 118, 101], 'logprob': -22.04745}, {'token': ' ', 'bytes': [32], 'logprob': -22.35995}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -22.73495}, {'token': '５', 'bytes': [239, 188, 149], 'logprob': -23.10995}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -23.10995}, {'token': 'Five', 'bytes': [70, 105, 118, 101], 'logprob': -23.35995}, {'token': '六', 'bytes': [229, 133, 173], 'logprob': -23.67245}, {'token': ' seis', 'bytes': [32, 115, 101, 105, 115], 'logprob': -23.67245}, {'token': 'C', 'bytes': [67], 'logprob': -23.73495}, {'token': ' Five', 'bytes': [32, 70, 105, 118, 101], 'logprob': -23.98495}]",5,5,"[{'token': '5', 'bytes': [53], 'logprob': -0.5044705}, {'token': '4', 'bytes': [52], 'logprob': -1.5044706}, {'token': '6', 'bytes': [54], 'logprob': -1.7544706}, {'token': '3', 'bytes': [51], 'logprob': -7.2544703}, {'token': '7', 'bytes': [55], 'logprob': -8.004471}, {'token': '2', 'bytes': [50], 'logprob': -15.879471}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.00447}, {'token': '8', 'bytes': [56], 'logprob': -18.62947}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.37947}, {'token': ' five', 'bytes': [32, 102, 105, 118, 101], 'logprob': -20.62947}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -21.37947}, {'token': '５', 'bytes': [239, 188, 149], 'logprob': -21.56697}, {'token': ' ', 'bytes': [32], 'logprob': -21.94197}, {'token': '４', 'bytes': [239, 188, 148], 'logprob': -22.31697}, {'token': ' four', 'bytes': [32, 102, 111, 117, 114], 'logprob': -22.31697}, {'token': ' cinco', 'bytes': [32, 99, 105, 110, 99, 111], 'logprob': -22.50447}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -22.50447}, {'token': 'Five', 'bytes': [70, 105, 118, 101], 'logprob': -22.62947}, {'token': ' seis', 'bytes': [32, 115, 101, 105, 115], 'logprob': -22.62947}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -23.00447}]",4,4,"[{'token': '4', 'bytes': [52], 'logprob': -0.7881221}, {'token': '5', 'bytes': [53], 'logprob': -0.7881221}, {'token': '6', 'bytes': [54], 'logprob': -2.5381222}, {'token': '3', 'bytes': [51], 'logprob': -4.538122}, {'token': '7', 'bytes': [55], 'logprob': -7.038122}, {'token': '2', 'bytes': [50], 'logprob': -10.913122}, {'token': '8', 'bytes': [56], 'logprob': -15.413122}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.850622}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.913122}, {'token': '1', 'bytes': [49], 'logprob': -20.663122}, {'token': ' five', 'bytes': [32, 102, 105, 118, 101], 'logprob': -21.725622}, {'token': '４', 'bytes': [239, 188, 148], 'logprob': -21.725622}, {'token': '５', 'bytes': [239, 188, 149], 'logprob': -21.913122}, {'token': ' four', 'bytes': [32, 102, 111, 117, 114], 'logprob': -22.413122}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -22.850622}, {'token': ' cinco', 'bytes': [32, 99, 105, 110, 99, 111], 'logprob': -22.850622}, {'token': 'Five', 'bytes': [70, 105, 118, 101], 'logprob': -22.850622}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -22.975622}, {'token': ' ', 'bytes': [32], 'logprob': -22.975622}, {'token': '六', 'bytes': [229, 133, 173], 'logprob': -23.475622}]",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.18585804}, {'token': '7', 'bytes': [55], 'logprob': -1.935858}, {'token': '5', 'bytes': [53], 'logprob': -3.685858}, {'token': '4', 'bytes': [52], 'logprob': -9.060858}, {'token': '8', 'bytes': [56], 'logprob': -9.060858}, {'token': '3', 'bytes': [51], 'logprob': -15.185858}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -19.185858}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.123358}, {'token': '9', 'bytes': [57], 'logprob': -20.435858}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.623358}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -20.685858}, {'token': ' seis', 'bytes': [32, 115, 101, 105, 115], 'logprob': -21.373358}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -21.623358}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -21.623358}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -21.873358}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -21.998358}, {'token': '六', 'bytes': [229, 133, 173], 'logprob': -22.060858}, {'token': ' ', 'bytes': [32], 'logprob': -22.185858}, {'token': '2', 'bytes': [50], 'logprob': -22.248358}, {'token': 'six', 'bytes': [115, 105, 120], 'logprob': -22.373358}]"
8,21399726,"The use of Valeriana officinalis (Valerian) in improving sleep in patients who are undergoing treatment for cancer: a phase III randomized, placebo-controlled, double-blind study (NCCTG Trial, N01C5)",J Support Oncol,"Sleep disorders are a substantial problem for cancer survivors, with prevalence estimates ranging from 23% to 61%. Although numerous prescription hypnotics are available, few are approved for long‐term use or have demonstrated benefit in this circumstance. Hypnotics may have unwanted side effects and are costly, and cancer survivors often wish to avoid prescription drugs. New options with limited side effects are needed. The purpose of this trial was to evaluate the efficacy of a treatment A for sleep in people with cancer who were undergoing cancer treatment. Participants were randomized to receive treatment A or placebo orally 1 hour before bedtime for 8 weeks. The primary end point was area under the curve (AUC) of the overall Pittsburgh Sleep Quality Index (PSQI). Secondary outcomes included the Functional Outcomes of Sleep Questionnaire, the Brief Fatigue Inventory (BFI), and the Profile of Mood States (POMS). Toxicity was evaluated with both self‐reported numeric analogue scale questions and the Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Questionnaires were completed at baseline and at 4 and 8 weeks. A total of 227 patients were randomized into this study between March 19, 2004, and March 9, 2007. Twenty‐three patients withdrew before starting the study treatment. Primary end‐point data were available on 119 patients (62 receiving treatment A and 57 receiving placebo). Baseline characteristics and baseline patient reported outcomes were well balanced between arms. The AUC over the 8 weeks for treatment A was 51.4 (SD = 16 and for placebo was 49.7 (SD = 15), with a P value of 0.7. The FOSQ was not statistically significantly different between groups. There was no statistically significant difference between groups for the POMS week 8 treatment A 6.9 vs. placebo 6.0; p=0.90. For the BFI at week 8 the treatment A and placebo arm scored respectively for fatigue now 22.1 vs. 10.5; p<0.01; for usual fatigue 19.4 vs. 10.0; p=0.05; for worst fatigue 14.8 vs. 12.4; p=0.65; and for activity inference 12.3 vs. 10.8; p=0.75.There were no significant differences in toxicities as measured by self‐report or the CTCAE. Treatment A was not more effective than placebo on sleep quality in patients who were undergoing cancer treatment.",no_spin,This passage is about a study that looked at how well a treatment called treatment A helped people with cancer who were having trouble sleeping. The study involved 227 people who were randomly assigned to either receive treatment A or a placebo (a sugar pill) for 8 weeks. The researchers looked at how well the treatment helped people sleep by measuring how much they reported being disturbed by their sleep and how well they felt during the day. They also looked at how tired people felt and how they felt emotionally. The study found that treatment A did not help people sleep any better than the placebo. The researchers also looked at how safe the treatment was and found that it was safe.,0,0,"[{'token': '0', 'bytes': [48], 'logprob': -0.29848087}, {'token': '1', 'bytes': [49], 'logprob': -2.048481}, {'token': '2', 'bytes': [50], 'logprob': -2.048481}, {'token': '3', 'bytes': [51], 'logprob': -8.548481}, {'token': '4', 'bytes': [52], 'logprob': -14.673481}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.798481}, {'token': ' ', 'bytes': [32], 'logprob': -18.548481}, {'token': '5', 'bytes': [53], 'logprob': -18.673481}, {'token': '02', 'bytes': [48, 50], 'logprob': -18.923481}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.173481}, {'token': '01', 'bytes': [48, 49], 'logprob': -19.673481}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -20.610981}, {'token': '-', 'bytes': [45], 'logprob': -20.798481}, {'token': 'I', 'bytes': [73], 'logprob': -21.485981}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.548481}, {'token': '6', 'bytes': [54], 'logprob': -21.673481}, {'token': '00', 'bytes': [48, 48], 'logprob': -21.735981}, {'token': ' Score', 'bytes': [32, 83, 99, 111, 114, 101], 'logprob': -22.048481}, {'token': '  ', 'bytes': [32, 32], 'logprob': -22.360981}, {'token': '03', 'bytes': [48, 51], 'logprob': -22.360981}]",4,4,"[{'token': '4', 'bytes': [52], 'logprob': -0.63745016}, {'token': '3', 'bytes': [51], 'logprob': -0.88745016}, {'token': '5', 'bytes': [53], 'logprob': -3.0124502}, {'token': '2', 'bytes': [50], 'logprob': -4.76245}, {'token': '6', 'bytes': [54], 'logprob': -6.26245}, {'token': '7', 'bytes': [55], 'logprob': -10.38745}, {'token': '1', 'bytes': [49], 'logprob': -12.51245}, {'token': '0', 'bytes': [48], 'logprob': -15.76245}, {'token': '8', 'bytes': [56], 'logprob': -15.88745}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.01245}, {'token': ' ', 'bytes': [32], 'logprob': -18.26245}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.38745}, {'token': '9', 'bytes': [57], 'logprob': -19.19995}, {'token': 'C', 'bytes': [67], 'logprob': -21.26245}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.44995}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -21.51245}, {'token': '**', 'bytes': [42, 42], 'logprob': -21.57495}, {'token': '-', 'bytes': [45], 'logprob': -21.69995}, {'token': 'I', 'bytes': [73], 'logprob': -21.76245}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.94995}]",2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.3995346}, {'token': '3', 'bytes': [51], 'logprob': -1.1495346}, {'token': '4', 'bytes': [52], 'logprob': -4.7745347}, {'token': '1', 'bytes': [49], 'logprob': -5.6495347}, {'token': '0', 'bytes': [48], 'logprob': -7.7745347}, {'token': '5', 'bytes': [53], 'logprob': -8.524534}, {'token': '6', 'bytes': [54], 'logprob': -12.524534}, {'token': '7', 'bytes': [55], 'logprob': -16.024534}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.274534}, {'token': ' ', 'bytes': [32], 'logprob': -18.524534}, {'token': '8', 'bytes': [56], 'logprob': -19.024534}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.524534}, {'token': '9', 'bytes': [57], 'logprob': -20.149534}, {'token': '02', 'bytes': [48, 50], 'logprob': -20.899534}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.649534}, {'token': 'I', 'bytes': [73], 'logprob': -21.712034}, {'token': '-', 'bytes': [45], 'logprob': -21.837034}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.149534}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.274534}, {'token': '10', 'bytes': [49, 48], 'logprob': -22.399534}]",2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.23320708}, {'token': '0', 'bytes': [48], 'logprob': -1.9832071}, {'token': '1', 'bytes': [49], 'logprob': -3.233207}, {'token': '3', 'bytes': [51], 'logprob': -3.483207}, {'token': '4', 'bytes': [52], 'logprob': -8.358207}, {'token': '5', 'bytes': [53], 'logprob': -11.608207}, {'token': '6', 'bytes': [54], 'logprob': -15.608207}, {'token': '7', 'bytes': [55], 'logprob': -18.483208}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.858208}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.983208}, {'token': ' ', 'bytes': [32], 'logprob': -19.108208}, {'token': '02', 'bytes': [48, 50], 'logprob': -19.483208}, {'token': '8', 'bytes': [56], 'logprob': -20.170708}, {'token': '9', 'bytes': [57], 'logprob': -20.233208}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.420708}, {'token': '01', 'bytes': [48, 49], 'logprob': -21.483208}, {'token': '-', 'bytes': [45], 'logprob': -21.670708}, {'token': 'I', 'bytes': [73], 'logprob': -22.108208}, {'token': '30', 'bytes': [51, 48], 'logprob': -22.858208}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.920708}]",2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.2064377}, {'token': '0', 'bytes': [48], 'logprob': -2.7064376}, {'token': '3', 'bytes': [51], 'logprob': -2.7064376}, {'token': '1', 'bytes': [49], 'logprob': -2.9564376}, {'token': '4', 'bytes': [52], 'logprob': -6.9564376}, {'token': '5', 'bytes': [53], 'logprob': -10.956438}, {'token': '6', 'bytes': [54], 'logprob': -14.331438}, {'token': '7', 'bytes': [55], 'logprob': -16.956438}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.706438}, {'token': ' ', 'bytes': [32], 'logprob': -18.206438}, {'token': '8', 'bytes': [56], 'logprob': -18.581438}, {'token': '9', 'bytes': [57], 'logprob': -18.706438}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.081438}, {'token': '02', 'bytes': [48, 50], 'logprob': -19.456438}, {'token': '03', 'bytes': [48, 51], 'logprob': -20.956438}, {'token': '-', 'bytes': [45], 'logprob': -21.081438}, {'token': '01', 'bytes': [48, 49], 'logprob': -21.331438}, {'token': 'I', 'bytes': [73], 'logprob': -21.893938}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.206438}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.268938}]"
5,21471562,"Impact of a novel nurse-led prechemotherapy education intervention (ChemoEd) on patient distress, symptom burden, and treatment-related information and support needs: results from a randomised, controlled trial",Ann Oncol,"Background: 
High levels of distress and need for self‐care information by patients commencing chemotherapy suggest that current prechemotherapy education is suboptimal. We conducted a randomized, controlled trial of a prechemotherapy education intervention (treatment A) to assess impact on patient distress, treatment‐related concerns, and the prevalence and severity of and bother caused by six chemotherapy side‐effects.
Patients and methods:
One hundred and ninety‐two breast, gastrointestinal, and haematologic cancer patients were recruited before the trial closing prematurely (original target 352). Treatment A was administered before first treatment (intervention 1), 48 h after first treatment (intervention 2), and immediately before second treatment (intervention 3). Patient outcomes were measured at baseline (T1: pre‐education) and immediately preceding treatment cycles 1 (T2) and 3 (T3).
Results:
Treatment A did not significantly reduce patient distress. However, a significant decrease in sensory/psychological (P=0.027) and procedural (P=0.03) concerns, as well as prevalence and severity of and bother due to vomiting (all P=0.001), were observed at T3. In addition, subgroup analysis of patients with elevated distress at T1 indicated a significant decrease (P=0.035) at T2 but not at T3 (P=0.055) in treatment A patients.
Conclusion:
Treatment A holds promise to improve patient treatment‐related concerns and some physical/psychological outcomes; however, further research is required on more diverse patient populations to ensure generalisability.",spin,"The passage is about a study that looked at how well a prechemotherapy education intervention (treatment A) helped patients who were about to start chemotherapy. The study found that treatment A did not significantly reduce patient distress, but it did help reduce some other things like concerns about the treatment and how much vomiting they experienced. The study also looked at a group of patients who were feeling very upset before they started treatment and found that treatment A helped them feel better in some ways, but not all the way. The researchers think that more research is needed to see if treatment A works well for everyone and not just for certain groups of people.",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.030687435}, {'token': '5', 'bytes': [53], 'logprob': -3.7806873}, {'token': '7', 'bytes': [55], 'logprob': -4.9056873}, {'token': '4', 'bytes': [52], 'logprob': -11.530687}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -16.780687}, {'token': '8', 'bytes': [56], 'logprob': -17.405687}, {'token': ' seis', 'bytes': [32, 115, 101, 105, 115], 'logprob': -19.280687}, {'token': '3', 'bytes': [51], 'logprob': -19.405687}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -19.905687}, {'token': '六', 'bytes': [229, 133, 173], 'logprob': -20.405687}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -21.218187}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -21.280687}, {'token': 'six', 'bytes': [115, 105, 120], 'logprob': -21.280687}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.468187}, {'token': ' Six', 'bytes': [32, 83, 105, 120], 'logprob': -21.718187}, {'token': ' five', 'bytes': [32, 102, 105, 118, 101], 'logprob': -21.968187}, {'token': ' sei', 'bytes': [32, 115, 101, 105], 'logprob': -22.343187}, {'token': ' sixth', 'bytes': [32, 115, 105, 120, 116, 104], 'logprob': -22.405687}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -22.780687}, {'token': ' ', 'bytes': [32], 'logprob': -23.093187}]",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.09794535}, {'token': '7', 'bytes': [55], 'logprob': -2.5979455}, {'token': '5', 'bytes': [53], 'logprob': -3.9729455}, {'token': '4', 'bytes': [52], 'logprob': -9.847945}, {'token': '8', 'bytes': [56], 'logprob': -12.347945}, {'token': '3', 'bytes': [51], 'logprob': -17.472946}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -17.722946}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.285446}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.160446}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -19.722946}, {'token': ' ', 'bytes': [32], 'logprob': -20.285446}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -20.535446}, {'token': ' seis', 'bytes': [32, 115, 101, 105, 115], 'logprob': -20.722946}, {'token': '六', 'bytes': [229, 133, 173], 'logprob': -20.910446}, {'token': '9', 'bytes': [57], 'logprob': -21.035446}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -21.222946}, {'token': 'C', 'bytes': [67], 'logprob': -21.410446}, {'token': 'six', 'bytes': [115, 105, 120], 'logprob': -21.535446}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -21.660446}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -22.160446}]",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.6947202}, {'token': '7', 'bytes': [55], 'logprob': -0.6947202}, {'token': '5', 'bytes': [53], 'logprob': -6.5697203}, {'token': '8', 'bytes': [56], 'logprob': -8.69472}, {'token': '4', 'bytes': [52], 'logprob': -13.06972}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.69472}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -18.56972}, {'token': '9', 'bytes': [57], 'logprob': -18.94472}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -19.38222}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.38222}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -19.63222}, {'token': '3', 'bytes': [51], 'logprob': -19.88222}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -20.56972}, {'token': ' ', 'bytes': [32], 'logprob': -20.75722}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -20.81972}, {'token': ' seis', 'bytes': [32, 115, 101, 105, 115], 'logprob': -20.94472}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -20.94472}, {'token': '六', 'bytes': [229, 133, 173], 'logprob': -21.75722}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -21.75722}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -22.06972}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.5871998}, {'token': '6', 'bytes': [54], 'logprob': -0.8371998}, {'token': '5', 'bytes': [53], 'logprob': -4.5871997}, {'token': '8', 'bytes': [56], 'logprob': -6.9621997}, {'token': '4', 'bytes': [52], 'logprob': -9.5872}, {'token': '3', 'bytes': [51], 'logprob': -15.0872}, {'token': '9', 'bytes': [57], 'logprob': -16.2122}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.4622}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.3372}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -18.6497}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -19.8372}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -20.0247}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -20.1497}, {'token': '2', 'bytes': [50], 'logprob': -20.5872}, {'token': '70', 'bytes': [55, 48], 'logprob': -21.2122}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -21.2747}, {'token': 'I', 'bytes': [73], 'logprob': -21.3997}, {'token': ' ', 'bytes': [32], 'logprob': -21.3997}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.5247}, {'token': ' seis', 'bytes': [32, 115, 101, 105, 115], 'logprob': -21.6497}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.12985045}, {'token': '6', 'bytes': [54], 'logprob': -2.1298504}, {'token': '8', 'bytes': [56], 'logprob': -5.8798504}, {'token': '5', 'bytes': [53], 'logprob': -9.00485}, {'token': '4', 'bytes': [52], 'logprob': -16.00485}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -17.37985}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -18.50485}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -19.00485}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -19.62985}, {'token': '9', 'bytes': [57], 'logprob': -19.69235}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -20.25485}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -20.31735}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.37985}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -20.81735}, {'token': ' seis', 'bytes': [32, 115, 101, 105, 115], 'logprob': -21.00485}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -21.31735}, {'token': ' seventh', 'bytes': [32, 115, 101, 118, 101, 110, 116, 104], 'logprob': -21.37985}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.37985}, {'token': '七', 'bytes': [228, 184, 131], 'logprob': -21.56735}, {'token': '3', 'bytes': [51], 'logprob': -22.12985}]"
6,21471562,"Impact of a novel nurse-led prechemotherapy education intervention (ChemoEd) on patient distress, symptom burden, and treatment-related information and support needs: results from a randomised, controlled trial",Ann Oncol,"Background:
High levels of distress and need for self‐care information by patients commencing chemotherapy suggest that current prechemotherapy education is suboptimal. We conducted a randomized, controlled trial of a prechemotherapy education intervention (treatment A) to assess impact on patient distress.
Patients and methods:
One hundred and ninety‐two breast, gastrointestinal, and haematologic cancer patients were recruited before the trial closing prematurely (original target 352). Treatment A was administered before first treatment (intervention 1), 48 h after first treatment (intervention 2), and immediately before second treatment (intervention 3). Patient outcomes were measured at baseline (T1: pre‐education) and immediately preceding treatment cycles 1 (T2) and 3 (T3). The primary endpoint was psychological distress at T2 and T3 as measured by the HADS.
Results:
At T2 and T3 treatment A did not significantly reduce patients distress with mean (SD) HADS scores respectively for routine care vs. treatment A at T2 10.9 (6.8) vs. 9.9 (5.8); p=0.33; and T3 10.4 (7.0) vs. 9.0 (5.8), p=0.15. There was a statistically significant decrease in sensory/psychological (P=0.027) and procedural (P=0.03) concerns, but there was no statistically significant difference between groups for the prevalence, severity and bother of most chemotherapy side‐effects (nausea, infection, hair loss, mouth and throat problem and fatigue) except vomiting at T3.
Conclusion:
Treatment A was not more effective than usual care in patients commencing chemotherapy.",no_spin,"The passage is about a study that tried to help people who were going to start chemotherapy feel better. The study gave them information about chemotherapy before they started it, and then measured how they felt after they started it. The study found that the information did not really help them feel better.",2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.10295496}, {'token': '3', 'bytes': [51], 'logprob': -2.3529549}, {'token': '1', 'bytes': [49], 'logprob': -6.102955}, {'token': '4', 'bytes': [52], 'logprob': -7.727955}, {'token': '0', 'bytes': [48], 'logprob': -9.602955}, {'token': '5', 'bytes': [53], 'logprob': -14.477955}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.352955}, {'token': ' ', 'bytes': [32], 'logprob': -18.852955}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.102955}, {'token': '6', 'bytes': [54], 'logprob': -19.102955}, {'token': '02', 'bytes': [48, 50], 'logprob': -20.165455}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.415455}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.540455}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.665455}, {'token': '30', 'bytes': [51, 48], 'logprob': -21.852955}, {'token': '-', 'bytes': [45], 'logprob': -21.977955}, {'token': 'I', 'bytes': [73], 'logprob': -22.165455}, {'token': '20', 'bytes': [50, 48], 'logprob': -22.790455}, {'token': '7', 'bytes': [55], 'logprob': -23.040455}, {'token': '.', 'bytes': [46], 'logprob': -23.040455}]",4,4,"[{'token': '4', 'bytes': [52], 'logprob': -0.5199856}, {'token': '5', 'bytes': [53], 'logprob': -1.0199857}, {'token': '6', 'bytes': [54], 'logprob': -3.2699857}, {'token': '3', 'bytes': [51], 'logprob': -5.0199857}, {'token': '7', 'bytes': [55], 'logprob': -8.269985}, {'token': '2', 'bytes': [50], 'logprob': -12.769985}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.144985}, {'token': '8', 'bytes': [56], 'logprob': -16.519985}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.769985}, {'token': ' ', 'bytes': [32], 'logprob': -18.019985}, {'token': '1', 'bytes': [49], 'logprob': -20.332485}, {'token': 'C', 'bytes': [67], 'logprob': -20.394985}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -20.769985}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -20.894985}, {'token': '9', 'bytes': [57], 'logprob': -21.019985}, {'token': '４', 'bytes': [239, 188, 148], 'logprob': -21.269985}, {'token': '0', 'bytes': [48], 'logprob': -21.457485}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -21.582485}, {'token': 'I', 'bytes': [73], 'logprob': -21.644985}, {'token': '**', 'bytes': [42, 42], 'logprob': -21.707485}]",4,4,"[{'token': '4', 'bytes': [52], 'logprob': -0.41487268}, {'token': '3', 'bytes': [51], 'logprob': -1.1648726}, {'token': '5', 'bytes': [53], 'logprob': -3.6648726}, {'token': '2', 'bytes': [50], 'logprob': -6.4148726}, {'token': '6', 'bytes': [54], 'logprob': -7.9148726}, {'token': '7', 'bytes': [55], 'logprob': -12.664873}, {'token': '1', 'bytes': [49], 'logprob': -15.039873}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.039873}, {'token': ' ', 'bytes': [32], 'logprob': -18.164873}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.414873}, {'token': '0', 'bytes': [48], 'logprob': -18.539873}, {'token': '8', 'bytes': [56], 'logprob': -19.289873}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.727373}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.789873}, {'token': '9', 'bytes': [57], 'logprob': -21.789873}, {'token': '-', 'bytes': [45], 'logprob': -22.164873}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -22.289873}, {'token': '**', 'bytes': [42, 42], 'logprob': -22.289873}, {'token': 'I', 'bytes': [73], 'logprob': -22.352373}, {'token': 'C', 'bytes': [67], 'logprob': -22.477373}]",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.33403012}, {'token': '4', 'bytes': [52], 'logprob': -1.5840302}, {'token': '2', 'bytes': [50], 'logprob': -2.5840302}, {'token': '5', 'bytes': [53], 'logprob': -5.70903}, {'token': '6', 'bytes': [54], 'logprob': -10.58403}, {'token': '1', 'bytes': [49], 'logprob': -11.45903}, {'token': '7', 'bytes': [55], 'logprob': -16.08403}, {'token': '0', 'bytes': [48], 'logprob': -16.83403}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.95903}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -21.08403}, {'token': '8', 'bytes': [56], 'logprob': -22.14653}, {'token': ' ', 'bytes': [32], 'logprob': -23.45903}, {'token': '３', 'bytes': [239, 188, 147], 'logprob': -24.27153}, {'token': 'I', 'bytes': [73], 'logprob': -24.58403}, {'token': '-', 'bytes': [45], 'logprob': -24.70903}, {'token': '.', 'bytes': [46], 'logprob': -24.89653}, {'token': 'Three', 'bytes': [84, 104, 114, 101, 101], 'logprob': -25.14653}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -25.27153}, {'token': '４', 'bytes': [239, 188, 148], 'logprob': -25.45903}, {'token': '03', 'bytes': [48, 51], 'logprob': -25.64653}]",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.43758854}, {'token': '4', 'bytes': [52], 'logprob': -1.1875886}, {'token': '2', 'bytes': [50], 'logprob': -3.0625885}, {'token': '5', 'bytes': [53], 'logprob': -5.9375887}, {'token': '6', 'bytes': [54], 'logprob': -10.437589}, {'token': '1', 'bytes': [49], 'logprob': -10.937589}, {'token': '0', 'bytes': [48], 'logprob': -14.312589}, {'token': '7', 'bytes': [55], 'logprob': -15.312589}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.687588}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.437588}, {'token': ' ', 'bytes': [32], 'logprob': -18.750088}, {'token': '8', 'bytes': [56], 'logprob': -20.125088}, {'token': 'I', 'bytes': [73], 'logprob': -21.250088}, {'token': '9', 'bytes': [57], 'logprob': -21.375088}, {'token': '-', 'bytes': [45], 'logprob': -21.500088}, {'token': '03', 'bytes': [48, 51], 'logprob': -22.375088}, {'token': '30', 'bytes': [51, 48], 'logprob': -22.437588}, {'token': '04', 'bytes': [48, 52], 'logprob': -22.500088}, {'token': 'D', 'bytes': [68], 'logprob': -22.500088}, {'token': '.', 'bytes': [46], 'logprob': -22.500088}]"
48,22112969,"Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer",Ann Oncol,"Background:
Treatment A, has activity alone and in combination with docetaxel (Taxotere) and prednisone (DP) in metastatic castration‐resistant prostate cancer (mCRPC). A randomized, double‐blind, placebo‐controlled phase II trial compared DP combined with either treatment A (A) or placebo in chemonaive mCRPC.
Patients and methods:
Men with progressive mCRPC despite androgen deprivation were eligible and randomized 1:1. Patients received docetaxel (75 mg/m2 day 1) and prednisone 5 mg orally twice daily every 21 days with either treatment A or placebo twice daily orally on days 1‐3. The primary end point was overall survival (OS).
Results:
Two hundred and twenty‐one patients were randomly assigned. Median OS for treatment A plus docetaxel‐prednisone (ADP) and placebo‐DP was 18.1 versus 17.8 months [hazard ratio (HR) 1.07, 95% confidence interval 0.72‐1.55, P=0.63]. Secondary end points were also not statistically different. Grade 3/4 toxic effects for ADP versus placebo‐DP were cardiac events (5% versus 2%), lymphopenia (23% versus 16%), neutropenia (47% versus 40%), ileus (2% versus 0%) and pulmonary embolism (6% versus 2%). In a subgroup of high‐risk mCRPC (n=34), outcomes appeared to favor ADP (median OS 19 versus 14 months).
Conclusion:
Treatment A was not more effective than placebo in metastatic castration‐ resistant prostate cancer patients.",no_spin,"This passage is about a study that looked at a treatment for a type of cancer called metastatic castration‐resistant prostate cancer (mCRPC). The treatment included a combination of a medicine called docetaxel (Taxotere) and a steroid called prednisone (DP), along with another medicine called treatment A. The study compared this treatment to a placebo (a medicine that has no effect) to see if it was better at helping patients with mCRPC.

The study looked at how long patients lived and how well they responded to the treatment. The results showed that the treatment with docetaxel, prednisone, and treatment A was not better than the placebo at helping patients with mCRPC. However, there were some side effects that were more common with the treatment, such as cardiac events, lymphopenia, neutropenia, ileus, and pulmonary embolism.

The study also looked at a group of patients who were at higher risk for the cancer and found that the treatment with docetaxel, prednisone, and treatment A seemed to be better at helping these patients.

Overall, the study showed that the treatment with docetaxel, prednisone, and treatment A was not better than the placebo at helping patients with mCRPC, but it did have some side effects that were more common with the treatment.",2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.061266597}, {'token': '3', 'bytes': [51], 'logprob': -3.3112667}, {'token': '1', 'bytes': [49], 'logprob': -3.8112667}, {'token': '0', 'bytes': [48], 'logprob': -7.3112664}, {'token': '4', 'bytes': [52], 'logprob': -8.686267}, {'token': '5', 'bytes': [53], 'logprob': -14.436267}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.936266}, {'token': '6', 'bytes': [54], 'logprob': -18.436266}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.561266}, {'token': ' ', 'bytes': [32], 'logprob': -18.936266}, {'token': '02', 'bytes': [48, 50], 'logprob': -19.811266}, {'token': '-', 'bytes': [45], 'logprob': -21.561266}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.623766}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.998766}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.123766}, {'token': '7', 'bytes': [55], 'logprob': -22.248766}, {'token': 'I', 'bytes': [73], 'logprob': -22.248766}, {'token': '01', 'bytes': [48, 49], 'logprob': -22.311266}, {'token': '30', 'bytes': [51, 48], 'logprob': -22.436266}, {'token': '.', 'bytes': [46], 'logprob': -22.936266}]",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.48320025}, {'token': '5', 'bytes': [53], 'logprob': -1.2332003}, {'token': '7', 'bytes': [55], 'logprob': -2.4832003}, {'token': '4', 'bytes': [52], 'logprob': -4.8582}, {'token': '8', 'bytes': [56], 'logprob': -7.6082}, {'token': '3', 'bytes': [51], 'logprob': -9.2332}, {'token': '2', 'bytes': [50], 'logprob': -14.4832}, {'token': '9', 'bytes': [57], 'logprob': -14.9832}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.2332}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.1082}, {'token': ' ', 'bytes': [32], 'logprob': -19.1707}, {'token': '1', 'bytes': [49], 'logprob': -19.4207}, {'token': '0', 'bytes': [48], 'logprob': -20.6707}, {'token': 'C', 'bytes': [67], 'logprob': -20.7332}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -21.2957}, {'token': '10', 'bytes': [49, 48], 'logprob': -21.7957}, {'token': 'I', 'bytes': [73], 'logprob': -22.1707}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.2332}, {'token': 'Rating', 'bytes': [82, 97, 116, 105, 110, 103], 'logprob': -22.2957}, {'token': '-', 'bytes': [45], 'logprob': -22.3582}]",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.24818033}, {'token': '4', 'bytes': [52], 'logprob': -1.9981804}, {'token': '2', 'bytes': [50], 'logprob': -2.4981804}, {'token': '5', 'bytes': [53], 'logprob': -6.2481804}, {'token': '6', 'bytes': [54], 'logprob': -10.87318}, {'token': '1', 'bytes': [49], 'logprob': -11.37318}, {'token': '7', 'bytes': [55], 'logprob': -16.99818}, {'token': '0', 'bytes': [48], 'logprob': -18.62318}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.49818}, {'token': ' ', 'bytes': [32], 'logprob': -21.37318}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.37318}, {'token': '8', 'bytes': [56], 'logprob': -22.74818}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -24.37318}, {'token': '-', 'bytes': [45], 'logprob': -24.74818}, {'token': 'I', 'bytes': [73], 'logprob': -24.74818}, {'token': 'Three', 'bytes': [84, 104, 114, 101, 101], 'logprob': -24.87318}, {'token': '３', 'bytes': [239, 188, 147], 'logprob': -24.99818}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -24.99818}, {'token': '**', 'bytes': [42, 42], 'logprob': -25.18568}, {'token': '.', 'bytes': [46], 'logprob': -25.31068}]",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.55766463}, {'token': '2', 'bytes': [50], 'logprob': -1.0576646}, {'token': '4', 'bytes': [52], 'logprob': -2.5576646}, {'token': '5', 'bytes': [53], 'logprob': -6.057665}, {'token': '1', 'bytes': [49], 'logprob': -8.057665}, {'token': '0', 'bytes': [48], 'logprob': -10.307665}, {'token': '6', 'bytes': [54], 'logprob': -11.182665}, {'token': '7', 'bytes': [55], 'logprob': -15.182665}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.682665}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.995165}, {'token': '8', 'bytes': [56], 'logprob': -19.495165}, {'token': ' ', 'bytes': [32], 'logprob': -20.370165}, {'token': '02', 'bytes': [48, 50], 'logprob': -20.870165}, {'token': '9', 'bytes': [57], 'logprob': -21.057665}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.057665}, {'token': '30', 'bytes': [51, 48], 'logprob': -21.495165}, {'token': '04', 'bytes': [48, 52], 'logprob': -21.745165}, {'token': '-', 'bytes': [45], 'logprob': -22.182665}, {'token': 'I', 'bytes': [73], 'logprob': -22.245165}, {'token': '25', 'bytes': [50, 53], 'logprob': -22.432665}]",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.33739358}, {'token': '2', 'bytes': [50], 'logprob': -1.8373935}, {'token': '4', 'bytes': [52], 'logprob': -2.0873935}, {'token': '5', 'bytes': [53], 'logprob': -5.8373938}, {'token': '1', 'bytes': [49], 'logprob': -8.712394}, {'token': '6', 'bytes': [54], 'logprob': -10.087394}, {'token': '0', 'bytes': [48], 'logprob': -11.837394}, {'token': '7', 'bytes': [55], 'logprob': -14.712394}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.712393}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.087393}, {'token': ' ', 'bytes': [32], 'logprob': -18.649893}, {'token': '8', 'bytes': [56], 'logprob': -19.212393}, {'token': '9', 'bytes': [57], 'logprob': -20.524893}, {'token': '-', 'bytes': [45], 'logprob': -21.399893}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.649893}, {'token': 'I', 'bytes': [73], 'logprob': -22.024893}, {'token': '02', 'bytes': [48, 50], 'logprob': -22.087393}, {'token': '04', 'bytes': [48, 52], 'logprob': -22.149893}, {'token': 'D', 'bytes': [68], 'logprob': -22.399893}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.399893}]"
47,22112969,"Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer",Ann Oncol,"Background:
Treatment A, has activity alone and in combination with docetaxel (Taxotere) and prednisone (DP) in metastatic castration‐resistant prostate cancer (mCRPC). A randomized, double‐blind, placebo‐controlled phase II trial compared DP combined with either treatment A (A) or placebo in chemonaive mCRPC.
Patients and methods:
Men with progressive mCRPC despite androgen deprivation were eligible and randomized 1:1. Patients received docetaxel (75 mg/m2 day 1) and prednisone 5 mg orally twice daily every 21 days with either treatment A or placebo twice daily orally on days 1‐3. The primary end point was overall survival (OS).
Results:
Two hundred and twenty‐one patients were randomly assigned. Median OS for treatment A plus docetaxel‐prednisone (ADP) and placebo‐DP was 18.1 versus 17.8 months [hazard ratio (HR) 1.07, 95% confidence interval 0.72‐1.55, P=0.63]. Secondary end points were also not statistically different. Grade 3/4 toxic effects for ADP versus placebo‐DP were cardiac events (5% versus 2%), lymphopenia (23% versus 16%), neutropenia (47% versus 40%), ileus (2% versus 0%) and pulmonary embolism (6% versus 2%). In a subgroup of high‐risk mCRPC (n=34), outcomes appeared to favor ADP (median OS 19 versus 14 months).
Conclusion:
Treatment A was tolerable but did not extend OS when combined with DP in mCRPC; a potential benefit was observed in high‐risk patients.",spin,"This passage is about a study that looked at a treatment for a type of cancer called prostate cancer. The treatment included a medicine called docetaxel and another medicine called prednisone, and it was combined with a treatment called Treatment A. The study compared this treatment to a placebo (a medicine that doesn't do anything) to see if it helped.

The study looked at men with a type of prostate cancer that had come back despite being treated with another medicine. These men were randomly assigned to either get the treatment with docetaxel and prednisone (called ADP) or a placebo. They both got the same amount of docetaxel and prednisone, but the ADP group also got Treatment A.

The study looked at how long the men lived (called overall survival) and other things like how well the treatment worked and how many side effects they had. The results showed that the men who got ADP lived for about the same amount of time as the men who got the placebo. However, there were some side effects that were more common in the ADP group, like cardiac events (which can be serious heart problems), lymphopenia (which can weaken the immune system), neutropenia (which can make it harder for the body to fight off infections), ileus (which can cause problems with digestion), and pulmonary embolism (which",4,4,"[{'token': '4', 'bytes': [52], 'logprob': -0.19151716}, {'token': '5', 'bytes': [53], 'logprob': -2.191517}, {'token': '3', 'bytes': [51], 'logprob': -2.816517}, {'token': '6', 'bytes': [54], 'logprob': -5.9415174}, {'token': '2', 'bytes': [50], 'logprob': -9.191517}, {'token': '7', 'bytes': [55], 'logprob': -12.566517}, {'token': '1', 'bytes': [49], 'logprob': -16.316517}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.566517}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.066517}, {'token': ' ', 'bytes': [32], 'logprob': -19.254017}, {'token': '8', 'bytes': [56], 'logprob': -20.441517}, {'token': '0', 'bytes': [48], 'logprob': -20.816517}, {'token': 'C', 'bytes': [67], 'logprob': -20.816517}, {'token': '-', 'bytes': [45], 'logprob': -21.754017}, {'token': 'D', 'bytes': [68], 'logprob': -21.941517}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.254017}, {'token': '４', 'bytes': [239, 188, 148], 'logprob': -22.316517}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -22.441517}, {'token': 'Overall', 'bytes': [79, 118, 101, 114, 97, 108, 108], 'logprob': -22.441517}, {'token': '**', 'bytes': [42, 42], 'logprob': -22.629017}]",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.20217404}, {'token': '7', 'bytes': [55], 'logprob': -1.9521741}, {'token': '5', 'bytes': [53], 'logprob': -3.202174}, {'token': '4', 'bytes': [52], 'logprob': -8.327174}, {'token': '8', 'bytes': [56], 'logprob': -8.702174}, {'token': '3', 'bytes': [51], 'logprob': -14.577174}, {'token': '9', 'bytes': [57], 'logprob': -17.452173}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -18.202173}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.077173}, {'token': ' ', 'bytes': [32], 'logprob': -19.264673}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -20.452173}, {'token': '2', 'bytes': [50], 'logprob': -20.514673}, {'token': 'C', 'bytes': [67], 'logprob': -20.827173}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -21.077173}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -21.702173}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -21.952173}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -22.139673}, {'token': '-', 'bytes': [45], 'logprob': -22.452173}, {'token': 'Rating', 'bytes': [82, 97, 116, 105, 110, 103], 'logprob': -22.577173}, {'token': 'I', 'bytes': [73], 'logprob': -22.702173}]",5,5,"[{'token': '5', 'bytes': [53], 'logprob': -0.33480692}, {'token': '6', 'bytes': [54], 'logprob': -1.8348069}, {'token': '4', 'bytes': [52], 'logprob': -2.084807}, {'token': '3', 'bytes': [51], 'logprob': -8.084806}, {'token': '7', 'bytes': [55], 'logprob': -8.334806}, {'token': '2', 'bytes': [50], 'logprob': -16.084806}, {'token': '8', 'bytes': [56], 'logprob': -19.209806}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.084806}, {'token': ' five', 'bytes': [32, 102, 105, 118, 101], 'logprob': -20.709806}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.772306}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -21.459806}, {'token': '５', 'bytes': [239, 188, 149], 'logprob': -21.897306}, {'token': ' ', 'bytes': [32], 'logprob': -21.959806}, {'token': ' cinco', 'bytes': [32, 99, 105, 110, 99, 111], 'logprob': -22.772306}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -22.897306}, {'token': ' Five', 'bytes': [32, 70, 105, 118, 101], 'logprob': -23.022306}, {'token': ' seis', 'bytes': [32, 115, 101, 105, 115], 'logprob': -23.084806}, {'token': ' four', 'bytes': [32, 102, 111, 117, 114], 'logprob': -23.334806}, {'token': '４', 'bytes': [239, 188, 148], 'logprob': -23.397306}, {'token': 'Five', 'bytes': [70, 105, 118, 101], 'logprob': -23.397306}]",5,5,"[{'token': '5', 'bytes': [53], 'logprob': -0.38728523}, {'token': '4', 'bytes': [52], 'logprob': -1.6372852}, {'token': '6', 'bytes': [54], 'logprob': -2.1372852}, {'token': '7', 'bytes': [55], 'logprob': -5.387285}, {'token': '3', 'bytes': [51], 'logprob': -5.512285}, {'token': '2', 'bytes': [50], 'logprob': -11.762285}, {'token': '8', 'bytes': [56], 'logprob': -13.387285}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.512285}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.137285}, {'token': '1', 'bytes': [49], 'logprob': -18.449785}, {'token': '9', 'bytes': [57], 'logprob': -19.637285}, {'token': ' ', 'bytes': [32], 'logprob': -20.449785}, {'token': '0', 'bytes': [48], 'logprob': -20.762285}, {'token': '５', 'bytes': [239, 188, 149], 'logprob': -22.012285}, {'token': 'C', 'bytes': [67], 'logprob': -22.199785}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.387285}, {'token': 'I', 'bytes': [73], 'logprob': -22.449785}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -22.512285}, {'token': '-', 'bytes': [45], 'logprob': -22.637285}, {'token': ' five', 'bytes': [32, 102, 105, 118, 101], 'logprob': -22.637285}]",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.39500573}, {'token': '5', 'bytes': [53], 'logprob': -1.3950057}, {'token': '7', 'bytes': [55], 'logprob': -2.8950057}, {'token': '4', 'bytes': [52], 'logprob': -3.7700057}, {'token': '3', 'bytes': [51], 'logprob': -9.145006}, {'token': '8', 'bytes': [56], 'logprob': -10.270006}, {'token': '2', 'bytes': [50], 'logprob': -15.895006}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -16.020006}, {'token': '9', 'bytes': [57], 'logprob': -17.520006}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.895006}, {'token': ' ', 'bytes': [32], 'logprob': -19.332506}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -20.520006}, {'token': '1', 'bytes': [49], 'logprob': -21.207506}, {'token': 'C', 'bytes': [67], 'logprob': -21.207506}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -21.207506}, {'token': 'I', 'bytes': [73], 'logprob': -21.270006}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.332506}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.332506}, {'token': '-', 'bytes': [45], 'logprob': -22.020006}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -22.082506}]"
13,9093724,Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group,Ann Oncol,"Purpose:
A phase III study was performed in patients with metastatic breast cancer (MBC) to evaluate the effect on response rate and survival of a treatment A.
Patients and methods:
Four hundred fifty‐six patients were randomized to receive either treatment A or comparator B in combination with 5‐FU (500 mg/m2) and cyclophosphamide (500 mg/m2) i.v., every 21 days for a maximum of six cycles (eight in case of CR).
Results:
Of 456 patients, 390 were evaluable for efficacy. Objective response (CR + PR) was seen in 57% (treatment A) vs. 41% (comparator B) of the evaluable patients (P = 0.003). The CR rate was higher in the treatment A arm (12% vs. 7%, P = 0.07). Treatment A produced significantly higher response rates in patients with visceral localization (50% vs. 34%, P = 0.011) and in patients with more than two metastatic organ sites (64% vs. 37%, P = 0.001). Median time to progression (7.6 vs. 7 months) and overall survival (18 months vs. 17 months) were similar. Myelosuppression was the principal toxic effect, with grade IV neutropenia observed in 57% of the patients treated with treatment A vs. 9% of those on comparator B. Grade IV infection or febrile neutropenia were observed in 8% (treatment A) vs. 0.4% (comparator B), but the incidence of septic death was the same in the two arms (two patients each). Cardiac toxicity was similar in the two treatment groups, with 5% vs. 3% of the patients taken off study due to cardiac events, primarily due to a decline in LVEF. Only three patients (two in treatment A) experienced congestive heart failure.
Conclusion:
This trial shows that treatment A can be administered for repeated cycles without bone marrow support with increased, though acceptable, toxicity and with a significant increase of antitumor effect (especially in visceral and/or high‐burden disease), but no increased survival.",spin,"This study was done to see if a certain treatment (treatment A) would help people with a type of cancer called metastatic breast cancer (MBC). The study involved 456 people who were randomly divided into two groups. One group got treatment A and the other group got a different treatment (comparator B) along with some other drugs. The study lasted for up to six cycles of treatment and the researchers looked at how well the treatment worked and how safe it was.

The results showed that treatment A worked better than the other treatment in terms of how many people responded to the treatment. However, treatment A also caused more side effects, such as a decrease in the number of white blood cells and an increased risk of infection. Despite this, treatment A was still found to be safe and effective in treating certain types of MBC.

Overall, the study showed that treatment A can be used to treat MBC, but it may cause more side effects and may not increase the chances of survival.",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.080286495}, {'token': '6', 'bytes': [54], 'logprob': -2.5802865}, {'token': '8', 'bytes': [56], 'logprob': -6.5802865}, {'token': '5', 'bytes': [53], 'logprob': -11.705286}, {'token': '4', 'bytes': [52], 'logprob': -18.205286}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -18.830286}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -20.392786}, {'token': '9', 'bytes': [57], 'logprob': -20.455286}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -20.580286}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -20.642786}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -21.142786}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -21.205286}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.330286}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -21.642786}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -22.205286}, {'token': '3', 'bytes': [51], 'logprob': -22.392786}, {'token': '七', 'bytes': [228, 184, 131], 'logprob': -22.642786}, {'token': ' ', 'bytes': [32], 'logprob': -22.705286}, {'token': ' seis', 'bytes': [32, 115, 101, 105, 115], 'logprob': -22.767786}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -23.517786}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.20321079}, {'token': '8', 'bytes': [56], 'logprob': -1.7032108}, {'token': '6', 'bytes': [54], 'logprob': -6.328211}, {'token': '9', 'bytes': [57], 'logprob': -11.578211}, {'token': '5', 'bytes': [53], 'logprob': -13.578211}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.07821}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.82821}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -18.89071}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -19.32821}, {'token': '4', 'bytes': [52], 'logprob': -19.45321}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -20.20321}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -20.45321}, {'token': ' ', 'bytes': [32], 'logprob': -20.64071}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -21.20321}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -21.39071}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -21.64071}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.70321}, {'token': 'Rating', 'bytes': [82, 97, 116, 105, 110, 103], 'logprob': -21.82821}, {'token': '-', 'bytes': [45], 'logprob': -21.82821}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -21.95321}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.14544803}, {'token': '8', 'bytes': [56], 'logprob': -2.020448}, {'token': '6', 'bytes': [54], 'logprob': -5.895448}, {'token': '9', 'bytes': [57], 'logprob': -11.270448}, {'token': '5', 'bytes': [53], 'logprob': -12.395448}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -15.270448}, {'token': '4', 'bytes': [52], 'logprob': -17.395449}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -18.707949}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.770449}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -19.645449}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -20.020449}, {'token': ' Score', 'bytes': [32, 83, 99, 111, 114, 101], 'logprob': -20.645449}, {'token': ' ', 'bytes': [32], 'logprob': -20.770449}, {'token': 'I', 'bytes': [73], 'logprob': -21.020449}, {'token': 'Rating', 'bytes': [82, 97, 116, 105, 110, 103], 'logprob': -21.207949}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -21.207949}, {'token': '70', 'bytes': [55, 48], 'logprob': -21.332949}, {'token': '75', 'bytes': [55, 53], 'logprob': -21.332949}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.457949}, {'token': '710', 'bytes': [55, 49, 48], 'logprob': -21.520449}]",8,8,"[{'token': '8', 'bytes': [56], 'logprob': -0.5766523}, {'token': '7', 'bytes': [55], 'logprob': -0.8266523}, {'token': '6', 'bytes': [54], 'logprob': -7.3266525}, {'token': '9', 'bytes': [57], 'logprob': -9.826653}, {'token': '5', 'bytes': [53], 'logprob': -13.951653}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -19.201653}, {'token': ' eight', 'bytes': [32, 101, 105, 103, 104, 116], 'logprob': -19.826653}, {'token': '4', 'bytes': [52], 'logprob': -19.826653}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -19.826653}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -20.264153}, {'token': 'eight', 'bytes': [101, 105, 103, 104, 116], 'logprob': -20.514153}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.764153}, {'token': '<|end|>', 'bytes': None, 'logprob': -21.264153}, {'token': ' siete', 'bytes': [32, 115, 105, 101, 116, 101], 'logprob': -21.389153}, {'token': 'Seven', 'bytes': [83, 101, 118, 101, 110], 'logprob': -21.701653}, {'token': 'seven', 'bytes': [115, 101, 118, 101, 110], 'logprob': -21.701653}, {'token': 'Eight', 'bytes': [69, 105, 103, 104, 116], 'logprob': -21.826653}, {'token': '10', 'bytes': [49, 48], 'logprob': -22.451653}, {'token': ' Seven', 'bytes': [32, 83, 101, 118, 101, 110], 'logprob': -22.514153}, {'token': ' ocho', 'bytes': [32, 111, 99, 104, 111], 'logprob': -22.701653}]",7,7,"[{'token': '7', 'bytes': [55], 'logprob': -0.22600761}, {'token': '8', 'bytes': [56], 'logprob': -1.7260076}, {'token': '6', 'bytes': [54], 'logprob': -3.7260077}, {'token': '5', 'bytes': [53], 'logprob': -8.726007}, {'token': '9', 'bytes': [57], 'logprob': -10.101007}, {'token': '4', 'bytes': [52], 'logprob': -13.101007}, {'token': '3', 'bytes': [51], 'logprob': -17.476007}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.476007}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.288507}, {'token': '７', 'bytes': [239, 188, 151], 'logprob': -19.663507}, {'token': '70', 'bytes': [55, 48], 'logprob': -20.288507}, {'token': '10', 'bytes': [49, 48], 'logprob': -20.413507}, {'token': ' ', 'bytes': [32], 'logprob': -20.976007}, {'token': '2', 'bytes': [50], 'logprob': -21.038507}, {'token': '75', 'bytes': [55, 53], 'logprob': -21.351007}, {'token': 'I', 'bytes': [73], 'logprob': -21.601007}, {'token': '８', 'bytes': [239, 188, 152], 'logprob': -21.913507}, {'token': ' seven', 'bytes': [32, 115, 101, 118, 101, 110], 'logprob': -21.976007}, {'token': '68', 'bytes': [54, 56], 'logprob': -21.976007}, {'token': '710', 'bytes': [55, 49, 48], 'logprob': -22.538507}]"
14,9093724,Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group,Ann Oncol,"Purpose:
A phase III study was performed in patients with metastatic breast cancer (MBC) to evaluate the effect on response rate and survival of a treatment A.
Patients and methods:
Four hundred fifty‐six patients were randomized to receive either treatment A or comparator B in combination with 5‐FU (500 mg/m2) and cyclophosphamide (500 mg/m2) i.v., every 21 days for a maximum of six cycles (eight in case of CR). The primary outcome was overall survival.
Results:
Of 456 patients randomized to treatment A (214) or comparator B (242), 390 were evaluable for efficacy (treatment A 182, comparator B 208). There was no statistically significant difference between the 2 groups for the primary outcome with a median survival of 18 and 17 months, respectively for treatment A and comparator B (P = 0.54). Objective response (CR + PR) was seen in 57% (treatment A) vs. 41% (comparator B) of the evaluable patients (P = 0.003). The median duration of response was 9.1 months on treatment A and 9.3 on comparator B, the median Time to Treatment Failure (TTF) was, respectively, 5.8 vs. 5.3 months (P = 0.7). Myelosuppression was the principal toxic effect, with grade IV neutropenia observed in 57% of the patients treated with treatment A vs. 9% of those on comparator B. Grade IV infection or febrile neutropenia were observed in 8% (treatment A) vs. 0.4% (comparator B), but the incidence of septic death was the same in the two arms (two patients each). Cardiac toxicity was similar in the two treatment groups, with 5% vs. 3% of the patients taken off study due to cardiac events, primarily due to a decline in LVEF. Three patients (two in treatment A) experienced congestive heart failure.
Conclusion:
Treatment A was not more effective than comparator B in patients with metastatic breast cancer.",no_spin,"The study was done to see if a certain treatment (A) would help people with a type of cancer called metastatic breast cancer (MBC) better than another treatment (B). The study had 456 people who were randomly given either treatment A or B along with other drugs. The main goal of the study was to see how long people lived. The results showed that there was no big difference in how long people lived between the two groups. However, the study also found that more people who got treatment A had a better response to the treatment, which means that their cancer got better. The study also found that more people who got treatment A had a longer time before their cancer got worse. However, the study also found that more people who got treatment A had a higher chance of getting a serious infection or having a fever because their immune system was weakened by the treatment. The study also found that more people who got treatment A had a higher chance of having their heart stop working properly. Overall, the study showed that treatment A was not better than the other treatment in helping people with MBC live longer.",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.6011247}, {'token': '2', 'bytes': [50], 'logprob': -0.8511247}, {'token': '4', 'bytes': [52], 'logprob': -3.7261248}, {'token': '1', 'bytes': [49], 'logprob': -7.226125}, {'token': '5', 'bytes': [53], 'logprob': -9.976125}, {'token': '0', 'bytes': [48], 'logprob': -11.476125}, {'token': '6', 'bytes': [54], 'logprob': -14.476125}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.476124}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.851124}, {'token': ' ', 'bytes': [32], 'logprob': -18.351124}, {'token': '7', 'bytes': [55], 'logprob': -18.726124}, {'token': '-', 'bytes': [45], 'logprob': -21.226124}, {'token': '02', 'bytes': [48, 50], 'logprob': -21.476124}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.726124}, {'token': '30', 'bytes': [51, 48], 'logprob': -21.788624}, {'token': 'I', 'bytes': [73], 'logprob': -21.851124}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -21.851124}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -21.913624}, {'token': 'D', 'bytes': [68], 'logprob': -22.351124}, {'token': 'Three', 'bytes': [84, 104, 114, 101, 101], 'logprob': -22.351124}]",6,6,"[{'token': '6', 'bytes': [54], 'logprob': -0.4076792}, {'token': '5', 'bytes': [53], 'logprob': -1.1576792}, {'token': '7', 'bytes': [55], 'logprob': -4.407679}, {'token': '4', 'bytes': [52], 'logprob': -4.782679}, {'token': '3', 'bytes': [51], 'logprob': -10.40768}, {'token': '8', 'bytes': [56], 'logprob': -12.03268}, {'token': '2', 'bytes': [50], 'logprob': -17.282679}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -20.782679}, {'token': '<|end|>', 'bytes': None, 'logprob': -20.845179}, {'token': ' ', 'bytes': [32], 'logprob': -21.907679}, {'token': ' six', 'bytes': [32, 115, 105, 120], 'logprob': -21.970179}, {'token': '9', 'bytes': [57], 'logprob': -22.157679}, {'token': '６', 'bytes': [239, 188, 150], 'logprob': -23.157679}, {'token': 'C', 'bytes': [67], 'logprob': -23.282679}, {'token': 'Six', 'bytes': [83, 105, 120], 'logprob': -23.970179}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -24.095179}, {'token': ' five', 'bytes': [32, 102, 105, 118, 101], 'logprob': -24.095179}, {'token': '５', 'bytes': [239, 188, 149], 'logprob': -24.345179}, {'token': 'Five', 'bytes': [70, 105, 118, 101], 'logprob': -24.657679}, {'token': '六', 'bytes': [229, 133, 173], 'logprob': -24.720179}]",4,4,"[{'token': '4', 'bytes': [52], 'logprob': -0.475162}, {'token': '3', 'bytes': [51], 'logprob': -1.475162}, {'token': '5', 'bytes': [53], 'logprob': -1.975162}, {'token': '6', 'bytes': [54], 'logprob': -4.975162}, {'token': '2', 'bytes': [50], 'logprob': -5.600162}, {'token': '7', 'bytes': [55], 'logprob': -8.975162}, {'token': '1', 'bytes': [49], 'logprob': -12.600162}, {'token': '8', 'bytes': [56], 'logprob': -14.975162}, {'token': '0', 'bytes': [48], 'logprob': -15.350162}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.100163}, {'token': ' ', 'bytes': [32], 'logprob': -17.850163}, {'token': '9', 'bytes': [57], 'logprob': -18.475163}, {'token': '<|end|>', 'bytes': None, 'logprob': -18.600163}, {'token': '-', 'bytes': [45], 'logprob': -21.725163}, {'token': 'C', 'bytes': [67], 'logprob': -21.975163}, {'token': '**', 'bytes': [42, 42], 'logprob': -21.975163}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.037663}, {'token': 'I', 'bytes': [73], 'logprob': -22.100163}, {'token': '10', 'bytes': [49, 48], 'logprob': -22.225163}, {'token': 'The', 'bytes': [84, 104, 101], 'logprob': -22.225163}]",3,3,"[{'token': '3', 'bytes': [51], 'logprob': -0.6084124}, {'token': '4', 'bytes': [52], 'logprob': -1.1084124}, {'token': '2', 'bytes': [50], 'logprob': -2.3584123}, {'token': '5', 'bytes': [53], 'logprob': -3.4834123}, {'token': '6', 'bytes': [54], 'logprob': -8.108413}, {'token': '1', 'bytes': [49], 'logprob': -9.108413}, {'token': '0', 'bytes': [48], 'logprob': -11.358413}, {'token': '7', 'bytes': [55], 'logprob': -11.858413}, {'token': '8', 'bytes': [56], 'logprob': -16.983412}, {'token': '<|end|>', 'bytes': None, 'logprob': -17.608412}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.733412}, {'token': '9', 'bytes': [57], 'logprob': -19.420912}, {'token': ' ', 'bytes': [32], 'logprob': -19.858412}, {'token': 'I', 'bytes': [73], 'logprob': -21.233412}, {'token': '04', 'bytes': [48, 52], 'logprob': -21.795912}, {'token': '-', 'bytes': [45], 'logprob': -21.795912}, {'token': '30', 'bytes': [51, 48], 'logprob': -21.920912}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.920912}, {'token': '02', 'bytes': [48, 50], 'logprob': -22.108412}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.295912}]",2,2,"[{'token': '2', 'bytes': [50], 'logprob': -0.41746962}, {'token': '3', 'bytes': [51], 'logprob': -1.1674696}, {'token': '4', 'bytes': [52], 'logprob': -3.6674695}, {'token': '1', 'bytes': [49], 'logprob': -5.6674695}, {'token': '0', 'bytes': [48], 'logprob': -7.4174695}, {'token': '5', 'bytes': [53], 'logprob': -7.5424695}, {'token': '6', 'bytes': [54], 'logprob': -11.91747}, {'token': '7', 'bytes': [55], 'logprob': -15.79247}, {'token': 'Score', 'bytes': [83, 99, 111, 114, 101], 'logprob': -17.042469}, {'token': ' ', 'bytes': [32], 'logprob': -18.792469}, {'token': '<|end|>', 'bytes': None, 'logprob': -19.042469}, {'token': '8', 'bytes': [56], 'logprob': -19.667469}, {'token': '02', 'bytes': [48, 50], 'logprob': -20.292469}, {'token': '9', 'bytes': [57], 'logprob': -20.729969}, {'token': '03', 'bytes': [48, 51], 'logprob': -21.167469}, {'token': '-', 'bytes': [45], 'logprob': -21.542469}, {'token': '04', 'bytes': [48, 52], 'logprob': -21.854969}, {'token': 'I', 'bytes': [73], 'logprob': -21.979969}, {'token': ' score', 'bytes': [32, 115, 99, 111, 114, 101], 'logprob': -22.042469}, {'token': 'score', 'bytes': [115, 99, 111, 114, 101], 'logprob': -22.167469}]"
